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Medicines-related hospital admissions are responsible for 3.7% - 7.7% of all hospital 
admissions. Discharge from hospital is a particularly challenging time regarding medicines 
management. When patients transfer from one setting to another, 52.7% experience at 
least one medicine-related problem. Post-discharge medication review by community 
pharmacists has been postulated as a way of minimising medicines-related problems after 
hospital discharge with the aim of reducing medicines-related hospital-readmissions. 
 
The aims of this study were to explore the knowledge and attitudes of patients and 
community pharmacists around post-discharge medicines support and to determine how 
pharmacists could help patients manage their medicines better once discharged from 
hospital. 
 
A preliminary phase of the study used Hospital Episode Statistics data to establish the trends 
in medicines-related hospital admissions from 2008 to 2015. Following this a mixed-
methods sequential exploratory design was used. Qualitative data were generated from 
interviews with seven patients who had a medicines-related hospital admission and five 
community pharmacists providing the MUR service. Quantitative data were produced from 
a survey of 495 community pharmacists in England. 
 
The study found that community pharmacists have the expertise, are willing and well 
positioned to support patients managing their medicines after a hospital discharge. Barriers 
persist around their ability to build key relationships, effective methods of communication 
and integration into the primary healthcare team. Further work is required to ensure that 
patients and healthcare professionals are aware of community pharmacists’ expertise and 
how embedding their role, and that of GP practice pharmacists, in discharge pathways 
would benefit patient care. 
 
In conclusion, new ways of working and enhanced use of IT are required to facilitate and 
optimise patient care during transitions from hospital to primary care. Community 
pharmacists are well placed to support patients after hospital discharge but should be 
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another consultant or to a different provider during a spell of treatment (the 
total time a patient is in hospital, from admission to discharge) a new record 
is generated’ (HSCIC, 2013b). 
Glycated haemoglobin 
(HbA1c) 
A blood test to measure the amount of glucose bound to haemoglobin. It 
reflects the average level of glucose in the blood over the past 2-3 months 
(Lab Tests Online UK, 2018). 
Hyperkalaemia Raised potassium level in the blood. 
Integrated Medicines 
Management (IMM) 
The services vary by location but generally include, medicines reconciliation, 
intensive pharmaceutical care for the patient whilst in hospital, 
communication and follow-up of patients after discharge. 
Living with Medicines 
Questionnaire, version 3 
(LMQ-3) 
Validated patient questionnaire that measures the burden of using prescribed 
medicines (Katusiime, Corlett and Krska, 2018). 
Medicines reconciliation ‘Medication reconciliation is the process of creating the most accurate list 
possible of all medications a patient is taking — including drug name, dosage, 
frequency, and route — and comparing that list against the admission, 
transfer, and/or discharge list, with the goal of providing correct medications 
to the patient at all transition points‘ (Institute for Healthcare Improvement, 
2018). 
NVivo Software produced by QSR International, used for qualitative data analysis. 
Off-label A medicine with an existing UK marketing authorisation that is used outside 
the terms of its marketing authorisation, for example by indication, dose, 
route or patient population and it is not expected that the existing UK 
marketing authorisation will be extended to cover this use in the next two 
years (NICE, 2017). 
Prescription review A practical medicines-management review to improve the safety, clinical and 
cost-effectiveness of the prescription, conducted without the patient 




Quality and Outcomes 
Framework (QOF) 
‘A voluntary reward and incentive programme. It rewards GP practices, in 
England for the quality of care they provide to their patients and helps 
standardise improvements in the delivery of primary care’ (NHS Digital, 
2018d). 
Summary Care Record 
(SCR) 
‘An electronic record of important patient information created from GP 
medical records. It can be seen and used by authorised staff in other areas of 
the health and care system involved in the patient's direct care’ (NHS Digital, 
2018e). 
Unlicensed A medicine that does not have a UK marketing authorisation and is not 
expected to do so in the next two years (NICE, 2017). 
Yellow Card  The Yellow Card Scheme allows healthcare professionals and the public to 
report side effects, defective and counterfeit medicines (amongst other 
things) to the medicines and healthcare products regulatory agency (MHRA) 














This introductory chapter outlines the research area and provides a brief rationale for the 
research that has been conducted. It starts by providing a short synopsis of medicines-related 
hospital admissions, and introduces how medication reviews by community pharmacists in 
England could have an impact on this issue. The aims, objectives and research questions are 
then stated, followed by an overview of the thesis chapters. 
 
1.1 General overview 
Systematic reviews have estimated that medicines-related problems account for between 
3.7% and 7.7% of all hospital admissions in England (Wiffen et al., 2002; Howard et al., 2007) 
and the problem is increasing over time (Wu et al., 2010). Some of these medicines-related 
admissions would have been unforeseen and therefore unavoidable, but a significant 
proportion could have been predicted and therefore potentially prevented (Howard, Avery 
and Bissell, 2008). Based on a study in England that involved over 18,000 patients 
(Pirmohamed et al., 2004), it has been estimated that preventable adverse drug reaction 
(ADR)-related hospital admissions cost the National Health Service (NHS) £530 million in 2015 
(NICE, 2015b).  
 
It is well known that when patients are transferred from one setting to another medication 
problems can occur (Garcia-Caballos et al., 2010) and this is particularly true when patients are 
discharged from hospital. A systematic review exploring medicines-related problems in older 
people after hospital discharge found that 52.7% of patients suffered at least one medicines-
related problem at this time (Garcia-Caballos et al., 2010). These medication problems at care 
transitions can result in the patient being readmitted to hospital (Coleman, Smith, Raha and 
Min, 2005). 
 
In England, hospital readmissions are increasing year-on-year; it has recently been found that 
between 2010/11 and 2016/17, emergency readmissions to hospitals in England increased 
from 1.1 million to over 1.3 million, an increase of 19.2% (Quality Watch, 2018). A proportion 
of these emergency readmissions would have been secondary to medication-related problems 
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(Ruiz et al., 2008). A prospective observational study has estimated that the cost to the NHS of 
post-discharge medication-related harm in older adults is £396 million each year (Parekh et al., 
2018). 
 
Reducing the burden of medicines-related problems is therefore a priority for the NHS. 
Medication review is one tool that could potentially be used to mitigate the problem. 
Community pharmacists in England provide the medicines use review (MUR) service as part of 
their contract with the NHS. This service involves the pharmacist having a consultation with 
the patient with the aim of enabling patients to optimise the use of the medicines they have 
been prescribed. Patients who have recently been discharged from hospital with changes to 
their regular medicines are one group that community pharmacists target when considering 
the patients who will benefit most from a MUR. Ensuring that these post-discharge MURs (PD-
MURs) occur in a timely manner for eligible patients could be one way of helping to reduce 
preventable medicines-related readmissions to hospital. 
 
Many of the studies of medicines-related problems and their impact on hospital admissions 
are quantitative rather than qualitative  (Pirmohamed et al., 2004; Leendertse et al., 2008; 
Pedros et al., 2014). In particular, there is a paucity of evidence around what it is like to be a 
patient who experiences a medicines-related hospital admission and whether initiatives such 
as MURs or GP medication reviews assist the patient in managing their medicines - thus 
potentially avoiding complications such as hospital admissions and readmissions. A relatively 
recent PhD project in England investigated patients’ views of MURs, but this was focussed on 
the MUR consultation rather than medication reviews in general or the effect of these 
consultations on hospital admissions or readmissions (Latif, Boardman and Pollock, 2013). 
 
1.2 Defining the research problem 
MURs were introduced into the community pharmacy contract in 2005 with the aim of 
improving patients’ knowledge and use of their medicines. Since 2011, when target groups 
were introduced, a specified proportion of MURs should be completed for patients who would 
gain most benefit from them. Patients who have recently been discharged from hospital are 
part of this target group and are eligible for a PD-MUR (NHS Employers and PSNC, 2013a). The 
experiences and attitudes of community pharmacists and patients to PD-MURs are an 
important factor in the success, or otherwise, of this initiative. 
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1.3 Research Questions 
1. Are medicines-related admissions to hospital a problem in England and what 
medicines are implicated? 
2. What are the experiences of patients who have had a medicines-related admission to 
hospital? 
3. What are the experiences and attitudes of patients towards PD-MURs and medication 
reviews in general? 
4. What are the attitudes of community pharmacists conducting PD-MURs and do these 
attitudes have any effect on the engagement of community pharmacists with PD-
MURs?  
 
1.4 Aims and Objectives 
1.4.1 Aims 
The aims of the study are: 
1. To explore the knowledge and attitudes of patients and community pharmacists 
around post-discharge medicines support particularly PD-MURs. 
2. To determine how pharmacists can more effectively use their clinical skills, and tools 
such as PD-MURs, to help patients manage their medicines better once discharged 
from hospital, with a view to reducing medicines-related hospital admissions. 
 
1.4.2 Objectives 
The objectives of the study are to: 
1. Establish how many medicines-related admissions to hospital occur in England using 
hospital episode statistics (HES) data. 
2. Recruit patients who have a medicines-related hospital admission for interview about 
their experience. 
3. Refer the recruited patients to their community pharmacist for a PD-MUR. 
4. Follow up referred patients and discover their experience of a PD-MUR and 
medication reviews in general. 
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1.5 Research approaches and methods 
The study used a mixed-methods, sequential exploratory approach, incorporating a variety of 
strategies to explore patients’ and community pharmacists’ views and experiences (Creswell 
and Plano Clark, 2011. p.69). Preceding the sequential exploratory stage, the study used 
descriptive statistics to analyse and summarise routinely collected HES data to determine the 
trends over time in medicines-related admissions to hospitals in England. The sequential 
exploratory approach then commenced with the qualitative patient study which explored the 
‘lived experience’ of a patient’s medicines-related admission to hospital through semi-
structured interviews analysed using interpretative phenomenological analysis (IPA). This was 
accompanied by the qualitative community pharmacist study, which investigated the 
experiences of community pharmacists providing the MUR service through semi-structured 
interviews which were analysed thematically. The final quantitative phase was an electronic 
survey, enquiring about community pharmacists’ beliefs and experiences around MURs and 
their provision. 
 
The use of these research techniques in a sequential manner allowed each stage to build on 
the findings of the previous one and guide the course of the research. 
 
1.6 Research originality 
This research has added to the current evidence base as it used IPA to investigate the patient 
experience of a medicines-related admission to hospital and community-based medication 
review in this cohort of patients. The survey of community pharmacists is believed to be the 
first to use factor analysis as the analytical technique to determine what influences them when 
they make decisions about various aspects of MURs and PD-MURs. 
 
1.7 Thesis overview 
Following on from Chapter 1 is the background chapter. This provides a summary of the policy 
context of MURs provided by community pharmacists in England and summarises the rationale 
for the service, how it has developed over time and statistics to show the current uptake of the 
service by patients attending community pharmacies. 
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Next, is the literature review, Chapter 3, which presents the published evidence around the 
causes of hospital admissions and readmissions and whether medication reviews have any 
effect on reducing medicines-related hospital admissions.  
 
The methodology chapter, Chapter 4, summarises the rationale for the research approach that 
was employed when conducting the study. The methods for each phase of the research are 
presented sequentially in the subsequent chapters, which follow the same format of methods, 
results and a brief discussion of each part of the research. 
 
Chapter 5 presents the methods and findings of a preliminary piece of fieldwork using HES; an 
investigation into the scale of the problem of medicines-related admissions to hospital and 
how the trends have changed over time. 
 
In Chapter 6, a description of the methods utilised in the in-depth examination of patients’ 
experiences of a medicines-related admission to hospital and medication reviews are stated. 
Patients participated in in-depth interviews which were analysed using the qualitative 
analytical technique IPA, and the findings and discussion are presented in this chapter. 
 
Chapter 7 begins with an outline of the methods used for interviewing community 
pharmacists. It then goes on to present the findings of the community pharmacist interviews 
where they gave their accounts of their experiences and attitudes of the MUR service. These 
interviews were analysed using the qualitative technique, thematic analysis. The results of 
both the patient and community pharmacist interviews were used to guide the development 
of a questionnaire for community pharmacists and this chapter concludes by demonstrating 
how the final questionnaire was formulated. 
 
The methods, results and discussion of the survey of community pharmacists’ attitudes and 
experiences of MURs are presented in Chapter 8. The responses to the questionnaire provided 
quantitative data that were analysed using descriptive and inferential statistical techniques.  
 
A discussion of the results from all phases of the study, how they relate to each other and to 
the published literature is presented in Chapter 9. This chapter also considers the strengths 
and limitations of the fieldwork and summarises the study as a whole. 
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The thesis concludes with Chapter 10; the conclusions and recommendations, which 
summarises the research, policy and practice implications. 
 
The final sections, following the references, are the appendices which contain supplementary 











This chapter focusses on the policy background of the MUR service provided by community 
pharmacists in England. 
 
2.1 Introduction 
This section concentrates on medication reviews and specifically the MUR service that is 
provided by community pharmacists in England. MURs were introduced in 2005 as part of the 
new Community Pharmacy contract (NHS Employers and PSNC, 2013a). Over the years there 
have been several updates to this guidance such as the introduction of national target groups, 
which are discussed below.  
 
2.1.1 Types of medication review 
In the published literature the term ‘medication review’ encompasses many different types of 
activity conducted by different healthcare professionals (HCPs), in different locations. For 
clarity, it is essential to define what is meant by the different terms used. A synopsis of the 
most common types of medication review specific to England is presented below: 
1. Prescription review: practical medicines-management review to improve the safety, 
clinical and cost-effectiveness of the prescription, conducted without the patient. 
2. Compliance and concordance review: (also called an adherence review in some 
references, this is akin to a MUR conducted by a community pharmacist in England): to 
find out about the patient’s beliefs about medicines and how they are taking them, 
conducted with the patient. 
3. Clinical medication review: consideration of the patient’s medication with regard to 
their conditions and symptoms with access to the medical notes, laboratory tests and 
the patient. 
4. Clinical medication review and prescribing: the same type of review as point 3, but 
the HCP conducting the review is able to prescribe or adjust the doses of medication. 
(Blenkinsopp, Bond and Raynor, 2012; Hatah et al., 2014) 
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The location of these medication reviews will also vary with prescription reviews and clinical 
medication reviews most likely to occur in the GP surgery, conducted by the GP or a practice-
based pharmacist, while compliance and concordance reviews usually take place in a 
community pharmacy, conducted by the pharmacist. 
 
2.1.2 Services provided by community pharmacists in England 
2.1.2.1 MURs and PD-MURs 
Community pharmacies are independent contractors which provide services to the NHS; the 
services provided are categorised as essential, advanced or locally commissioned: 
• Essential services cover aspects such as dispensing, providing advice about medicines, 
self-care and healthy lifestyles, clinical governance and disposal of unwanted 
medicines (PSNC, 2018d). 
• Advanced services cover six different activities including MURs and the new medicine 
service (NMS) (PSNC, 2018a). 
• Locally commissioned services are agreed locally between community pharmacies and 
Clinical Commissioning Groups (CCGs), local authorities, or local NHS England teams, 
and can include services such as providing a minor ailments service, home delivery 
service, providing emergency hormonal contraception, needle exchange or stop 
smoking services (NHS Digital, 2017a; PSNC, 2018e). 
 
MURs were introduced in England in 2005 as the first advanced service to be provided by 
community pharmacies. There have been changes to the service since this time, most notably 
the introduction of target groups in 2011 and the addition of further target groups in 2015. To 
undertake MURs, pharmacists must comply with the rules around the provision of essential 
services, they must hold a MUR certificate and have a suitable private consultation area within 
the pharmacy for the MUR to take place (NHS Employers and PSNC, 2013a).  
 
The aim of a MUR is: 
“…with the patient’s agreement, to improve the patient’s knowledge and use of drugs  
by in particular – 
(a) establishing the patient’s actual use, understanding and experience of taking drugs. 
(b) identifying, discussing and assisting in the resolution of poor or ineffective use of drugs by 
the patient. 
(c) identifying side effects and drug interactions that may affect the patient’s  
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compliance with instructions given to them by a health care professional for  
the taking of drugs. 
(d) improving clinical and cost effectiveness of drugs prescribed to patients,  
thereby reducing the wastage of such drugs.” 
(NHS Employers and PSNC, 2013a) 
 
MURs are not a full clinical review of a patient’s medication, an agreement to change 
medication, a discussion about a patient’s medical condition or a review of treatment based 
on test results (PSNC, 2018j). This is partly because the community pharmacist does not have 
access to the patient’s GP record or medical notes. Pharmacists providing the MUR service 
must be accredited to do so by completing an assessment based on the national competency 
framework (PSNC, 2018m). 
 
The MUR should take place in a private consultation area which is signposted as such, the 
space should contain seating and the pharmacist and the patient must able to speak in 
confidence without being overheard (PSNC, 2018g). Patients must provide written consent to 
participate in the MUR process (PSNC, 2018f). The pharmacist is required to keep records of 
any MURs undertaken using a nationally agreed dataset which captures details of the patient, 
which target group they belong to, number of medicines taken, advice given, any action taken 
and the outcome of the MUR consultation (PSNC, 2018h). If during the MUR consultation, a 
pharmacist has identified an issue that the patient’s GP needs to be informed about, they 
should complete the agreed MUR feedback form and send it to the GP. If necessary, they 
should also telephone or speak to the patient’s GP. The GP surgery can then follow-up the 
patient in the manner that they see fit for the issue identified during the MUR (PSNC, 2018b). 
 
MURs were designed to be conducted in the community pharmacy but pharmacists can apply 
to NHS England to conduct MURs in other locations such as GP surgeries, care homes, patients’ 
homes or over the telephone (PSNC, 2018c).  
 
Patients should normally only have one MUR consultation per year unless the pharmacist 
believes that their circumstances have changed sufficiently to warrant another MUR 
consultation sooner. If a pharmacist deems a patient’s circumstances have changed, they are 
able to conduct a MUR and it is recommended that they document the reason for conducting 
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more than one MUR in a 12 month period for that particular patient (NHS Employers and 
PSNC, 2013a). 
 
Community pharmacists are currently paid £28 per MUR consultation and they are permitted 
to conduct up to 400 MURs per year in each pharmacy (NHS Employers and PSNC, 2013a). 
From 1st January 2015, there has been a requirement for pharmacists to conduct 70% of the 
MURs in each financial year on patients in national target groups. The four national target 
groups are as follows: 
• High-risk medicines: Patients taking certain high-risk medicines. The following groups 
of medicines are classified as high risk for the purposes of MURs: NSAIDs, 
anticoagulants (including low molecular weight heparin), antiplatelets and diuretics. 
• Post-discharge: Patients taking two or more medicines, who have recently been 
discharged from hospital and have had changes made to their medicines while they 
were in hospital. Ideally patients discharged from hospital will receive a MUR within 
four weeks of discharge but in certain circumstances the MUR can take place within 
eight weeks of discharge. This is referred to as a PD-MUR in this study. 
• Respiratory: Patients taking two or more medicines for respiratory disease. One 
medicine must be from the following groups: adrenoceptor agonists, antimuscarinic 
bronchodilators, theophylline, compound bronchodilator preparations, 
corticosteroids, cromoglicate and related therapy, leukotriene receptor antagonists or 
phosphodiesterase type-4 inhibitors. 
• Cardiovascular: Patients at risk of, or diagnosed with, cardiovascular disease and 
regularly being prescribed at least four medicines, at least one of which must be from 
the following categories: cardiovascular medicines, drugs used in diabetes or thyroid 
and anti-thyroid drugs. 
(PSNC, 2015) 
 
These target groups have been chosen based on which patients are most likely to gain benefit 
from a MUR. The medicines on the high-risk list were chosen based on the fact that they are 
associated with preventable harm due to missed doses, patients taking too much or using 
them incorrectly and a MUR with a community pharmacist could prevent this occurring (NHS 
Employers and PSNC, 2013a).  
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2.1.2.2 New Medicine Service 
The NMS was introduced in October 2011 as an additional advanced service that could be 
provided by community pharmacists in England (PSNC, 2018k). Hospital pharmacists can refer 
eligible patients to their community pharmacist for this service in a similar way as for PD-
MURs. Patients may qualify for both the NMS and a PD-MUR dependent on the changes made 
to their medicines whilst in hospital. 
 
The aim of the NMS is for patients to get additional support when they are commenced on 
certain medicines. The rationale for this is so that patients have: 
• Increased adherence to their new medicine. 
• Increase patient engagement with their medicine and condition. 
• Reduced waste of medicines. 
• Reduced hospital admissions due to ADRs. 
• Increased reporting of ADRs through the Yellow Card reporting scheme. 
(PSNC, 2018k) 
 
The NMS covers certain medicines specified by BNF chapter for four conditions which are: 
asthma and chronic obstructive pulmonary disease (COPD), type 2 diabetes, antiplatelet or 
anticoagulation therapy and hypertension (PSNC, 2018l). Patients can be recruited to the NMS 
when they present a prescription for an eligible medicine to the community pharmacy for the 
first time or if they are referred by a hospital where an eligible medicine was initiated. If no 
hospital to community referral takes place the patient is not eligible for the NMS even if they 
are receiving a specified medicine for the first time from their community pharmacy (NHS 
Employers and PSNC, 2013b). Once a patient has been given information about the NMS and 
provided written consent to take part, they have a consultation with the community 
pharmacist. The pharmacist checks adherence, whether the patient is experiencing any 
problems with the medicine they have been prescribed and provision of any additional 
information the patient requires about the medicine or their condition. The patient then has a 
follow-up consultation after 14 to 21 days to check adherence, to determine if any problems 
have manifested themselves during this time and again to provide information to the patient if 
necessary. If the patient is experiencing problems with the medicine, the community 
pharmacist may refer them back to their GP for further management. The community 
pharmacy is currently paid between £20 and £28 for each NMS depending on the total number 
of NMS consultations they provide in a month (NHS Employers and PSNC, 2013b). 




An NHS commissioned review of the NMS found that it increased patients’ adherence to their 
medication by approximately 10%. Patients who participated in the NMS cost the NHS £215 
compared to £260 for those receiving standard care, giving a saving of £45 per NMS. This 
reduced to a non-statistically significant saving of £21 when the cost of providing the service 
was accounted for. Patients had better outcomes and even though there were increased costs 
for the service as community pharmacists were remunerated, this was offset by a reduction in 
other contacts made by the patient with the NHS, resulting in an overall cost saving. The NMS 
was also well received by patients (Elliott et al., 2014). 
 
If patients discharged from hospital do not fulfil the criteria for a PD-MUR, they may qualify for 
a NMS referral instead. Hospital pharmacists should consider referring patients for these 
community pharmacist services to help patients to adhere to a new regime of medication after 
a hospital discharge and also to ensure that patients receive the information they need to gain 
the most out of their medicines to benefit their overall health. 
 
2.1.3 Community pharmacy MUR statistics 
In 2016/17 there were 11,699 community pharmacies in England and they dispensed over 1 
billion prescription items; the average number of prescription items dispensed each month per 
community pharmacy was 7,218 (NHS Digital, 2017a). These data cover only the population of 
England, which was 54.7million people; this equates to 21 community pharmacies per 100,000 
population (NHS Digital, 2017a). The types of community pharmacies were split into 
independent and multiple contractors as follows: 4,434 (37.9%) independent contractors 
(having ≤5 pharmacies) and 7,265 (62.1%) multiple contractors (having ≥6 pharmacies) (NHS 
Digital, 2017a). 
 
From the total number of community pharmacies in England, 11,244 (96.1%) conducted over 
3.3million MURs at a cost to the NHS in England of £93.6million in 2016/17 (NHS Digital, 
2017a; PSNC, 2018i). The average number of MURs per pharmacy was 300 (NHS Digital, 
2017a). 
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2.2 Summary of Background chapter 
This chapter has sought to describe MURs and the current policy surrounding them. In the 
present climate of reduced financial support from Government departments, and with the 
NHS in England spending almost £100million per year on the provision of the MUR service, it is 
important to ensure that the money is being spent wisely on evidence-based interventions 
that will benefit patients.  
 
There are many published studies that focus on MURs in the UK, as well as similar schemes in 
other countries. The aim of the next chapter is to provide an overview of the literature around 
hospital admissions generally, medicines-related hospital admissions, medication reviews and 
opinions of the individuals involved in medication reviews. 
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This chapter will summarise the pertinent published literature that underpins the rationale for 
this study. In the first instance, it considers emergency hospital admissions and readmissions in 
England followed by a review of the role medicines play in contributing to this. It then 
examines the evidence-base for medication review and how tools such as this can potentially 
mitigate some of the problem. Finally, the opinions of pharmacists and others involved in the 
medication review process will be summarised. This chapter will ‘set the scene’ for the current 
study and provide a rationale for the different stages of the research process that were 
conducted. 
 
3.1 Structure of the literature review 
The literature review will follow the structure detailed in Figure 3-1. 
 
 
Figure 3-1 Structure of literature review 
 
3.2 Identification of published papers 
Before embarking on any fieldwork, it was critical to review the literature to establish the base 
on which to start designing a study to discover more about the place of patients and 
community pharmacists in the post-discharge medication review system and suggest 
improvements to reduce the problem of medicines-use resulting in an admission, or 
Opinions and experiences of those involved in the medication 
review process
Medication review
Medicines-related admissions and readmissions
Hospital admissions and readmissions
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readmission to hospital. The initial search of the literature was conducted using Medline (from 
2000 to 2013), Embase (from 2000 to 2013), Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) (from 2000 to 2013), and by searching the reference lists of the papers 
identified as useful. The search strategies used can be found in Appendix A. This was 
supplemented with internet searches, identifying articles in professional journals through 
hand-searching, and subscribing to email table of contents circulation lists to locate further 
papers of interest. Initially, only systematic reviews were examined to gain an overview of the 
subject area. This allowed a wide range of individual studies to be identified from the 
reference lists. Since several years have elapsed since the literature searches were first 
completed in 2013/14, at the time of writing-up in 2018, further searches were conducted to 
update aspects of the literature review. 
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3.3 Hospital admissions and readmissions 
 
Figure 3-2 Literature review: Area One - hospital admissions and readmissions 
 
In this section, emergency admissions to hospital will be considered, followed by readmissions 
to hospital. Then, the medicines that are most commonly identified as being the cause of a 
hospital admission will be explored. 
 
3.3.1 Emergency admissions to hospitals in England 
The NHS collects data about every admission, emergency department (ED) attendance and 
outpatient appointment in England and stores them in a database called HES. These data are 
primarily collected for payment purposes but can also be used for research and healthcare 
planning (NHS Digital, 2018b). Each HES record contains information about diagnoses, 
operations, patient’s demographic details, administrative details of the admission and 
discharge and geographical information about location of treatment and where the patient 
lives (NHS Digital, 2018b). These data can be used to reveal trends in hospital activity in 
England and determine whether they have changed over time. 
 
In 2011/12, at the outset of the current study, there were 17.5 million finished consultant 
episodes (FCEs) which included 5.2 million emergency admissions to hospitals in England. For 
the financial year 2017/18, there were 20.0 million FCEs and 6.1 million emergency admissions 
(NHS Digital, 2018a). This represents a 14.7% increase in FCEs and a 16.4% increase in 
emergency admissions over this time period. NHS Digital has stated that between 2007/8 and 
2017/18 there was a 28% increase in emergency hospital admissions (NHS Digital, 2018a) and 
the greatest increase was in admissions for the 65 to 84 year old age group; (NHS Digital, 
Opinions and experiences of those involved in the medication 
review process
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2017d). These data demonstrate that year-on-year, emergency admissions to NHS hospitals in 
England are still increasing. 
 
3.3.2 Emergency readmissions to hospitals in England 
Once patients have been discharged from hospital there is a potential that they could be 
readmitted, either for the same or a different problem. Hospital readmissions are often used 
as a quality indicator with the suggestion that high readmission rates are associated with poor 
standards of in-patient care during an initial, or index, admission. In 2010, the UK Government 
decided to withhold payment from hospital Trusts for patients readmitted within 30 days of an 
elective admission and this was later extended so that Trusts would also be penalised for a 
certain locally agreed proportion of readmissions following emergency admissions 
(Department of Health, 2010b). The aim of this policy was to ensure that patients received 
optimum care during their primary admission and were not discharged too early. 
 
The use of readmissions as a measure of quality is controversial as readmissions can occur for 
a variety of reasons. Readmissions can be affected by many factors including the ‘severity, 
predictability and chronicity of the patient’s underlying condition’ with factors such as social 
support and co-morbidities also having an impact (Clarke, 2004). In fact, for some patients a 
readmission could indicate a positive aspect of care, for example, if they have a condition that 
may require frequent admissions, such as cancer (Clarke, 2004). 
 
A recent study from the UK aimed to classify emergency 30-day readmissions and identify 
ways of reducing them (Blunt, Bardsley, Grove, & Clarke, 2014). The authors used HES data 
from 2004 to 2010 and found that there were 5.8 million emergency 30-day readmissions 
during this period, which gave a readmission rate of 7.0%. Of the patients that were 
readmitted, only 5.3% were due to a complication of an index admission. When the 
preventability of readmissions was assessed, 30% of all readmissions were classified as 
‘potentially preventable’ (Blunt et al., 2014). 
 
The use of routinely collected data to monitor readmissions is complicated by the fact that 
hospitals are changing the way that they deliver services, with an increase in the use of frailty 
units and ambulatory care units which have altered the way patients are managed in hospitals 
(Future Hospital Commission, 2013). Over time the way that hospital admissions are coded 
and reported in HES datasets has also changed (HSCIC, 2013b). There are also other 
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confounding factors that can affect a particular hospital’s readmission rate including: 
socioeconomic status of patients, whether patients are transferred to other locations for 
rehabilitation, variations in length of stay, self-discharges, admissions for issues unrelated to 
the initial admission and differences in coding (HSCIC, 2013a). 
 
Previously, NHS Digital published data that showed the number of readmissions to hospital 
within 28 days of discharge. The latest published data covered the financial year 2011/12 so a 
direct comparison between readmission and admission data was not possible for more recent 
years (HSCIC, 2013a). The National Audit Office emergency admission report stated that there 
were 5.3 million emergency admissions to hospital in England between 2012 and 2013, costing 
approximately £12.5 billion. They reported that 19%, or over a million emergency admissions, 
were in fact readmissions (National Audit Office, 2013) that cost the economy over £2.4 billion 
(NICE, 2015a). 
 
Since this original literature review was written, other reports have been published that show 
the more recent impact of readmissions on the NHS. Healthwatch England published a report 
in October 2017 titled: What do the numbers say about emergency readmissions to hospital? 
(Healthwatch England, 2017). The data for 2016/17 showed that for the 72 trusts that 
submitted data, the number of emergency readmissions increased from 372,805 in 2012/13 to 
457,880 in 2016/17. Of these emergency readmissions, 21.61% occurred in the first 48 hours 
after the initial discharge (Healthwatch England, 2017). The authors note that the situation 
was complicated, and readmissions do not necessarily indicate substandard care. The report 
recommended that trusts collect more detailed data to allow them to understand and improve 
their readmission rates and for NHS Digital to recommence the publication of the annual 
readmission reports (Healthwatch England, 2017). 
 
A more recent report from Quality Watch (a collaboration between the Health Foundation and 
The Nuffield Trust) reported that between 2010/11 and 2016/17 the total number of 
emergency readmissions each year increased from 1,157,570 to 1,379,790. This represents an 
increase of 19.2% and far outstrips the 10.5% increase in the number of all hospital 
admissions, over the same time period (Quality Watch, 2018). The Quality Watch team also 
found that between 2010/11 and 2016/17, potentially preventable readmissions increased by 
41.3% from 130,760 to 184,763, giving an increase in the rate of potentially preventable 
readmissions from 0.8% to 1.1% (Quality Watch, 2018). 
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A recently published paper examined hospital readmissions to 150 NHS Trusts in England using 
HES data from 2006 to 2016 (Friebel et al., 2018). They found that there had been a 
statistically significant increase in 30-day readmissions from 6.56% in 2006/7 to 6.64% in 
2015/16 (p<0.01). This represented an absolute increase in emergency readmissions of 80,384; 
from 338,565 out of 5,204,263 emergency admissions in 2006/7 to 418,949 out of 6,219,153 
emergency admissions in 2015/16. The paper suggested that different types of data need to be 
combined with readmission data to determine how the emergency readmission rate can be 
decreased (Friebel et al., 2018). 
 
These data show that emergency readmissions are still a burden for the NHS and any 
measures that can be taken to minimise the proportion of patients that are readmitted to 
hospital should be investigated further. 
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3.4 Medicines-related hospital admissions and readmissions 
 
Figure 3-3 Literature review: Area Two – Medicines-related admissions and readmissions 
 
The previous sections have outlined the current situation in England with regard to hospital 
admissions and readmissions. This section will initially provide background information about 
the terminology used in the studies that involve medicines-related problems. Following this 
will be an examination of the published literature concerning how medicines contribute to 
hospital admissions and readmissions. 
 
3.4.1 Background to adverse drug event terminology 
Before the published data around medicines-related admissions and readmissions is reviewed, 
it was important to outline the different terminology that was used in the published papers to 
describe adverse drug reactions, adverse drug events (ADEs) and related terms. 
 
3.4.2 ADRs and ADEs 
In the published literature there are a variety of different terms used to describe a medicines-
related problem that results in a negative outcome for the patient. A summary diagram of the 
different terms and how they are interrelated was published in the journal Quality and Safety 
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From, Morimoto et al., (2004), reproduced with permission 
Figure 3-4 Relationship between ADEs, potential ADEs and medication errors 
 
The authors also defined the various terms that were used to describe ADEs due to 
medication: 
• ADE - an injury due to medication. 
• Potential ADE - the medication could have caused an injury but in that particular 
situation it did not.  
• Preventable ADE - an injury due to an error in the use of a medication.  
• Non-preventable ADE - also known as an ADR, resulting from an injury due to 
medication where no error was involved.  
• Ameliorable ADE - the injury could have been less severe or lasted for less time, if a 
different course of action had been taken. 
• Non-ameliorable ADE - an injury where the severity or duration could not have been 
reduced. 
(Morimoto et al., 2004) 
The authors categorised ADRs as a subset of ADEs and noted that, ADEs could occur 
spontaneously or be caused by medication error, although not all medication errors result in 
an ADE. Depending on the location, the authors found that approximately a third to a half of 
all ADEs were associated with medication errors (Morimoto et al., 2004). 
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There have been various definitions of the term ADR. In 1972, The World Health Organisation 
defined an ADR as ‘a response to a medicine which is noxious and unintended, and which 
occurs at doses normally used in man’ (WHO, 2002). In the year 2000, Edwards and Aronson, 
proposed an alternative definition: ‘an appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product’(Edwards and Aronson, 2000). And, an EU 
directive in 2010, clarified the definition of an ADR to include ‘noxious and unintended effects 
resulting not only from the authorised use of a medicinal product at normal doses, but also 
from medication errors and uses outside the terms of the marketing authorisation, including 
the misuse and abuse of the medicinal product’ (EU Directive, 2010). The terms ADE and ADR 
are often used interchangeably in the literature and this can lead to difficulties when 
interpreting the results of studies (Lavan and Gallagher, 2016). The majority of studies report 
the use of the WHO definition despite its criticism by Edwards and Aronson (2000). 
 
3.4.3 Identifying medicines-related problems in practice 
3.4.3.1 Sources of data for studies of ADRs 
ADRs are under-reported, both in primary and secondary care settings (Hazell and Shakir, 
2006); this means that it can be difficult to determine the impact of medicines-related 
problems on hospital admissions and readmissions. It has been suggested that the diagnosis of 
ADRs is often by the process of exclusion (Hazell and Shakir, 2006). 
 
There are a variety of different sources of information and methods for collecting data about 
ADRs. Morimoto et al., (2004) described three methods their research group had used in 
primary care settings: (i) collecting practice data (which included charts, laboratory data, 
prescription data and administrative data), (ii) soliciting reports from HCPs and (iii) surveying 
patients. In secondary care settings, the sources of information include: medical notes, 
laboratory reports, prescription charts and discharge summaries. Each type of information can 
be used on its own or in combination. Data can be collected by various different individuals 
including HCPs, assistants or students. The use of information technology (IT) can also assist in 
these tasks which can reduce subjectivity but relies on correct diagnosis, coding and accurate 
data entry (Morimoto et al., 2004). 
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Other options for data collection include the use of administrative data and coding, such as the 
previously mentioned use of the HES database, and also analysis of the reports received by the 
Yellow card scheme in the UK (Dobson, 2007). 
 
3.4.3.2 Assessment of causality, severity and preventability of ADEs 
Causality 
There are many published studies that detail the medicines that are most likely to result in a 
medicines-related hospital admission; these medicines are often referred to as high-risk. When 
reviewing studies, it is important to consider how the authors have made the decision that a 
medicine has been the cause of the patient’s problem and resulted in the hospital admission. It 
can be difficult to determine whether the signs and symptoms that a patient is displaying and 
experiencing are due to the medicine or other factors. 
 
There are different scoring systems that can be used to judge whether a medicine is the 
culprit; one of the most commonly used is known as the Naranjo criteria (Naranjo et al., 1981). 
This ten question assessment tool is an ADR probability scale that when completed gives a 
score that can be used to determine the certainty that an ADR has occurred (Naranjo et al., 
1981). The other assessment tool that studies use is the WHO-UMC criteria which is a six point 
scale that can be used to determine the probability that an ADR has occurred (WHO-UMC, 
2000). When reviewing studies that have investigated the medicines most commonly 
implicated in hospital admissions it is important to consider how the authors decided the 
medicine was the cause of the ADE. 
 
Severity 
ADEs are often categorised using an arbitrary scale based on the subjective opinions of 
clinicians or researchers. The Hartwig and Siegal severity criteria is an eight point scale that 
allows the severity of ADEs to be classified using an objective approach based on severity of 
the level of harm and the extent of medical intervention required (Lavan and Gallagher, 2016). 
 
Preventability 
Many studies also attempt to categorise ADEs based on whether they were idiosyncratic or 
predictable and therefore, to some extent preventable. One of the most common rating scales 
was developed by Hallas and is a four-point scale denoting the certainty with which the 
medicines were the cause of hospital admission (Hallas et al., 1990). 
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3.4.4 Medicines-related hospital admissions – scale of the problem and medicines 
involved 
3.4.4.1 Systematic reviews 
As already stated, in 2016/17 there were 5.8 million emergency admissions to hospitals in 
England (NHS Digital, 2017d) and a proportion of these admissions would have been 
medicines-related . Many authors have conducted systematic reviews examining medicines-
related admissions to hospital and these are detailed in Table 3-1. These reviews have found 
that between 3.7 and 7.7% of all hospital admissions were medicines-related; excluding 
studies of only drug-drug interactions (DDIs) (Dechanont et al., 2014) and those that reported 
results as a range from the included studies (Leendertse et al., 2010). 
 
Another meta-analysis, worthy of mention here, has been published which included 16 papers 
concerning preventable ADR-related hospital admissions. As the study focussed only on 
preventable admissions, rather than all admissions, it was unsuitable for inclusion in Table 3-1. 
It showed that in the out-patient setting, 2% of patients experienced a preventable ADR and 
52% of ADRs were preventable (Hakkarainen et al., 2012). 
 
A further non-systematic review of observational studies analysed 22 papers specifically 
focussed on medicines-related hospital admissions due to ADRs in Europe. It found that a 
median of 3.6% (range 0.5% - 12.8%) of all hospital admissions were due to ADRs. Twenty-
three studies analysed data to determine the rate of fatal ADRs and the highest percentage 
found was 0.49% of all admissions (Bouvy, De Bruin and Koopmanschap, 2015). 
 
 
Chapter Three | Literature Review 
 
 52 
Table 3-1 Systematic reviews focussing on medicines-related hospital admissions 













Beijer and de Blaey 
(2002) 







4.9% +/- 0.1% 
(Mean +/- Confidence 
interval (CI)) 
Not stated. ADR-related admissions 
four times higher in elderly 
population; 16.6% v. 4.1%. 
Dechanont et al., 
(2014) 
To estimate the prevalence 
of hospital admissions or 
hospital visits associated 
with drug-drug interactions 
(DDI). 
 
13 ü Not stated. 1.1% (median) 




DDIs are a subset of 
medication-related 
admissions. More DDIs 
identified with medical 
record review and 
retrospective studies. 
Howard et al. 
(2007) 


















Most common causes were 





To determine the 
prevalence of hospital 







2.7 – 9.0% (IQR) 
NSAIDs 
Cardiovascular drug 
Central nervous system 
(CNS) agents 
Combining methods for 
ADR detection resulted in 
higher prevalence of ADRs 
compared to medication 




To estimate the prevalence 













(95% CI 3.1 – 6.2%) 
Not stated. 0.13% (95% CI 0.04 – 
0.21%) ADRs causing 
admissions to hospital 
were fatal. 
Only studies from US 
included. 
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Leendertse et al., 
(2010) 
To explore the influence of 
study characteristics 
(setting, population, 
outcome, method of data 
collection and continent) 
on the prevalence of 
medication-related 
hospitalizations. 
95 X WHO 
definition. 
0.1 – 54% (range) Not stated. Higher prevalence of ADRs 
in all hospital admissions 
compared to emergency 
admissions only. 
Medication chart review 
gave higher prevalence of 
medicines-related 
hospitalisations compared 
to spontaneous reports or 
database methods. 
Roughead et al., 
(1998) 
To examine the extent of 
drug-related hospital 
admissions in Australia. 




2.4 – 3.6% Cytotoxics 





Focussed on Australian 
papers only. 
Wiffen et al.,  
(2002) 
To estimate the incidence 
of ADRs resulting in 
hospital admissions, 
estimate the burden of 
ADRs, identify risk factors 
for ADRs and identify 
research into reducing the 
impact of ADRs. 
108 X WHO 
definition. 
5.5% in prospective 
studies 
7.7% in retrospective 
studies 
60-70% of all ADRS in 








Winterstein et al., 
(2002) 
To estimate the prevalence 
of preventable drug-
related hospital admissions 
and to explore if selected 
study characteristics affect 







5.7 – 16.2% (IQR) 
Not stated. More than half were 
preventable and caused by 
inappropriate care or 
medication error. 
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3.4.4.2 Individual studies 
Many of the systematic reviews included in Table 3-1 were published several years ago and 
there are some very large studies of medication-related hospital admissions that are worthy of 
further description.  
 
Table 3-2 shows a summary of some of the important individual studies that have been 
conducted to investigate the extent of medication-related admissions. The studies were all 
carried out using data collection from individual patients using techniques such as case note 
review and patient interview. There are advantages and disadvantages to using these 
methods; advantages include the ability to review potential medicines-related admissions on a 
case-by-case basis in real time. The disadvantages include having to rely on HCPs correctly 
identifying medicines-related problems and accurate information recall by patients.  
 
The studies demonstrate wide variation in the percentage of hospital admissions that are due 
to medicines-related problems; between 4.2% and 20.9% (Somers et al., 2010; Pedros et al., 
2014). The potential explanations for these differences are:  
• studies conducted in different countries with different healthcare systems and 
infrastructures. 
• various methods of identification of medicines-related admissions (as mentioned 
previously, some methods, such as medication chart review (Leendertse et al., 2010) 
result in higher percentages of medicines-related hospital admissions than other 
methods and combining different techniques is preferable to using only one technique 
(Morimoto et al., 2004; Kongkaew, Noyce and Ashcroft, 2008)). 
• retrospective and prospective study designs (retrospective data collection methods 
gave higher percentages of medicines-related admissions (Kongkaew, Noyce and 
Ashcroft, 2008; Dechanont et al., 2014)). 
• varying definitions of ADE and ADR. 
 
The majority of studies conducted in developed countries had a medication-related admission 
rate of between 4.2% and 6.5%. 
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Table 3-2 Individual studies of medication-related hospital admissions 
Study (year) Location 
and country 
of study 
Aim of study Number of 
participants 



















To evaluate the 
role of different 
types of drug-
related problems 
in causing hospital 
admissions. 




WHO criteria for 
ADRs. 
Expert opinion. 
16% Not stated. ADRs caused more 
admissions in women. 










520 Case note 
review. 
WHO criteria for 
ADRs. 
WHO criteria for 
causality. 
















To assess the 
incidence of drug-
related problems 
in elderly patients. 
1 011 Case note 
review. 
Hallas criteria for 
causality and 
preventability. 











To explore the 
impact of ADRs on 
NHS hospital in-
patients. 




definition of ADR. 
Naranjo criteria 
for causality. 
Hallas criteria for 
preventability. 
Hartwig scale for 
severity. 




ADRs more common in 
women, older patients 
and medical patients 
also link with number of 
medicines taken. 
Majority of ADRs caused 
by drug initiated in 
hospital. 
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4 093 Case note 
review. 










cardiac glycosides, and 
beta-blockers. 














347 Case note 
review. 
Hallas criteria for 
causality and 
preventability. 
10.8% Not stated. All medication-related 
admissions were judged 




















criteria for ADRs. 














related admissions were 
avoidable. 
Four variables predictive 
of experiencing an ADR: 
age, length of time since 
starting new drug, total 
number of prescribed 
medicines and type of 















12 793 Case note 
review. 










5.6% Not stated. Medication-related 
admissions more 
common in patients 
with impaired cognition, 
≥ 4 co-morbidities, 
dependent living, 
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EU definition of 
ADR. 
4.2% Diuretics, anticoagulants, 
antiplatelets, ACE inhibitors 
and angiotensin-2 receptor 
blockers, NSAIDs. 
ADRs causing admission 
more common in older 
patients and those 









To ascertain the 
burden of ADRs. 











Hallas criteria for 
preventability. 
6.5% Aspirin, NSAIDs, diuretics, 
warfarin, ACE/A2RAs, 
antidepressants, beta-
blockers, opioids, digoxin, 
prednisolone, clopidogrel. 
ADRs significantly more 
common in older 
patients and females. 





To determine the 




were admitted to 
hospital. 
5 757 Case note 
review. 
Hepler and Strand 
definition of drug-
related problems. 
0.63%** Cardiovascular drugs, 
electrolytic, caloric or water 
balance agents. 
 










in patients >65 





110 Case note 
review. 
WHO criteria for 
ADRs. 
Hallas criteria for 
drug-related 
problems. 
20.9% Central nervous system 
drugs, antidiabetics, 




medicines were the 
dominant reason for the 
admission or were partly 
the reason. 
Patients with drug-
related problems took 
significantly more 
medicines and were 
more likely to have been 
in hospital in the 
previous 6 months. 

















1 000 Case note 
review. 










11.5% Not stated.  
*Patients experiencing an ADR during their admission, but they may not have been admitted due to the ADR. 
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As well as the individual studies that are detailed in Table 3-2, a published paper was found 
that specifically focussed on the patient experience of a medicines-related hospital admission. 
The authors interviewed 15 people who had been admitted to hospital due to an ADR. The 
patients described the experience as frightening and also felt anger, isolation, resentment and 
blame. Patients felt that the information they received from the prescriber and 
communication should be improved (Lorimer, Cox and Langford, 2011). 
 
3.4.4.3 Studies using administrative data 
Several authors have used administrative data, such as HES, to investigate medicines-related 
hospital admissions on a population scale; these studies are summarised in Table 3-3. HES data 
analyses has shown that 0.35 – 0.90% of hospital admissions in England are due to medicines 
(Waller et al., 2004; Patel et al., 2007; Wu et al., 2010), and the majority of medicines-related 
admissions occurred in older people (Patel et al., 2007; Wu et al., 2010). This is a much lower 
percentage than from the systematic reviews and individual studies already summarised in 
Table 3-1 and Table 3-2. This discrepancy could be as a result of using routinely collected data; 
with issues of data quality due to so many different individuals entering information leading to 
errors during data entry and inconsistencies in coding across different Trusts, along with mis-
coding by clinicians. Also, the HES data only cover England, not Scotland or Wales, which could 
limit generalisability in these populations. Despite these limitations, HES provide a source of 
vast amounts of data which can still be useful when attempting to discover temporal trends. 
This was the rationale for conducting preliminary work using the HES database; it allowed an 
assessment to be made about whether medicines-related hospital admissions were still a 
problem and were therefore a worthy area for research. 
 
Another study that utilised HES data to identify factors in primary care that were associated 
with ADR-related hospital admissions between 2010 and 2012 did not report a rate of ADR-
related admissions and therefore was not suitable for inclusion in Table 3-3. This study utilised 
85 International Classification of Diseases, 10th Edition (ICD-10) codes which indicated an ADR 
had occurred as well as the ‘external’ codes which detailed the medicines involved in a 
hospital admission. The authors showed that ADR-related hospital admissions were more 
common in very young children, older people and women. Higher rates of ADR-related 
admissions were also seen in patients with higher deprivation scores amongst other measures 
(McKay et al., 2015). 
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Table 3-3 Studies utilising HES and HES-type data 








Garrido et al., 
(2010) 
2001-2006 Spain. To estimate the burden 
of hospital admissions 
for ADRs. 
173 ‘external 
cause’ codes from 
ICD-9. 
1.69% Drugs most commonly associated with an ADR-related hospital 
admission were antineoplastic and immunosuppressive agents, 
corticosteroids, anticoagulants and antibiotics. 
The rate of ADR-related hospitalisation was 35.9% in patients 
75 years and over.  
Patel et al., 
(2007) 
1998 - 2005 England. To examine the 
epidemiology of 
hospital admissions for 
ADRs, the age 
distribution and their 
impact on hospital 
activity. 
85 ICD-10 codes 
which contained 
the words ‘drug-
induced’ or ‘due 
to a drug’ plus ‘Y 
external cause’ 
codes. 
0.5% Five fastest growing ADRs were: induced haemolytic anaemia, 
nephropathy, adrenocortical failure, cardiomyopathy and 
aplastic anaemia. The five fastest growing ADRs as external 
causes were drugs relating to: water balance, autonomic 
system, CNS stimulants, cardiovascular system and 
biologics/vaccines. 






2000-2005 Netherlands. To study the 
differences in ADR-
related hospitalizations 







0.44% Drugs most commonly associated with hospitalizations: 
antineoplastic and immunosuppressive drugs, anticoagulants 




2003 - 2007 Germany 
(From 2003-
2006; 72-79% of 
all admissions, 
for 2007; 10% 
sample of all 
hospitals in 
country). 
To assess the frequency 
and type of drug-
related admissions and 
hospital acquired ADEs. 
505 ICD-10 codes 
indicating an ADE. 
0.54 – 0.67% Figure is for admissions that were very likely caused by drug-
related problems. 
5% of admissions were possibly drug-related. 
Most common cause of DR admission was enterocolitis 
Clostridium difficile.  
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Waller et al., 
(2004) 
1996 - 2000 England. To review and describe 
HES data coded as ‘drug 
induced’ to assess the 
public health impact of 
ADRs. 
59 ICD-10 codes 
including the 
words ‘drug-
induced ‘or which 
indicated ‘due to 
a drug’ or a 
definite ADR plus 
‘Y external cause’ 
codes. 
0.35% Largest group of drug–induced admissions were mental 
disorders caused by opioids or multiple psychoactive drugs. 
When this group was combined with mental disorders due to 
sedatives/hypnotics they accounted for 74-78% of all drug-
induced admissions each year. 
Wu et al., 
(2010) 
1999 – 2009 England. To analyse trends in 
hospital admissions 
associated with ADRs. 
85 Primary or 
secondary ICD-10 
codes indicating 
an ADR plus ‘Y 
external cause’ 
codes. 
0.9% Most common drug group implicated in ADRs were systemic 
agents (19.2%), analgesics (13.3%) and cardiovascular drugs 
(12.9%). 58.5% of ADR admissions were for patients >65 years, 
median age 70 years.  
No differences in ADRs admissions based on socioeconomic 
status. 
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3.4.4.4 Which medicines are most implicated in hospital admissions? 
The studies summarised in Table 3-1, Table 3-2 and Table 3-3 show that the medicines most 




• Cardiovascular medicines including diuretics, cardiac glycosides and beta-blockers 
• Central nervous system medicines including anti-epileptics, medicines for Parkinson’s 
Disease and anti-depressants 
• Corticosteroids 
• Cytotoxic medicines 
• Medicines used in the treatment of diabetes mellitus 
• NSAIDs 
• Opioid analgesics 
 
Examples of adverse events that are associated with these medicines are gastrointestinal 
toxicity with antiplatelets or NSAIDs, failure to optimise treatment for patients with 
cardiovascular conditions leading to angina or exacerbations of heart failure, and 
subtherapeutic doses of antiepileptic medicines resulting in seizures (Howard et al., 2003). 
 
The medicines that were most likely to cause a medicines-related hospital admission were 
relatively consistent across studies and the method of data collection did not appear to alter 
the list. 
 
These studies have shown that medicines make a significant contribution to hospital 
admissions, not only in England but around the world and therefore are not dependent on the 
way healthcare is funded in a particular country. This is an indication of a global issue, 
suggesting that research is important in this area to try and reduce the burden of medicines-
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3.4.5 Medicines-related readmissions to hospital 
NICE have highlighted that when patients are discharged from hospital, this transition of care 
can be a time of heightened risk due to errors or unintended changes in medication, with 30% 
to 70% of patients affected (NICE, 2015c). A study conducted by Moore et al. (2003) in the US, 
investigated medicines-related errors that occurred when patients were discharged from 
hospital. They found that 42% of the 82 patients in their study experienced at least one 
medication-related error (Moore et al., 2003). A systematic review has shown that during 
transitions of care, 34% of unintended discrepancies are clinically significant and medicines 
reconciliation alone is insufficient to prevent medicines-related hospital readmissions due to 
these discrepancies (Kwan et al., 2013). A further systematic review has shown that only 55% 
of discharge summaries were available to primary care physicians within 48 hours of the 
patient being discharged from hospital and there were deficiencies in the information 
provided especially around diagnostic tests performed, outstanding test results and 
medications (Kattel et al., 2016). 
 
Table 3-4 summarises individual studies that have focussed on medicines-related hospital 
readmissions. 
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Table 3-4 Individual studies of medication related hospital readmissions 




Aim of study Number of 
participants 







































76% of medication 
related 
readmissions were 















To assess the 


























and result was 
non-significant. 





To evaluate the 
impact of ADRs 
on 
readmissions 
after a period 
as an in-
patient. 



















caused 1/3 of 
readmissions 
within 28 days. 
Increasing age was 
a significant factor 
in readmissions 
overall. 









To determine if 



















6 months. 4.2% CNS drugs, 
Electrolytic, 








number of ADRs 
significantly 
prolonged length 
of stay in hospital. 
44.3% of ADRs 
were judged to 
have been 
preventable. 

























from Institute of 
Medicine 
report, ‘To err is 
human’. 













91% ADEs were 















over the age of 
















the risk of 
readmission for 
ADRs (odds ratio 




considered to be 
avoidable. 
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in older adults; 
to describe the 








with harm.  















8 weeks. 7.8% Opioids, antibiotics 
and 
benzodiazepines. 





It was estimated 
that post-discharge 
medication-related 
harm cost the NHS 
£396 million per 
year, of which 90% 
was due to 
readmissions, and 
£243 million was 













































mainly due to gaps 
in communication. 
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increased risk of 




and the higher the 





























30 days. 4.3% Not stated. No readmissions 
were coded as 
being due to ADEs 






















































within 28 days. 









of medicine to 
readmission. 







judged to have 
been preventable. 




more than one 
medication-related 












trends in ADRs 
causing 
readmissions. 





















increases with age 
and is significantly 
higher for patients 
over 80 years 
compared to 
younger patients. 










due to ADRs. 





















*Patients in these studies had already experienced an ADR-related hospital admission. 
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Table 3-4 shows that medicines are responsible for 4.2% to 38% (Dormann et al., 2004; 
Witherington, Pirzada and Avery, 2008) of hospital readmissions but this was dependent of the 
study. The largest observational studies show a medication-related readmission rate of 
between 4.5% and 18.4% (Zhang et al., 2006; Ruiz et al., 2008). Many studies assessed a 
significant number of medication-related readmissions as preventable; range 22% to 87% 
(Rothwell et al., 2011; Hauviller et al., 2016). These percentages vary considerably due to 
differences in the populations being studied and the methods used to determine the number 
of medicines-related readmissions. 
 
Many of the studies presented in Table 3-4 have also examined the medicines implicated in 
readmissions. Unsurprisingly, the medicines involved in readmissions are very similar to those 
involved in admissions; i.e. antiplatelets, anticoagulants, NSAIDs, cardiovascular medicines, 
and anti-epileptics (Davies et al., 2010; Forster et al., 2005; Moore et al., 2003; Ruiz, Garcia, 
Aguirre, & Aguirre, 2008). 
 
3.4.6 Tools to identify patients at risk of medicines-related problems 
The published evidence presented thus far demonstrates that strategies are required to try 
and reduce medicines-related admissions and readmissions. Certain patient groups or patients 
with particular co-morbidities have higher rates of readmission than others and several tools 
have been devised to try and predict the patients who are at highest risk of hospital 
readmission. These risk stratification strategies could allow targeted interventions to be 
implemented for certain patients with the aim of reducing the risk of emergency hospital 
readmissions. In the current financial climate, resources need to be targeted towards those 
that will gain most benefit; the tools that are described in the following section allow 
stratification and identification of those patients.  
 
Tools to identify patients at risk of hospital readmission have been developed in other 
countries such as the LACE index in Canada which used length of stay, acuity of admission, co-
morbidities and ED visits in the previous six months as indicators (Van Walraven et al., 2010). 
When tested in a cohort of 507 older patients in England it was judged to be only ‘fair’ at 
predicting readmission or death (Cotter et al., 2012). In another study conducted at a trust in 
central England (n=91,922), it performed no better than clinical judgement and only 25% of 
readmitted patients were those with the highest scores, indicating the highest risk of 
readmission (Damery and Combes, 2017). 
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Another, more complex tool, that has been validated in various non-UK populations is the 
HOSPITAL score which uses haemoglobin, contact with an oncology service, sodium level, 
procedure during hospital stay, acuity of index admission, number of hospital admissions in 
the previous year and length of stay as indicators (Donze et al., 2016). This tool has not been 
validated in the UK population but when trialled on over 19,000 patients in Denmark it did not 
perform well and the research team acknowledged that complex elements including medical, 
social and environmental factors can also determine readmission (Cooksley et al., 2016). 
 
In England, the Nuffield Trust1 have devised the PARR-30 tool which is designed to predict the 
risk of hospital readmission within 30 days of an initial discharge. The PARR-30 tool used a 10% 
sample of all NHS hospital admissions over a one year period to derive the factors that could 
predict hospital readmissions (Nuffield Trust, 2012). This tool calculated a risk of readmission 
by applying a coefficient to a score that included the following parameters: NHS organisation 
of admission, age, postcode (to determine deprivation level), number of emergency 
admissions in previous 30 days, acuity of admission and past medical history of certain 
conditions (Billings et al., 2012). 
 
The tools mentioned above are focussed on preventing readmissions due to all causes and not 
those specific to medicines. In some areas of England, efforts have been made to identify a 
wide variety of risk factors for a preventable medicines-related hospital readmission and to 
use these as indicators of patients that may require additional support when they transition 
from one setting to another. In London, the Integrated Medicines Management Service (IMM) 
have devised the PREVENT tool which includes the following parameters: physical impairment, 
frailty, adherence issues, cognitive impairment, new diagnosis or exacerbation of existing 
condition, medicines-related admission or risk from specific medicines and cultural and social 
factors (Barnett, Athwal and Rosenbloom, 2016). The PREVENT intervention involves 
medicines reconciliation, medicines optimisation, patient-centred consultations, enhanced 
communication between secondary and primary care, discharge planning, pre-discharge 
referral to primary care services and post-discharge telephone follow-up (Barnett et al., 2017). 
 
 
1 The Nuffield Trust is an independent think tank which aims to improve the quality of healthcare in the 
UK by providing evidence-based research and policy analysis and informing and generating debate. 
www.nuffieldtrust.org.uk/about 
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Similar IMM schemes have been shown to be effective at reducing preventable medicines-
related readmissions in Sweden (Hellström et al., 2011), the prevalence of medication errors at 
discharge in Ireland (Grimes et al., 2014) and the identification of medication discrepancies 
that would have resulted in long-term adverse effects in Norway (Nilsson et al., 2015). 
 
Between October 2008 and October 2014, 744 patients were assessed and supported by the 
team using the PREVENT tool in London. Of this cohort, 119 patients (16%) were readmitted 
within 30-days but only two (1.7%) of the 119 readmissions were deemed to have been 
preventable. In contrast, there were 17 readmissions (18.5%) in the control group of 92 
patients and of these, four (23.5%) were preventable (Barnett et al., 2016, 2017). Based on the 
published literature, the authors estimated that 18 (2.4%) to 74 (10%) of patients in the 
original cohort would have been expected to experience a preventable medicines-related 
hospital admission but in reality the number was much lower (Barnett et al., 2017). Most 
pertinent for the health economy at the current time was the finding that for every £1 spent 
on pharmacist time, £3 was saved (Barnett et al., 2016). A similar scheme in Northern Ireland 
estimated that £5 to £8 was saved for each £1 spent on such an intervention (Scott et al., 
2015). The use of tools such as PREVENT could be expanded into other geographical areas in 
England to determine whether they could successfully reduce medicines-related hospital 
readmissions there also. 
 
Another tool that has been developed in England is the PINCER tool. This tool has been 
designed to identify patients in primary care who are prescribed medicines that are frequently 
connected with medication errors, a consequence of which could be a medicines-related 
hospital admission or readmission. The study involved a pharmacist-led intervention that 
utilised data on the GPs’ computer system to identify patients at risk of specific medicines-
related problems. The study population included over 480,000 patients. If patients fell into any 
of the chosen categories, the computer system would identify them, the pharmacist would 
educate the practice team about the problems and support them to resolve the issued 
identified. The results of the study showed that the intervention had a statistically significant 
effect on reducing the incidence of the prescribing problems that it intended to resolve (Avery 
et al., 2012). 
 
These studies have shown that there is some published evidence supporting the use of 
pharmacist follow-up of patients after a hospital admission to reduce the risk of a medicines-
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related readmission. The next section will focus on the evidence base for medication review to 
reduce medicines-related admissions and readmissions to hospital. 
 
3.4.7 The role of medication review and community pharmacists 
Although some tools have shown promise, there have not been any large-scale trials to 
demonstrate they are generalisable to larger sections of the population. Medication review 
has been suggested as one way of reducing medicines-related admissions and readmissions. As 
previously mentioned, the term medication review encompasses a number of different 
processes provided by various HCPs, working in a variety of settings with access to varying 
amounts of information about the patient, their morbidities and medication. This current 
study focussed on medication review by community pharmacists in England. 
 
Other authors have also highlighted the important role that community pharmacists can play 
in reducing medicines-related readmissions. Barnett and Blagburn, (2016) have highlighted five 
challenges that clinicians and managers in the NHS must overcome when trying to prevent 
medicines-related readmissions: 
1. The complexity of ICD coding and HES data which are prone to human error. 
2. Published evidence around medicines-related readmissions is mainly from North 
America rather than the UK. 
3. Identification of patients at high risk of readmission is difficult and prediction models 
are not very sensitive or accurate. 
4. There are a multitude of factors affecting medicines-related readmissions and those 
around the health beliefs of the patient may need to be addressed through behaviour 
change. 
5. Financial pressures mean that high-resource interventions may be hard to justify. 
 
They suggest four of ways of reducing medicines-related readmissions, all of which can be 
facilitated by community pharmacists alone or working in conjunction with other HCPs: 
1. Medicines reconciliation on admission and discharge. 
2. Person-centred patient education. 
3. Shared decision-making. 
4. Follow-up through community pharmacy. 
(Barnett and Blagburn, 2016) 
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Specifically, the follow-up by patients in community pharmacy through the use of the NMS or 
PD-MURs would enshrine the role of the community pharmacist as fundamental to the smooth 
transition of care when patients are discharged from hospital. 
 
The next part of the literature review is focussed on the evidence for medication review when 
conducted by community pharmacists and whether there is a mandate for this to become a 
compulsory part of post-discharge patient care. 
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3.5 Medication review 
 
Figure 3-5 Literature review: Area Three – Medication review 
 
It is well known that medicines-related problems occur after hospital discharge and they can 
be due to a number of factors, particularly poor communication during the transition period 
and patients who are not clear about the medicines they should take. In their Medicines 
Optimisation guideline NICE have stated that 30-70% of patients have an unintended change 
or error in their medicines when they move from one care setting to another (NICE, 2015c). 
Only 10% of patients are discharged from hospital taking the same medicines as on admission 
and changes to medicines are linked to increased mortality at three months post-discharge 
(Mansur, Weiss and Beloosesky, 2008). Over 60% of patients have three or more changes to 
their medicines whilst in hospital (Himmel et al., 2004). A systematic review of 20 studies 
found that combining hospital discharge measures, such as discharge planning, with home 
follow-up was beneficial to reduce medicines-related problems in older people after discharge 
(Garcia-Caballos et al., 2010). 
 
3.5.1 Medication reviews 
This section will focus on systematic reviews of medication review with the aim of providing an 
overview of the current published evidence. It focuses on services that are provided by 
community pharmacists but also includes some interventions delivered by other HCPs in 
various settings. When appraising the various systematic reviews, it became apparent that 
many of them included studies that were not specific to community pharmacists or the 
community pharmacy setting. There appeared to be a lot of studies but when the detail was 
inspected, they did not reflect the real-world situation and were either experimental or the 
Opinions and experiences of those involved in the medication 
review process
Medication review
Medicines-related admissions and readmissions
Hospital admissions and readmissions
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HCPs and settings were heterogenous. The combination of RCTs and non-RCTs in meta-
analyses also confounded the analyses and conclusions that were drawn in some reviews. 
 
3.5.1.1 Umbrella reviews and overviews of systematic reviews 
Ryan et al., (2014) updated a Cochrane overview of systematic reviews that was first published 
in 2011. They found 75 systematic reviews of interventions to improve the safe and effective 
use of medicines by consumers. The study populations, interventions and outcomes of the 
systematic reviews were diverse and were not limited to community pharmacy or pharmacists. 
The authors concluded that pharmacist-led interventions such as medicines reviews and 
pharmaceutical care showed positive effects on adherence, resolution of medicines-related 
problems, reduced prescribing of unnecessary medicines and increased patient knowledge 
about their medicines. More evidence was needed around how pharmacists could benefit 
patients under their care and there was a lack of evidence of benefit for interventions that 
targeted patients with multimorbidity who were subject to polypharmacy (Ryan et al., 2014). 
 
An umbrella review of community pharmacist interventions was published in 2013 by UK 
based authors (Mossialos, Naci and Courtin, 2013). The authors noted that numerous 
systematic reviews already existed which had attempted to summarise the evidence for 
various interventions, but whether the experimental studies contained in the systematic 
reviews were suitable for policy-making was not clear. The authors included 33 systematic 
reviews in their study. The inclusion criteria aimed to ensure that all the included systematic 
reviews focussed on community pharmacist interventions conducted in out-patient settings. 
The strongest themes to emerge were around the heterogeneity of the studies included in the 
systematic reviews: there were different HCPs delivering the interventions in the studies, 
interventions and outcomes were not well defined, they were conducted in various settings 
and RCTs and non-RCTs were combined for analyses. This made the interpretation of the 
results difficult. The authors also questioned whether RCTs were the best method to assess the 
effectiveness of interventions by community pharmacists due to the Hawthorne effect and 
they postulated that observational studies may be better suited to this area of research. The 
results of some of the included systematic reviews showed community pharmacists could 
benefit patients in terms of increasing the safe, effective and appropriate use of medicines but 
many were inconsistent or inconclusive. The authors concluded that there was insufficient 
evidence from their umbrella review to show the benefit of extending the role of community 
pharmacists. They questioned whether the current policies of expanding the community 
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pharmacists’ role with increased funding were justified when the underpinning evidence was 
not conclusive (Mossialos, Naci and Courtin, 2013). 
 
Since the start of the current study, an overview of systematic reviews that concerned 
specifically pharmacist-led medication reviews in community settings was published in 2017 
(Jokanovic et al., 2017). This comprehensive evaluation of 31 systematic reviews included 297 
unique primary studies of pharmacist-led medication review. The authors concluded that 
pharmacist-led medication review had positive impacts on blood pressure, glycosylated 
haemoglobin (HbA1c), blood pressure and the number and appropriateness of medications 
(Jokanovic et al., 2017). This overview appeared to provide a useful summary of the published 
systematic reviews on this topic but on further investigation there were some important 
differences between the included systematic reviews and the focus of this study. 
 
The included systematic reviews used the Australian definition of ‘Home Medicines Review’, 
which is the equivalent of a clinical medication review in the UK (see section 2.1.1); this is a 
step-up from the MUR service provided by community pharmacists where the only 
information sources are the patient and details of their medicines (Blenkinsopp, Bond and 
Raynor, 2012). The inclusion criteria for the included systematic reviews meant that 
interventions had to involve pharmacists but ultimately, less than half of the included reviews 
were focussed only on pharmacist-led medication reviews. Likewise, only two reviews were 
solely located in community pharmacies, the remainder included patients’ homes, outpatient 
and specialist clinics (Jokanovic et al., 2017). 
 
The authors did complete a very comprehensive and transparent quality assessment of the 
included reviews and ensured that only moderate and high-quality reviews were included, but 
it was noted that the systematic reviews included did themselves incorporate all study designs 
not just RCTs. Unsurprisingly, the systematic reviews with the highest quality ratings were 
Cochrane reviews (Jokanovic et al., 2017). Meta-analyses of the systematic reviews were 
assessed particularly with regard to hospitalisations and mortality. Concerning hospitalisations 
and whether pharmacist-led medication review had any effect, the results were contradictory 
(Jokanovic et al., 2017). It was noted that in one particular meta-analysis, RCT and non-RCT 
studies had been combined to suggest that clinical medication reviews significantly reduced 
hospitalisations. When the non-RCT studies were removed from the meta-analysis, the result 
was non-significant (Hatah et al., 2014). This highlighted the difficulties faced when conducting 
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systematic reviews and meta-analyses of heterogenous primary studies. Regarding mortality, 
which two of the meta-analyses analysed, no significant effect was found for pharmacist-led 
medication review. The authors of the overview acknowledged that more RCTs were required 
to investigate whether pharmacist-led medication reviews have any effect on hospitalisations 
or mortality (Jokanovic et al., 2017).  
 
The Centre for Policy on Ageing, a charity established by the Nuffield Foundation (Centre for 
Policy on Ageing, 2018), published a rapid review of the effectiveness of community pharmacy 
MURs in 2014 that included an overview of systematic reviews. Their summary of evidence 
found that MURs reduced the risk of medicines-related problems and improved the 
appropriateness of medicines, but there was not definitive evidence that cost-effectiveness 
was improved. The effect of MURs on hospital admissions and mortality was also unproven 
(Centre for Policy on Ageing, 2014). The report based its conclusions on various published 
papers, although the search strategy was not included to allow an assessment of how 
thorough the literature review was. The reviews that were included did focus on practice in 
England and arguably provided a better summary of evidence of MURs compared to other 
international reviews such as that by Jokanovic et al., (2017). 
 
There was evidence that increased community pharmacist-GP collaboration was possible when 
they were co-located, and this had benefits for the patients in terms of implementation of the 
pharmacists’ recommendations (Jokanovic et al., 2017). This is a very complex area to explore 
and gain meaningful and explicit results due to the complex interplay between the settings of 
the interventions, how the invention was delivered, the context and priorities of the health 
system and the patient groups selected for study. 
 
3.5.1.2 Systematic reviews of community pharmacist-led medication review 
Table 3-5 provides an overview of the systematic reviews that have been published focussing 
on medication review provided by community pharmacists. 
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Table 3-5 Summary table of systematic reviews of pharmacist-led medication review 








age of patients 
included 













Not reported. A: To identify and assess the 
evidence for community 
pharmacy-based 




Diabetes control, adherence, 
medication problems, patient 
knowledge. 
No meta-analysis conducted. 
There is some evidence that 
community pharmacy-based 
services improve diabetic 
control, increased adherence 
and patients are more likely 
to make lifestyle changes. 
Community pharmacists were 
positive about their extended 
role. 
Only 2 studies included any 





16 RCTs in 
systematic 












3 032 in 
systematic 





A: To conduct a systematic 
review and meta-analysis of 
RCTs concerned with 
community pharmacist-led 
interventions on blood 
pressure (bp) control in 
hypertensive patients. 
I: Community pharmacist-led 
interventions for bp control 
(patient education on 
hypertension and lifestyle, 
management of prescribing 
and safety of medicines). 
Reductions in systolic and 
diastolic blood pressures 
measured in the community 
pharmacy or at home. 
Meta-analysis conducted. 
Statistically significant 
reductions in systolic and 
diastolic bp, p<0.00001. 
Intervention conducted only 
by community pharmacists. 























ages of patients 
not stated. 
A: To conduct a systematic 





conducted by pharmacists. 
Efficacy and cost. 
No meta-analysis conducted. 
7/8 RCTs of medication 
review or patient-specific 
prescribing advice showed 
statistically significant results 
(e.g. reductions in bp, 
cholesterol, drug-related 
problems) and 1/8 presented 
cost-effectiveness data with 
no significant effect of 
intervention on cost-
effectiveness. 
Included studies were 
heterogenous and therefore 
difficult to summarise. Hard 
to generalise results as often 
RCTs involved a single 
pharmacist/setting. 












ages of patients 
not specified for 
all studies. 
A: To systematically review 
the literature on the impact 
of pharmacist and GP 
collaboration and the 
outcome on their patients’ 
health. 
I: Collaboration between 
pharmacists and GPs. 
Various different 
interventions included. 
Various different outcome 
measures included. 
No meta-analysis conducted. 
9/77 studies focussed on 
hospitalisations as main 
outcome measure but 
conflicting results as to 
whether medication review 
had any significant effect. 
Cooperation between 
patients and HCPs resulted in 
increased identification and 
resolution of medicines-
related problems. 
Medication reviews were 
conducted in various settings 
including the community 
pharmacy, the GP surgery or 
the patient’s home. Many of 
the studies were not able to 
recruit the number of 
patients they had intended to 
ensure the studies had 
sufficient power. None of the 
included studies from the UK 
were conducted on the 
community pharmacy MUR 
service, the majority of UK 
studies were conducted 
before the introduction of 
MURs.  
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Hatah et al., 
(2013) 
21 of 36 studies 







cohort studies in 















Ages of patients 
not stated. 
A: To examine the impact of 
fee-for-service pharmacist-led 
medication review, of various 
types, on patient outcomes. 
I: Medication-review service 
provided by pharmacists 
involving pharmaceutical 
care. 
9/21 studies were conducted 
in community pharmacies. 
5/21 studies used adherence 
reviews i.e. MUR type 
reviews. 
Mortality, hospitalisation, 
clinical outcome measures or 




review significantly reduced 
bp (OR 3.50, 95% CI 1.58-
7.75, p=0.002) and low-
density lipoprotein (OR 2.35, 
95% CI 1.17-4.72, p=0.02). 
There was no significant 
effect on hospitalisations (OR 
0.69, 95% CI 0.39-1.21, 
p=0.19) or mortality (OR 1.50, 
95% CI 0.65-3.46, p=0.34). 
When sub-groups were 
analysed, clinical medication 
review reduced 
hospitalisations (OR 0.46, 95% 
CI 0.26-0.83, p=0.01) but not 
adherence support reviews 
did not (OR 0.88, 95% CI 0.59-
1.32, p=0.54). 
When the non-RCT studies of 
clinical medication review 
were removed from the 
meta-analysis there was no 
significant effect on 
hospitalisations. This study 
did conclude that both clinical 
and adherence reviews 
increased patients’ adherence 
to their medication. 
Pharmacists were 
remunerated for the services 
provided as per the MUR 













Singapore 1 UK 
13 
US 10 




A: To evaluate and quantify 
the effects of medication 
review by pharmacists on 
clinical outcomes. 
I: Pharmacist-led medication 
review. 
Emergency hospital 
admissions and mortality. 
Meta-analysis conducted. 
Hospital admissions; relative 
risk (RR) 0.99 (CI 0.87-1.14), 
p=0.92. 
Mortality RR 0.96 (CI 0.82-
1.13), p=0.62. 
Number of drugs prescribed 
was slightly reduced. 
Some increases in patient 
knowledge and adherence to 
medicines but no effect on 
quality of life (QoL). 
Only 3 included studies were 
conducted in community 
pharmacies. 

























Ages of patients 
not stated. 
A: To examine the effect of 
pharmacists non-dispensing 
roles on patients’ and health 
professionals’ outcomes. 
I: Studies included focused 
on: 
1. Pharmacist services for 
patients versus services 
delivered by other health 
professionals. 
2. Pharmacist services 
targeted at patients versus no 
service. 
3. Pharmacist services 
targeted at health 
professionals versus the 
delivery of no comparable 
service. 
Various different outcomes 
included. 
No meta-analysis conducted. 
1. 1 study – significant 
improvement in bp for 
patients cared for by 
pharmacist compared to 
doctor. 
2. 5 studies – pharmacists 
reduced therapeutic 
duplication and reduced the 
number of medicines 
prescribed. 
Pharmacists were able to 
have statistically significant 
effects by reducing systolic 
and diastolic bp and HbA1c. 
3. 2 studies showed 
statistically significant 
improvements in prescribing 
patterns. 
Pharmacists were in out-
patient settings which could 
include out-patient clinics at 
hospitals. 
 
Royal et al., 
(2006) 
38 studies in 
systematic 























A: To identify and evaluate 
interventions in primary care 
aimed at reducing 
medication-related adverse 
events that result in 
morbidity, hospital 
admissions or mortality. 
I: Interventions in primary 




hospitalisation and death. 
15/38 studies reported 




review significantly reduced 
hospitalisations (OR 0.64, 95% 
CI 0.43-0.96) but restricting 
the analysis to RCTs only 
showed no significant effect 
on hospitalisations (OR 0.92, 
95% CI 0.81-1.05). 
No evidence of benefit of 
interventions conducted by 
other HCPs in primary care. 
Lack of high-quality studies of 
effect of medication reviews 
on hard outcomes. 






20 RCTs in 
systematic 
review. 












2 774 in hospital 
intervention 
studies. 







A: To evaluate the 
effectiveness of interventions 
led by hospital or community 
pharmacists to reduce 
unplanned hospital 
admissions in older people. 
I: 3/9 trials of intervention in 
community pharmacies. 
5/9 trials were of community 
pharmacists conducting home 
medication review (HMR) 
with access to medical notes. 
1/9 trials of medication 





No reduction in unplanned 
hospital admissions, relative 
risk (RR) 1.08 (95% CI 0.96-
1.21). 
No effect when trials were 
analysed for admissions at 3, 
6 or 12 months. 
Interventions by hospital 
pharmacists also did not have 
any effect on hospital 
















(paper does not 
say why this is 
greater than 44).  
Individual 
studies included 





A: To assess the effect of 
medication management 
therapy interventions among 
outpatients with chronic 
illnesses. 
I: Medication therapy 
management: comprehensive 
medication review, patient 
directed education, care co-
ordination and opportunity of 
follow-up; delivered by a 
pharmacist. 
Medication-related problems, 
morbidity, mortality, quality 
of life, health care use, costs, 
and harms 
Meta-analysis conducted. 
No effect on overall 
hospitalisations (p=0.412) but 
reduced hospitalisations for 
patients with diabetes OR 
0.91-0.93 and heart failure OR 
0.55 (95% CI 0.39-0.77). No 
difference in the number of 
outpatient visits (p=0.247). 
Improved medication 
appropriateness (p<0.001), 
adherence and reducing 
dosing. 
Only 16 studies described 
interventions conducted in a 
community pharmacy and 
only 22 studies described 
face-to-face interventions. 
No evidence that medication 
therapy management 
improved outcomes globally 
regardless of study design. 
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These systematic reviews have highlighted the large number of variables that exist when 
conducting research in this area that give a high level of heterogeneity and mean there are 
inherent difficulties comparing and interpreting the findings of the various reviews. The 
variables are listed below: 
• Types of study - different types of study have been included in the reviews i.e. RCTs, 
cohort studies, etc. There has been some debate about whether this is appropriate, 
one published paper has suggested that the advantages of combining different types 
of study in a systematic review outweigh the disadvantages although combining 
outcome data in a meta-analysis was more complex (Shrier et al., 2007). 
• HCPs conducting medication reviews – different HCPs delivered the medication 
reviews e.g. GPs, community pharmacists. 
• Settings - medication reviews were conducted in various settings e.g. patients’ homes, 
GP surgeries, pharmacies, nursing or care homes, hospitals. 
• Study population - some of the primary studies were conducted in specific populations 
e.g. those with specific conditions or over a certain age. 
• Level of medication review - different levels of medication review have been 
conducted in the studies and it was not always clear from the systematic reviews 
which level had been included. 
• Experimental or ‘real-world’ settings - primary studies have been conducted in 
experimental and ‘real life’ situations and combining them could be challenging. 
• Remuneration – following on from the above point, medication review in the real 
world is remunerated in several countries and it is not always clear whether the 
studies of medication review fell into this category. 
• Country of study – various healthcare systems exist in the countries of study so 
comparing interventions could prove troublesome. 
• Outcome measures – various measures have been used to determine the 
effectiveness of medication review e.g. ‘softer’ outcomes such as adherence and 
patient knowledge, ‘medium’ outcomes such as blood pressure, cholesterol, blood 
sugar control and ‘hard’ outcomes such as hospital admissions or mortality. 
• Study quality – the studies included in the reviews were of variable quality and 
consequently the risk of bias varied. 
 
The systematic reviews included in Table 3-5 did not find any definitive effect of medication 
review for the general population on hospital admissions. In smaller cohorts of patients with 
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specific conditions, such as diabetes or heart failure (Viswanathan et al., 2015), or for more 
intensive variants of medication review (Hatah et al., 2013) there appears to be some evidence 
that medication review has a beneficial effect on these outcomes. 
 
A very recent systematic review and meta-analysis by Huiskes et al., (2017) was not eligible for 
inclusion in Table 3-5 as it focussed on medication review in the normal clinical practice and 
did not restrict studies according to the HCP conducting the review or the setting. The authors 
included 31 RCTs in their best evidence synthesis and conducted various meta-analyses. It 
warrants inclusion here as the authors conducted a meta-analysis that focused on the ‘hard’ 
outcomes of mortality and hospital admissions. Meta-analysis of 11 studies showed that 
medication review had no effect on mortality, RR 0.94 (95% CI 0.76-1.17) and meta-analysis of 
five studies, that included over 2000 patients, found no effect on hospital admissions, RR 0.94 
(95% CI 0.81-1.08). The only statistically significant result was a reduction in the risk of falls, RR 
0.68 (95% CI 0.52-0.90) (Huiskes et al., 2017).  
 
At the current time, it appears that there are no published systematic reviews that investigate 
solely community pharmacist delivered, remunerated medication reviews, conducted in a 
community pharmacy, and focussed on hard outcomes such as hospital admissions or 
mortality. Some authors have suggested a large-scale RCT to determine whether remunerated 
community pharmacist MURs have any effect on hospital admissions or mortality (Holland et 
al., 2008; Geurts et al., 2012) and if studies such as these were conducted a systematic review 
would be possible. 
 
In 2016, the Chief Pharmaceutical Officer (CPO) for England commissioned an independent 
review of community pharmacy clinical services which was conducted by Richard Murray 
(Murray, 2016). This was not a systematic review but aimed to provide an overview of the 
evidence-base. This was deemed necessary because of the opportunities for new models of 
working in community pharmacy based on the proposals in the Five Year Forward View 
published by NHS England in 2014 (NHS England, 2014) and the General Practice Forward View 
in 2016 (NHS England, 2016a). These two reports highlighted, amongst other things: 
1. the greater potential input of pharmacists to urgent and emergency care. 
2. the roll-out of clinical pharmacists working in GP practices. 
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As part of the CPO’s independent review, a rapid review of the evidence around clinical 
services commissioned from community pharmacies was compiled (Wright, 2016). This rapid 
review searched for ‘primarily systematic reviews’ that provided evidence for the effectiveness 
or otherwise of various clinical services including MURs. Ultimately, very few studies were 
included in the rapid review and those that did, concentrated on the patient’s perspective and 
included both MURs and MUR-like services. The review found that there were no RCTs that 
evaluated the effectiveness of MURs from the patient’s perspective; although at the time of 
the report a study was underway in Italy (Wright, 2016). Since the rapid review was written, 
the results of the Italian RCT have been published. Even though the study only recruited 816 of 
the 1800 intended patients, they found that MURs conducted by community pharmacists for 
patients with asthma significantly improved their asthma control, as measured using the self-
completed Asthma Control Test scoring system with an OR of 1.76 (95% CI 1.33-2.33) and a 
number needed to treat (NNT) of 10 (95% CI 6-28). They also significantly reduced the number 
of active ingredients prescribed, increased adherence and were cost-effective (Manfrin et al., 
2017). 
 
Based on the rapid review written by David Wright (Wright, 2016), the Murray report (Murray, 
2016) recommended that the MUR service should be redesigned with a MUR as a full clinical 
medication review, with an independent prescriber, who has full access to the patient’s 
medical record at the time of the review. In the meantime, MURs should be enhanced to 
include follow-up and monitoring of the patient with a focus on optimising medication and 
providing information for those with long-term conditions to enable them to stay well 
(Murray, 2016). 
 
Professor Wright also explained in a commentary piece how he thought the MUR service 
should be changed. He felt that the service had problems that had not been resolved since its 
inception. One of the main issues was that the service is based on remuneration, which drives 
service provision rather than focussing on the quality or outcomes of the service; in his opinion 
this is not how healthcare should be commissioned. He believes that the MUR service should 
be redesigned so that GPs refer patients to community pharmacists and the MUR process 
would include a review of treatment, support adherence, and include follow-up to monitor 
patients’ progress. This service would require closer pharmacist-GP collaboration and 
community pharmacists would be able to support fewer patients due to their increased 
involvement. He suggested that payment should be outcome based e.g. if a patient on 
Chapter Three | Literature Review 
 
 86 
antihypertensives reached their blood pressure target. This refreshed approach to MURs 
would require excellent communication and engagement between the GPs and pharmacists 
and pharmacist access to the patient’s medical records (Wright, 2017). 
 
The systematic reviews discussed thus far included studies that were heterogenous and it was 
therefore challenging to combine them to make meaningful judgements about the outcomes 
related to community pharmacist medication review. The following section focuses on 
individual studies where medication review has been investigated. 
 
3.5.1.3 Community pharmacist-led interventions and the effect on hospital admissions 
The following published studies, detailed in Table 3-6, were all conducted to discover whether 
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Table 3-6 Individual studies investigating medication review with hospital admissions as primary/secondary outcomes 
Author, 
(year) 
Study population Aim of study Method Intervention Results  Comments (Limitations/gaps) 
Farris et al., 
(2004) 
199 patients recruited 
182 had medication 
histories completed by a 
pharmacist and 
presented to the primary 
healthcare team. 
Patients taking ≥ 3 
medicines per day, at 




changed more than 4 
times in last year, drug-
related problem, history 
of non-compliance or 




among providers not 
located in the same 
clinic. The aim was to 
improve or maintain 
the health status of 
high- risk community-
dwelling patients, with 








HMR by community 
pharmacist with follow-up and 
resolution of issues by team.  
Primary healthcare team set 
up, consisting of family doctor, 
nurse (some teams did not 
have a nurse), pharmacist and 
home care manager who was 
also a nurse. 
Weekly meetings held to 
discuss patient care and 
medication issues and how 
issues could be resolved. 
Of 182 patients and 151 team 
discussions, an average of 3.9 
medication issues per patient 
were identified.  
 
Compliance was improved at 3 
months (p<0.001) and 6 
months (p=0.2). 
 
Non-significant trend towards 
fewer ED visits, hospital 
admissions and GP visits. 
Authors concluded that ‘policy 
initiatives that should be 
considered include the 
development of a larger, 
randomized controlled study 
to compare patients in several 
communities.’ 
 
Patients reported improved 
medication adherence but 
could be biased as patient 
reported.  
 
Too few patients were studied 
for statistical significance and 






402 patients >65 years, 
living independently, 
taking ≥ 5 medications 
per day and one other 
risk factor from list in 
paper. 
202 patients in 
intervention group in 
Australia. 
To determine whether 
medication review 
affects QoL and assess 











medication of eligible patients 
and then presented each case 
to the GP during a case 
conference. The GP then 
followed up the patient. 
No significant difference in 
medication-related hospital 
admissions between control 
and intervention groups. 
Only significant difference 
between groups was improved 
vitality (p<0.009) and mental 
health (p<0.0001) in 
intervention group. The 
authors acknowledge this 
could be due to increased 
medical attention due to 
participation in the study. 
Pharmacists identified 687 
medication issues for GPs to 
review but only 243 actual 
changes were made to 
prescriptions. No mention was 
made in the paper about the 
disparity between the two 
figures. 
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Krska et al., 
(2001) 
Patients recruited from 
GP practices in Scotland; 
381 patients in total (168 
in intervention group and 
164 in control group). 
Patients were > 65 years 
and taking ≥ 4 medicines. 
To study the effect of 
pharmacist-led 
medication review on 
the resolution of 
pharmaceutical care 
issues, medicine costs, 
use of health and social 
services and health-
related quality of life.  
RCT. Pharmacist reviewed 
medicines then prepared a 
pharmaceutical care plan 
which included assessment of 
medicines, extraction of 
information from medical 
records and patient interview. 
Control group patients only 
had a pharmacist review of 
medicines but no care plan. 
1380 pharmaceutical care 
issues identified in the 
intervention group compared 
with 1206 in control group. At 
3 months, 70% pharmaceutical 
care issues had been resolved 
in intervention group 
compared to 14% in control 
group; this was statistically 
significant (no p value stated). 
Slightly fewer hospital 
admissions in intervention 
group, but numbers were too 
small to determine 
significance. 
The most common 
medications associated with 
pharmaceutical care issues 
were: diuretics, nitrates, 
calcium channel blockers, 
potassium channel activators, 






364 intervention patients 
and 310 control patients 
in the Netherlands who 
were over 65 years, 
taking ≥ 5 medicines, 
with indicators of non-
compliance and taking 
medicines acting on the 
gastrointestinal tract or 
for the blood. 
To investigate the 











Pharmaceutical care provided 
by usual pharmacist and GP. 
Patients had an initial 
interview with the pharmacist 
to identify any drug-related 
issues and a pharmaceutical 
care plan was implemented 
after discussion with the GP. 
Patients followed up by the 
pharmacist at least twice more 
during the study.  
Hospital admissions; 6 in 
intervention group and 10 in 
control group but difference 
not statistically significant, 
hazard ratio (HR) 0.5 (95% CI 
0.12-1.59). Only statistically 
significant for patients with ≥ 5 
co-morbid conditions, HR 0.28 
(95% CI 0.056-0.73). 
Pharmacists conducting 
medication reviews had access 
to patients’ medical records. 
Study was massively 
underpowered as aimed to 
recruit 14200 patients. 
Conclusions suggest larger 
study required. 








136 patients from 1 GP 
practice living in the east 
of England who were 
over 80 years old, living 
at home and taking ≥ 4 
medicines per day with 
at least one medication 
‘risk factor’. 69 patients 
in the intervention group 
and 67 in the control 
group. 
To assess whether 
home-based 
medication review by a 
pharmacist for at-risk 
older patients in a 
primary care setting 
could reduce hospital 
admissions. 
 
RCT. Home-based medication 
review by pharmacist. 
No statistically significant 
difference in hospital 
admissions between 
intervention and control 
groups at 6 months (20 
admissions v. 21 admissions), 
RR 0.92 (95% CI 0.50-1.70), 
p=0.80, or care home 
admissions (p=0.3), death 
(p=0.81) or QoL (p=0.10). 
Statistically significant 
reduction in the number of 
medicines prescribed in the 
intervention group, 0.87 
medicines fewer (95% CI -1.66 
to -0.08), p=0.03. Attributed to 
face-to-face contact between 
pharmacist and GP after MUR. 
Suggested further studies 
should investigate cost-
effectiveness of intervention 
as no clear health gain but 
signs of reduction in 
prescribing costs. 
The intervention cost £12 per 
patient and was conducted by 
one pharmacist so 
generalisability could be an 
issue but as the intervention 
focussed on a high-risk 
population it could be cost-







pharmacies in Spain. 688 
patients in intervention 
group and 715 in control 





To assess the impact of 
a medication review 
with follow-up service 
provided in community 
pharmacy to aged 
polypharmacy patients 
on the number of 
medication-related 
hospital admissions and 
to estimate the effect 





review over a 6-month period. 
The OR of hospital admission 
was significantly higher in the 
control group; OR 2.7 (95% CI 
1.1-6.7, p=0.036). Mean cost 
per medicines-related hospital 
admission was €6672. Cost per 
medicines-related admission 
was significantly higher in the 
control group; €301 v. €94 in 
intervention group (95% CI 
35.9 -378.0), p=0.018. 
Community pharmacists 
providing the service attended 
a 3-day training course prior to 
the study. There was no 
mention of remuneration in 
paper. 






132 patients taking at 
least one medicine in 
Spain. 
 
To evaluate the clinical, 
economic, and 
humanistic impact of a 
pharmacist-conducted 











Patients took their medical 
records when they saw the 
pharmacist each month, for 18 
months. 
The pharmacist then identified 
medication-related issues and 
complied an action plan for 
the patient and liaised with 
other HCPs as appropriate; 
known as medication review 
with follow-up. 
Patients who participated in 
the intervention experienced a 
significant decrease in the 
number of medicines used, 
from 6.1 to 3.3, a significant 
decrease in hospitalisations, 
OR 0.31 (95% CI 0.10-0.99), 
p=0.039 and in ED visits, OR 
0.16 (95% CI 0.05-0.55), 
p=0.001. 
Focus of medication review 
with follow-up is on outcomes 





273 veterans over 65 
years old, taking specific 
beta-blockers for heart 
failure received the 
intervention and were 
compared with 5444 
controls in Australia. 
To examine the effect 
of HMR on time to next 
hospitalisation for 




Pharmacist home medication 
review in collaboration with 
GPs (now a standard 
pharmacy service in Australia). 
For veterans who had a HMR 
there was a 5.5% hospital 
admission rate compared to 
12% in the control group, this 
equated to a 45% reduction in 
rate of hospitalisations and 
was statistically significant, HR 
0.55 (95% CI 0.39-0.77), 
p=0.0007. 
Study highlights effectiveness 
of HMR in Australia in contrast 
to MURs in UK. 
 
Veterans were chosen as in 
Australia there is a database of 
all prescriptions, hospital 




Veterans and war 
widows in Australia. 
Patients aged > 65 years, 
had ≥ 2 warfarin 
prescriptions dispensed 
in last 6 months, 
received fully funded 
healthcare and had had a 
HMR.  
 
816 patients in 
intervention group and 
16, 320 in control group. 
To determine the 




medication review on 
hospitalisations for 






Intervention group = HMR 
(patients referred by GP, 
pharmacist carried out review 
in patient’s home, GP follows 
up any issues highlighted by 
review). 
Control group = Patient who 
had not had a HMR. 
Statistically significant, 79% 
reduction in likelihood of 
hospital admission for 
warfarin-related bleeding in 2-
6 months following HMR, HR 
0.21 (95% CI 0.05-0.87) but 
effect not sustained for > 6 
months. 
There was also an increased 
likelihood of hospital 
admission for warfarin related 
bleeding for patients in the 
intervention group more than 
12 months after the HMR. 
Study of patients in usual 
setting.  
Intervention group patients 
more unwell at baseline so 
may explain why increased 
admission rate after > 1 year. 
 
No limitations detailed in the 
study but assessed as high 
quality based on CASP criteria. 
 
Recommend 6 monthly HMR 
for patients taking warfarin. 






889 patients over 65 
years of age taking ≥ 5 
medications in Ontario, 
Canada. 
431 patients in the 
intervention group and 
458 patients in the 
control group. 
To examine whether an 
intervention by a 
specially trained 
pharmacist could 
reduce the number of 
daily medication units 
taken by elderly 
patients, costs and 
health care use (which 
included hospital 
admissions. 
Cluster RCT. Pharmacists met with patients 
in the doctor’s surgery for a 
medication review. The 
pharmacist gave written 
recommendations to the GP 
with the aim of resolving any 
drug-related problems. 
There were no significant 
differences between the 
intervention and control group 
in terms of the number of 
medications taken (p=0.87), 
health-related QoL (p=0.35) or 
medicines-related hospital 
admissions (p=0.08). 
GPs resolved 72% of drug-
related problems that were 
highlighted by pharmacist 
review. The authors conclude 
that this shows promising 
collaboration is possible 




GPs in Australia recruited 
400 patients (177 in 
intervention group and 
233 in control group). 
To examine the 
effectiveness of a 
multidisciplinary service 
model delivering 
medication review to 
patients at risk of 
medication 
misadventure in the 
community. 
 
RCT. GP referred eligible patients 
for home-based medication 
review. Pharmacists 
conducted the review, wrote 
the report and the GP 
followed up the patient. 
No statistically significant 
effect on cost, quality of life 
(p=0.17), hospital admissions 
(no p value stated) or GP 
appointments (no p value 
stated). Pharmacists’ 
recommendations were 
mainly around ADRs, 
monitoring, adherence and 
concordance. Only 54% of 
interventions were acted on 
and 70% had a positive 
outcome. 
Aimed to reflect ‘real world’ 
practice and produce more 
generalisable results; since 
this study was published 
Australia has implemented 
this system. 






1188 patients recruited 
from 3 GP surgeries in 
the UK; 560 patients 
received intervention in 
north UK. Patients were 
> 65 years taking ≥ 1 
repeat medicine. 
To determine whether 




with elderly patient in 
general practice. 
RCT. Pharmacist medication review 
(which was more in-depth 
than a standard MUR) in a 
pharmacist clinic. 
No difference between 
intervention and control 
groups in terms of the number 
of daily doses (p=0.17), 
number of GP appointments 
(p=0.69), outpatient 
appointments (p=0.41) and 
hospital admissions (p=0.16). 
19 intervention group patients 
and 17 control group patients 
were admitted to hospital 
(p=0.16). Trend of increased 
cost and number of 
prescriptions in both groups, 
but significantly less in the 
intervention group. 
Pharmacist medication review 
was cost effective even when 
the cost of the intervention 
was deducted. 
Results of this RCT may not be 
generalisable as only one 
pharmacist and four GPs 
participated, but this study 
provides some useful evidence 
of the effectiveness of 
medication review. 
Pharmacists were located in a 
GP practice for this study. 
High quality study according to 
CASP criteria but not easy to 
extrapolate the results as only 
1 pharmacist and 4 GP 
practices involved. 
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Table 3-6 shows that only four studies (Roughead et al., 2009, 2011; Ocampo et al., 2015; 
Malet-Larrea et al., 2016) showed statistically significant reductions in hospital admissions as a 
result of medication review. In both studies by Roughead et al. (2009, 2011) specific 
populations were targeted; those taking beta-blockers for heart failure and those taking 
warfarin. The study by Ocampo et al. (2015) involved a very intense intervention whereby 
patients saw the pharmacist every month for 18 months which is very different to the English 
MUR service. The study by Malet-Larrea et al., (2016) included patients over 65 years old 
taking ≥5 medicines and was therefore more representative of the general population. 
 
Nearly half of the studies presented in Table 3-6 described HMR, where the pharmacist 
delivered the medication review in the patient’s home. This is clearly not the same as the 
MURs that are offered by English community pharmacists. It is therefore unclear whether the 
location of the medication review had an impact on the results of the studies. It is worth 
noting that HMR is now a standard community pharmacy service in Australia, with GPs 
referring patients in the community for a HMR with their community pharmacist 
(Pharmaceutical Society of Australia, 2011). 
 
There are certainly difficulties determining the effect of medication review in preventing 
hospital admissions. An observational study of 14 community pharmacies involved 
pharmacists recording details of clinical interventions for one week each month, for a period of 
a year. The results showed a 0.75% intervention rate. The interventions were then assessed by 
a clinical panel who deemed 19 to 242 (0.01 - 0.12%) of the interventions to have prevented a 
medicines-related hospital admission. The paper did not state the locations of the pharmacies, 
who sat on the expert panel and gave no examples of the interventions. This made it hard to 
assess the accuracy of the figures (Hawksworth et al., 1999). The results of this study have 
been used by other studies, such as Sorensen et al., (2004), to definitively state that 
community pharmacists reduce drug-related hospital admissions. 
 
There are also difficulties with GPs actioning the recommendations made by community 
pharmacists during the MUR process. A small-scale study conducted in a discreet region of the 
UK examined patients with coronary heart disease who had participated in a MUR. They 
compared 294 intervention group patients with 360 patients in a control group and reviewed 
changes in prescribed medicines 3 months after the MUR. They found that 56.3% of 
Chapter Three | Literature Review 
 
 94 
interventions were acted on by GPs and intervention group patients had more changes to their 
prescribed medicines compared to control group patients (Wilcock and Harding, 2008).  
 
These studies focussed only on medication reviews that occurred for patients in community 
settings. The next section summarises studies that included patients who had recently been 
discharged from hospital. 
 
3.5.1.4 Studies of the effects of post-discharge medication reviews on hospital 
readmissions 
Studies that have investigated the effect of post-discharge medication reviews on hospital 
readmissions are shown in Table 3-7. Often these interventions were conducted during or 
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Table 3-7 Individual studies investigating post-discharge medication review with hospital admissions as primary/secondary outcomes  
Author, (year) Study population Aim of study and intervention Method Results  Comments (Limitations/gaps) 
Gillespie et al., 
(2009) 
182 intervention patients 
and 186 control group 
patients over 80 years 
old from a University 
hospital in Sweden.  
To investigate the effectiveness of 
interventions performed by ward-based 
pharmacists in reducing morbidity and 
use of hospital care among older patients. 
Enhanced hospital pharmacist service 
which included: drug history on 
admission, medication review, patient 
education and monitoring, 
communication with primary care and 
follow-up telephone call at 2 months 
post-discharge. 
RCT. Statistically significant reduction in drug-
related readmissions (reduced by 80%) and 
ED visits (reduced by 47%) in intervention 
group up to 12 months after discharge. 9 
drug-related readmissions (of which 4 were 
avoidable as the pharmacist had 
recommended a change to therapy that had 
not been actioned) in intervention group 
compared to 45 in control group. 
Intervention group patients cost $230 less 
than control group patients. 
A study showing the 
statistically important benefit 
of pharmacist involvement in 
secondary care to prevent 
readmissions. 
Hellström et al., 
(2011) 
210 patients, ≥65 years 
who were admitted to 
internal medicine wards 
at a University Hospital in 
Sweden.  
 
To examine the impact of a medication 
review while in hospital on the number of 
inappropriate medications and 
unscheduled drug-related hospital revisits 
in elderly patients. 
Intervention group received IMM model 
of care which included medicines 
reconciliation on admission and 
discharge, medication review and 
monitoring. 




Statistically significant reduction in drug-
related readmissions: 6 readmissions in 
intervention group, 12 readmissions in 
control group (p=0.0469). 
Greater decrease in number 
of inappropriate medicines in 
intervention group compared 
to control group (p=0.0446). 
More intensive intervention 
than English MUR system. 
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Holland et al., 
(2007) 
3 district general 
hospitals in UK. 
 
Adults > 18 yrs, 
emergency admission 
with heart failure and 
discharged taking ≥ 2 
drugs. 
 
17 study pharmacists. 
149 patients in 
intervention group. 
144 patients in control 
group. 
 
To test whether a drug review and 
symptom self-management and lifestyle 
advice intervention by community 
pharmacists could reduce hospital 
admissions or mortality in heart failure 
patients. 
Intervention group = Community 
pharmacists received a copy of the 
patient’s discharge letter and conducted a 
home medication review within 2 weeks 
and 8 weeks of discharge. 
Control group = standard care. 
 
RCT 112 emergency readmissions in control 
group and 134 in intervention group within 
6-months of discharge, (p=0.28); not a 
statistically significant result. 
Full mediation review evaluating efficacy of 
each drug and the patient’s condition i.e. 
more detailed than a MUR. 
Statistically significant increase in contact 
between patients and primary care (p=0.002) 
and increased number of items prescribed 
(p<0.001). 
There was no effect on mortality or quality of 
life. 
Emergency admission data 
from HES. 
Heart failure nurse specialist 
interventions have shown 
reductions in readmissions. 
 
High quality study according 
to CASP criteria for RCTs. 
 
 
Holland et al., 
(2005) 
872 patients aged > 80 
years, discharged from 
hospital to their own 
home, taking ≥ 2 
prescribed medicines. 
To determine whether home based 
medication review by pharmacists affects 
hospital readmission rates among older 
people. 
Home based medication review by 
community pharmacist at 2- and 8-weeks 
post-discharge. 
RCT. Intervention group patients had statistically 
higher rates of hospital readmission 
compared to the control group, 234 v. 174, 
rate ratio 1.30, (95% CI 1.07-1.58), p = 0.009. 
Intervention group patients also had more 
GP visits (p=0.002) and poorer quality of life 
(p=0.042).  
No significant differences in care home 
admissions or death between the groups. 
 
Authors suggest that home-
based medication review may 
increase patients’ knowledge 
of their condition and 
medication so patients spot 
warning signs and seek help. 
Increased adherence to 
medication increased 
iatrogenic disease. Home-
based medication review 
caused increased anxiety 
about condition and resulted 
in hospital readmission. 
High quality study according 
to CASP criteria. 
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Luder et al., 
(2015) 
90 patients, >18 years 
discharged from two US 
hospitals with a diagnosis 
of congestive heart 
failure, chronic 
obstructive pulmonary 
disease, or pneumonia. 
To determine if a community pharmacy 
transition of care program that included 
medication review amongst other 
activities decreased hospital admissions. 
Pharmacists reconciled the patients’ 
medications, identified drug therapy 
problems, recommended changes to 
therapy and provided self-management 
education. Intervention occurred within 7 





Pharmacist intervention significantly reduced 
hospital readmissions within 30 days, OR 
0.072 (95% CI 0.008-0.628), p=0.017. 
No difference in patient 
satisfaction between the 





Australian study of 121 
patients; 57 in 
intervention group and 
64 in control group at 
high risk of hospital 
readmission (over 60 
years, with at least 2 
chronic conditions and 
taking 4 or more 
medicines).  
To evaluate pharmacist-conducted follow-
up at home of high-risk elderly patients 
discharged from hospital. 
HMR review for intervention patients at 5 
days post-discharge and for both groups 
at 90 days post-discharge. 
RCT. Statistically significant differences in 
intervention and control groups for 
unplanned readmissions (28% intervention 
groups patients v. 45% control group 
patients readmitted, p=0.05), patients with > 
1 DRP, DRP per patient and patients taking a 
NSAID. Patients were positive about the 
medication review and 79% of the 
pharmacists’ suggestions were implemented 
by the GPs. 
 
Nazareth et al., 
(2001) 
362 patients evenly 
distributed to 
intervention and control 
groups. Patients were 
over 75 years old, taking 
≥ 4 medications and had 
been recently discharged 
from hospital in London, 
UK. 
To investigate the effectiveness of a 
pharmacy discharge plan in elderly 
hospitalized patients. 
Hospital pharmacists prepared a 
medication discharge plan that was given 
to the patient and the community 
pharmacist. Home-based medication 
review by community pharmacists 7-14 
days after hospital discharge. 
RCT. There were no differences between the 
groups in readmissions at 3 or 6 months. 
The only statistically significant difference 
between the groups was in patient 
knowledge. No p-values stated. 
Pharmacists spent 5.5 hours 
on the discharge plan.  
Only 71% (132) of eligible 
patients actually received the 
intervention despite a power 
calculation of 195 patients 
required per arm. 









Horng, Roy, et 
al., 
(2006) 
178 patients discharged 
from a teaching hospital 
in US. 79 patients 
analysed in intervention 
group and 73 in control 
group. 
To identify drug-related problems during 
and after hospitalization and to determine 
the effect of patient counselling and 
follow-up by pharmacists on preventable 
ADEs 
Intervention group patients had a 
pharmacist resolve any medication 
discrepancies prior to discharge and 
medication counselling and resolution of 
issues. 
RCT. For preventable ADEs; 1% intervention group 
and 11% control group had an ADE (p=0.01). 
Rate of preventable ED visits/readmissions 
was 1% in intervention group and 8% in 
control group (p=0.03). Medication 






240 patients were 
included; 113 in 
intervention group and 
127 in control group.  
To evaluate the effects of a medication 
liaison service on quality of medication-
related information associated with 
hospital admission, risk of drug 
misadventure and other patient 
outcomes, and health resource utilisation. 
Medication Liaison Service; Drug history 
confirmed on hospital admission from GP 
and community pharmacy. Usual ward 
care. Discharge communication sent to GP 
and community pharmacist within 24 
hours that included: duration of 
treatment, DRPs, supply issues, ADRs, 
allergies and new prescriptions. 
RCT. Intervention group had 12 readmissions v. 17 
in control group. Just non- significant with 
p=0.055. The intervention group had 
increased clinical interventions, more 
interventions per patient and more changes 
to medicines but fewer visits to health care 
professionals. 
Larger number of patients 
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Five of the nine studies included in Table 3-7 demonstrated a statistically significant reduction 
in hospital readmissions when patients had participated in some form of medication review 
(Naunton and Peterson, 2003; Schnipper et al., 2006; Gillespie et al., 2009; Hellström et al., 
2011; Luder et al., 2015) and one study demonstrated a statistically significant increase 
(Holland et al., 2005). The studies that showed a decrease in readmissions included 781 
patients in various locations but of note is that none of the interventions were directly 
comparable to the MUR service that is currently operational in England. In two studies the 
intervention was initiated by hospital pharmacists prior to discharge (Schnipper et al., 2006; 
Gillespie et al., 2009), in a further two studies the intervention was more complex than a MUR 
(Hellström et al., 2011; Luder et al., 2015), and in one study the intervention was conducted in 
the patient’s home (Naunton and Peterson, 2003). 
 
Table 3-7 also shows that some studies have demonstrated positive effects of medication 
review on other outcomes such as the appropriateness of medications, adherence, and patient 
knowledge about their medicines (Nazareth et al., 2001; Holland et al., 2005; Hellström et al., 
2011). PD-MURs have also been shown to be useful in identifying medicines-related problems 
and contributing to cost savings. Ahmad et al., (2014) conducted a study in the Netherlands on 
post-discharge medication review. They recruited 340 patients over 60 years old who were 
taking more than five prescribed medicines. They found that on average, each patient had 2.9 
medicines-related problems post-discharge and the more medicines the patient was 
prescribed, the higher the chance of experiencing a medicines-related problem (Ahmad et al., 
2014). Ramsbottom, Rutter and Fitzpatrick (2018) conducted a PD-MUR study that involved 
referring hospital in-patients who were over 65 years for a PD-MUR after discharge. During the 
9-month study period they managed to recruit just 30 patients to their study, of whom only 20 
participated in a PD-MUR. Community pharmacists identified an average of 2 interventions per 
PD-MUR; these were mainly around the provision of information to the patient. It was 
estimated that the cost to community pharmacies of providing the service was £70.44 per PD-
MUR, but the savings were estimated to be in the range of £113 to £255 per PD-MUR, which 
highlighted the potential cost saving to the NHS (Ramsbottom, Rutter and Fitzpatrick, 2018). 
 
As previously mentioned, two of the studies in Table 3-7 that generated statistically significant 
results described the use of a home-based medication review model (Naunton and Peterson, 
2003; Holland et al., 2005). The study by Holland et al., (2005) showed a statistically significant 
increase in hospital readmissions whilst the study by (Naunton and Peterson, 2003) showed a 
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decrease in hospital readmissions. Bowyer and Barnett (2005) and Petty (2005) have criticised 
the study conducted by Holland et al., (2005) because it did not include a full clinical 
medication review, there was disparity between the intervention and control groups in terms 
of diagnosed conditions, the patients had recently been discharged from hospital and 
therefore had recently had their medicines reviewed, and it was unclear whether the 
interventions made by pharmacists to GPs were actioned. There was also no assessment of 
whether the readmissions were iatrogenic and therefore it was difficult to say that post-
discharge home-based medication review by pharmacists definitely resulted in an increase in 
hospital readmissions (Bowyer and Barnett, 2005; Petty, 2005). The study by Naunton and 
Peterson (2003) was conducted in Australia where HMR is already a commissioned service. 
 
Only the study by Luder et al., (2015) described a service similar to the English PD-MUR but 
this was conducted in the US where the healthcare system is funded differently. There have 
been attempts to investigate the effect of PD-MURs more robustly, but difficulties in recruiting 
patients have been highlighted as a barrier (Ramsbottom, Fitzpatrick and Rutter, 2016). One 
large-scale study has been conducted using routinely collected administrative data covering 
nearly 300,000 community-pharmacist medication reviews over a 14-month period between 
2012/13 in British Colombia, Canada. It found that medication review by community 
pharmacists did not result in a significant change in the number of prescriptions issued to 
patients, adherence, deprescribing or potentially inappropriate prescribing in the elderly 
(Kolhatkar et al., 2016).  
 
These studies highlight the apparent lack of strong evidence of MURs or PD-MURs having any 
effect on hospital admissions or readmissions. This is despite the fact that the UK Government 
spent £85.5 million on them in 2013/4 rising to £94.1 million in 2017/18 (PSNC, 2018i). The 
literature does show that there is some evidence to support specific types of medication 
review, for example reviews that take place in the patients’ home, those that are focussed on 
a particular condition or medication and clinical medication reviews using the patients’ 
medical notes. However, there appears to be a paucity of evidence to support unfocussed, 
adherence support medication reviews, such as the current UK community pharmacy MURs; 
especially in terms of measurable, hard outcomes such as hospital admissions or mortality. 
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3.6 Opinions about and experiences of MURs 
 
Figure 3-6 Literature review: Area Four – Opinions and experiences 
 
3.6.1 Community Pharmacists 
There have been several studies that have garnered the opinions and experiences of 
community pharmacists providing the MUR service; these studies have shown that there are 
various facilitators and barriers to community pharmacists conducting MURs.  
 
3.6.1.1 Facilitators to conducting MURs 
Latif, Boardman and Pollock carried out a mixed-methods study in Nottingham during 2008. 
They surveyed 280 community pharmacists working for multiples, directly observed 54 MUR 
consultations and interviewed a proportion of the pharmacists and patients about their 
experiences (Latif and Boardman, 2008; Latif, Pollock and Boardman, 2013). They found that 
community pharmacists working for multiples conducted more MURs if they worked over 20 
hours per week, were store-based and had a dedicated consultation area (Latif and Boardman, 
2008). Pharmacists were more likely to conduct MURs for patients who had good relationships 
with pharmacy staff and were therefore more likely to agree to participate in a MUR (Latif, 
Boardman and Pollock, 2013). 
 
Another mixed-methods study involving a survey of 216 Primary Care Organisations (PCO) 
followed by interviews with 43 PCO representatives conducted by Bradley et al. (2008) found 
that multiples carried out more MURs than independents and pharmacies dispensing more 
items carried out more MURs (Bradley et al., 2008). 
 
Opinions and experiences of those involved in the medication 
review process
Medication review
Medicines-related admissions and readmissions
Hospital admissions and readmissions
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Community pharmacists viewed MURs as an opportunity to engage in additional training 
(Bradley et al., 2008; Harding and Wilcock, 2010) and extend their role (Latif and Boardman, 
2008). They perceived MURs to be of high quality when they had the support of pharmacy 
staff (Harding and Wilcock, 2010), enhanced the patients’ use of their medicines (Latif and 
Boardman, 2008), increased adherence, involved patients being give advice and resulted in 
changes to the prescription (Harding and Wilcock, 2010). 
 
3.6.1.2 Barriers to conducting MURs 
Latif and Boardman (2008) found that lack of time, staff support and suitable consultation 
areas were barriers to conducting MURs (Latif and Boardman, 2008). Bradley et al. (2008) 
found that fewer MURs occurred in areas of deprivation and for patients with long-term 
illnesses (Bradley et al., 2008). Another study of 49 community pharmacists interviewed in 
2007/8 found that workload pressures affected the delegation of tasks to other staff that 
would facilitate MUR activity (McDonald et al., 2010). 
 
Examples of poor-quality MURs were when there was a lack of support from GPs (Bradley et 
al., 2008) who did not act on recommendations from the MUR (Harding and Wilcock, 2010) 
and did not provide any feedback (Wilcock and Harding, 2008). 
 
3.6.1.3 Pressure to complete MURs 
Studies of pharmacists’ views of MURs have shown that patients taking simpler medication 
regimes are more likely to be offered a MUR compared to patients on complex regimes (Latif, 
Pollock and Boardman, 2011). This was generally for financial reasons as simple MURs would 
be quicker to complete for the same financial gain (Latif, Pollock and Boardman, 2011) 
ensuring that MUR targets were achieved and financial loss was avoided (Latif, Pollock and 
Boardman, 2013). Youssef, Karia and Hall (2011) received 80 responses from community 
pharmacists to their survey; when community pharmacists were asked about why the 
Department of Health had called for an improvement in MUR quality some thought that 
unnecessary MURs were being conducted for financial gain (Youssef, Karia and Hall, 2011). All 
MURs attract the same fee, currently £28, and some employee pharmacists felt the limit of 
400 MURs, per pharmacy, per annum, was seen as a target rather than a limit (Bradley et al., 
2008; Harding and Wilcock, 2010; McDonald et al., 2010; Youssef, Karia and Hall, 2011). Elvey, 
Hassell and Hall (2013) also found that pharmacists were put under pressure by non-
pharmacist managers to complete MURs (Elvey, Hassell and Hall, 2013). 
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3.6.1.4 Opinions about PD-MURs 
There is a paucity of evidence regarding the opinions of community pharmacists towards PD-
MURs; just two studies were found. Rutter, Ramsbottom and Fitzpatrick (2017) surveyed 19 
community pharmacists about their opinions of the PD-MUR service they had provided to 
patients who were referred from hospital as part of a feasibility study. The pharmacists 
reported that the main barrier to conducting PD-MURs was that certain patients were 
housebound and therefore unable to attend the pharmacy, and restrictions in conducting 
HMRs further compounded the problem (Rutter, Ramsbottom and Fitzpatrick, 2017). 
Meanwhile, Ensing et al. (2017) conducted a mixed-methods study of community pharmacists 
to establish the facilitators and barriers to initiating a HMR scheme for post-discharge patients. 
The facilitators that emerged were good interprofessional collaboration between primary and 
secondary care and the community pharmacists’ skills in communication and 
pharmacotherapy. The barriers were identified as having an adequate reimbursement fee and 
the ability of pharmacists to incorporate home visits into their daily schedule (Ensing et al., 
2017). 
 
3.6.1.5 Information requirements for conducting MURs and PD-MURs 
When community pharmacists were asked about the information they required to conduct 
effective PD-MURs, Bruhwiler, Hersberger and Lutters (2017) found that they thought the 
following were essential: patient details, list of discharge medicines, changes made to 
medicines whilst in hospital, if any off-label medicines were prescribed, allergies and the 
contact details of the prescribing doctor (Bruhwiler, Hersberger and Lutters, 2017). 
Additionally, in the study reported by Latif and Boardman (2008), community pharmacists 
thought a lack of access to the patients’ medical notes reduced the benefit of a MUR; although 
the authors proposed that this showed some pharmacists viewed MURs as a clinical rather 
than a concordance review (Latif and Boardman, 2008). These studies underline the desire of 
community pharmacists to have access to the appropriate information to enable them to 
provide patients with the best possible care. 
 
3.6.1.6 Professionalism in community pharmacy 
Elvey, Hassell and Hall (2013) interviewed 43 pharmacists from community, hospital and CCGs 
about professionalism. Based on the opinions and experiences of participants, the authors 
devised nine different descriptors: the scientist, the medicines adviser, the clinical practitioner, 
the social carer, the medicines maker, the medicines supplier, the manager, the business 
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person and the unremarkable character (Elvey, Hassell and Hall, 2013). When pharmacists are 
providing MURs and PD-MURs in the community they ideally need to see themselves as 
‘medicines advisers’ or ‘clinical practitioners’ in preference to any of the other descriptors. 
 
Another study looked at how community pharmacists contributed to ‘social order’ with the 
authors suggesting pharmacists were intervening when disorder (in patients’ medications) was 
not present and therefore performing MURs predominantly for commercial reasons. The 
authors postulated that both of these factors could undermine the professionalism of 
community pharmacists (McDonald et al., 2010). 
 
3.6.1.7 Summary of community pharmacists’ opinions of the MUR and PD-MUR service 
These studies show that community pharmacists are keen to be involved in medicines review 
services especially for the benefit of their patients. They are willing to take advantage of the 
training opportunities to provide a high-quality service. Their efforts are hampered by a lack of 
support staff, time and, in some circumstances are under pressure to conduct high-volume 
rather than high-quality reviews. 
 
The PD-MUR service could be developed to allow community pharmacists to conduct reviews 
in the patient’s home and permit community pharmacists to access the patient’s medical 
record. Only two studies were found that exclusively investigated the opinions of community 
pharmacists about PD-MURs (Ensing et al., 2017; Rutter, Ramsbottom and Fitzpatrick, 2017), 
therefore more research in this area is warranted. 
 
3.6.2 GPs 
The opinions and attitudes of GPs towards MURs and community pharmacists providing the 
service have also been investigated. Wilcock and Harding (2007) outlined the results of a 
survey of 52 GPs from one Primary Care Trust (PCT) in south west England shortly after the 
introduction of the MUR service. Sixty per cent of GPs thought they had a good working 
relationship with their community pharmacist, 96% were aware of MURs and 88% had 
received a completed MUR form from their community pharmacist. GPs highlighted the good 
points about MURs such as increased patient understanding of their medicines and 
pharmacists advising on compliance problems or interactions and ADRs. GPs did seem to be 
quite negative towards some aspects of MURs and were critical when pharmacists: advised 
them of monitoring that had already been carried out; conducted a MUR for a patient whose 
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GP practice had recently completed a review and discussed side effects with patients when the 
GP had already assessed the risk-benefit of the treatment. The authors proposed that this 
reflected on the GPs as the patient had brought up these issues as part of the MUR discussion 
with the pharmacist and therefore some resolution was required (Wilcock and Harding, 2007). 
 
The study conducted by Latif, Pollock and Boardman (2013) found a lack of evidence for 
engagement from GPs with the MUR service. This was because they did not refer patients for 
MURs, or aid in the identification of patients who would be suitable for the service. GPs did 
not feedback to community pharmacists on the outcomes of the interventions they had made, 
pharmacists felt that GPs overlooked the service and there was some evidence that 
pharmacists were deferential to GPs (Latif, Pollock and Boardman, 2013). There were similar 
findings from another study in which it was reported that GPs did not place any value on the 
content of MUR forms (McDonald et al., 2010). Latif, Pollock and Boardman (2013) suggested 
that a more ‘joined-up’ service was required, that cut across traditional boundaries to support 
and benefit patients (Latif, Pollock and Boardman, 2013). 
 
A piece written by Howard Stoate, a GP and past chair of the All-Party Parliamentary Group on 
Pharmacy, also criticised MURs. His opinion was that they increased GPs workload by 
providing GPs with information which they did not have the time to use and the form was too 
long and difficult to input into the GP computer system (Stoate, 2006). It should be noted that 
since this time the MUR form has been revised and is more succinct (PSNC, 2018b). 
 
A commentary paper by Chen and Almeida Neto (2007) examined the collaboration between 
pharmacists and GPs. They found that typically, interactions were episodic and informal, and 
strong collaborative relationships were the exception rather than the norm; this constituted a 
‘significant cultural barrier’. The MUR process assumed that any recommendations made by 
the community pharmacist were automatically implemented by the GP, but this was not 
always the case. They postulate that face-to-face discussions of the MUR process between 
community pharmacists and GPs would increase trust in the relationship, result in greater 
cooperation and increase the quality of interactions (Chen and Almeida Neto, 2007). 
 
Based on this evidence, it appears that MURs are not fully understood or appreciated by all 
GPs. This means that community pharmacists are placed in a difficult position; on the one 
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hand being encouraged to conduct MURs, and on the other, receiving negative or no feedback 
from GPs about the service. 
 
3.6.3 Patients 
It is vitally important to understand patients’ views and experiences of MURs if the service is to 
be optimised and, in time, driven by patients and other HCPs rather than just community 
pharmacists. A questionnaire survey of 232 users of four community pharmacies in England 
examined what information patients with chronic conditions required from community 
pharmacies and assessed their adherence to medication, dependent on whether they had 
received an advanced community pharmacy service such as a MUR or NMS (Twigg et al., 
2016). Patients who had received an advanced service were statistically significantly more 
likely to be satisfied with the level of medicines information they had received (p=0.001) and 
the likelihood of them being adherent to their medicines was doubled, OR 2.34 (95%CI 1.21-
4.53), p=0.012. They did have some unmet needs with regard to the medicines information 
they required which had not been fulfilled by the advanced service they had received (Twigg et 
al., 2016). 
 
Other studies have also shown that patients’ adherence and knowledge about their medicines 
has improved. Of 81 patients, from one community pharmacy in the Midlands, who were 
surveyed after they had participated in a MUR, 68% felt they knew more about their medicines 
and 83% said their adherence to their medicines had increased. Patients over 65 years 
perceived that they had gained more benefit from the MUR than younger patients (Youssef, 
Hussain and Upton, 2010). Meanwhile, in Australia, White, Klinner and Carter (2012) 
conducted 14 focus groups with 87 patients to investigate their views of the HMR programme. 
Patients reported that the main advantages were feeling cared for, reassured, gaining new 
knowledge about their medicines and feeling they could speak to their GP about medication 
changes (White, Klinner and Carter, 2012). 
 
Conversely, Latif, Boardman and Pollock (2013) reported opposing findings in their MUR study. 
They investigated patients’ perspectives of MURs by interviewing 34 patients who had 
participated in an observed MUR. They found patients reported MURs to be satisfying and 
interesting, but they did little to alter the way they took their medicines or increase their 
knowledge about them. Patients did not feel reassured about their medicines and were more 
likely to accept advice if they perceived it to be beneficial or easy to implement (Latif, Pollock 
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and Boardman, 2013). It should be noted that this study had fewer participants than those 
reported above. 
 
There appears to have been some confusion from patients about the purpose of a MUR. In the 
study by Latif, Pollock and Boardman (2013), some patients thought MURs were an activity 
that pharmacists were required to complete and agreed to a MUR to assist the pharmacist. 
Patients generally accepted the offer of a MUR from their usual pharmacist, due to politeness 
and co-operation, but would not from an unfamiliar pharmacist. They valued the opportunity 
to discuss their medication, but some viewed the MUR as simply a check of their medicines or 
a monitoring activity (Latif, Pollock and Boardman, 2013). In an Australian study of patients 
views towards the HMR service, some patients though they were an adherence check (White, 
Klinner and Carter, 2012). 
 
Patients also voiced concerns about participating in MURs for other reasons; in more than one 
study patients were worried about how a MUR would impact on their relationship with their 
GP. Latif, Pollock and Boardman (2013) found that patients had concerns about MURs 
interfering with their GPs’ prescribing, and also impacting on their relationship with their GP. 
The authors proposed that if patients had more complex problems with their medicines they 
would discuss them with their GP (Latif, Boardman and Pollock, 2013). A qualitative study of 26 
known users and non-users of community pharmacy services in Scotland investigated public 
trust in services provided by community pharmacies relative to those provided by GPs. 
Patients with long-term conditions were much more likely to report consulting their GP as they 
were the HCP who had access to their medical records, were able to diagnose, prescribe and 
refer to specialists; all tasks that a community pharmacist would not be able to complete. The 
participants trusted their GPs much more than pharmacists; this was partly because they were 
able to build strong relationships with their GP over time. The relationships they had with 
community pharmacists were more fragmented and rarely sustained. There was also some 
conflict from the patients about the commercial aspects of the community pharmacy and 
whether the community pharmacists would prioritise profit or patient care (Gidman, Ward and 
McGregor, 2012). In Australia, patients reported the following barriers to the HMR service; 
concerns about affecting their relationship with their GP, worries about the privacy and safety 
of the home visit, their confidence interacting with a pharmacist they did not know and their 
own pride and independence being undermined (White, Klinner and Carter, 2012). 
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In summary, patients in several studies have reported that MURs increased their adherence 
and knowledge about their medicines and made them feel more cared for, but some had 
concerns about how participating in a MUR would affect their relationship with their GP. 
Patients were not always clear about the purpose of a MUR. Gidman, Ward and McGregor 
(2012) suggested that the use of extended pharmacist services were being undermined by the 
lack of trust from patients and possible ways to resolve this would be to increase the number 
and type of interactions between patients and pharmacists and having GPs’ support or 
endorsement for extended services (Gidman, Ward and McGregor, 2012).  
 
3.7 Summary of literature review chapter 
This literature review has demonstrated that there is very little published evidence for the 
effectiveness of MURs conducted by community pharmacists in the pharmacy on outcomes 
such as hospital admission rates, morbidity and mortality. There is some evidence from small 
scale studies showing the benefit of home-based medication reviews and MURs targeted at 
patients with specific conditions. Nonetheless, MURs as provided by community pharmacists 
in England, have shown benefit for patients in terms of increased knowledge about medicines 
and improved adherence. 
 
Patients, GPs and community pharmacists have differing and sometimes opposing views about 
the MUR service and the role of community pharmacists in providing advanced services for 
patients over and above their dispensing function. The attitudes of individuals also appear to 
be determined by whether they have experienced beneficial interactions with community 
pharmacists previously. 
 
In the current study, one of the aims is to determine how pharmacists can use their skills, and 
tools such as PD-MURs, to help patients manage their medicines better once they are 
discharged from hospital, with a view to reducing medicines-related hospital admissions. This 
literature review has set the scene in terms of medicines-related admissions and readmissions 
to hospital, the scale of the issue, the medicines implicated and the views of patients and 
HCPs. The next chapter will provide an overview of the methodological theories underpinning 
the different phases of the study. This is then followed by the chapters explaining the 
methods, results and a brief discussion of each phase of the fieldwork. 
 
  






This chapter will focus on the methodology that was employed in the study. It starts with an 
outline of the philosophical approach that was taken. As this study used a mixed methods 
approach, a summary of the rationale for mixing methods is then presented.  
 
4.1 Introduction 
This chapter presents the underpinning methodology for the current study. The methods for 
each phase of the study are not presented in this chapter but are included in Chapters 5, 6, 7 
and 8. This is to ensure that all pertinent information, such as the methods, results and a brief 
discussion, for each stage of the study are found together, in the same chapter. The rationale 
for this is to aid the reader in navigating the thesis and understanding how each phase was 
conducted and allowing them to appreciate how each phase informed the subsequent phases. 
The Discussion, chapter 9, will discuss the results of the thesis as a whole. 
 
4.2 Methodology 
Methodology is the ‘system of methods used in a particular area of study ’ (Oxford University 
Press, 2019), and is underpinned by the stance the researcher has taken when conducting the 
research. This chapter initially focusses on the theoretical underpinnings of the research 
before discussing and justifying the use of a mixed methods approach. 
 
4.2.1 Ontology, epistemology and methodology 
The nature of the research process means that researchers must consider the underlying 
beliefs or paradigms on which their study is based. A research paradigm, or worldview, is a set 
of assumptions or beliefs about the ‘world’ and the place of individuals within it (Guba and 
Lincoln, 1994). There are essentially four main elements of each paradigm: 
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• Ontology – what is the nature of reality and what can be known about it? 
• Epistemology – what is the relationship between the ‘world’ and the researcher? 
• Methodology – how can the researcher find out what they want to know about the 
‘world’. 
• Methods – the procedures and techniques used to collect and analyse data. 
(Guba and Lincoln, 1994) 
The answers to these questions vary, depending on the stance that the researcher takes. There 
are various competing research paradigms and authors classify them in different ways, hence 
the overarching theories are presented here: 
• Positivism: the ontology of positivism is realism, the epistemology is objectivism 
(Crotty, 1998; Scotland, 2012) and the methodology used aims to explain relationships 
(Scotland, 2012). This approach aims to test a theory through the collection of 
observations or measurements and is objective in nature so the researcher can 
investigate the object without influencing it or being influenced by it (Guba and 
Lincoln, 1994; Bryman, 2008; Creswell, 2014). This view includes realist knowledge 
generation; that through the collection of appropriate data, the researcher can 
establish what reality is. The researcher only has to discover the patterns, structures or 
laws to determine what happens in the real world (Willig, 2012). Hypotheses are 
stated and tests can be used to verify them (Guba and Lincoln, 1994) meaning that the 
data generated are generally quantitative. 
• Interpretivism: the ontology of interpretivism is relativism, the epistemology is 
subjectivism (Crotty, 1998; Scotland, 2012) and the methodology aims to understand 
the issue of interest from an individual’s perspective (Scotland, 2012). This suggests 
that each individual has a subjective experience and interpretation of the world. It 
acknowledges that there is more than one reality, and this lends itself to the use of 
qualitative methods to discover the different lived experiences of individuals. There is 
also a recognition that the researcher brings their own prior knowledge and 
experiences to the research meaning they are linked to the object. This position does 
not usually test a predetermined theory but rather aims to generate its own theory or 
meaning (Guba and Lincoln, 1994; Bryman, 2008; Willig, 2012; Creswell, 2014). 
 
Another paradigm that exists is that of pragmatism; where researchers can use any methods, 
techniques and procedures that will enable them to better comprehend the problem being 
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investigated. Researchers use ‘what works’ and utilise whichever approaches are necessary to 
understand the issue. This view underpins the mixed methods approach (Creswell, 2014). 
 
4.2.2 Mixed methods 
Mixed methods research has been defined as: 
“the type of research in which a researcher or team of researchers 
combines elements of qualitative and quantitative research approaches 
(e.g., use of qualitative and quantitative viewpoints, data collection, 
analysis, inference techniques) for the broad purposes of breadth and 
depth of understanding and corroboration.” 
(Johnson, Onwuegbuzie and Turner, 2007) 
 
The technique has been attributed in the first instance to Campbell and Fiske who, in 1959, 
described the use of more than one technique to validate, or triangulate, data to ensure that 
their results were valid (Johnson, Onwuegbuzie and Turner, 2007). 
 
4.2.2.1 Rationale for the use of mixed methods 
The decision to choose mixed methods can be multifactorial but is broadly because qualitative 
and quantitative techniques produce different types of data and for some research questions a 
combination is better suited to the subject of interest. 
 
There are many reasons for mixing methods. Bryman (2008, pp. 608–609) has specified sixteen 
main reasons why researchers mix methods. In relation to the current study the rationale for 
mixing methods was for the following reasons: 
• Triangulation – the combination of both qualitative and quantitative approaches to 
triangulate or corroborate the findings. 
• Offset – offsetting the limitations of both qualitative and quantitative methods to 
maximise the strengths of each. 
• Completeness – using both qualitative and quantitative methods to gain a more complete 
account of the area being investigated. 
• Different research questions – if the research question has multiple parts, qualitative and 
quantitative methods can be used to answer each part. 
• Explanation – when one method helps to explain the other. 
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• Unexpected results – when one method is used to explain unexpected results from the 
other method. 
• Instrument development – when the results of the qualitative phase are used to develop 
an instrument to collect quantitative data (in a sequential exploratory strategy). 
• Credibility –using both methods enhances the integrity of the research. 
• Utility – when combining both methods provides results that will be more useful to 
practitioners. 
• Enhancement – when a second method is used to build on findings from the initial 
method. 
 
4.2.2.2 Choice of mixed methods format  
Mixed methods studies can use a variety of different formats depending on the order in which data 
are collected, the emphasis given to the different stages of the study and where the ‘mixing’ occurs 
(Creswell, 2014). In this study it was decided to collect the qualitative data first to gain a fuller 
understanding of the individuals, the system and their experiences. These data were then analysed 
to inform the development of the questionnaire which generated the quantitative data. This 
technique is defined as the sequential exploratory strategy as each phase is given equal weight and 
one phase follows on from the other. This method is well suited if a tool needs to be developed for 
the quantitative phase of data collection (Creswell, 2014), see Figure 4-1. 
 
  


























Figure 4-1 Schematic of Sequential Exploratory Strategy 
 
As with all techniques, there are advantages and disadvantages of employing the sequential 
exploratory strategy. The advantages are that a tool, in this case a questionnaire, can be 
developed based on the results of the qualitative phase and therefore has some evidence 
underpinning the choice of questions asked. The disadvantages are that, due to the sequential 
nature there is a large time commitment to ensure that each phase can run in the correct 
order and sufficient time is allowed for all of the stages involved. 
 
HES data study 
Investigating medicines-related 
admissions to hospital from 2008 - 2015
Patient interviews
Hospital in-patients who were admitted 
with a medicines-related problem
Pharmacist interviews
Community pharmacists providing the 
Medicines Use Review service
Development of questionnaire
Using data from both patient and 
pharmacist interviews
Community pharmacist survey
Available online and publicised using 
professional pharmacy networks, 











Chapter Four | Methodology 
 
 114 
Often studies conducted using the sequential exploratory technique use the same population 
for the qualitative and quantitative phases of the study. In this instance two different 
populations were included in the qualitative phase; patients and community pharmacists. This 
was to ensure that a wider breadth of information was gathered about the patients’ and 
community pharmacists’ experiences. This enabled the questionnaire to ask the correct 
questions to gain as full an insight as possible into the community pharmacists’ attitudes and 
experiences towards MURs. 
 
The mixed-method approach was chosen as it would allow the research questions to be 
answered more effectively. The research questions, which are restated below, cannot be 
answered using a single qualitative or quantitative technique; they require both types of data 
to give a thorough and convincing picture of the current landscape of post-discharge 
medicines support, its potential relationship to medicines-related hospital admissions, and to 
enable recommendations to be made about how to improve the system. 
 
Research questions: 
1. Are medicines-related admissions to hospital a problem in England and what 
medicines are implicated? 
2. What are the experiences of patients who have had a medicines-related admission to 
hospital? 
3. What are the experiences and attitudes of patients towards PD-MURs and medication 
reviews in general? 
4. What are the attitudes of community pharmacists conducting PD-MURs and do these 
attitudes have any effect on the engagement of community pharmacists with PD-
MURs?  
 
4.2.2.3 Mixed methods and theoretical perspectives 
Creswell & Plano Clark (2011) subscribe to a similar view as Crotty (2003) in terms of how they 
view the inter-relationships between worldviews, philosophical perspectives, methodology 
and methods. They present various philosophical assumptions that are made when conducting 
mixed methods research. In this study, which used the sequential exploratory strategy, for the 
initial qualitative phase an interpretivist stance is assumed. This indicated that the study was 
aiming to find out what the experience was like for an individual and how they ascribed 
meaning to their experience. The results of this phase were then analysed to inform the 
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development of an instrument for the quantitative phase of the study. The assumptions for 
the quantitative phase of the study were based on a positivist stance where less emphasis was 
given to how an individual attributed meaning to their experiences and greater emphasis was 
given to trying to discover the ‘real world’. 
 
4.3 Overview of methods used 
For this study there were various different methods employed at different phases of the research. 
Figure 4-1 gave an overview of the study in a graphical format showing the distinct phases. The 
methods used for each phase are shown in Table 4-1. 
 
Table 4-1 Methods used, data generated, and analytical techniques used in fieldwork 
Stage of study Source of data Analytical technique used 
HES data study. Routinely collected HES data. Quantitative descriptive analysis. 
Patient interviews. Semi-structured interviews. Interpretative phenomenological 
analysis. 
Pharmacist interviews. Semi-structured interviews. Thematic analysis. 
Community pharmacist survey. Questionnaire. Quantitative descriptive and 
inferential analysis of numerical 
data and linkage to demographic 
data. 
Factor Analysis. 
Qualitative thematic analysis of 
free text responses. 
 
As mentioned at the start of this chapter, a description of the methods for each stage of the 
study are included in the corresponding chapter. 
 
4.3.1 Ethical considerations 
When conducting research, it is vitally important that ethical considerations are made at all 
stages of the study. This is essential not only to protect the participants but also the 
researchers conducting the study. The Economic and Social Research Council have six key 
principles of ethical research: 
• research should aim to maximise benefit for individuals and society and minimise risk 
and harm. 
• the rights and dignity of individuals and groups should be respected. 
• wherever possible, participation should be voluntary and appropriately informed. 
• research should be conducted with integrity and transparency. 
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• lines of responsibility and accountability should be clearly defined. 
• independence of research should be maintained and where conflicts of interest cannot 
be avoided, they should be made explicit. 
(Economic and Social Research Council, 2018) 
In order to obtain the necessary approvals to conduct the study, it was mandatory to detail the 
ethical considerations. The considerations for each stage of the study are explained in 
Chapters 5, 6, 7 and 8. 
 
4.3.2 Ethical approvals 
The protocol and related documents for the study were reviewed by the required NHS and 
University panels and approvals were granted as follows: 
• University of Bath’s agreement to act as sponsor under the Department of Health’s 
Research Governance for Health and Social Care (2005) framework on 30th April 2015. 
• NHS research ethics committee approval was gained from the National Research Ethics 
Services (NRES) Committee, East Midlands, Nottingham 2, on 11th June 2015, 
reference 15/EM/0239. 
• NHS Research and Development service approval for the study to be conducted at 
Gloucestershire Hospitals NHS Foundation Trust was received on 1st July 2015, 
reference 15/003/MTS. 
 
Due to the nature of the sequential exploratory strategy, with the plan to develop the 
questionnaire based on the findings from the preceding qualitative phases of the study, it was 
necessary to first gain approval for the qualitative phases only. Once these phases were 
completed and the questionnaire developed, it was necessary to gain approval for the 
quantitative phase of the study. As previously agreed, an amendment was submitted to the 
NRES committee but in the interim period, the process for gaining NHS approvals for 
conducting research changed. Health Research Authority (HRA) approval was required in place 
of the previous local R&D approval. These approvals were granted and are detailed below: 
• NHS research ethics committee East Midlands, Nottingham 2, amendment approval on 
13th January 2017, amendment number SA1. 
• HRA approval on 18th January 2017. 
 
Copies of the ethical approval documents are included in Appendix B. 
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4.4 Summary of methodology chapter 
This chapter has provided a synopsis of the methodology that underpinned this study. It has 
stated the rationale for the methodology used and the basis for using a mixed methods 
approach; the sequential exploratory strategy. The following chapters describe the methods, 
results and a brief discussion of each phase of the fieldwork conducted during the study. This 









Chapter Five | Hospital Episode Statistics Study 
 119 




This chapter presents the findings of the preliminary phase of fieldwork that utilised routinely 
collected data, namely hospital episode statistics, to determine whether medicines-related 
admissions to hospital have changed over time. A summary of the methods used to collect and 
analyse the data is presented, followed by the results. To conclude the chapter is a brief 
discussion of how these results compare to other studies that have used HES data in the 
published literature. 
 
5.1 Introduction  
This chapter will concentrate on the analysis of HES data that are routinely collected by all NHS 
hospitals in England. The rationale for conducting this preliminary work was to determine 
whether medicines-related admissions to hospital were a growing or diminishing problem. A 
previously published paper by Wu et al. (2010) focused on medicines-related hospital 
admissions from 1999 to 2009 and the aim of this phase of the study was to analyse more 
recent data to discover whether the situation had changed. 
  





Figure 5-1 Schematic of study – HES data study 
 
5.2 Methods for the HES study 
This phase of the study focussed on using routinely collected, HES data from NHS Trusts in 
England, to determine whether the burden of medicines-related admissions to hospital had 
changed between 2009 to 2015. The rationale for choosing these dates was based on a 
previously published paper Wu et al. (2010) which covered the years from 1999 to 2009. Wu et 
al., (2010) investigated medicines-related admissions to NHS hospitals in England and reported 
that they were an increasing problem over the time period they studied. The first phase of the 
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current study used publicly available HES data to try and establish whether medicines-related 
admissions to hospital were still an increasing problem and if the medicines implicated in these 
admissions had changed over time. 
 
5.2.1 Critique of published paper by Wu et al. (2010) 
The paper written by Wu et al. (2010) was published in the Journal of the Royal Society of 
Medicine. It was assessed using the RECORD statement (Benchimol et al., 2015) which is the 
reporting guideline for studies conducted using routinely-collected health data. This checklist 
showed that the authors reported most of the items that should be included in a high-quality 
study. The title and abstract detailed the type of data included, the database used and the 
geographical area and timeframe of the study. It did not, however, include information about 
the linkage between databases. 
 
The main body of the paper included information about the selection of the population and 
details of the ICD-10 codes that were used in the study and available in an appendix. Although 
validation of the included codes was not specified, detailed methods were provided. Details 
about how records were linked was included in the text but there was no accompanying 
annotated diagram to summarise the process or a description of methods of data linkage. The 
authors did not include details of the extent of their access to the HES database or include 
information about how the data were cleaned. 
 
Finally, the authors did include a discussion about the limitations of using routinely collected 
data for research. On the whole, the paper performed well against the criteria in the RECORD 
statement. It must be borne in mind that the paper was published before the RECORD 
statement had been developed. 
 
A note about nomenclature: Wu et al. (2010) used the term ADR in their paper and this term 
has been used in this chapter. They defined an ADR as ‘an undesirable effect of a drug beyond 
its anticipated therapeutic effects occurring during clinical use’. 
 
5.2.2 The HES database 
As briefly discussed in section 3.3.1, HES data are collected and submitted each month by 
every NHS hospital trust in England, detailing in-patient admissions, out-patient appointments 
and ED attendances (NHS Digital, 2018b). Although the data are collected primarily for 
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payment purposes, they are designed to be used for non-clinical purposes also. The in-patient 
data have been collected since 1989 and the monthly reports are freely available on the NHS 
Digital website (NHS Digital, 2017c, 2017b). 
 
Each HES record contains data on an individual patient admitted to a NHS hospital in England 
and includes details such as their diagnosis, age, gender, ethnicity, dates of admission and 
discharge and geographical information about the hospital and where the patient lives (NHS 
Digital, 2018b). There are strict rules which ensure that if there are small numbers of patients 
that fall into a particular category the numbers are supressed to avoid patients being 
identified, thereby maintaining patient confidentiality (NHS Digital, 2018b). 
 
Each record in the database that relates to hospital admissions is referred to as a ‘finished 
consultant episode’ (FCE); this is the time a patient is under the care of one consultant in a 
particular hospital. If the patient transfers to the care of a different consultant or moves to a 
different hospital, this would represent another FCE (NHS Digital, 2015b). 
 
5.2.3 Ethical considerations of using routinely collected data 
The use of routinely collected data for research purposes does raise some ethical issues, 
especially if data are linked, which does involve a form of identification, even if results are then 
anonymised. 
 
The use of routinely collected patient data for health research has been discussed by Foster 
and Young (2011) who considered the ethical implications of using these data for research. The 
majority of patients are willing to allow their routinely collected data to be used for research, 
although it can depend on several factors including the data required and the purpose of the 
research (Foster and Young, 2011). 
 
Patients have often consented to the use of their data for research, such as the ‘secondary 
uses service’ within the summary care record (SCR), but it is debateable whether they fully 
understand that data about them, although anonymised, will be used for research purposes, 
hence they may not have made a truly informed choice or consent (Foster and Young, 2011). It 
would be impossible to gain informed consent from every patient in a database such as HES. 
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Research using routinely collected data can have societal benefits, but this assumes that the 
research is ‘good’ or ‘important’. It is often assumed that patients have a responsibility to help 
others through ‘altruistic participation’ (Foster and Young, 2011). 
 
In the current study only publicly available, anonymised data were used and no linkage of 
records occurred, hence it was not possible to identify any individuals. The study protocol 
received ethics approval from the bodies detailed in section 4.3.2. 
 
5.2.4 Sampling of HES database 
HES data use ICD-10 (WHO, 2018) for coding the diagnoses of each hospital admission. HES 
annual reports are published and publicly available on the NHS Digital website (known as the 
Health and Social Care Information Centre, until July 2016 (NHS, 2016)). The datasheets for 
emergency in-patient admissions from 2008/9 to 2014/15 were used for this study so that the 
data followed on from that used by the Wu et al. (2010) study. 
 
5.2.5 Data extraction and checking 
The study by Wu et al. (2010) contained a list of four-character ICD-10 codes that indicated a 
medicines-related admission to hospital had occurred. This was based on the use of the 
following keywords: ‘adverse drug reaction’, ‘drug-induced’, ‘due to drug’, ‘due to 
medicament’ or ‘drug allergy’. They also included ADRs that were due to immunisations as 
they considered vaccines to be a medication. The same list was used for this study, see Table 
14-1 in Appendix C. Table 14-2 in Appendix C illustrates the codes that indicated a particular 
medicine was responsible for the admission, known as external codes. For the purposes of this 
study, any admission that was due to an overdose was excluded as it could not be determined 
from the data whether this was intentional or accidental. 
 
The HES annual reports were scrutinised and emergency admissions that had one of the ICD-
10 codes of interest as the primary diagnosis, or an external code in any diagnoses field were 
included in the study. There was no linkage in the current study as only the publicly available 
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For each ICD-10 code or external code of interest, for each year, the number of FCEs and bed 
days were copied into a spreadsheet that was created in Microsoft Excel (2013). As this 




To analyse the data, formulae were used in Excel to total the FCEs and bed days for each ICD-
10 and external code. The data relating to the ICD-10 codes were then combined into 
‘chapters’, which group similar diagnoses/causes together, as per the ICD-10 coding system. 
 
5.3 Results of HES study 
5.3.1 Emergency hospital admissions 
Table 5-1 shows that between 2008 and 2015 there were 37,085,460 all-cause emergency 
admissions to hospitals in England; of these 541,416 (1.5%) were due to an ADR. The number 
of all-cause emergency admissions increased from 5,010,670 in 2008/9 to 5,615,707 in 
2014/15, representing an increase of 12.1%. The total number of emergency admissions that 
were coded as being due to an ADR increased from 60,055 in 2008/9 to 92,114 in 2014/15, 
representing an increase of 53.4%. These data show that the proportion of emergency hospital 
admissions that were due to ADRs increased from 1.2% in 2008/9 to 1.6% in 2014/15, 
demonstrating that the burden of ADRs is increasing in the NHS in England year-on-year.  
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Table 5-1 Total number of emergency hospital admissions and emergency hospital 

















































due to ADRs 




due to ADRs 
1.2 1.3 1.4 1.5 1.5 1.6 1.6  
 
5.3.2 Bed days utilised 
Table 5-2 shows the number of bed days utilised for all causes decreased from 51,841,443 in 
2008/9 to 48,183,084 in 2014/15, representing a decrease of 7.1%. Over the same period, the 
number of bed days that were utilised due to an ADR increased from 625,011 in 2008.9 to 
947,016 in 2014/15, representing an increase of 51.5%. The percentage of the total bed days 
that were used due to an ADR increased from 1.2% in 2008/9 to 2.0% in 2014/15, again 
showing that ADRs are an increasing problem for the NHS in England. 
  
Chapter Five | Hospital Episode Statistics Study 
 
 126 
Table 5-2 Total number of bed days and number of bed days utilised for a primary diagnosis 
















































542,869 625,025 667,375 676,391 726,541 806,184 851,866 36.3 
Total FCE 
bed days 
due to ADRs 
625,011 706,072 759,575 760,869 818,805 896,270 947,016 51.5 
Percentage 
FCE bed 
days due to 
ADRs 
1.2 1.4 1.5 1.6 1.7 1.9 2.0  
 
 
5.3.3 Emergency admissions due to ADRs by ICD-10 code 
The ICD-10 diagnoses codes that indicated an ADR had occurred were combined into their 
corresponding ICD-10 chapters; a chapter contains ICD-10 codes that are linked, generally by 
body system. The results, by chapter, are presented in Table 5-3. Some of the numbers of 
patients in certain chapters are quite small and show high levels of variation from year to year 
as they include conditions that are rare. 
 
In 2014/15, the main reason that patients were admitted to hospital as an emergency due to 
an ADR were for mental and behavioural disorders due to drugs, followed by complications 
following injection, immunisations or anaesthesia, and then cardiovascular consequences due 
to drugs. From 2013 to 2014 there was a 4.4% increase in the number of prescription items 
dispensed for the central nervous system; this category includes medicines used to treat 
mental health conditions, insomnia and pain (Prescribing and Medicines Team HSCIC, 2015b), 
which are more likely to result in this type of ADR. 
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Looking at the temporal trends, between 2008/9 and 2014/15, ADR-related hospital 
admissions caused by mental and behavioural disorders increased by 95%, toxic liver disease 
increased by 87.7% and drug-induced metabolic disorders increased by 79.1%. The increase in 
the last category was solely due to emergency admissions for drug-induced hypoglycaemia 
without an accompanying coma. Between 2005/6 and 2014/15, there was a 74% increase in 
the number of prescriptions for all medicines used to treat diabetes and a 41.4% increase in 
the number of prescription items for insulins (Prescribing and Medicines Team HSCIC, 2015a). 
This huge increase in prescribing could explain the corresponding increase in emergency 
admissions for hypoglycaemia. 
 
Between 2008/9 and 2014/15, the only category to show a decrease in emergency hospital 
admissions were those due to drug-induced cataracts or hearing loss but no conclusions can be 
drawn about this as such small numbers were involved. 
 





























Chapter         
D Drug-induced anaemia 113 102 114 130 151 170 156 
E Drug-induced metabolic 
disorders 627 753 904 945 1,037 1,090 1,123 
F Mental and behavioural 
disorders due to drugs 1,481 1,568 1,789 1,874 2,189 2,378 2,888 
G Drug-induced neuromuscular 
disorders 486 505 551 537 594 632 638 
H Drug-induced cataract and 
hearing loss 3 0 2 1 2 2 0 
I Cardiovascular consequences 
due to drugs 1,401 1,488 1,668 1,609 1,752 1,709 1,693 
J Drug-induced liver disorders 47 50 52 47 53 35 50 
K Toxic liver disease 171 211 198 213 212 270 321 
L Dermatitis due to drugs 1,148 1,181 1,308 1,346 1,407 1,542 1,527 
M Drug-induced immune disorders 82 78 91 85 90 79 87 
N Nephropathy due to drugs 54 62 83 83 73 71 56 
T Complications following 
injection, immunisation or 
anaesthesia 
1,808 2,028 1,999 1,926 1,830 2,016 1,973 
 TOTALS 7,421 8,026 8,759 8,796 9,390 9,994 10,512 
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5.3.4 Medicines which caused emergency hospital admissions due to ADRs 
Table 5-4 shows the medicines that were implicated in medicines-related admissions to 
hospital from 2008/9 to 2014/15. In 2014/15 the most common group of medicines involved in 
ADRs were systemic agents, which accounted for 23.6% of all ADR emergency admissions 
where a medicine was recorded. This group includes antineoplastic and immunosuppressant 
medicines. These medicines have well documented, and sometimes serious side-effects, it 
would be expected that some patients taking this group of medicines would require hospital 
admission due to an ADR. 
 
The next most commonly implicated group of medicines in 2014/15 were analgesics, 
antipyretics and anti-inflammatory drugs (12.6% of ADR-related emergency admissions where 
a medicine was recorded) followed by medicines primarily affecting the cardiovascular system 
(11.2% of ADR-related emergency admissions where a medicine was recorded). The analgesic 
category includes medicines such as aspirin, non-steroidal anti-inflammatory medicines and 
opioids, which often appear on the lists of medicines that are most likely to cause a medicines-
related problem (Howard et al., 2007). 
 
Again, looking at the temporal trends over the study period 2008/9 to 2014/15, the 
medications that resulted in the greatest increases in emergency hospital admissions were: 
agents affecting the gastrointestinal system (122.3% increase), hormones and their synthetic 
substitutes (86.2% increase) and sedatives, hypnotics and anti-anxiety drugs (73.4% increase). 
The huge increase in emergency admissions coded as secondary to gastrointestinal drugs could 
be a reflection of the fact that between 2005 and 2015 the number of prescription items 
dispensed for antisecretory drugs increased by 125.4%, from 26.9 million items to 60.8 million 
items (Prescribing and Medicines Team HSCIC, 2016). 
 
The only reduction in medicines-related admissions was for topical medicines affecting the 
skin, mucous membranes, eyes, mouth, throat and teeth, which showed a reduction of 41.3% 
from 2008/9 to 2014/15. 
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Y40 Systemic antibiotics 5,394 5,670 6,316 6,707 7,257 7,635 8,132 
Y41 Other systemic anti-infectives 
and anti-parasitics 1,151 1,476 1,510 1,648 1,795 1,817 1,820 
Y42 Hormones and their synthetic 
substitutes and antagonists 3,570 4,237 4,855 5,107 5,901 6,432 6,648  
Y43 Primarily systemic agents 11,746 13,669 15,673 16,434 17,028 18,491 19,253 
Y44 Agents primarily affecting blood 
constituents 2,406 2,567 2,784 2,831 3,044 3,317 3,620 
Y45 Analgesics, antipyretics and anti-
inflammatory drugs 6,536 7,600 8,031 8,520 8,822 9,548 10,242  
Y46 Antiepileptics and anti-
Parkinsonism drugs 1,157 1,282  1,308 1,460 1,446 1,615 1,686 
Y47 Sedatives, hypnotics and anti-
anxiety drugs 451 555 528 637 644 796 782 
Y48 Anaesthetics and therapeutic 
gases 256 299 284 310 327 318 400 
Y49 Psychotropic drugs, not 
elsewhere categorised 1,821 2,177 2,259 2,484 2,541 2,697 2,829 
Y50 Central nervous system 
stimulants, not elsewhere 
classified 
56 79 84 96 106 93 87 
Y51 Drugs primarily affecting the 
autonomic nervous system 2,805 3,162 3,287 3,299 3,595 3,765 3,626 
Y52 Agents primarily affecting the 
cardiovascular system 6,555 7,257 7,528 7,852 8,518 8,973 9,142 
Y53 Agents primarily affecting the 
gastrointestinal system 637 773 784 866 973 1,227 1,416 
Y54 Agents primarily affecting the 
water-balance and mineral and 
uric acid system 
4,220 4,739 5,120 5,360 5,966 6,389 6,606 
Y55 Agents primarily acting on 
smooth and skeletal muscle and 
respiratory system 
270 295 316 362 364 368 447 
Y56 Topical agent primarily affecting 




829 863 1053 966 501 495 487 
Y57 Other and unspecified drugs and 
medicaments 2,261 2,587 2,778 2,976 3,293 3,562 3,793 
Y58 Bacterial vaccines 139 140 130 151 145 160 166 
Y59 Other and unspecified vaccines 
and biological substance 374 546 395 415 376 465 420 
 TOTALS 52,634 59,973 65,023 68,481 72,642 78,163 81,602 
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5.4 Discussion of findings of HES study 
This study has shown that ADR-related admissions have increased each year, both in terms of 
the proportion of total emergency admissions and bed days utilised. This has been found both 
in this study, and in data published by NHS Digital (NHS Digital, 2017c). The proportion of ADR-
related admissions in this study was 1.6% in 2014/15. This compares to 1.1% in the study that 
was conducted by Wu et al., (2010), on which the current study was based. This result implies 
that ADR-related emergency hospital admissions are a persistent and increasing problem for 
the NHS. This study also found that 2% of bed days were utilised treating patients who had 
experienced an ADR.  
 
It could be argued that the increase in the proportion of hospital admissions due to ADRs is a 
result of an increase in the number of prescription items issued over the same period. This 
does not appear to be the case, as the 53.4% increase in emergency admissions due to ADRs 
between 2008 and 2015 (financial years) outstripped the 28.6% increase in prescription items 
dispensed (from 842 million to 1,083 million) between 2008 and 2015 (calendar years) 
(Prescribing and Medicines Team HSCIC, 2016). 
 
Other studies, that used different methods of data collection, found higher rates of ADR-
related emergency hospital admissions. A major prospective observational study conducted by 
Pirmohamed et al., (2004), found 6.5% of emergency admissions were due to an ADR. This 
higher prevalence would be expected as researchers were specifically able to identify ADR-
related admissions in real-time rather than relying on analysing routinely collected data 
retrospectively. 
 
It could be argued that using routinely collected data, such as HES, would underestimate the 
true prevalence of ADR-related admissions because it is often difficult to accurately identify 
that a medicine has been the main cause of a hospital admission; an ADR may be confused 
with a new symptom or a complication of an existing condition. There are other inherent 
difficulties in using routinely collected data such as the input of data by a huge number of 
different organisations and changes in coding practices over time which would lead to 
variations in the accuracy and quality of the data. There is also no indication of when the ADR 
may have occurred; it could have been prior to or during the admission. 
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In this study the medicines which caused most ADR-related emergency admissions were 
systemic agents (23.6%); analgesics, anti-pyretics and NSAIDs (12.6%); and cardiovascular 
drugs (11.2%). These were the same medicines found by Wu et al., (2010) to be the main 
causes of ADR-related emergency admissions with comparable percentages also; systemic 
agents (19.2%), analgesics (13.3%) and cardiovascular drugs (12.9%). Other studies have also 
concluded that these medicines are amongst those most commonly implicated in ADR-related 
hospital admissions (Smith et al., 1997; Roughead et al., 1998; Howard et al., 2003, 2007; 
Pirmohamed et al., 2004; Kongkaew, Noyce and Ashcroft, 2008; Brvar et al., 2009; Davies et 
al., 2009; Kongkaew et al., 2013; Pedros et al., 2014). 
 
The consequences of these ADR-related hospital admissions were again comparable between 
this study and that conducted by Wu et al., (2010), with mental and behavioural disorders due 
to drugs, complications following injection, immunisation or anaesthesia and cardiovascular 
consequences due to drugs being the most common manifestations of ADRs (Wu et al., 2010). 
 
This phase of the study has emphasised that medicines-related hospital admissions are still a 
persistent problem for patients and the NHS as a whole. As discussed earlier in the thesis, 
some of these medicines-related problems could have been predicted and therefore 
potentially prevented. Medicines-related problems that result in a hospital admission cause 
distress to the patients affected, both physiologically and psychologically, as well as higher 
costs to the NHS through increased length of stay and treatments required. It was estimated 
that in 2015, avoidable ADR-related hospital admissions cost the NHS £530 million (NICE, 
2015b). 
 
All these data showed the ‘big picture’ in relation to ADR-related hospital admissions, but it is 
important to consider the burden for the individual patients. Before focussing on how 
community pharmacy-based medication review could contribute to ameliorating medicines-
related hospital admissions, it was important to find out first-hand how a medicines-related 
admission to hospital affected a cohort of patients and what their experiences of medication 
review had been.  
 
5.5 Strengths and limitations of the HES study 
This study used data from every emergency patient admission to NHS hospitals in England 
from 2008/9 to 2014/15, which represented a vast dataset. The advantage of using routinely 
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collected data is that they are collected in a standard way, cleaned, collated and quality 
assessed. These data have been collected since 1989, so trends can be shown in areas such as 
emergency hospital admissions (NHS Digital, 2017b). 
 
The limitations of using routinely collected data are that they are collected and entered by so 
many different people there are bound to be variations in the process of recording the data 
from each hospital and also missing or inaccurate data. There is the inherent problem of 
correct identification of an ADR and the subsequent accurate coding as such. Brvar et al., 
(2009) found that only one patient out of the 30 in their study had their ADR-related hospital 
admission coded correctly. Over time the ways of recording data may also have changed; it is 
possible that the increases in ADR-related emergency admissions shown in the current study 
could reflect an improvement in the identification and recording of ADRs over time. The HES 
data used in this study only covered England and the situation may be different in other 
countries such as Wales or Scotland, due to different NHS systems and data recording in place 
there. The use of HES also means that there is no information about when the ADR occurred, 
whether that was prior to or during the hospital admission. The data also do not include the 
source of medicines that patients are taking, so some medicines may have been purchased 
over the counter rather than prescribed by a doctor. 
 
This phase of the study used only publicly available HES data, meaning that no patient linkage 
was possible. This means that a patient with more than one FCE covering their single hospital 
admission could be counted more than once in the dataset. This lack of data linkage also 
meant that the emergency admissions due to ADRs that were coded with an ICD-10 as a 
primary diagnosis were not linked to emergency admissions that were also coded with an 
external or medicine tagged code; these may have been recorded as the secondary or tertiary 
diagnosis. This again means that a single patient admission could be counted more than once if 
the primary diagnosis was one of the chosen ICD-10 codes and a subsequent code also 
recoded the medicine implicated. The data used for this study were not linked to mortality 
data either, which would have given an insight into the seriousness of the ADRs recorded. It 
has recently been suggested that avoidable ADRs directly result in 712 deaths and contribute 
to 1,708 deaths per year in the NHS (Elliott et al., 2018). It was also not possible to confirm 
whether medicines were definitely the cause of the admissions, the severity of the ADRs, or to 
deduce whether the ADRs were preventable. 
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5.6 Future research 
If HES data linkage were used, further studies could be conducted to gain a fuller 
understanding of the burden of ADR-related admissions on the NHS in England. For example, it 
would be useful to find out whether an ADR-related admission was more likely to occur in 
someone who has recently been discharged from hospital. If it were possible to combine HES 
data with GP practice data, it would be beneficial to identify the characteristics of patients that 
put them at higher risk of an ADR-related hospital admission with regard to factors such as age 
or comorbidities. 
 
5.7 Summary of the HES study chapter 
The results of the analyses of the HES data between 2008/9 and 2014/15 demonstrate that 
medicines-related admissions to hospital are an increasing problem for the NHS in England. It 
is therefore vitally important for all HCPs working within the NHS to ensure that everything 
possible is done to try and reduce the number of ADRs that are occurring. 
 
Community pharmacists have a crucial role in trying to minimise ADRs, whether through 
patient education, HCP education, prescription monitoring or enhanced support for patients 
around the time of hospital discharge, which is a high-risk time for patients managing their 
medicines.  
 
Through the PD-MUR service, community pharmacists can help patients to manage their 
medicines effectively after discharge, but this is currently an under-utilised service for a 
number of reasons. The next phase of the study investigated what it was like to be a patient 
admitted to hospital due to a medicines-related problem and looked for insights from patients 
into how the MUR service could be improved for their benefit. Investigating these issues from 
the patient perspective allowed the patients’ voice to be heard and their experiences 
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This chapter presents the findings of the in-depth, semi-structured interviews that were 
conducted with patients who had been admitted to hospital with a medicines-related 
problem.  Patients were asked about their experiences of their hospital admission and 
medication reviews in the community. The chapter starts with a summary of how the patients 
were identified, the process of consent and being interviewed, through to an analysis of their 
responses using the technique, interpretative phenomenological analysis (IPA). 
 
6.1 Introduction  
This chapter will focus on the patient interviews that were conducted after the analysis of HES 
data. Figure 6-1 shows where the patient interviews fit into the study as a whole. They are the 
first part of novel data collection in this study and form the first qualitative stage of the 
sequential exploratory strategy. As well as providing a unique insight into what it is like to be a 
patient who has been admitted to hospital because of a medicines-related problem, the 
results of the patient interviews helped to shape the content of the questionnaire for 
community pharmacists which was the final quantitative stage of the sequential explanatory 
strategy. 
  




Figure 6-1 Schematic of study – Patient interviews 
 
6.2 Methods for patient interviews 
The first qualitative phase of the study focussed on the patient experience. Patients who were 
admitted to hospital because of a medicines-related problem were interviewed during their in-
patient stay. The focus of the interview was their experience of being admitted to hospital and 
medication reviews in primary care. The plan was to follow them up after their discharge to 
establish whether a post-discharge medication review had occurred and their opinions and 
experiences of that process.  
 
HES data study 
Investigating medicines-related 
admissions to hospital from 2008 - 2015
Patient interviews
Hospital in-patients who were admitted 
with a medicines-related problem
SEVEN PATIENTS RECRUITED
Pharmacist interviews
Community pharmacists providing the 
Medicines Use Review service
Development of questionnaire
Using data from both patient and 
pharmacist interviews
Community pharmacist survey
Available online and publicised using 
professional pharmacy networks, 
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Semi-structured interviews were chosen because they allowed the researcher to ask open-
ended questions, enabling the participants to give their experiences and opinions in their own 
words. The principal investigator (PI) was also able to give a face-to-face explanation of the 
study to participants, which was preferable to only a letter or information sheet; especially for 
participants with reading difficulties or less well-educated participants (Oppenheim, 1992). Not 
all participants will be eloquent or insightful and that can affect the data generated during the 
interview process (Creswell, 2014). Other qualitative techniques such as unstructured 
interviews, focus groups or ethnography would not produce such personal in-depth accounts 
which were required for the development of the questionnaire (Oppenheim, 1992; Bryman, 
2008). The use of semi-structured interviews was also necessary for the use of IPA as the 
analytical technique (Smith, 2011).  
 
6.2.1 Ethical considerations for patient interviews 
As hospital in-patients were interviewed for this phase of the study it was vitally important 
that their health and wellbeing was the priority. The PI did not approach any patient before an 
independent person had introduced the study to them and they had agreed to speak to the PI. 
This was to ensure that any participation was voluntary and to respect the patient’s rights and 
dignity without pressurising them. Patients were provided with oral and written information 
about the study, they were given sufficient time to consider the information and informed 
how to withdraw from the study at a later date if they wished. Anonymity and confidentiality 
were also maintained throughout their participation in the study. 
 
6.2.2 Sampling process for patient interviews 
Patients were recruited from wards at Gloucestershire Royal Hospital (GRH), a district general 
hospital with 683 beds in South West England, using a purposive sampling method. The PI was 
employed as a clinical pharmacist by the Trust and therefore had access to patient information 
as part of their usual role. Other pharmacists and doctors working on the in-patient wards 
were also encouraged to identify patients who had been admitted with a medicines-related 
problem. The evidence shows that medicines-related hospital admissions are more prevalent 
in patients over 65 years old (Garcia-Caballos et al., 2010). These patients were most likely to 
be found on the admissions ward or the care of the elderly wards, but suitable patients on any 
wards were also sought. The PI organised a publicity campaign for the study, focussing 
particularly on staff who worked in areas where suitable patients were most likely to be found. 
The PI sent periodic emails informing and reminding colleagues about the study, a lunchtime 
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meeting for pharmacists was arranged to explain the study in more detail and posters were 
displayed within the pharmacy department and on the elderly care wards (see Appendix D) 
reminding pharmacists and doctors to look for patients during their ward duties. 
 
Potential participants for this phase of the study were highlighted to the PI, who reviewed the 
patient’s medical notes to assess the patient against the inclusion and exclusion criteria for the 
study which are detailed in Figure 6-2. Patients who met any of the exclusion criteria were 




Figure 6-2 Inclusion and exclusion criteria for patient interviews 
 
If the inclusion criteria were met and no exclusion criteria applied, the case was discussed with 
one of the doctors caring for the patient. This was to ensure that the patient’s current 
admission was definitely medicines-related, the patient was aware that they had been 
admitted to hospital due to a medicines-related problem and, they had capacity to consent to 
participate in the study. An independent member of hospital staff, for example the doctor, a 
nurse or pharmacy technician, then informed the patient about the study, and if the patient 
agreed, they were then approached by the PI. The PI spoke to the patient to explain the study 
and gave them a participant information sheet. If time allowed, the patient was given 24 hours 
to consider their participation in the study before the PI returned to ask whether they gave 
consent to participate and if so, they were interviewed. If the patient was due to be discharged 
within the next 24 hours, the study was introduced and, if they were willing to participate, 
they were consented and interviewed on the same day. If the patient did not have the 24-hour 
Inclusion criteria
Registered with a GP in England and use a 
community pharmacy in England.
Admitted to hospital with a medicines-related 
problem.
Able to manage their own medicines at home.
Able to attend their community pharmacy for a 
PD-MUR.
Have capacity to consent to participate – this 
may require physician assessment.
Exclusion criteria
Unable to consent to participate.
Live in a residential or nursing home.
Do not manage their own medicines.
Are unable to attend their community 
pharmacy.
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period to consider whether they wanted to participate in the study, the contact details of the 
PI and an explanation of how to withdraw from the study was emphasised to the patient at the 
time of the interview. 
 
The aim was to recruit up to 10 patients for this phase of the study. This was to ensure that a 
range of different patient types were represented in terms of gender, age, and if possible, 
ethnicity. The sample size was chosen based on the use of IPA as the technique for analysis of 
the interview transcripts. This technique uses an in-depth focus on the individual experience 
and a smaller sample size to gain rich data for this type of analysis (Smith, Flowers and Larkin, 
2009). 
 
6.2.3 Interview process for patient interviews 
Figure 6-3 shows how recruited patients progressed through the study.  
 
 
Figure 6-3 Patients’ progression through the study 
 
If the patient agreed to participate in the study, they were asked to sign a consent form and 
were then interviewed, whilst they were still in hospital, about their experiences of having a 
medicines-related hospital admission, the events leading up to their hospital admission and 
their opinions of medication reviews. The consent form and topic guide for the patient 
interviews can be found in Appendix D. The interviews were audio recorded then transcribed 
verbatim by the PI. The patient was given a £5 High Street voucher as a token of appreciation 
for taking part in the study. 
 
Follow-up interview in community within 12 weeks of discharge
Discharge medication information sent to community pharmacy
Interview whilst an in-patient
Inclusion criteria fulfilled and consent obtained
Patient identified as having a medicines-related admission
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When patients signed the consent form, they also agreed for the details of their discharge 
medication to be sent to their local community pharmacist. During the interview the patient 
was asked for details of their usual community pharmacy and when they were discharged from 
hospital, the PI sent (by post or fax) a copy of the discharge prescription to the pharmacy with 
a covering letter. This was designed to act as a prompt for the community pharmacist to 
conduct a PD-MUR. If the community pharmacy did not conduct MURs, if they had reached 
their annual MUR quota, or for a variety of other reasons, a PD-MUR may not always take 
place. This study aimed to reflect a ‘real-world’ scenario where the community pharmacist had 
the patient’s discharge information from the hospital to encourage them to engage the patient 
in a PD-MUR, whilst also acknowledging that this is not always possible. 
 
Once the patient had been discharged, the plan was to contact them by telephone, post or 
email (depending on their preference) up to 12 weeks after their discharge for a follow-up 
interview about their views and experiences of medication reviews. This was planned whether 
or not they had had a PD-MUR with their usual community pharmacist. This length of time was 
chosen as community pharmacists have up to 8 weeks to conduct a PD-MUR and this also 
allowed the patient time to recover from their hospital admission. Prior to the second 
interview taking place, the patient needed to sign the second section of the consent form. The 
plan was for these interviews to again be semi-structured and conducted face-to-face, either 
at the hospital or another agreed public location e.g. coffee shop. If the patient had to pay a 
car parking charge to attend the interview this would be reimbursed. If a face-to-face 
interview was not possible, a telephone interview would be offered as an alternative. The 
patient would be given a second £5 High Street voucher as a token of appreciation for 
participating in the second interview. Unfortunately, no patients participated in a second 
interview; more details about this can be found in section 6.2.8. 
 
After the interview had taken place, the audio-recording was transcribed verbatim by the PI 
and anonymised. The patients’ views remained confidential as per the ethical considerations 
presented in section 4.3.1; to respect the rights and dignity of individuals and conducting the 
research with integrity. If a patient wished to withdraw from the study, they were informed 
that they could do so at any time, without giving a reason, and they were given information 
about how to do this when they signed the consent form. Their responses would have been 
removed from the analysis, but no patients requested this. 
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The audio files were stored in password-protected files on an NHS computer. A file linking the 
patient’s demographic details to their audio recording was kept in a password protected file on 
an NHS computer. After the completion of the study the audio recordings were deleted 
without any break in confidentiality. The anonymised transcripts were analysed on a 
password-protected personal computer.  
 
The interviews were analysed using NVivo software, version 11 (QSR International), using the 
technique IPA. After the analysis was complete, the anonymised transcripts were stored in 
password-protected files on a personal computer. Five years after the finish date of the study, 
they will be deleted without any break in confidentiality. 
 
6.2.4 Analysis of patient interviews - Interpretative Phenomenological analysis (IPA) 
6.2.4.1 What is IPA? 
Smith, Flowers and Larkin (2009) have summarised IPA as: 
“a qualitative research approach committed to the examination of how 
people make sense of their major life experiences.” 
 
There are three main philosophical threads to this technique: phenomenology, hermeneutics 
and idiography, and each are discussed in turn below. 
 
6.2.4.2 Phenomenology 
The phenomenological underpinning of this technique comes from the work of the 
philosopher Edmund Husserl, who focussed on the ‘careful examination of human experience’ 
(Smith, Flowers and Larkin, 2009). This approach aims to find out how a person perceives an 
experience rather than trying to categorise an experience into a pre-existing framework. For 
this technique the researcher must bracket off, as much as possible, their own preconceptions 
and allow the individual’s account to speak for itself (Smith and Shinebourne, 2012; 
Pietkiewicz and Smith, 2014). This phenomenological stance was expanded on by philosophers 
that came after Husserl, such as Heidegger, who was concerned with the ways in which 
individuals make sense of an experience (Smith, Flowers and Larkin, 2009; Smith and 
Shinebourne, 2012); Merleau-Ponty, who developed the idea that an individual has an 
‘embodied’ relationship with the world and the lived experience of this can never be fully 
elucidated but must not be ignored (Smith, Flowers and Larkin, 2009); and Satre, who 
suggested that individuals interpret their experiences dependent on social and personal 
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relationships with others (Smith, Flowers and Larkin, 2009). These later philosophers all 
developed Husserl’s original stance of the importance of the lived experience and postulate 
that an individual interprets an experience in the context of their relationship with the world 
(Smith, Flowers and Larkin, 2009). This lived experience of an individual cannot just be 
‘obtained’ by the researcher. The researcher must engage with the individual and interpret 




Hermeneutics is derived from the Greek word, hermeneuo, meaning ‘to interpret’ or ‘to make 
clear’ (Pietkiewicz and Smith, 2014). Heidegger, who was a student of Husserl’s, was a 
proponent of hermeneutic phenomenology, whereby there has to be some interpretation of 
an individual’s account of an experience (Smith, Flowers and Larkin, 2009; Smith and 
Shinebourne, 2012). IPA is concerned with examining a particular experience and the 
researcher facilitates the interpretation of this experience. This has been described as a 
‘double hermeneutic’ process where the researcher is trying to make sense of an experience 
that an individual is trying to make sense of (Smith and Shinebourne, 2012). 
 
6.2.4.4 Idiography 
Finally, IPA is idiographic, meaning a concern for the detail and depth of the analysis (Smith, 
Flowers and Larkin, 2009). This means there is a focus on attempting to comprehensively 
understand what an experience is like for an individual. This is achieved by having a small, 
purposively-chosen sample to allow a greater depth of interrogation of the individual’s 
account of an experience. Some IPA studies have used single case analyses (Smith, Flowers and 
Larkin, 2009). Before any generalisations are made about an experience, the particular details 
of the experience from the individual(s) account(s) are analysed in turn. Generalisations are 
then tentatively developed whilst maintaining the depth of the individuals’ accounts of the 
experience (Smith and Shinebourne, 2012). 
 
6.2.5 Choice of IPA for this study 
6.2.5.1 Why IPA was chosen 
An in-depth study, intent on gaining a comprehensive account from patients would add to the 
knowledge base in this area due to its ideograph focus. Also, from a patient’s point of view, 
having a medicines-related admission to hospital may be a traumatic experience and could 
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become a significant event in their lives. This topic was therefore suited to a hermeneutic 
phenomenological approach, where there was an attempt to interpret what this experience 
was like for them. IPA was particularly suitable for the analysis of the patient interviews in this 
study because it was anticipated that there may have been a limited number of potential 
participants. This was because even though medicines-related hospital admissions are 
relatively common, they can be difficult to categorically identify. Also, there are a lack of data 
in the published literature about the experiences of patients who have been admitted to 
hospital with a medicines-related problem. There is a plethora of published literature about 
medicines-related admissions to hospital (Beijer and de Blaey, 2002; Winterstein et al., 2002; 
Pirmohamed et al., 2004; Kongkaew, Noyce and Ashcroft, 2008), the medicines implicated 
(Howard et al., 2007; Brvar et al., 2009; Davies et al., 2010), the scale of the problem and how 
to reduce the phenomena (Kongkaew et al., 2013; Pedros et al., 2014), but very little about the 
experiences of the patients involved. The use of IPA in this study aimed to give these patients a 
voice and attempt to discover how they processed what had happened to them. 
 
6.2.6 How the IPA analysis was conducted 
There is not a rigid procedure for conducting an analysis using IPA. Smith, Flowers and Larkin 
(2009) suggested the following steps but acknowledged that this method could be amended 
depending on the experience of the researcher and area being studied. The overall process 
involved analysing each interview transcript individually before all the transcripts were 
considered together. Table 6-1 shows the stages in the IPA analysis for the current study. 
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Table 6-1 Stages in IPA analysis (Biggerstaff and Thompson, 2008; Smith, Flowers and Larkin, 
2009) 
Stage Task Rationale/outcomes 
1 Initial reading and re-reading of the individual 
paper interview transcripts; thoughts, 
observations and reflections noted whilst 
attempting to ‘bracket off’ any preconceptions 
on the part of the researcher. 
Researcher became immersed in the data and 
began to understand the patients’ experiences. 
2 Descriptive comments noted in left-hand 
margin of paper transcript. 
Collection of descriptive comments focussed 
on events of experiences of participant. 
3 Linguistic comments noted on paper transcript. Demonstrated use of language to describe 
their account. 
4 Interpretative comments noted in right-hand 
margin of paper transcript. 
Collection of interpretative comments based 
on what the researcher thought were the 
underlying meanings of the participant’s 
account. 
5 Transcripts uploaded into NVivo. Electronic transcripts fully annotated with all 
hand-written comments from paper 
transcripts. 
Quotations tagged with themes to facilitate 
the organisation of the analysis. 
6 Interpretative comments arranged into 
thematic groups using NVivo software. 
Using interpretative comments to determine 
themes that were apparent in each interview. 
7 Thematic groups printed out for each interview 
and grouped into main themes by sticking 
them on to ‘participant theme maps’ (see 
example in Appendix D). 
Main themes from each interview established. 
8 Integration of the analysis across cases by 
looking at overarching themes from each 
individual interview to discover themes that 
applied to the whole dataset. 
Integrated analysis of all patient interviews 
produced overarching themes. 
By using NVivo, it was possible for all the 
participants’ quotes relating to each theme to 
be printed as a list, which helped greatly with 
the analysis and writing-up. 
 
The development of themes for the individual participants analyses (stage 6) and the 
integrated analysis (stage 8) could have been done in a variety of different ways. Smith, 
Flowers and Larkin (2009) suggested two methods:  
• typing out a list of themes, then moving them around on the computer screen until 
related themes were eventually grouped together. 
• printing out the full list of themes, cutting them up and moving them around until 
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To establish the themes from the patient interviews, again there were various methods that 
could be chosen, including: 
• looking for and grouping together themes that were similar (this was the method 
chosen for the current study). 
• identifying where a participant appeared to have opinions that contradicted 
themselves. 
• highlighting the number of times a theme appeared in a particular transcript. 
(Smith, Flowers and Larkin, 2009). 
6.2.7 Recruitment of patients 
The aim was to recruit between eight and ten hospital in-patients for this part of the study. 
Seven patients were finally recruited, and this was for a variety of reasons. Firstly, it was quite 
difficult to identify which patients had definitely been admitted due to a medicines-related 
problem. Often a medicine was suspected of causing a particular problem, but on speaking to 
the doctor caring for the patient, it became clear that there were other factors at play, such as 
comorbidities that could explain the patient’s symptoms. Secondly, the pharmacists at the 
hospital were asked to identify patients during the course of their normal work. As for all 
hospitals, in-patient wards are an extremely busy working environment and remembering to 
identify patients for a study did not rank highly on the list of essential tasks that had to be 
undertaken during a ward visit. This was echoed in a paper that found that the competing 
priorities of ward pharmacists hampered recruitment of patients to a PD-MUR study 
(Ramsbottom, Fitzpatrick and Rutter, 2016). Thirdly, some eligible patients did not wish to 
participate in the study and fourthly on some occasions the researcher was not able to talk to 
participants at an appropriate time before they were discharged. 
 
Characteristics of the seven patients recruited can be seen in Table 6-2. This shows that there 
were a mix of genders (four females, three males) and a range of older ages (between 67 and 
88 years) but all participants were of the same ethnicity. The reasons for hospital admission 
were varied but all signs or symptoms were listed in the Summaries of Product Characteristics 
(SmPC) as possible undesirable effects for the medicines in question. Most of the undesirable 
effects were listed as common in the medicine’s SmPC, which means they were expected for 
<1/10 but ≥1/100 of patients taking that particular medicine. No assessment was made as to 
whether the medicines-related admission was preventable or not. 
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Table 6-2 Summary of characteristics of hospital in-patients recruited 
Patient 
ID 



























2 88/Female White 
British 






3 67/Male White 
British 




4 78/Male White 
British 




5 73/Male White 
British 







6 69/Female White 
British 
Rivaroxaban Headache Common ≥1/100 
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6.2.8 Patient referral to community pharmacies and follow-up 
Following the in-patient interview, the patients were referred, with their consent, to their 
regular community pharmacist for a PD-MUR. In all cases, this referral was made by faxing a 
copy of the discharge medication list and a covering note to the community pharmacy 
explaining the study and informing them that the patient was eligible for a PD-MUR. The plan 
was then to contact the patient after eight to twelve weeks for a follow-up interview to find 
out whether they had participated in a PD-MUR and their experiences of it. 
 
Unfortunately, despite all the discharged patients having a referral to their community 
pharmacist, no follow-up interviews were conducted. This was for a variety of reasons: two 
patients were no longer looking after their own medicines; one had died during the admission 
and one was discharged to a nursing home. The remaining five patients did not get in touch 
when prompted for the follow-up interview, hence were lost to follow-up. 
 
There are many reasons why this may have happened including; loss of interest in the study, 
too unwell to participate/housebound, died, no longer eligible to participate e.g. if admitted to 
residential care, too inconvenient to participate in an interview once discharged or recovered, 
and too busy. These are all possible reasons, but as the patients were not contactable, it was 
not possible to confirm the circumstances in each case. 
 
6.3 Results and discussion of the patient interviews 
6.3.1 Introduction to the analysis of the patient interviews 
The seven patient interviews were analysed using IPA to discover whether there were any 
overarching themes that could be used to describe the data that had been obtained. The 
patients gave very rich and sometimes extremely detailed accounts of what had happened to 
them and their views and experiences of taking medicines. These accounts gave further insight 
into how they interpreted these experiences and how they planned to move forward with 
their lives after this event. The analyses of the interviews have considered the patients as a 
group of individuals who all experienced the same phenomena; a medicines-related admission 
to hospital, rather than an account of each individual patient’s experiences. 
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6.3.2 Themes from the patient interviews 
The analysis of the interviews generated one overarching theme and three subordinate 
themes which are summarised in Figure 6-4. All the participants’ interviews covered the same 
topic areas and it was interesting to discover that despite their varied views and experiences, 
overall, what they said could be summarised by these themes. The overarching theme was 
locus of control and the subordinate themes were health journey and outlook, relationships, 





Figure 6-4 Themes from patient interviews 
 
The quotations used in the following sections are annotated, in some circumstances, to 
indicate the speaker. An annotation of ‘I’, indicates the interviewer and an annotation ‘P’ 
indicates the participant. If there is no annotation, the words are those of the participant. 
  




















Health literacy and 
MURs
HCPs and medication 
review
Locus of control 
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Figure 6-5 Themes from patient interviews: overarching theme - locus of control 
 
The overarching theme to emerge from the patient interviews was around the locus of control. 
The term control refers to whether a person thinks that they have the ability to affect things 
that happen in their lives. The locus refers to where the control lies in relation to the person 
and can therefore be internal or external. This model can be applied to a person’s health 
beliefs and how much control they think they can have over their health outcomes, and is 
referred to as health locus of control (HLOC) (Wallston and Wallston, 1982). It can be 
measured using the Multidimensional Health Locus of Control questionnaire (Wallston, 
Wallston and DeVellis, 1978). An internal health locus of control (I-HLOC) means that a person 
believes they have control over their health outcomes through their own behaviour. People 
with an external health locus of control (E-HLOC) feel that other people or things affect their 
health rather than themselves (Wallston and Wallston, 1982). The term E-HLOC can also be 
subdivided into: powerful others health locus of control (PO-HLOC), doctors health locus of 
control (D-HLOC), chance health locus of control (C-HLOC) or God health locus of control (G-
HLOC) (Nafradi, Nakamoto and Schulz, 2017). 
 
 
Locus of control 
Health journey 
and outlook Relationships Health literacy 




Figure 6-6 Health Locus of control  
(Red = internal health locus of control, blue = external health locus of control) 
 
The beliefs that a person holds around HLOC have been found to affect various health 
behaviours. It has been shown that people with an I-HLOC are more likely to; make healthy 
lifestyle choice around issues such as smoking, alcohol consumption, exercise and diet 
(Norman et al., 1998), and are more likely to be adherent to their medicines (Nafradi, 
Nakamoto and Schulz, 2017). 
 
6.3.3.1 Control over health issues 
Some participants had felt in control of their health and had been satisfied with their level of 
control prior to their hospital admission. They showed gratitude for their previous good health 
and compared themselves favourably to others by saying they were in good health for their 
age and acknowledging that they had done ‘a good job’ of maintaining their health until this 
point. 
“So, really and truly, I got to be satisfied with what I’ve got, apart from 
what’s happening now.” 
Patient Two 
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The current situation they found themselves in was a revelation for some of the patients. They 
showed desperation with their current situation and as they had been in hospital, they had 
been able to think about, and reflect upon what had happened to them. One of the 
participants who displayed an I-HLOC had been in excellent health until recently, they 
described how they had gone from being active to being unable to stand, and how this had 
been a shock for them personally: 
“And I’m not using an awful lot of energy in the day, these days…a week 
before I came into hospital, I was walking half an hour, three-quarters of an 
hour with my dog. She’s an old dog now so she’s more interested in sniffing 
than looking at the landscape. Two kilometres or something. And when I 
came here one or two people said, ‘beware of a shock or two, if you are 
going to be in there for a week’, they said, ‘if you don’t use any of your 
muscles for four days, you can’t stand up.’ Which surprised me, but it 
proved to be true.” 
Patient Five 
Another of the participants who displayed a PO-HLOC had been unwell for a very long time 
with back and neck pain. They revealed their desperation with constant pain over a prolonged 
period of time; they wanted to proactively take control of their situation and had been willing 
to undergo a high-risk operation, but the surgeon was not prepared to go ahead as the risks 
were too great. 
“And he said, ‘no, I’m not operating’. He said, ‘I’ve only got to slip and she’s 
paralysed…no, no, it isn’t worth it.’ I wanted to, but he wouldn’t let me.” 
Patient One 
They had tried to regain some control of their pain by using opioid patches for analgesia, but 
this had resulted in the medicines-related admission to hospital. 
“of course, my back…it affects my neck…so they put morphine [sic - 
buprenorphine] patches on me.” 
Patient One 
One of the other participants with an I-HLOC, described how they thought they should be 
recovering more quickly after a procedure and sought help because this was not the case. They 
had contacted the GP who confirmed they were experiencing a medicines-related side effect 
that was hampering their recovery. 
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“And I said, ‘this is not right’…and I thought, this isn’t right, I should be 
picking up a bit.” 
Patient Two 
For some participants, the deterioration in their health was accompanied by a lack of control 
over their current health status. For some participants who had an E-HLOC, they accepted this: 
“I don’t worry him (the GP) because I’ve got nurses coming in every 
morning…they take messages back to him. And then if I need to see the 
doctor, then he comes because it’s only down across the field.” 
Patient Seven 
“The thing is, I’m housebound…he (the GP) can get to me but I can’t go to 
him.” 
Patient One 
For others, this shift from their usual I-HLOC to an E-HLOC proved difficult. They did not like 
being reliant on others to resolve their health-related problems and preferred to seek help 
independently. 
“I want to go home. Back to me own home…I’ve looked after my own home 
for years…and I looked after my husband for 5 or 6 years; he had 
Alzheimer’s. I looked after him and I thought, I must try and pick up.” 
Patient Two 
Despite this lack of control and desperation with the current situation, the participants showed 
incredible resilience and motivation to improve their health status. The majority of patients 
expressed hope for the future in terms of improvements in their health and returning to their 
previous level of functioning. 
 
6.3.3.2 Discussion of control over health issues  
As mentioned above, an unexpected change from an I-HLOC to an E-HLOC can be disturbing 
for some patients. This outcome was also found in a study which interviewed 77 residents in 
assisted living in the US. The authors illustrated that when older people actively entrusted 
someone else to make decisions for them, the participants reported a positive response. If the 
control for making decisions had been taken from the older person, this elicited a negative 
reaction (Morgan and Brazda, 2013). For patients who previously had an I-HLOC, regaining it in 
future would be their aim.  
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In the UK, the Government is also keen to allow patients to be more in control and actively 
involved in decision-making, which represents a focus on promoting an I-HLOC. The 2010 
White paper, Equity and Excellence: Liberating the NHS, stated that shared-decision making 
would become the norm with the strapline: no decision about me without me (Department of 
Health, 2010a). It has been shown that involving patients in shared-decision making about 
their health improves patient knowledge, adherence, health outcomes and satisfaction 
(Bechel, Myers and Smith, 2000; Stevenson et al., 2004). Even though this is the goal, it may 
not be possible for all patients, for some, support from others may be both welcome and 
necessary. 
 
Some respondents to the 2010 White Paper also thought that shared-decision making would 
not be possible for everyone, especially those individuals who required extra support. The 
Royal College of General Practitioners stated that: 
“There is a risk that shared decision-making will have a distorting effect on 
consultation time spent with patients – put simply, the more articulate, 
better educated and more assertive patients may be encouraged to 
demand more time with their GP to discuss options – whilst those who are 
less literate but who have greater needs may lose out.” 
(Department of Health, 2012) 
This view highlighted that shared-decision making must be individualised for each patient and 
some patients may need to involve others if they have delegated control to them. This 
overarching theme affected patients’ attitudes and experiences relating to all the subthemes 
that are presented and discussed in the following sections. 
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Figure 6-7 Themes from patient interviews: first subordinate theme- health journey and 
outlook 
The first subordinate theme that emerged from the patient interviews was around the topic of 
health journey and outlook. Participants were asked about their experience of taking 
medicines, what had brought them into hospital, and what it had been like to be admitted to 
hospital with a medicines-related problem. There were three sub-themes of the health journey 
and outlook area which unfolded during the analysis of the interviews: feelings towards 
prescribed medicines, experiences of a medicines-related problem and motivation to improve 
current health status. They are explored in the following sections. 
 
6.3.4.1 Attitudes towards taking medicines 
The participants were asked how they felt about having to take medicines. For some, it was 
about the acceptance of taking something that was going to do them good, for others it was 
something they had become used to over a long period of time and had reluctantly accepted. 
Patients seemed to use medicine-taking as a surrogate acknowledgement that they were 
unwell and that was difficult for them to accept. The routine of having to take medicines for a 
long period of time had gradually helped them to come to terms with their health problems. 
For some participants, when they were asked about their feelings towards taking prescribed 
medicines, they were internally conflicted; on one hand they understood the importance of 
medicine taking and complied but on the other hand they did not like it. 
I: “How do you feel about having to take medicines?” 
P: “Not very good, but I suppose I’ve had to do it for years. Years and years 
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I: “Thinking now more generally about medicines, how do you feel about 
having to take medicines?” 
P: “I’m used to it, I don’t like it, but I’m used to it. And five in the morning, 
no four in the morning and four at night and then paracetamol so you get 
used to it.” 
Patient Six 
Some of the participants were accepting of taking medicines ‘as long as it did them good.’ They 
seemed to concede that the medicines were there to treat their medical conditions and 
therefore taking them was part and parcel of maintaining their health. 
“In the mornings, I was taking…I was taking eight, eight tablets in the 
morning look. Might as well bloody crush them and put them in a bloody 
omelette, there were that many. You know, they have done me good. Me 
heart’s ticker…heart’s ticker is no good anyway. If I don’t take them, I’ll be 
bad again, like [sic].” 
I: “…and how do you feel about having to take medicines?” 
P: “Umm, if it do me good…I don’t mind.” 
Patient Three 
I: “…and how do you feel about having to take medicines?” 
P: “I don’t mind taking them if they make me all right.” 
Patient Seven 
One participant described how they had tried to avoid taking prescribed medicines for a long 
period of time by concentrating on a healthy diet, but eventually they had to accept that 
medicines were necessary. 
I: “Now thinking about medicines generally. Are you happy to take 
medicines?...How do you feel?” 
P: “I don’t mind taking them. For years I had all the health food…so I used 
to go there. They said it wasn’t doing any good.” 
Patient One 
How the participants spoke about taking prescribed medicines gave an insight into their 
underlying feelings, not just about the medicines themselves but also their diagnosed 
conditions. It is perhaps unsurprising that previously healthy people displayed some reluctance 
to take medicines, which could reveal a hidden denial of the existence of their health 
problems. Others took medicines to improve their health, despite their dislike of having to 
take them. These different views help to understand how patients rationalise their medicine-
taking. 
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6.3.4.2 Discussion of attitudes to taking medicines 
These different mechanisms for rationalising medicine-taking appeared to be linked to the 
HLOC of the participants. The group with an E-HLOC seemed to be more accepting of 
medicine-taking, they had faith that the medicines would have a positive effect on their health 
and appreciated their GPs’ efforts to prescribe medicines that would benefit them. They were 
less health literate, did not want lots of information about their medicines and were more 
reliant on family members when making health and medicines-related decisions. These 
characteristics were echoed in a systematic review and meta-synthesis of 34 qualitative 
studies that focussed on medication-related burden and patients’ lived experience with 
medicines (Mohammed, Moles and Chen, 2016). The study reported that patients mainly had 
positive attitudes towards taking prescribed medicines. This was due to their trust in HCPs, 
having previous positive experiences when taking medicines, and hope that the medicine 
would have the desired outcome. These attitudes motivated individuals to persist in taking 
their medicines (Mohammed, Moles and Chen, 2016). 
 
The I-HLOC group seemed to be more questioning; they wanted information about their 
medicines and thinking about taking medicines seemed to trigger more negative feelings and 
attitudes around overall health and illness. This alternative view was also seen in a published 
synthesis of qualitative studies concerning medicine taking which found that people ‘disliked 
depending on medicines’ (Pound et al., 2005). Studies of patients interviewed in primary care 
in England about attitudes to medicine-taking have also found that some patients prefer not to 
take medicines if they can avoid it (Britten, 1994; Benson and Britten, 2002). A study of 544 
patients who were surveyed in general practice in London, found that 86% agreed with the 
statement ‘I prefer not to take any medicine if I can avoid it’ (Britten, Ukoumunne and 
Boulton, 2002). This was also echoed in a study of 50 patients interviewed in the community 
about medicine-taking by Dowell and Hudson (1997). The authors argued that medicine-taking 
was associated with being ill and if patients did not accept that, they were unlikely to take 
medicines for their illnesses (Dowell and Hudson, 1997). This sentiment was also displayed by 
another patient who told a medicines-adherence researcher that ‘medications remind people 
that they're sick. Who wants to be sick?’ (Rosenbaum, 2015). This author also found that some 
people associated medicine-taking with weakness and they did not like being associated with a 
‘sick identity’ (Rosenbaum, 2015). For the patients with long-standing health problems in the 
current study, time seemed to have helped them to accept that medicine-taking was necessary 
and perhaps this equated to an acceptance of their health-problems. 
Chapter Six | Patient interviews 
 157 
 
The study by Dowell and Hudson (1997) proposed that three types of medicines user exist. The 
first were those who passively accepted medicines and took them as the doctor had 
prescribed, the second actively took medicines but took them as they wanted, and the third 
rejected medicines altogether (Dowell and Hudson, 1997). HCPs need to appreciate that when 
they prescribe and dispense medicines, the patient’s underlying attitudes to medicine-taking 
will have perhaps the greatest effect on effectiveness. 
 
6.3.4.3 Experience of a medicines-related admission to hospital 
For all the participants, their admission to hospital with a medicines-related problem was a 
negative and, in some cases, an extremely traumatic experience for them. They used very 
emotive language when describing their experiences. In the following quotes from the 
participants, the strength of their feelings is indicated linguistically by the use of certain words 
and phrases; these are indicated in bold text. 
“I went to bed, my bed turned around. My furniture was coming off the 
wall. Terrible. And I’m there on my own I’m frightened.” 
Patient One 
“It’s been like a roller-coaster. In, out, in, out.” 
I: “I don’t want to go through all this again, you know. Backwards and 
forwards. Thinking I’m going to get better and then having to come back to 
hospital.” 
I: “How do you feel about it all?” 
P: “Fed up.” 
Patient Two 
“…they got mixed up, they were giving me a tablet that made me feel really 
giddy look…And all the room had gone to jelly, you know what I mean, you 
know wobbly, wobbly…terrible, I’m better now though.” 
Patient Three 
“So, I’ve been in hell with pain” 
Patient Five 
“I couldn’t stand the pain anymore. It was horrific…it was constant…I mean 
I’ve had headaches but that was more than a headache. It really was bad.” 
Patient Six 
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The other participants were not aware of why they had been admitted to hospital. Participants 
four and seven had both been admitted with hyperkalaemia and were not able to convey their 
feelings about their medicines-related admission. 
 
None of the participants appeared to blame the prescriber for the adverse event, although one 
participant appeared to blame themselves. This was because they had gone to the GP to 
instigate the change in medication; the GP had actioned the change but had been reluctant to 
do so. 
“I just stopped my warfarin and took that (rivaroxaban). Worst thing I ever 
done [sic].” 
Patient Six 
These accounts help us to understand the effect of a medicines-related admission on a person. 
Even though the ultimate aim of the admission was to resolve the medicines-related problem, 
the whole experience was extremely distressing. It is therefore vitally important to try and 
avoid medicines-related admissions to hospital whenever possible to prevent psychological 
distress. 
 
6.3.4.4 Discussion of experience of medicines-related admission to hospital 
Unsurprisingly, all the patients interviewed described their medicines-related admission to 
hospital in negative terms and used very emotive language to do so. A systematic review of 
medication-related burden and patients’ experiences of taking medicines also examined how 
patients described experiencing an ADE (Mohammed, Moles and Chen, 2016). ADEs were 
described as one of the most difficult features of medicines taking. A wide range of ADEs were 
reported in the included studies and patients revealed emotional distress about the ADE and 
anxiety about recurrence (Mohammed, Moles and Chen, 2016). In a similar study to the 
current one, 15 hospital in-patients in England were interviewed about their ADR-related 
hospital admission. The authors highlighted the negative emotional impact of this event for 
patients, who described feelings of disbelief, anger, fear, frustration and isolation (Lorimer, 
Cox and Langford, 2011). 
 
Due to the negative impact on patients, it is therefore vitally important to minimise medicines-
related admissions to hospital. The NICE guidelines on Medicines Optimisation (NICE, 2015c) 
detail several ways that HCPs and organisations can learn from medication-related safety 
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incidents; better identification of medication-related events, enhanced reporting, adherence 
to national medication-related guidelines, education and training of HCPs and using screening 
tools to identify patients at high-risk of medication-related ADEs. Although it would be 
impossible to eliminate all medicines-related hospital admissions, adoption of these principles 
would help to identify patients at risk and reduce preventable admissions. 
 
6.3.4.5 Motivation to improve current health status 
All participants, without exception, expressed a desire to improve their health following on 
from the acute medicines-related problem that had brought them into hospital. Some of the 
participants talked about what they had been able to do before the admission and showed 
pride in the amount of physical activity they had been capable of. 
“And I’m quite active…well, like I said, I go kickboxing every Friday with me 
grandson until…this. Yeah, he’s got his own club so…I keep quite active.” 
Patient Four 
Even during the medicines-related admission, one of the participants described how they tried 
to think positively and were keen to maximise their level of mobility to ensure that they were 
ready to go home. This suggested that the participant wanted to get better in order that they 
would be able to manage to look after themselves at home. 
“...they were the ones to take me to the toilet, I couldn’t walk, look, it was 
so awful I couldn’t get out…but it was alright…and I got right to the door 
and then I was thinking ‘I’ve got to do this, I’ve got to do this’…” 
Patient One 
The participants appeared to be using their mental strength and positive attitude to try and 
push themselves to improve physically and get back to normality. Maybe this also showed an 
underlying fear that their current illness could prevent them getting back to their baseline level 
of health or mobility and the consequences of this could be difficult for them to contemplate; 
for example, an admission to a residential home or requiring carers. 
 
This section has shown that the health status of an individual is a complex meeting of both the 
physical and mental aspects of a person’s health. Participants were interviewed during a 
distressing period of their lives and although they described their hospital admission in wholly 
negative terms, they were eager to return home and to their previous level of health. How a 
person talks about their health status can also reveal other more deeply hidden aspects of 
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their hopes and fears for the future. In these instances, participants often showed their 
underlying fears focussed on their loss of control when making health-related and more 
general decisions, and their attitudes to taking prescribed medicines. 
 
6.3.4.6 Discussion of motivation to improve function after a medicines-related hospital 
admission 
Hospital admissions in older people have been associated with ‘deconditioning’, a term which 
covers a whole host of signs and symptoms including reduced bone mass, muscle strength and 
mobility, increased dependence, confusion and demotivation. It has been suggested that ‘re-
conditioning’ can take twice as long as ‘deconditioning’ (Arora, 2016). This ‘deconditioning’ 
process can occur in patients who have been admitted to hospital with a medicines-related 
problem and was described by one of the participants in this study. 
 
The desire of patients to return to their previous level of functioning is completely 
understandable and was raised by several of the participants in the current study. The 
motivation of patients to get back to their normal level of functioning demonstrated positive 
aspirations for the future and by completing activities of daily living (ADLs) independently 
during and after their admission they hoped to be able to achieve and regain some control 
over their health. 
  
Chapter Six | Patient interviews 
 161 






Figure 6-8 Themes from patient interviews: second subordinate theme - relationships 
 
The second sub-ordinate theme was relationships. There were a number of different and 
valued relationships that the participants described during their interviews. The main ones 
involved relationships with their GP, other HCPs (both qualified and non-qualified) and their 
families. The utility of these relationships to the patient depended on various factors such as 
accessibility to the individuals, trust and how they viewed that individual’s role in their health-
making decisions. Not all these relationships were described in positive terms by the 
participants and there was perhaps some reluctance to rely on others, but the current health 
status of the participant meant they had little choice. 
 
Most of the participants spoke very highly of their GP and underlined the pivotal role of the GP 
in their health. Some participants also spoke very eloquently about why they would choose 
one HCP over another in various situations. 
 
6.3.5.1 Relationships with family members 
Several of the participants expressed that they had very good relationships with their family 
members, which included spouses, children and grandchildren. These relatives had helped 
them when they were faced with a health or medicines-related problem. Several participants 
had been ill for some time prior to their current admission and had experienced multiple 
hospital admissions in a short space of time. The reduction in their physical capability had 
meant that they had become more reliant on their families and had lost some of their previous 
autonomy around making health-related decisions. The participants placed huge trust in their 
families to help them make the right decisions, such as when to seek help for a medical 
problem. This was done either as a joint decision between the participant and the family 
member, or the family member made the decision on behalf of the participant. 
I: “Did you go to your GP or…?” 
P: “No, no, I didn’t bother…and I came in here (the hospital) to visit my 
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wife...and I told her about it…and she know about it [sic], that I’m feeling 
giddy. And she said we better go to A&E, so I went there and came in here 
(the ward) last night.” 
Patient Three 
P: “And during the night I woke up with this terrible pain…so she (patient’s 
daughter) gave me this tablet and I must have gone off to sleep for about 
an hour. And I woke up again with pain…and called her and I said 
‘(daughter’s name), I’ve got such a terrible pain in my chest, you must help 
me.’ And she said, ‘I’m phoning the paramedics’.” 
Patient Two 
Another of the participants let their wife deal with any medicines-related information or 
health-related queries. 
P: “The misses reads everything, mind you.” 
I: “And would she read those leaflets about your medicines as well?” 
P: “Yeah, she reads everything…I call her nurse Nightingale!” 
Patient Four 
For one of the participants, their family member acted in a more impartial, supportive capacity 
which involved discussing the patient’s situation and helping them to come to a decision about 
the best course of action. This was because the participant’s daughter was highly educated, 
and the participant trusted her ability to make a wise decision. 
I: “Would you go to anyone else for advice about your medicines at all? Or 
would you tend to just discuss that sort of thing with your GP? “ 
P: “I would go to someone I trust…my GP…” 
I: “So your GP, and anyone else?” 
P: “My daughter…my daughter’s background is biochemistry…oncology.” 
(patient goes on to describe how their daughter has a PhD). 
Patient Five 
Another of the participants, described how they would rely on their family for practical help 
but would not ask them about medicines-related issues. Perhaps they did not see this as their 
role and preferred to keep the family and health advocate roles separate. 
I: “Would you ask your daughters for advice about tablets?” 
P: “No, no.” 
Patient One 
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One participant did say that their family would give their opinions whether or not they had 
been solicited, but they did not seem to mind this. 
I: “…your son and daughter, would you think of asking them for advice 
about tablets or medicines?” 
P: “Well, they tell me anyway.” 
I: “So, they tell you whether you ask them or not?” 
P: “Yeah. They’re good.” 
Patient Seven 
This high-level of trust in family members is, in some ways unsurprising, as most family 
members would be keen to ensure that their relative gets the best possible care at the right 
time. For the participants in the current study, this input from their family members was either 
purely supportive to help them make the right decisions or it was more prescriptive, in that the 
family member made decisions on the participant’s behalf. Again, this could be symptomatic 
of a loss of control for the participant. 
 
6.3.5.2 Discussion of relationships with family members 
Some of the patients in this study relied heavily on other family members to support them 
with the practical aspects of taking medicines and also when making health and medicines-
related decisions. This was generally a mutually agreeable arrangement. Mohammed, Moles 
and Chen (2016), in their systematic review of patients’ experiences of medication-related 
burden, found that partners, family members and friends all appeared to influence patients’ 
beliefs about medicines and this also had an impact on how people behaved towards 
medicines-use. 
 
Furthermore, a systematic review of 30 studies on the effect of family behaviours on health 
outcomes showed that patients experienced better outcomes if their families were cohesive, 
encouraged self-reliance and responded to symptoms of disease. Patients had poorer 
outcomes if their families displayed signs of being overprotective, controlling or critical 
(Rosland, Heisler and Piette, 2012). This review demonstrated how a supportive family 
network can be beneficial for patients. 
 
6.3.5.3 Relationships with GPs 
As expected, participants rated their GPs very highly and trusted their decision-making and 
judgement with regard to their health. Without prompting, several of the participants talked 
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about the loss of a well-trusted GP who they had built up a long-term relationship with. They 
expressed this almost as a grief at losing someone who knew them well. For some of the 
participants there had been insufficient time to develop that type of relationship with their 
new GP. 
“I used to have a lovely doctor but, umm, he up and went...he was a lovely 
doctor, very good to me and my husband…actually I’ve not met this new 
doctor…the majority of the doctors up there now, bar Dr (name), they’ve 
retired.” 
Patient Two 
“Well, my doctors, my doctors where I go now, you’re not guaranteed what 
doctor you’re gonna see from day to day…well you might see one doctor 
one time, then a different doctor another time like.” 
Patient Three 
The participants also perceived that their GP was busy and felt that this impacted on their 
care. When participants were asked about medication reviews with their GP, some felt that 
their GP was too busy to provide that service. They sensed that GPs dealt with the immediate 
problems resulting in a quick consultation. This was interpreted by some patients as the GP 
being too busy, but another connotation could be that the GP does not care enough about 
them or their particular situation. This could account for participants also relying heavily on 
other HCPs or family members 
I: “Have they (the GP) ever had a sit down and had a review, where they’ve 
gone through everything, all your medicines with you?” 
P: “No…too busy for that!” 
Patient Six 
I: “When you were in last time did anyone give you any information about 
your tablets that you were going home on?” 
P: “Nah…they just give me them.” 
I: “And how about from your GP…do they normally give you any 
information when they prescribe things?” 
P: “No, no…don’t tell me nothing. Just give our (name)…and he’ll bugger off 
and that’s it.” 
Patient Three 
This perception of busyness also applied to the hospital consultants. 
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“consultants don’t have much time to err…hang around and talk about 
actually what it is they are actually talking about. They have always got 
somewhere else to go or someone else to see.” 
Patient Five 
Some patients put their complete faith in their GP with regard to health-related decisions and 
the prescribing of medicines. They did not want to know anything about their prescribed 
medicines such as the indication or what side-effects to monitor for. Interestingly, this group 
of patients all expressed the same opinion about medicines taking; they were happy to take a 
medicine “as long as it did them good”. They expected the medicine to resolve their symptoms 
and did not feel the need to know any more about it. This demonstrated a completely trusting, 
deferent, paternalistic patient-GP relationship. For three of the participants this appeared to 
be related to their health literacy, which will be discussed in section 6.5.6.6. 
I: “You just take what the doctor has prescribed, or would you like to know 
more?” 
P: “I just take what’s given to me. As long as it does me good…as long as it 
does me good. They know what they are doing…that’s their job look.” 
Patient Two 
I: “And how much information would you like about those changes? Would 
you like someone to go through and explain them all?” 
P: “No, it doesn’t bother me…just told me they’re changing me medicines 
[sic], that’s it…and as long as it’s doing me good, I don’t care.” 
Patient Four 
I: “Now thinking a little bit about medicines in general, who would you go 
to, if you thought you might have a problem, or thought you wanted to 
know a bit more about one of your medicines?” Who would you go and ask 
for advice?” 
P: “Oh, my doctor...well, if he doesn’t know what’s going on, who do? [sic]” 
Patient Four 
P: “I don’t know why I came in…no. My doctor just says I want you to go in 
hospital, like that.” 
I: “And you came because he’s asked you to come in?” 
P: “Yes.” 
Patient Seven 
Other patients were more questioning of decisions made by doctors and the information they 
were given about their medicines or health. They understood that doctors may have different 
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opinions about their treatment and that treatment decisions could change depending on the 
information available, and they accepted this. 
“It’s a series of ups and downs with doctors and it’s not quite…what’s the 
word…not fiddle…but they change their mind depending on the latest 
evidence.” 
Patient Five 
This trust of the participants in their GP is not at all surprising given that in the most recent GP 
Patient Survey (IPSOS Mori Social Research Institute, 2017), 91.9% of patients reported having 
trust and confidence in their GP. There is more about the patient-GP relationship specifically 
related to MURs in section 6.3.6.8. 
 
6.3.5.4 Discussion of relationships with GPs 
A literature review published on the topic of medical decision-making found that opinions 
varied considerably regarding whether doctors should involve patients in the decision-making 
process. Shared decision-making is often suggested as a panacea, but this is not true for all 
situations. Rather, some patients, as in this study, prefer to defer treatment decisions to their 
doctor, representing a more paternalistic patient-GP relationship. A study of 479 patients 
consulting their GPs in London found that 45% of patients wanted their GP to be the main or 
only decision maker regarding their care and only 16% wanted to be the main or only decision-
maker themselves (Cox et al., 2007). GPs correctly assessed the desired level of patients’ 
involvement in decision-making in just 32% of cases (Cox et al., 2007), which shows how 
difficult it can be for HCPs to determine the level of involvement patients would like. 
 
Doctors appreciate that all patients are different but they need to assess the preferences of 
the patient, and potentially their families, so that they can offer the chance to participate in 
shared-decision making for those patients who desire it (Rodriguez-Osorio and Dominguez-
Cherit, 2008). These differing patient preferences were found in this current study and other 
studies conducted in England. A qualitative study of patients in the community in North West 
England reported that there was an inseparable connection between doctors and the 
medicines they prescribed. Some patients put all their trust in their doctor, which did lead to 
some feelings of powerlessness, whilst other patients were more questioning. Again, there 
were different preferences for having additional information, with some patients seeking it 
and others avoiding it. Very few patients felt able to discuss their concerns about medicines 
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with their doctor and cited lack of time, language (use of complex medical terms) and lack of 
experience for this (Krska et al., 2013). 
 
Even though shared-decision making is advocated in practice, HCPs and, in particular, doctors 
need to assess the quantity and depth of information that a patient requires. This is much 
easier for GPs who know their patients well and have had time to build up a trusting 
relationship with them. When the sustained GP-patient relationship is not present it is much 
more difficult for the GP to assess the level of involvement the patient wants in decision-
making and for the patient to be satisfied with the outcome of the consultation. 
 
The patient-GP relationship is vitally important for both patients and also GPs and varies 
significantly depending on the individuals and how well they know one another. In the 2017 
GP patient survey, 46.2% of patients had a GP that they preferred to see (IPSOS Mori Social 
Research Institute, 2017). A postal questionnaire sent to patients in one county in England 
found that being able to see a GP who was familiar to them, knew about their past medical 
problems and understood them was more important than being able to get the most 
convenient appointment (Kearley, Freeman and Heath, 2001). This was echoed by some of the 
participants in this current study who were missing a GP they had come to know over a 
prolonged period of time. 
 
6.3.5.5 Relationships with HCPs 
Participants also described good relationships with various trained and untrained HCPs 
involved in their care. This group included practice nurses, employed carers and community 
pharmacists. It appeared that often the decision to consult a particular HCP was based on their 
accessibility and whether they had a trusting interpersonal relationship with them. 
 
One participant had been almost housebound recently and carers had been attending on a 
daily basis. They had been asking the carers about their medicines even though, in this 
geographical area, they were not trained in that respect. As the patient was in frequent 
contact with the carers and had a trusting relationship with them, they felt that the carers 
would be able to offer appropriate advice. 
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I: “Who would you normally ask for advice about your tablets? Who would 
you normally go to if you had a question?” 
P: “Oh, my own doctor…or the carer that comes round…they’re very good, 
very good.” 
Patient One 
For another of the patients, it was the district nurses who provided this accessible link to 
health-related information and advice. 
“I’ve got nurses coming in every morning…they take messages back to him 
(the GP). And then if I need to see the doctor, then he comes because it’s 
only down across the field.” 
Patient Seven 
The one participant who had previously participated in a MUR with their community 
pharmacist reported that they would contact their community pharmacist first if they had a 
query about their medicines. They also reported that on certain occasions when they had 
consulted their doctor, they had not been satisfied with the outcome of the consultation. 
I: “In terms of getting information about your medicines, if you have a 
query, who would you go to in the first instance? Who would you ask?” 
P: “I’d go to the chemist…I would, if I was a bit worried about any…a certain 
medicine, I would go to the chemist…it’s easier to go and ask your chemist 
first rather than wait…for the appointment to see the doctor. And 
sometimes you don’t always get a real satisfactory answer off the doctor…I 
shouldn’t have said it! You shouldn’t say it, should you, but, umm, I think 
sometimes you think oh, that was a waste of time.” 
Patient Three 
Other participants also reported they would ask their community pharmacist if they had any 
medicines-related queries. 
I” “Who do you think would be the best person to give you advice about 
medicines?” 
P: (Pause to think) “Well I’m gonna say my chemist…he’s good, he’ll explain 
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I: “Who do you think would give the best information and advice about 
your medicines?” 
P: “I think the chemist meself [sic]…I mean, with all the drugs they’re 
dealing with all the time they’ve got to be well up on their information on 
that…I think the chemist, they’re the best people to go and see.” 
Patient Four 
I: “Who would you go to, to ask for advice about anything to do with the 
tablets and medications that you’re taking?” 
P: “I’d phone the pharmacist…they’re pretty good. They’re usually pretty 
good, aren’t they? They know straight away, or they’ll look it up for you.” 
Patient Six 
The reliance of the participants on these other HCPs may reflect the difficulty they have had 
accessing their GP in a timely manner in the past. This means they have had to devise different 
strategies to get the information they require to help them make health or medicines-related 
decisions. For some participants this means they will use their preferred HCP, but for others 
the HCP they use will represent a compromise that is necessary due to their health status or 
accessibility. 
 
The preferences for different HCPs demonstrated a complex interplay between trust, 
accessibility, power, and position of the HCP in the medical hierarchy. When participants 
reported that they would consult their pharmacist about medicines-related queries, there may 
have been an element of social desirability bias. This is where participants respond in a 
manner that would be judged favourably by others; for example, in this case by telling the PI 
what they thought were the ‘right’ answers or those that the PI wanted to hear as they were 
aware the PI was also a pharmacist. 
 
6.3.5.6 Discussion of relationships with different HCPs 
As already mentioned in 6.5.5.3, patient trust in GPs is high. This is also the case for nurses as 
84.5% of patients had confidence and trust in the last nurse they saw (IPSOS Mori Social 
Research Institute, 2017). Trust in pharmacists is also high with 87% of a sample of 1160 
members of the general public saying that they trusted health advice from pharmacists a great 
deal or a fair amount (IPSOS Public Affairs, 2015). The same percentage of people, 87%, also 
stated they were satisfied or very satisfied with the service they received from pharmacists in 
a survey conducted for the veterinary profession in 2015 (Vet Futures, 2015). This was the 
highest level of satisfaction of all of the professionals listed which included, opticians, dentists, 
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vets, GPs, solicitors and accountants (Vet Futures, 2015). This shows that the qualified HCPs 
that patients are most likely to consult about medicines-related queries are all highly trusted. 
 
Who a person consults about a medicines-related issue is not only determined by who they 
trust most but is a complex interplay of many factors which also include accessibility and the 
power to effect changes in medication. The survey of the general public about perceptions of 
the pharmacy profession enquired who they would ask for advice about medicines; 40% would 
ask a pharmacist but this was much lower than the 62% who would ask their GP. Thirty-six 
percent of those who would not seek advice from a pharmacy would always go to their GP 
(IPSOS Public Affairs, 2015). This is despite the fact that community pharmacists are much 
more accessible than GPs. 
 
Patients consulting GP for medicines-related queries may indicate an underlying 
acknowledgement of the power of GPs to make prescribing decisions. Those patients that 
displayed a paternalistic relationship with their GP may not appreciate the roles of different 
HCPs in the current NHS and therefore may be more likely to discuss medicines-related issues 
with their GP even though an alternative HCP may be more accessible and better suited to 
advise them. 
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Figure 6-9 Themes from patient interviews: third subordinate theme – health literacy 
 
The third subordinate theme to develop from the patient interviews was health literacy. 
During the analysis of the patients’ interview transcripts, it became apparent that patients 
broadly fell into two groups in terms of how involved and engaged they were with their health 
and managing their medicines. Participants two, five and six could be described as ‘expert’ 
patients who knew about their diagnoses, why they had been admitted to hospital, what 
medicines they were taking and why. This group appeared to have good two-way relationships 
with their GPs, discussed their health and medicines with them, were able to make decisions 
about their health and had an I-HLOC. Conversely, participants one, three, four and seven 
were not able to say why they were in hospital, they did not have a thorough understanding of 
their diagnoses or medicines, they did not question anything their GP told them, did not 
appear to be interested in finding out more about their medicines and had an E-HLOC. This 
group also involved their families and other HCPs heavily in making decisions about their 
health. As well as differences in HLOC, it appeared that there was something fundamentally 
different about these two groups in terms of their health literacy. 
 
6.3.6.1 Health literacy 
Health literacy is defined as: 
“people having the skills (language, literacy and numeracy), knowledge, 
understanding and confidence to access, understand, evaluate, use and 
navigate health and social care information and services.” 
(Public Health England, 2015) 
An individual’s functional health literacy is their ability to read and comprehend information 
and instructions in health settings. It has been linked to a person’s educational attainment, 
general literacy and IT skills. In the UK, it has been estimated that 42% of adults between the 
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ages of 16 and 65 are not able to understand and use health information (Public Health 
England, 2015). Individuals with low health literacy have been found to be more likely to be 
admitted to hospital, struggle to manage their health and wellbeing, find it more difficult to 
access the appropriate health services, have more ED attendances, longer in-patient stays, 
have less effective communication with HCPs and are less able to have discussions with HCPs 
about their health (Public Health England, 2015). It has also been found that individuals with 
limited financial and social resources are more likely to have lower levels of health literacy, 
which restricts their ability to have control over their health (Public Health England, 2015). 
 
6.3.6.2 Patients’ ability and confidence in their own health literacy 
For some of the participants, their apparent lack of (confidence in their) health literacy was 
demonstrated at the very start of the interview as they did not have any appreciation of why 
they had been admitted to hospital. They had been admitted in a very poorly state but at the 
time of the interview they had recovered sufficiently to consent and participate in an 
interview, and therefore sufficient time had elapsed for them to enquire about why they were 
in hospital if they had wished. 
I: “First of all, I was going to ask you about what brought you into hospital?” 
P: “Ummm, well, I don’t seem to know actually.” 
Patient Three 
I: “And so what happened this time? You had your blood taken and 
then…?” 
P: “Don’t know what happened, all of a sudden my daughter come and tells 
me [sic]…I think he (the GP) did (telephone) because I’m sure it was me 
daughter who answered the ‘phone.” 




These participants appeared to be completely deferential to their GP, and if the GP had 
advised a hospital admission, the participant would concur without question. 
 
Conversely, the participants who appeared to have higher levels of health literacy exhibited a 
confident and more questioning stance with the GP. It seemed that they would follow their 
GP’s advice but with a greater depth of understanding about what was being recommended 
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and why. They were prepared to suggest alternative treatments, ask about the aims of the 
treatment and be compelled to resolve any medicines-related problems. 
I: “So was that something that the GP suggested, it would be easier for you 
to have this rivaroxaban?” 
P: “No, it was my idea…she (the GP) was a little bit reluctant.” 
Patient Six 
(The GP told the patient) “sometimes these combinations of drugs cause 
other side effects and getting you completely under control again requires 
us to find the optimum dose.” So, I said, “what are your criteria for the 
optimum dose having been reached?”...”I don’t think he’s (the GP) often 
asked that one.” 
Patient Five 
…”I’d have gone back to the doctor, straight back to the doctor and said, ‘I 
just can’t take these anymore and I’m not going to take them’…I just said to 
(daughter), ‘I can’t go on like this.’ She said ‘Mum, you must take them.’ I 
said, ‘I can’t go on’…’So I think really and truly, if people are not satisfied 
with what the doctor gives them, they should go back to the doctor straight 
away and say there’s either something wrong here, I just can’t take them, 
and I know they are upsetting my stomach.’” 
Patient Two 
The health literacy of the participants was also shown by who they would ask for medicines-
related advice and how much information they wanted before they started taking a newly 
prescribed medicine. 
I: “…do you feel you’ve been given enough information about the 
medicines you’ve been prescribed?” 
P: “On the whole, yes.” 
Patient Five 
P: “…when I first started, I used to go down and he (the GP) used to give me 
a talk” 
I: “I see, yeah. So, do you mean that when you started new medicines, he 
explained them to you?”  
P: “When I first started taking tablets, I used to go down and he used to talk 
like. I can’t remember what he said.” 
I: “No, no. And he used to explain to you, did he, what you were taking any 
why?” 
P: “That’s right, the nurses as well do that.” 
Patient Seven 
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It appears that prescribers did attempt to give patients information about newly prescribed 
medicines. Whether this information was absorbed and understood or whether it was 
disregarded depended on the patient and how interested and involved they were with their 
medicines and their level of confidence in their ability to understand and interpret the 
information they had been given. 
 
6.3.6.3  Discussion of ability and confidence in their own health literacy 
For some participants, health literacy appeared to have a significant effect on who they would 
approach for medicines-related advice and support. By improving health literacy, there could 
be an opportunity to help this group of patients become more self-reliant, have more 
confidence in their own ability to absorb and comprehend health-related information and 
consider approaching other HCPs rather than their GP for advice. 
 
For patients with limited health literacy, improvements have been shown to: reduce disease 
severity, improve health knowledge, improve adherence to medical instructions, improve 
engagement and involvement in health and empower people to effectively manage long-term 
conditions (Public Health England, 2015). The simplest approaches to improving health literacy 
include ensuring that information about health is presented in a clear and accessible format. In 
terms of specific instructions for tasks such as administering medication, it can be helpful to 
demonstrate how to take or use medicines and ask the patient to repeat this back to check 
understanding (Public Health England, 2015). Strategies such as improving general literacy by 
increasing access to further adult education or lifelong skills training for the whole population 
are more difficult to implement and beyond the scope of this study. 
 
Despite initiatives to improve health literacy, there is still a paucity of evidence about the 
effects on health outcomes. One longitudinal cohort study published in the BMJ did appear to 
show that low levels of health literacy were associated with higher levels of mortality but 
studies demonstrating the impact of improved health literacy on mortality have not yet been 
conducted (Bostock and Steptoe, 2012). A caveat to increased health literacy, as highlighted by 
Raynor, is that people with better health literacy may still make health-related decisions that 
are not recommended by HCPs (Raynor, 2012). 
 
HCPs need to ensure that all health and medicines-related information is available in different 
formats, the ‘teach back’ technique is used for all patients and, as far as possible, health-
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related information is presented in a way that is individualised for each person. Using these 
strategies should help to ensure that patients’ needs are met, which hopefully will have 
positive effects for the patient, HCPs caring for them and the NHS in general. 
 
6.3.6.4 Sources of medicines-related information and advice 
The participants who did not know why they had been admitted to hospital appeared to be 
more likely to ask family members for advice about their medicines or not ask any questions at 
all. Two participants sought advice from family members; one thought that because his wife 
took medicines herself it meant that she was knowledgeable about medicines generally. 
Another had delegated all responsibility for his medicines to his wife; again, this could have 
been because he felt that she had superior health literacy amongst other reasons. 
I: “…if you’ve got a question about medicines, who would you ask?” 
P: Err, my wife…because she knows quite a lot about medicines. I mean 
she’s on medicines herself…she got emphysema and her’s bad with it but 
she know [sic] quite a lot about medicines…” 
I: “…is there anyone else you would think of asking, or just her?” 
P: “Just her.” 
Patient Three 
“Don’t ask me what they (tablets) are because I haven’t got a clue…the wife 
does all that for me, she sees to all that.” 
Patient Four 
Two of the other participants did not want any information about the medicines they had 
been prescribed or why they needed them. One had a lower level of health literacy and 
appeared to delegate responsibility to the prescriber. 
I: “Who would you ask for advice about your medicines?” 
P: “Wouldn’t really. I just take what’s given me.” 
Patient Seven 
For the second participant, who displayed a higher level of health literacy, the location of the 
prescribing appeared to have an impact on the information that was sought prior to starting a 
new medicine. This participant was willing to ask their GP for medicines-related information 
but in hospital felt that there was not the opportunity to ask the same types of questions. Also, 
they had not had sufficient time to build a trusted relationship with the prescriber. 
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I: “…when you were in hospital, did anyone give you any information about 
your, umm, the tablets you were taking?” 
P: “No…just taking it for granted. You’ve got them, and you’ve got to take 
them.” 
Patient Two 
The other three participants were more health literate and reported that they would utilise 
the patient information leaflets (PIL) to find out more about the medicines they had been 
prescribed. They were self-reliant and able to identify the PIL as a useful source of information 
that they would be able to read and comprehend.  
I: “Yes. So, had you looked through the leaflet in the pack when you were 
newly started on it (rivaroxaban)?” 
P: “I never do that until something happens because I think if you read the 
leaflet you think oh, my word, look at all this, I’m not going to take this. So, 
I wait until I see something is wrong, then I have a look at it, the leaflet 
information.” 
Patient Six 
I: “And thinking about information that people such as yourself are given 
about medicines, do you feel it’s about right, do you feel you get too little 
information or…” 
P: “Well, I’ve never thought of it…as I said, I read the leaflet if I need to.” 
Patient Six 
One participant had the confidence to read the PIL and then went on to have a discussion with 
their GP about its contents. This participant therefore put themselves on an equal footing with 
the GP and had confidence in their own ability to have a complex two-way dialogue with their 
GP. 
I: “…by the sounds of it, you probably like to know a bit more information 
about what you are taking and why.” 
P: “Well, if my GP prescribed medicines for me, there’s a big leaflet in the 
pack and I will go and question them or question him about it.” 
I: “So you would refer back to the leaflets in the pack about your medicine 
if you wanted more information?” 
P: “Or go back to my GP.” 
Patient Five 
For other participants, the PIL was something they said they could not be bothered to read, 
but in reality this apparent lack of interest seemed to be because they did not have the skills 
required to absorb, understand and interpret the information within it.  
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I: “Often when you start a new medicine, you’ll get an information pack…an 
information leaflet in the pack with it…” 
P: “I don’t read it…no, no, I never read ‘em, I just listen to what they say 
and that’s it. I take them and that’s it.” 
I: “And what’s your reason for not reading them?” 
P: “Ohh, can’t be bothered…can’t be bothered. I can’t sit down there and 
just read all these different things because I wouldn’t understand half of it 
anyway, and all these things they come out with drugs and things like that, I 
haven’t got a clue.” 
Patient Four 
One of the other participants stated that they would choose the pharmacist as their preferred 
HCP to consult if they had a medicines-related query. 
I: “…thinking about information about your medicines, who would you go 
to, to ask for advice about anything to do with tablets and medications that 
you’re taking?” 
P: “I’d phone the pharmacist…they’re pretty good. They’re usually pretty 
good, aren’t they? They know straight away, or they’ll look it up for you.” 
Patient Six 
I: “Is there anyone else you would think of asking or would you just go to 
them?” 
P: “No, I’d go to somebody like that pharmacist, yes.” 
I: “That’s good. And thinking about all of the medical people that you come 
into contact with, so doctors, pharmacists, nurses, whoever else you might 
see at your practice, who do you think would give the best advice about 
medicines? Who would you trust the most?” 
P: “Oh, I think I’d go for the pharmacist, again…they are used to it aren’t 
they. They are dealing with it 24 hours a day. I think, yes.” 
Patient Six 
From these responses it is clear that people have different requirements when it comes to 
information about medicines; from no information at all, through verbal and written 
information, to having a full discussion with the prescriber after conducting their own 
assessment of the information they had been given. It is therefore important to try and 
establish the amount and format of medicines-related information that a particular person 
requires, and this is perhaps best done by a HCP that knows them well. 
 
6.3.6.5 Discussion of sources of medicines-related information and advice 
Patients vary in terms of their preferred amount, depth and method of delivery of medicines-
related information. This diversity in what patients want was also illustrated by Krska et al., 
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(2013) who found that more than half of the patients in their study of factors affecting QoL in 
patients with long-term conditions, wanted verbal information about medicines. More than 
half of their patients also wanted information in addition to that given by the prescriber, which 
they would obtain themselves from the PIL, books or the internet. As in the current study, they 
also found a cohort of patients did not want any information about the medicines they were 
prescribed; they allowed their doctor to manage their medicine use and felt that accessing 
information worsened their concerns (Krska et al., 2013). Weinman (1990) found that 
information affected patients’ coping mechanisms; some patients were keen to know about 
their treatment when they received a new diagnosis, whilst others eschewed information as 
they found it distressing (Weinman, 1990). 
 
Weinman (1990) summarised some of the factors around providing written information for 
patients and postulated that patients required written information as they often 
misunderstood or forgot verbal information. Written information also resulted in increased 
adherence (Weinman, 1990). A Cochrane review also found that supplementing verbal 
information with written information increased knowledge and satisfaction scores for patients 
being discharged from hospital (Johnson, Sandford and Tyndall, 2003). 
 
This range of patient preferences means that HCPs should consider each individual’s needs 
when providing medicines-related information. This approach is also endorsed by NICE in their 
guidance on medicines adherence, which states that HCPs should adapt their consultation 
style and communicate in the most effective way for each individual patient (NICE, 2009). 
 
6.3.6.6 Health literacy and MURs 
Of the participants interviewed, only one had taken part in a MUR; the others appeared to be 
unfamiliar with MURs. During the interview process, the MUR service was explained to the 
participants who were unaware of it, and they were asked for their opinions based on what 
they had been told. Again, there was an apparent split in the group in terms of whether they 
thought a MUR would be something that they would be willing to engage with. The 
participants who had lower health literacy felt that a MUR would not be for them as they 
would not understand or retain the information they would be given. 
I: “…the chemist can sometimes do something for people called a medicines 
review, like we said before it’s where they go through all the medicines and 
you can say how you take them and if you get problems with them. What 
do you think about that? Do you think that would be a useful service that 
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the chemist would provide?” 
P: “Might be to them, yeah…probably be whatsit to me…double Dutch.” 
Patient Seven 
I: “…as I said you can have this medicines review with a chemist 
where...they go through all your medicines with you and ask you how you 
take them, if you are having any problems with them and that sort of thing. 
Do you think that would be a useful thing to have?” 
P: “It is for a lot of people, but I mean for people like me like, by the time 
I’ve gone out the door it’s gone…I just forget it.” 
Patient Four 
One of the participants with lower health literacy did acknowledge that they thought a 
medication review might be useful. Although their other responses during the interview 
suggested that they may not have been so willing to engage in the process if they were invited 
to participate in the ‘real world’. 
I: “I’m wondering, have you ever had a chat with either your GP or your 
chemist and you’ve gone through the medicines that you’re taking and 
they’ve explained them to you?” 
P: “No.” 
I: “No. And do you think that sort of thing would be useful?” 
P: “I reckon it would be, yeah, yeah. I reckon it would be to everybody, I 
reckon, yeah.” 
I: “…some chemists offer a service where they sit down with people and 
they go through each of your medicines in turn and you can say how you 
get on with it in terms of if you have any side effects from it and that sort of 
thing…” 
P: “I’ve never had that in me life, never.” 
I: “You’ve never had it…not from your GP or anybody?” 
P: “No, no. They just give you a script but that’s it, goodbye.” 
I: “And you’ve never had anything like that, but you think it would be 
useful?” 
P: “Yeah, yeah.” 
Patient Three 
 
Participants who had a higher level of health literacy had divergent views on whether they 
thought that a MUR might be useful. One participant felt that it would, but they were unaware 
of the service. 
I: “…thinking about sitting down and having a chat with a pharmacist or a 
GP about your medicines, do you think that would be something that you 
would find useful?” 
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P: “I’ve never actually thought of it…no, I think I’m so used to dealing with 
my medicines and I know what I’m taking…I’ve been taking a lot of them for 
years, so no I’ve never thought of that.” 
I: “And is it something you would be particularly interested….?” 
P: “It might be worth a shot…yes, yes.” 
Patient Six 
Another did not think MURs were for them as only the GP had the authority to change their 
prescription and the community pharmacist did not. Underlying this was a belief that the GP 
would have the final say in any discussions about medicines and they would have to ratify any 
medicines-related decisions.  
“I would expect there to be something…about the GP…who would explain 
why they changed the medicines, but I don’t think he’d (the GP) let 
anything change unless he agreed to it…no disrespect to anyone else.” 
Patient Five 
 
The participant who had participated in a MUR thought it was a really useful process.  
P: “Every now and again they get you into the office and explain all of the 
tablets, you know, have you got 5 minutes to spare.” 
I: “… they call that a medicines review don’t they?” 
P: “Yes, that’s right.” 
I: “Have you had one of those with the pharmacist…your chemist there?” 
P: “It was good, very good…they talk to you and ask you whether what 
you’re taking…and are you happy to keep on…keep on using it, you know, 
taking them…” 




From the HCP perspective, there may be an expectation that all patients would be willing to 
participate in a MUR and recruiting them was simply a matter of better publicity. This does not 
appear to be the case as some participants in the current study did not see the benefit of 
participating. Enhanced publicity of the MUR service may help but the MUR service needs to 
be tailored to the needs and requirements of the different patient types that attend the 
pharmacy, irrespective of their level of health literacy. 
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6.3.6.7 Discussion of health literacy and MURs 
All but one of the participants interviewed were unaware of the MUR service. This was 
perhaps surprising given that MURs have been available in community pharmacies since 2005 
and most of the patients in the current study had been taking medicines for a long period of 
time. In the press, there has been some controversy about MURs, with pharmacists reporting 
that: they had been put under pressure to complete them, they were not being conducted on 
the patients who would benefit most, and the annual 400 MUR limit being treated as a target 
(Sukkar, 2013). This negative publicity could have potentially deterred patients from taking 
part in a MUR, but as most patients in the current study were not aware of their existence, this 
seemed unlikely. 
 
Specific studies with patients about the MUR service provided by community pharmacies in 
England have given useful insights into how patients view them. MURs have been generally 
well received by patients who have participated in the service; this was reflected in the 
opinions of the patient in the current study who had participated in a MUR. As discussed in the 
literature review, Latif, Boardman and Pollock (2013) found that patients were not clear about 
the rationale for MURs, they did not increase their knowledge but did provide them with 
reassurance that they were ‘doing the right thing’ with regard to their medicine-taking. There 
have been concerns from patients that participating in a MUR or HMR could introduce tension 
into their relationship with their GP around medicines-use (White, Klinner and Carter, 2012; 
Latif, Pollock and Boardman, 2013) but none of the patients in the current study described this 
phenomenon directly in relation to MURs. 
 
The apparent finding that patients with high levels of health literacy were not always willing to 
participate in a MUR has also been seen in other studies. In the study by Twigg et al. (2016) 
into patients’ satisfaction with information about medicines, some of the quotes from patients 
who appeared to have high levels of health literacy mirrored what the participants said in the 
current study: 
“as I understand my medication, I didn’t really need this facility (MUR or 
NMS) but I’m sure it is useful for many people.” 
“neither services (MUR or NMS) will be of interest to me as this is 
something my doctor and I review regularly. I don’t think I would want to 
review this with a pharmacist anyway.” 
(Twigg et al., 2016) 
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In Australia, a study investigating patients’ perspectives of the HMR service (White, Klinner and 
Carter, 2012) found that some participants thought they did not need to have a HMR as they 
were in control of their medicines and had sufficient knowledge about them (White, Klinner 
and Carter, 2012). 
 
The community pharmacists providing the MUR service need to personalise their approach to 
ensure that patients are not only aware of the MUR service but also to ensure that they 
understand why it would benefit them, no matter what their level of health literacy. Patients 
with lower levels of health literacy may require encouragement to take an interest in what 
medicines they are taking and reassurance that the MUR would be tailored to their level of 
understanding. For patients with higher levels of health literacy, the pharmacists may need to 
emphasise the complementarity of MURs with services provided by their GP. 
 
6.3.6.8 Preferred HCP for a medication review 
Different HCPs offer different levels of medication review; the MUR service provided by 
community pharmacists has been described as a compliance and concordance review as the 
patient is present; it is not a full clinical review as the community pharmacist does not have 
access to the patient’s medical notes (Blenkinsopp, Bond and Raynor, 2012). Participants were 
asked who they thought would be the most appropriate HCP to conduct a medication review; 
they gave a variety of answers which reflected their own situation, their level of health literacy 
and their views about the skills and authority of different HCPs. 
 
Two participants with lower levels of health literacy reported that they would prefer to have a 
medication review with their GP; this was because they felt the GP had more knowledge about 
health and medicines generally and about their specific situation than any other HCP. 
I: “I’m just thinking…would you prefer to go to a doctor, or would you 
prefer to go to a chemist (for a medication review)?” 
P: “Doctor.” 
I: “You’d go to your doctor, and why would that be?” 
P: “Well, because they got more knowledge…I reckon they have.” 
I: “So, more knowledge about what, do you think? About the medicines, or 
the conditions that you’ve got, or…?” 
P: “Well, about both, both…” 
Patient Three 
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I: “And would you ever think to ask the chemist about your tablets at that 
time?” 
P: “No, no. ‘Cos the doctor knows me.” 
Patient Seven 
 
Other participants did think the community pharmacist would be the best HCP to provide the 
MUR service; this quote was from the participant who had participated in a MUR. 
I: “…but you found it (the MUR) was helpful?” 
P: “Helpful? If I wanted any help, I’d go and ask them (the community 
pharmacist)…if I had something I wanted to ask, I’d go there first before I 
went to the doctor.” 
I: “…and why would you do that?” 
P: “Well, they should be able to help you…they should really and that’s 
their job...and they are dealing with tablets, what people are taking, they 
know more or less all about these things don’t they…I mean it’s like, say, 
your job, you’ve got to know what you are doing…and what you are dishing 
out.” 
Patient Two 
It was interesting to note that two participants who did not see the benefit of a MUR for 
themselves, still thought that the community pharmacist would be suitable to advise and assist 
others with medicines-related problems. They viewed the community pharmacist as an expert 
in medicines as they were dealing with them every day, even though they would not 
personally utilise their skills. 
I: “…if you were going to have one of these reviews, obviously you’re not 
necessarily interested in having one, but if that was a service that was 
offered, who do you think would be the best person to offer that service?” 
P: “Like I said, the people for the drugs and that is the chemist…I mean they 
are dealing with…the millions of people they’re dealing with every day.” 
Patient Four 
I: “… Who do you think would be the best person to give advice about 
medicines…?” 
P: “I would think the chemist…well, yeah. They should know about the 
medicines they are giving, shouldn’t they?...The doctor prescribes them, 
but the chemist should know what they are giving.” 
Patient Seven 
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These findings, that patients think pharmacists are well placed to conduct reviews, are 
positive, but as noted previously, there is a possibility that response bias or social desirability 
bias were present as the participants knew the PI was a pharmacist, so they may have given 
the answer they thought the PI wanted to hear. 
 
6.3.6.9 Discussion of preferred HCP for a medication review 
Patients gave diverse opinions about who they thought would be best suited to conduct 
medication reviews. There were various factors that appeared to influence their preferred 
option, for example, their level of health literacy, support from others, confidence in their 
understanding of information that was given to them and how they viewed the different HCPs. 
As previously discussed in the literature review, some patients were concerned that partaking 
in a MUR with a community pharmacist would interfere with their relationship with their GP 
(Latif, Boardman and Pollock, 2013). Interestingly, this view has also been expressed by 
patients in Australia when asked about the HMR service there. This was in spite of GPs being 
able to refer patients for the service (White, Klinner and Carter, 2012). 
 
Perhaps one solution would be to further integrate community pharmacists into the primary 
healthcare system. This may help to change patients’ perceptions of the service, so they could 
ultimately view it as an essential part of coordinated care with their GP. The NICE guideline on 
Medicines Optimisation also suggests that further research is required into medication review. 
They propose a RCT with a one to two year follow-up, to determine the effect of the type of 
medication review, the HCP conducting the review and the frequency of the review on patient-
reported outcomes, clinical outcomes, medication-related problems, health and social care 
use and cost-effectiveness (NICE, 2015c). This would help to clarify the optimum conditions for 
medication reviews in primary care and facilitate them becoming embedded as standard 
practice through effective commissioning. 
 
The results and brief discussions of the patient interviews have been concluded. The following 
sections show how they provided a basis to keep patients as the focus of the study and ensure 
that the fieldwork conducted with community pharmacists was grounded on this base. 
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6.3.7 How the patient interviews informed the community pharmacist interviews 
Three of the themes that emerged from the patient interviews; locus of control, relationships 
and health literacy, were used to provide the foundations for the questions and statements 
that were included in the community pharmacists’ interviews and questionnaire. The concept 
was that the patient opinions could be presented to the community pharmacists in such a way 
that it could be established whether community pharmacists were aware of patients’ 
experiences and attitudes and how this could impact on the services they were offering, such 
as MURs. The health journey and outlook theme provided the patient-rooted foundation of 
the study and was not specifically used to inform the next stages of the fieldwork. It ensured 
that patients were at the heart of the research and established the essential need to reduce 
the personal cost of medicines-related admissions. 
 
The findings of the patient interviews were used to inform the topic guide for pharmacists’ 
interviews as follows: 
• For the theme of relationships, community pharmacists were asked about how they 
selected patients for MURs/PD-MURs, the willingness of patients to participate in the 
MUR process and aspects of the long-term relationships that they were able to build 
with their regular patients. 
• For the health literacy theme, community pharmacists were asked about whether 
patients were aware of the MUR and PD-MUR services, how they assisted patients to 
get the most out of their medicines and the provision of medicines-related information 
to patients. 
The theme of locus of control was deemed to be personal and individual to patients, so 
community pharmacists were not asked any specific questions about this area. There is more 
detail about the topics included in the community pharmacist interviews in Chapter 7. 
 
The findings of the patient interviews also directly contributed to some of the attitudinal 
statements that were included in the final questionnaire, particularly around the themes of 
relationships and health literacy. 
 
The statements for the community pharmacist questionnaire that stemmed from the patient 
interviews and were related to relationships were as follows: 
• Community pharmacists are able to build long-lasting trusted relationships with their 
patients. 
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• Patients value the contribution that community pharmacists make to their care, over 
and above the supply of medicines. 
• Patients see community pharmacists as just the suppliers of their medicines. 
• Patients are willing to discuss post-discharge medicines-related issues with their 
community pharmacist. 
 
The statements for the community pharmacists’ questionnaire that came from the patient 
interviews and were related to health literacy were as follows: 
• The majority of patients are aware of the MUR advanced services. 
• Community pharmacists are able to make valuable contributions to patient care 
through the MUR service. 
• I believe that MURs help patients to get the most benefit from their medicines. 
 
6.4 Strengths and limitations of patient interviews  
The patient interviews helped to gain an insight into what is was like to be a patient who 
experienced a medicines-related admission to hospital and also their experiences and opinions 
about medication reviews. The use of semi-structured interviews as part of the sequential 
exploratory mixed-methods study design had various strengths and limitations which are 
discussed below. This appears to be the first study to have analysed the patient experience of 
a medicines-related admission to hospital using IPA as the analytical tool. 
 
The strengths of this phase of the fieldwork stem from the determined focus on the patient 
experience in terms of how their medicines-related admission to hospital had impacted on 
them, and if they were familiar with medication reviews; this area lent itself to the use of 
qualitative methods. Using semi-structured interviews allowed an in-depth, detailed, personal 
account to be gained. Even though a topic guide was used to direct the interview, patients 
were free to say what they wanted; this helped to ensure issues that were important to them 
were voiced and consequently, this allowed issues that the researcher had not thought of to 
be expressed by the participants. The use of interviews enabled participants who may have 
been deterred from completing a questionnaire (in paper form or online) due to literacy skills 
or time pressures to participate in the study. The participants appeared to have different 
standpoints regarding HLOC, health literacy and the involvement of others in their health, this 
gave depth and richness to the data collected and suggested a heterogenous sample. 
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The limitations of this phase of the fieldwork were due to the relatively small number of 
participants and how this may have affected the interpretation and generalisability of the 
findings. Also, data saturation may not have been reached for this reason. Patients were 
recruited from one Trust in England and other geographical areas may have different policies 
and practices which would affect responses to the same interview questions. The use of semi-
structured interviews meant that the participants’ responses may have been biased by the 
presence of the researcher who they knew was a pharmacist who worked for the hospital they 
had been admitted to. The participants may have told the researcher what they thought they 
wanted to hear rather than their true opinion, an example of response or social desirability 
bias. Interviewer bias could also be present because it would be difficult for the researcher to 
truly bracket off their own opinions and experiences to allow the true and unencumbered 
voice of the participant to be fully heard. The vast amount of data generated by the qualitative 
interviews, even though there were only seven participants, meant that the transcription and 
analysis was very time-consuming. The lack of follow-up also meant that it was not possible to 
discover whether PD-MURs had occurred, and if not, the reasons for that. Consequently, it was 
also not possible to find out about the thoughts and attitudes of patients who had participated 
in a PD-MUR. 
 
6.5 Future research 
Future research should focus on finding out more about the views and experiences of patients 
towards PD-MURs specifically. Also, as per the suggestion from NICE, a RCT is required to 
determine the optimum conditions for conducting medication reviews in terms of the 
optimum HCP, location, type of review and frequency. Research is required for both MURs and 
PD-MURs as different parameters may result in better outcomes for each type of review. 
 
6.6 Summary of the patient interviews chapter 
The patient interviews gave a rich and varied account of what it was like to be admitted to 
hospital due to a medicines-related problem. The main findings from the patient interviews 
were the themes of locus of control, health journey and outcomes, relationships, and health 
literacy. These findings have answered research questions 1 and 2 that asked:  
1. What are the experiences of patients who have had a medicines-related admission to 
hospital? 
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2. What are the experiences and attitudes of patients towards PD-MURs and medication 
reviews in general? 
 
The most important findings of this phase of the research were around the impact of the 
medicines-related admission on the individual patients. All the patients described their 
medicines-related hospital admission in wholly negative language, which emphasised the 
psychological effect it had on them. This underlined the importance of listening to patients, 
understanding how health-related events impact on them and using this to inform practice. 
 
The other findings provided fascinating insights into how patients differed in their perceived 
needs regarding control over their health and the information they required. It highlighted 
that some patients wanted full control over their health and were motivated to seek 
information to make their own decisions. Conversely, others required support in these areas 
and delegated responsibility for decisions to others, be that their family or GP. These findings 
brought to the fore the difficulties in tailoring health information and services to everyone in 
the general population. There is no one size fits all approach. 
 
Patients placed high value on relationships with others, particularly GPs, who they had 
experienced an enduring relationship with. They often described situations where they had 
lost their preferred GP and had not been able to rebuild that relationship with a new GP. The 
value they placed on their relationship with their GP affected their attitudes towards 
medication reviews and the HCP conducting them.  
 
Patients who were not willing to participate in MURs had various reasons for that stance. On 
one hand a lack of ability or confidence in their own health literacy. On the other, for patients 
with high levels of health literacy, a perception that they were able to fulfil their own 
medicines-related needs and the acknowledgement of their GP’s authority over their 
medicines. 
 
The views of patients have a huge impact on how services, such as MURs, should be designed. 
For some patients, the MUR model works well, it achieves it aims, and empowers them to 
optimise their medicines-taking. For others, it does not work at all, either in encouraging them 
to use their community pharmacist or to improve their knowledge about their medicines and 
optimise how they use them. These differing views and experiences of patients need to be 
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considered when commissioning services if such services are going to have any benefit for the 
patients individually or the NHS as a whole. 
 
The following chapter will focus on the community pharmacist interviews and how the findings 
from the interviews with both patients and community pharmacists informed the 
development of the questions for the community pharmacists’ questionnaire. 
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The focus of the first part of the chapter is the community pharmacist interviews. The second 
part of the chapter details how the findings of these interviews, combined with the findings of 




The second qualitative part of the study involved interviewing community pharmacists about 
their attitudes towards, and experiences of, the MUR service in England. The findings of this 
phase were considered alongside the findings of the patient interviews and used to develop a 
series of attitudinal statements and demographic questions for inclusion in the community 
pharmacist questionnaire.  
 
7.2 Methods for community pharmacist interviews 
The community pharmacist interviews formed part of the qualitative phase in the sequential 
exploratory strategy, as shown in Figure 7-1. 
 
  




























Figure 7-1 Schematic of study - Community pharmacist interviews 
 
The use of semi-structured interviews as a tool for research has already been discussed in 
section 6.2 as this technique was also used for the patient interviews, albeit with a different 
focus and topic guide. 
 
7.2.1 Ethical considerations of semi-structured interviewing 
The community pharmacists’ participation in the interview phase of the study was anonymous 
and confidential. None of their responses could be attributed to them and only members of 
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the research team were aware of their identities. The pharmacists were sent an information 
sheet and were able to ask the PI questions before the interview took place; ensuring that they 
were able to give their fully informed consent to participate in the study. Interviews were 
conducted in a neutral, public location or over the telephone to ensure the safety of the 
interviewer and the interviewee. 
 
7.2.2 Sampling process for community pharmacist interviews 
Community pharmacists were sampled purposively, using a ‘snowballing’ technique involving 
various methods to invite potential participants to take part in the study: 
• letters sent to 24 community pharmacies closest in geographical distance to the PI’s 
home address. 
• emails sent to contacts at local pharmaceutical committees (LPC). 
• messages posted on professional group message boards e.g. the Royal Pharmaceutical 
Society (RPS). 
• posts on social media platforms such as Facebook, LinkedIn and Twitter by members 
of the research team. 
• emails sent to personal contacts of the research team. 
 
The call for participants on Twitter was particularly fruitful. A member of the research team 
with more than 380 followers tweeted the call for participants; this message was retweeted by 
32 Twitter accounts and the number of people who had the potential to see the retweets was 
over 32,000 (based on the number of followers of people who retweeted the original 
message). 
 
7.2.3 Recruitment for community pharmacist interviews 
Eight pharmacists volunteered to participate in an interview. Two pharmacists were recruited 
via email as they were personal contacts of the research team and six were recruited following 
the call for participants on social media. Five pharmacists were actually interviewed for the 
study; four female pharmacists and one male pharmacist. One female pharmacist was 
interviewed in person and the other pharmacists were interviewed by telephone. All 
participants worked for large multiples. The participants were sent a consent form and 
participant information sheet prior to the interview which they were asked to sign and return 
(either electronically or by post). The consent form and information sheet are included in 
Appendix D. Participants were given information about how to withdraw from the study if they 
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wished to do so after the interview. If they had wanted to withdraw, their responses would 
have been removed from the analysis, but no pharmacists requested this. The pharmacists 
who agreed to be interviewed received a £10 Amazon voucher at the end of the interview as a 
thank you for participating. 
 
7.2.4 Interview process for community pharmacists 
The interview topic guide was informed by issues raised by the patients in their interviews and 
also subjects that were deemed to be important to providing the MUR service. The topic guide 
can be viewed in Appendix D. The semi-structured interviews were audio-recorded. The audio 
files were stored on a password protected computer. A file linking the pharmacist’s 
demographic details to their audio recording was kept in a password-protected file on a 
personal computer. After the completion of the study, the audio recordings were deleted 
without any break in confidentiality. 
 
The interview recordings were transcribed verbatim and anonymised by removing any 
identifiable information. These transcripts were then checked and corrected against the 
original recordings. The finalised transcripts were imported into NVivo, a qualitative data 
analysis software package, to assist with the analysis. The transcripts were analysed on a 
password-protected computer. 
 
The interviews were analysed using thematic analysis, as described in the following sections. 
The findings of the pharmacist interviews were then used to inform the survey questions. The 
anonymised transcripts will be stored on a password-protected computer for five years after 
completion of the study. After this time, they will be deleted without any break in 
confidentiality. 
 
7.2.5 Thematic analysis 
The interview transcripts were analysed using thematic analysis, which has been defined as 
searching across a dataset to find repeated patterns of meaning (Braun and Clarke, 2006). 
There are different stages to the process, which are outlined in Figure 7-2. 
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Figure 7-2 Phases of thematic analysis (Braun and Clarke, 2006) 
This method was chosen as the aims of the community pharmacist interviews were to find out 
more about what providing the MUR service is like for them; it was not necessary to conduct 
an IPA-style analysis which would have investigated how pharmacists attributed meaning to 
these experiences. Rather, it was important to discover more about the practical and day-to-
day issues faced by community pharmacists. This information could then be used in the design 
of the survey of a larger cohort of community pharmacists to find out if these issues had any 
resonance with them also. 
 
7.2.6 Thematic analysis of community pharmacist interviews 
The transcripts of the community pharmacist interviews were read and checked. For the 
thematic analysis, the transcripts were re-read, and codes were generated during this process. 
In the first stage, interesting points raised by the community pharmacists were highlighted. 
Once all the interviews had been read and coded in this way, this information was transferred 
into NVivo. This allowed the codes to be more easily categorised into topics or themes, which 
were summarised in a mind-map annotated with further detail of these areas. 
 
Using these themes, short summaries were generated for each theme to promote discussion. 
These summarised the title of the theme, a list of codes relating to the theme, associated 
quotes from the interviews, a narrative passage written about the theme and potential 
attitudinal statements that could be included in the community pharmacist questionnaire. 
These summaries were discussed with the supervisory team and the attitudinal statements 
Writing-up
Defining and naming the themes 
Reviewing the themes
Searching for themes
Generating the initial codes
Familiarising yourself with the data
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that would be included as Likert scale questions in the questionnaire were finalised. Each 
theme is discussed in more detail in the next section. 
 
7.3 Results of community pharmacist interviews 
The themes from the community pharmacist interviews could be summarised in four main 
areas, which are shown in Figure 7-3.  
 
 
Figure 7-3 Themes from community pharmacist interviews 
 
Again, the convention is that the interviewer is denoted as ‘I’ and the participant as ‘P’ in the 
quotations. 
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Figure 7-4 Themes from community pharmacist interviews: Theme One - Views of self and 
relationships with others 
 
7.3.1.1 Views of self 
Community pharmacists view themselves as having a wider role, not only in the supply of 
medicines, but also in ensuring that patients are able to use their medicines safely. They were 
willing to conduct MURs for the benefit of their patients, but some did acknowledge that 
another healthcare professional may be better placed to conduct PD-MURs. This was mainly 
due to lack of access to the discharge summary and associated clinical information that would 
ensure the PD-MUR would provide benefit for the patient. Time was also another factor; one 
of the community pharmacists thought that a pharmacist in a GP surgery would be able to see 
the patient during a scheduled appointment, which was preferable to the community 
pharmacist having to fit it into their day in an ad hoc manner. 
“…in our area now, two of the three surgeries that we use most frequently, 
or we have closest contact with, have both got a full-time pharmacist 
working with them and to be honest they are probably better placed than I 
am because they would be able to allocate a slot of time to go and do that 
whereas I have no control over my workflow.” 
Interview Pharmacist 5 
A recent paper by Rutter, Ramsbottom and Fitzpatrick (2017) reported that community 
pharmacists involved in providing PD-MURs found them to be more complex than other types 
of MUR and took on average between 20-39 mins to complete (Rutter, Ramsbottom and 
Fitzpatrick, 2017), which could prove difficult to accommodate in a busy community pharmacy. 
This suggests that community pharmacists have an awareness that although they have the 
requisite skills, other pharmacists may be better placed to conduct post-discharge medication 
reviews. 
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7.3.1.2 Community pharmacists’ perspectives on their relationships with patients 
Community pharmacists perceived that some patients saw them as only the suppliers of their 
medicines and did not want them to be involved in their care any further. 
“sometimes I see patients who don’t want any intervention, they just see 
the pharmacy as a sort of supply process whereby we take in the 
prescriptions, get the medicines, and off you go…they don’t see the 
pharmacy as any other thing, other than supply; a packaged good provider. 
So, we try to intervene, and we try to say to individuals that we can provide 
more than just medicines.” 
Interview Pharmacist 4 
This suggests that this may be because patients are not aware of the extended roles of 
community pharmacists. Some patients appear to have a more paternalistic relationship with 
their GP and do not want community pharmacists to have any additional involvement in their 
care. 
“…that’s very much a hands-off approach from the patient, I think…‘the 
doctor knows what is best and knows what I am able to take.’ Yeah, so I 
have come across individuals like this, yeah. And this tends to be more of 
the older generation, those individuals who are...60 years plus individuals 
and they probably have grown up with that.” 
Interview Pharmacist 4 
All the other pharmacists also reported difficulties in engaging patients with the MUR process. 
This appeared to be because they had already had a review with their GP or did not want to 
jeopardise their relationship with their GP by involving the pharmacist. 
“their response is “Oh, I’ve spoken to the doctor and I don’t want to waste 
any more time doing this”.” 
Interview Pharmacist 1 
“Oh, yes, quite often yes. I have heard it many times that in a way they 
prefer to discuss that with their GP. 
Interview Pharmacist 2 
“...some patients they are a little bit reluctant, especially when they hear 
that we may need to share information with their GP.” 
Interview Pharmacist 2 
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”… and said, ‘I’ll talk to the doctor about it, I don’t want to talk to you.’” 
Interview Pharmacist 5 
Community pharmacists reported that they thought carefully about how they invited patients 
for MURs because patients tended to refuse, either because they did not know what it was, or 
the word ‘review’ put them off. 
 “…sometimes some people will say ‘I don’t think I want to do this.’ But 
when I explain that I’m checking how you’re getting on with the use of your 
medicines because it works well with what the doctor has already done.” 
Interview Pharmacist 1 
“I think people who refuse probably they were mainly people who didn’t 
actually know what it is….they didn’t want to get involved with something 
that they won’t like…so basically they…people didn’t get chance to explain 
to them what exactly it is for, it’s just a benefit for them but yes, 
somehow…again, there’s a lot of selling going on and it’s quite difficult to 
distinguish when, you know, something is genuine and something is 
something that may trick them into something else.” 
Interview Pharmacist 2 
“Right, well over the time, I’ve learned that you don’t say, ‘Do you want a 
review?’ because they run away a mile. My usual opening line is ‘have you 
got a few minutes just to talk about your medicines today?’”  
Interview Pharmacist 3 
One pharmacist felt that if GPs referred patients for PD-MURs, patients would be more likely 
to accept their role. 
“So, we might get a system where patients are referred from their GP to 
the community pharmacist, then the patient would know that it’s not just 
the community pharmacists just trying to get in the way, which is how we 
feel sometimes.” 
Interview Pharmacist 1 
Despite pharmacists having to persuade some patients to have a MUR, once patients had 
participated in one, they were generally agreeable to having another in future. 
“They can see the change and they say: ‘this is more helpful than what I got 
at the doctor' because they can actually see how to use it and practice how 
to use it, so you do get feedback like that.” 
Interview Pharmacist 1 
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“I’ve got an observation that if they have it once, they find it useful, then 
they are invited the following time, they are quite happy to have it done. 
Some of them are even more prepared, they know what it is about, and 
they are more willing to share. Umm, because some patients they are a 
little bit reluctant, especially when they hear that we may need to share 
information with their GP.” 
Interview Pharmacist 2 
I: “…do you find that people are quite willing to come back for a repeat 
MUR?” 
P: “Yes, yeah…different issues crop up or sometimes the same issues that 
they haven’t err…very often they’ve sort of followed up on suggestions 
you’ve made, and they are quite grateful.” 
Interview Pharmacist 3 
Patients must trust their community pharmacist otherwise they will not agree to a MUR. From 
talking to community pharmacists, it appeared to be relatively easy to start a relationship with 
the patient if they were coming to collect their prescription regularly from the pharmacy, as 
familiarity helped to build trust. 
“If you see them every 4 weeks you tend to get to know them and they get 
to know you better rather than some counties that give…there are some 
counties that give out three months’ supply at a time and then you only see 
them 4 times a year as opposed to 12 times…so that does make a 
difference. And it gives you more opportunity to sort of get to know them 
and them to feel happy asking you questions” 
Interview Pharmacist 3 
“…the patients, they see me throughout the year…they are more than 
happy to sit down with me just to get a check up on how they are getting 
on.” 
Interview Pharmacist 4 
“I’ve been here for a long time now and I know the patients, the patients 
know me so if I go out to them and say, ‘have you got time for a quick chat 
that I mentioned?’ then I’ll tell them a bit more about why I’m doing it.” 
Interview Pharmacist 5 
It seems that pharmacists need to have a greater depth of involvement with patients; 
educating them about MURs and how they can benefit them, and also taking time to build 
trusting relationships with them. 
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7.3.1.3  Community pharmacists’ perspectives on their relationships with GPs 
The relationships between community pharmacists and GPs was quite variable. This could be 
because each community pharmacy has to communicate with a potentially large number of 
different GP practices. In general, community pharmacists reported that they did not receive 
feedback from GPs when they made recommendations during a MUR. 
 
“No, no, no, I haven’t had feedback.” 
Interview Pharmacist 1 
“I don’t think I’ve ever had any feedback from anyone ever…well not from 
GPs anyway” 
Interview Pharmacist 5 
This was despite wanting feedback, so they knew their efforts were not wasted. 
 “…reliable feedback and to know that you’re not just sending notes into 
nothing.” 
Interview Pharmacist 3 
 
The community pharmacists appeared to circumvent this problem in a variety of ways. One 
pharmacist did not contact GPs directly with MUR recommendations, preferring instead to get 
the patient to discuss issues with their GP directly.  
“over the years I’ve found that rather than going to their doctor on their 
behalf I’m better off suggesting to them, this is what you need to go and 
talk to your doctor about…and letting them…pick it up with their GP 
themselves. And we have had people come back and say ‘I did what you 
suggested and spoke to them about this’ and now that’s sorted…I think, it 
also seems to give them the permission to go and question something 
because a lot of them don’t want to go…whereas if I suggest that maybe 
there might be an alternative, go and have a chat, then they’ll follow it up 
when they wouldn’t do otherwise.” 
Interview Pharmacist 5 
One pharmacist described having access to a pharmacy technician that was working in a GP 
practice and due to their pharmacy background, they had an innate understanding of 
pharmaceutical issues that the community pharmacist had identified. There was a perception 
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that the GP surgery may view the pharmacist negatively when they presented them with 
queries. 
“one of the senior technicians from the pharmacy, and they’ve been 
employing her for, I don’t know how long, 4 or 5 years, and even she’s 
really useful because she really understands the problem, you know. If you 
call with a problem, or whatever she’ll get it sorted out…I think if they can 
see both sides of it, they know what your problem is and you’re not just 
being a pain.” 
Interview Pharmacist 3 
Only one community pharmacist reported that they received feedback about the 
recommendations they made during MURs. 
“…that’s another good thing about the place I mostly work because the 
surgery’s just across the road and if I send a report, they sort of act on it 
straight away.” 
Interview Pharmacist 3 
Pharmacists did not feel that GPs were aware of the services they were able to offer patients. 
“doctors don’t know that we are offering the new medicines service, they 
don’t know we’re offering MURs, they don’t know we’re doing the ‘flu 
(vaccination service) and they go ‘why are you doing this?’, that sort of 
thing, because I think they also have their targets to meet.” 
Interview Pharmacist 1 
The lack of two-way communication between community pharmacists and GPs, and often 
negligible relationships coupled with feelings of negativity by the pharmacists in some 
geographical areas, gives the impression that GPs do not appreciate the role of community 
pharmacists over and above a supply function. This does not help community pharmacists to 
feel that they are a full part of the primary care team and this, combined with a lack of 
information around hospital discharge, does not help to dispel the problem. 
 
7.3.1.4 Summary of views of self and relationships with others 
Community pharmacists need to have increased confidence and pride in their role, and in their 
ability to support patients with their medicines after hospital discharge. Part of the lack of 
confidence arises from patients and GPs not always knowing about their role and how they can 
make positive contributions to patient care. Healthcare professionals, such as GPs and hospital 
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pharmacists, should promote the support that is available from community pharmacists after 
discharge. This could be done informally by talking to patients or formally through a secondary 
to primary care referral system. Ensuring that community pharmacists are part of the core 
primary healthcare team would mean that everyone was aware of the services they offered, 
and patients would be encouraged to use them. 
 
7.3.1.5 Potential attitudinal statements 
From the thematic analysis of the interviews with community pharmacists, a list of potential 
attitudinal statements that could be included in the questionnaire was formulated: 
• GPs have a high regard for the contribution of community pharmacists to the care of 
their patients. 
• Patients value the contribution that community pharmacists make to their care, over 
and above the supply of medicines. 
• The majority of patients are aware of the advanced services that community 
pharmacists offer e.g. MURs. 
• Patients see community pharmacists as just the suppliers of their medicines. 
• Community pharmacists are able to build long-lasting trusting relationships with their 
patients. 
• Patients are willing to discuss post-discharge medicines-related issues with their 
community pharmacist. 
• GPs view community pharmacists as just the suppliers of their patients’ medicines. 
• GPs/community pharmacists/practice pharmacists are better placed to conduct post-
discharge medicines use reviews. 
• GPs should conduct more thorough medicines reviews for patients, so MURs are not 
required. 
• Community pharmacists have the right skills to perform high-quality MURs. 
• I have a good relationship with GPs in my local area, that involves two-way 
communication. 
• GPs in my local area ask for my advice about medicines-related issues for their 
patients. 
• GPs should provide feedback to community pharmacists when recommendations are 
made as a result of a MUR. 
• GPs should refer patients to community pharmacies for MURs. 
• I find conducting MURs a satisfying part of my job.  
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Figure 7-5 Themes from community pharmacist interviews: Theme Two – Role in medication 
safety and education 
 
Talking to community pharmacists it was apparent that they took their role in patient safety 
and patient education very seriously and felt that they were well placed to offer medicines-
related advice to patients in these areas. 
 
7.3.2.1 Patient safety 
There are inherent risks when a patient transfers from secondary care back to primary care, 
especially as they may have had significant changes to their medication regime. Pharmacists 
gave examples of specific patient safety issues that they had experienced in their practice. One 
problem that was highlighted was that reception staff often updated the patient’s repeat 
medication list from the hospital discharge summary. This is far from ideal as hospital 
discharge summaries are written to be reviewed by a doctor or other health care professional. 
If a member of reception staff is the only person to review the discharge summary there is a 
risk that important follow-up information or monitoring could be missed. 
“…and in the GP surgery to be fair these discharge letters they go to the 
reception staff…they don’t go to the doctors and quite often they are not 
even properly entered, many things get missed off, it all depends on the 
prescription clerk whether they’ll pick up everything that (is) in the letter.” 
Interview Pharmacist 2 
“…there was one…that should have gone off the repeat…it should have 
gone off after…12 months or 18 months, something like that, so I queried it 
and he (the GP) said ‘I do not know how that has remained, I’m so grateful 
that you do this.’” 
Interview Pharmacist 1 
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Some community pharmacists did report that they had contacted hospital pharmacy 
colleagues to clarify medication-related issues, although they reported that it was difficult to 
know how to get in touch with the correct person in the hospital. 
I: “Have you had to go back and try to contact hospital pharmacists about 
anything?” 
P: “Occasionally, when something’s not been clear on discharge summaries, 
we’ve gone back to clarify stuff, or maybe they’ve asked us to find 
something out but that’s generally the extent of it, it just clarifying various 
issues around dispensing something, either what have we done before 
…they got to hospital or what you done [sic] in hospital that we now need 
to do because they’ve come out.” 
Interview Pharmacist 5 
Community pharmacists were keen to know what patient education had occurred in hospital 
as sometimes it was necessary to reiterate the message; they appreciated that patients may 
not be able to recall or understand everything they have been told in hospital.  
 
“…patients don’t really understand as much in terms of the medication 
that’s been given to them…and it would be good just to see what the 
pharmacist said in hospital so that we can repeat the same information but 
maybe in a different environment so that they are more likely to absorb 
and understand.” 
Interview Pharmacist 4 
This shows that community pharmacists were keen to ensure that patients were using their 
medicines as safely a possible. 
 
7.3.2.2 Education of patients and GPs 
As well as their patient safety role, pharmacists thought they were in a good position to offer 
medicines-related information and education to patients and GPs; they saw themselves as the 
‘medicines experts’ in the community. One of the community pharmacists was very passionate 
about being able to support GPs by providing medicines information to them. 
“…But we try to liaise with those doctors as well, to say that if there are any 
queries about a particular medicine that they are not sure of, drop it as an 
email or a phone call to the pharmacy and we use our medicines 
information services in the community to find out the right answer and get 
back to them…increasing our sort of profile about medicines information.” 
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Interview Pharmacist 4 
Patients also demonstrated a desire for further information about their medicines, about 
issues such as interactions and side effects. Perhaps more should be done to promote the 
information/education role of community pharmacists. Some patients appeared to appreciate 
the opportunity, within the MUR, to further their knowledge about their medicines and find 
out how to use them safely and effectively. 
“it’s a two-way sort of thing because I find out if they are doing well in 
terms of their therapy and taking of medicines, and in turn they find out 
whether or not they should be taking x, y, z painkillers or I’ve just heard 
about this new herbal remedy and then they give me the work to do. So, I 
will go back and say, ‘Let me find out, I’ll find out and then get back to 
you.’” 
Interview Pharmacist 4 
All the community pharmacists talked about conducting MURs which revealed hidden 
medicines-related issues for a particular patient. They felt the MUR discovered an untapped 
medicines-related need that had not been immediately apparent. The pharmacists felt that it 
was not always easy to identify the patients who had the greatest medicines-related needs. 
“sometimes you go in for routine use review and then you realise, oh 
actually this person needs an MUR more than I thought they did…and as 
you talk to them you find oh gosh, yeah, there are issues you should be 
handling.” 
Interview Pharmacist 1 
“…it’s like MURs, you can think it’s going to be really useful and actually 
you’ve got a patient who knows everything, understands everything and 
really doesn’t need any help and you get somebody else who’s only having 
a few medicines which seem straight-forward to us, which actually they 
haven’t got a clue about.” 
Interview Pharmacist 3 
The time around hospital discharge was again shown to be critical to patients taking their 
medicines effectively and an area where community pharmacists could support patients 
through a PD-MUR. 
I: “Do you think patients who’ve been discharged would be a good group of 
patients to be able to talk to? Do you think an MUR would be beneficial for 
them?” 
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P: “Yes, I think they are probably the best ones for MUR because obviously 
they…for many of them there is something major…after major surgery or 
something, they have started a lot of medication, it is quite good to know 
why they take it, and how to take it and how to maintain everything.” 
Interview Pharmacist 2 
7.3.2.3 Summary of patient safety and medicines-related education 
The main issue around education of patients and other HCPs is to ensure they are aware of 
how the community pharmacist can support patients with their medicines, not just around the 
time of a hospital discharge but also at other times, for example when medication regimes are 
altered, or new medicines are started. There is also an acknowledgement that to be able to 
provide this high-quality information, community pharmacists require access to information 
about the patient that has traditionally not been available to them, and also the time to use 
the information effectively. Quite radical changes are required in terms of IT infrastructure to 
allow this to happen but in the meantime, it is important to find out what information 
community pharmacists require to work in new and innovative ways for the benefit of their 
patients. 
 
7.3.2.4 Potential attitudinal statements: 
• Community pharmacists can provide patients with better information about medicines 
safety than GPs. 
• GPs have access to sufficient medicines-related information to make safe prescribing 
decisions. 
• Community pharmacists would be able to provide a better service to patients recently 
discharged from hospital if they could conduct MURs in the patient’s home. 
• PD-MURs are more complex and time consuming that other types of MUR. 
• MURs are not conducted on patients with the most complex medicines needs. 
• Community pharmacists regularly identify major issues relating to patient safety. 
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Figure 7-6 Themes from community pharmacist interviews: Theme Three – Primary-
secondary care interface issues 
 
7.3.3.1 Lack of communication around hospital discharge 
The major barrier for community pharmacists conducting PD-MURs was that they did not 
know when their patients had been in hospital. For certain cohorts of patients, such as those 
using compliance aids, the hospital pharmacy did inform them, in an attempt to reduce wasted 
efforts in dispensing or delivery, but this was unreliable. 
“…we also do the Dossett boxes…so those patients are easily identified 
because they probably wouldn’t have picked up or the delivery would be 
missed. Nobody tells us if they are going to go into hospital. So, we take the 
medication there, and there’s nobody there and then a neighbour will say, 
‘Oh, they’re in hospital’.” 
Interview Pharmacist 1 
Pharmacists also reported that they may receive a copy of the discharge summary for patients 
using compliance aids. For patients using medicines from standard boxes, these cues do not 
exist. Community pharmacists tended to discover patients had been in hospital by accident. 
This usually occurred when the patient told them, either because they had a query about their 
new medicines or if the community pharmacist invited them for the NMS and then discovered 
the new medicine was commenced in hospital. 
“…if they don’t tell us that they’ve been in hospital and they have been 
recently discharged there is no way to know that basically they have been 
in hospital.” 
Interview Pharmacist 2 
“…mainly I found out they were post-discharge when we start to talk, and 
patients mention that actually, they were not long ago in hospital and 
certain things and they started there and they stopped.” 
Interview Pharmacist 2 
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“…usually that’s when people would come to me and say, ‘I’ve come out of 
hospital and I’ve got all these, and I don’t know what they are.’ So then, I 
would opportunistically say, ‘Well, would you like me to go through them 
with you and explain them to you? So, it does happen occasionally but it’s 
rather the patient flagging it up than us being able to identify them 
normally.” 
Interview Pharmacist 3 
“…only when they presented with that prescription which you knew was 
part of the new medicines service because the patient said, no I’ve already 
taken it. My first course, my first lot was from the hospital on 
discharge…and this second lot is from my GP. And then you say okay, this 
would potentially be a discharge MUR.” 
Interview Pharmacist 4 
The patient safety issues around community pharmacists not knowing that someone had been 
in hospital was highlighted by one participant, who outlined the problem of ensuring that 
patients were taking the correct medication after discharge. 
“The most difficult thing is, if we are delivering out to them and we are 
managing their repeats, it means that we miss some. We are told that they 
are not there, they have missed a delivery, we don’t hear from them and 
then we try again and then they are there, maybe they are back from 
hospital, but they are getting their old medicines. But if we know ahead of 
time, we probably will chase up the dose change, or if it hasn’t changed, or 
if we receive a prescription we will say “oh, we’ve received this saying that 
the dose should have changed and it’s still the same.” So, definitely, it 
would be helpful.” 
Interview Pharmacist 1 
Community pharmacists are now managing more patients’ repeat medicines and if they do not 
know someone has been in hospital or have details of their updated medicines, there is a risk 
to patient safety if they continue their previous medicines either instead of, or in addition to, 
their new medicines. 
 
7.3.3.2 Good practice in discharge communication and improvements to the current 
system 
There were some pockets of good practice where community pharmacists received referrals 
for PD-MURs from the hospital, or where the discharge summary was sent to community 
pharmacists on the PharmOutcomes system. 
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 “I think he got referred to us by the hospital, I think the hospital did 
suggest that he was on so much new medication that if he wasn’t sure, he 
could have a chat to the chemist, so he did” 
Interview Pharmacist 5 
“…some areas are better than others…in one county that I sometimes go to, 
in a very busy place, they will send … the hospital pharmacy there will ask 
who the community pharmacist is and send instructions out to them about 
what they should be having, which obviously is very good, but that doesn’t 
happen everywhere.” 
Interview Pharmacist 3 
Community pharmacists were asked about how the current system could be improved, and a 
number of suggestions were made. One pharmacist suggested that anything would be an 
improvement on the current system. 
“…well just anything would be a help really…” 
Interview Pharmacist 5 
One pharmacist suggested that just being alerted to the fact someone had been in hospital 
would be sufficient. A note of this would be enough to trigger the offer of a PD-MUR the next 
time the patient visited the community pharmacy. 
“Having an alert, or something to say Mrs So-and-So has been in hospital 
and just to check their records or something would be great.” 
Interview Pharmacist 1 
 
7.3.3.3 Improvements at the primary-secondary care interface 
A more formal system of informing the community pharmacist that a patient had recently 
been discharged from hospital was suggested as a simple way to identify patients who would 
be eligible for a PD-MUR. This could come from the hospital or the GP surgery. If the 
notification came from the hospital, with the discharge summary, a PD-MUR could then occur 
in a timelier manner, rather than waiting to receive the cue from the GP. If the notification 
came from the GP, there may be a delay and also lack of access to the discharge summary. 
 
GPs could advise patients to go to their community pharmacists for a PD-MUR and this could 
increase patients’ use of the service. Referrals from GPs would validate the service and 
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encourage more patients to use the opportunity for a PD-MUR. Patients could also be 
educated about PD-MURs whilst in hospital which may persuade them to participate in one 
after discharge. 
“Whether or not they (hospital pharmacists) could ask the patient when 
they are being discharged, ‘would you like us to inform your chemist?...And 
then you can go and have a chat when you get home about what we’ve 
done.’ If they’ve changed lots of stuff. It’s got to come from…it’s going to 
have to come from either the GP or the hospital because we’re not going to 
know.” 
Interview Pharmacist 5 
7.3.3.4 Potential statements for questionnaire: 
• Patients should have a nominated community pharmacy that is informed when they 
are admitted to/discharged from hospital. 
• Discharge summaries for patients recently sent home from hospital should 
automatically be sent to the patient’s community pharmacy. 
• Hospital pharmacists should promote the PD-MUR service to patients when they are in 
hospital. 
• Hospital pharmacists should not inform patients about the PD-MUR service, as they 
are spending time promoting a service that the community pharmacy gets paid for, 
but they do not. 
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Figure 7-7 Themes from community pharmacist interviews: Theme Four – Practical issues 
 
7.3.4.1 Identifying patients for MURs 
Most pharmacists reported that patients were identified for general MURs using the pharmacy 
computer system. These systems appeared to be sophisticated in terms of being able to 
identify and highlight patients taking certain groups of medicines or those on certain numbers 
of medicines, and took into account whether the patient had participated in a MUR in the 
previous 12 months. 
“It would usually be the computer because every year we would record 
who’s done it and who hasn’t. The patient’s records would help identify if 
they’ve had it within the year and if not, we would look at what they are on 
and would be able to see if they would benefit from a use review.” 
Interview Pharmacist 1 
“I mean usually they are identified mostly by the computer system as being 
eligible for a check-up, so I would look at them, and other staff if they were 
checking or labelling would also highlight any they thought were necessary. 
So mostly that way…of course there are a few that will request and want to 
ask questions but mostly it’s just routinely, or just try and grab them when 
they’re in.” 
Interview Pharmacist 3 
7.3.4.2 Pharmacists’ professional autonomy 
Pharmacists did report that even though their employer may have a target for the number of 
MURs conducted, it was down to the pharmacist to decide which patients were in most need 
of a MUR and this maintained the professional autonomy of the pharmacist. 
 “It’s free choice, it’s very individually emphasised…it’s entirely up to 
myself…” 
Interview Pharmacist 4 
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Pharmacists did highlight that they had no control over certain aspects of their workload, so 
this sometimes made it difficult to prioritise MURs. 
“It doesn’t always work out like that because you get more walk-ins and 
more queries from patients who want to buy over the counter it’s really 
frustrating, but we definitely make the time.” 
Interview Pharmacist 1 
“…all the pharmacies I worked at were very, very busy…” 
Interview Pharmacist 2 
 
7.3.4.3 How discharge information is accessed in community pharmacy 
Considering how community pharmacists are able to access discharge medication information, 
it was clear that the situation varied depending on the location of the community pharmacy. 
Some pharmacists worked in areas where the discharge summary was sent to them through 
the PharmOutcomes system, or via fax for patients using compliance aids. Community 
pharmacists said that they often saw the discharge summary when a patient brought it to 
show them because they had a query about their medicines. 
“…they come in for medication and they are querying why they’ve been 
given a different strength, and then bring this sheet out to say that, “oh, 
look there has been this change.” 
Interview Pharmacist 1 
“I see discharge prescriptions mainly when there is a query and they are not 
quite sure, and they will say, ‘oh, I’ll bring you the letter from the hospital, 
so you can have a look.’”  
Interview Pharmacist 2 
Even when the discharge medication list was available, pharmacists reported that on occasion 
they had to try and contact the hospital to clarify details about the list. 
“Quite often, more clear directions because if the directions are not clear, 
or if I deal with the prescription that has come from hospital, and quite 
often it doesn’t say for how many days or the dose is not clear. Or there is 
some sort of error, it is, umm, sometimes it is a product we can’t get hold 
of straightaway so,…I need to clarify if they need it straightaway or if they 
can wait a couple of days, or a week if it is something special.” 
Interview Pharmacist 2 
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7.3.4.4 Pharmacists’ suggestions for improvements to the current system 
The current arrangements around hospital discharge are far from ideal and the community 
pharmacists that were interviewed were asked for suggestions about how things might be 
improved. The main issues were around having access to the discharge summary, for all 
patients, in an accessible format; for example, electronically or by accessing the hospital 
computer system. 
 “And, it (electronically) is probably slightly better than having a fax because 
sometimes the faxes don’t come through particularly clearly, or pages get 
stuck, or someone picks up the phone, so coming through electronically, if 
they can’t actually email it to us, that’s the next best thing.” 
Interview Pharmacist 5 
“…it would be nice from an ideal point of view to have the access to the 
hospital information…I know a lot of hospitals keep e-records now…” 
Interview Pharmacist 4 
The issues that the community pharmacists have discussed all point towards the problem that 
they are not included in the list of healthcare professionals that receive the discharge 
information automatically at the time of hospital discharge. The community pharmacists are in 
an excellent position to offer advice and ensure that medicines are reconciled after hospital 
discharge, but this is impossible unless they are aware a patient has been in hospital and they 
have some idea of how the medicines have been changed. It seems that in some practices the 
non-medically trained administration staff have better access to discharge information than 
community pharmacists. 
 
7.3.4.5 Summary of improvements to practical issues 
To improve on the current situation requires community pharmacists to have access to the 
discharge summary and ensure that patients are aware that community pharmacists can 
support them after a hospital admission. It seems that access to the discharge summary could 
be relatively easily done using the PharmOutcomes system, as has happened in some 
locations. A more sophisticated option would be to have a bespoke method for sending 
discharge summaries to community pharmacies, compatible with IT systems in both the 
hospital and the community pharmacies. This has been done with great success in East 
Lancashire, with the Refer to Pharmacy scheme (East Lancashire Hospitals NHS Trust, 2018). 
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Raising the profile of these post-discharge medication support services could be done by both 
hospital and community pharmacy staff. 
 
7.3.4.6 Potential attitudinal statements to include in questionnaire: 
• Arrangements for medicines-use reviews with patients should use an appointment-
based system. 
• Community pharmacists should automatically be sent a copy of the patient’s discharge 
summary. 
• It would be preferable to send hospital discharge summaries to community 
pharmacists by fax/PharmOutcomes/email/another electronic method/being able to 
access hospital pharmacy system (a non-Likert question may be better suited to find 
out this information). 
• Community pharmacists and hospital pharmacists should have two-way processes for 
communication. 
• Community pharmacists require access to the patient’s clinical/medical GP record to 
conduct a PD-MUR. 
• There is the right skill-mix in the pharmacy to enable MURs to be conducted. 
• MURs are a waste of time. 
• MURs are a waste of money. 
 
7.4 Discussion of findings from community pharmacist interviews 
The community pharmacist interviews gave a fascinating insight into what it is like to be 
involved in providing the MUR service at the current time. The pharmacists that were 
interviewed were strikingly honest in their accounts of the challenges they faced and what 
measures could be taken to improve the service, not only for themselves but also for patients 
and GPs. 
 
It is unsurprising that community pharmacists were so easily able to suggest improvements to 
the PD-MUR system, given that they have such inherent difficulties in identifying suitable 
patients. The basic lack of discharge information about their patients hampers their efforts to 
support patients at this vulnerable time. A study of older people in the US found that within 72 
hours of discharge, 14.1% of patients had at least one discrepancy in their medication. This 
contributed to a significantly higher readmission rate (p=0.04) within 30 days of discharge, 
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compared to patients with no medication discrepancies (Coleman et al., 2005). Problems with 
medicines after discharge have also been found in UK based studies (Latif, Waring, et al., 
2018). It is interesting to note that hospital trusts have been required to send discharge 
information to GP surgeries electronically since 2015, and secure fax is no longer permitted for 
sending this information (NHS England, 2018a). This directive does not apply to community 
pharmacies; hence they receive discharge information in an ad hoc and disjointed manner, 
often by fax. Community pharmacists were given the opportunity in the questionnaire to say 
what discharge information they required and how they thought it should be sent to them. 
 
This situation is not unique; a survey of 14.4% of community pharmacists in Switzerland 
assessed the information needs and problems faced by community pharmacists around the 
time of hospital discharge. The pharmacists surveyed reported a lack of access to all types of 
information about a patient’s hospital discharge (Bruhwiler, Hersberger and Lutters, 2017). 
Lack of information for community pharmacists at the time of hospital discharge is not a new 
phenomenon. Over 20 years ago, a survey that included community pharmacists in Scotland 
found that nearly all of them wanted information about changes in medication made during an 
in-patient stay, but the majority did not receive this information (Munday et al., 1997). It 
appears that not much has changed in the intervening period, although pockets of good 
practice do exist, such as the Refer-to-Pharmacy scheme in north-west England (East 
Lancashire Hospitals NHS Trust, 2018). The lack of information hampers efforts by community 
pharmacists to identify patients who have been discharged from hospital and are eligible for 
PD-MURs or may just require extra support with their medicines. 
 
The perceptions of community pharmacists from GPs and patients also impact on whether 
patients utilise the services they provide. The lack of involvement of community pharmacists in 
the discharge information pathway, may be deduced by patients as an endorsement from the 
wider NHS that pharmacists are not an essential part of the discharge process. A systematic 
review has shown that patients and the public perceive extended pharmacists’ roles to be 
beneficial but doctors’ supremacy, concerns about pharmacists’ knowledge and their motives 
were amongst the barriers to patients use of extended pharmacy services (Hindi, Schafheutle 
and Jacobs, 2017). This illustrates a missed opportunity for patients. A study of cardiology 
patients discharged from two hospitals in England showed that patients often chose HCPs, 
other than pharmacists, to discuss their medicines with, as they felt these others had a 
‘superior role’ in their care or contact was through an appointment-based system. The study 
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revealed that patients had unmet needs with regard to knowledge about their medicines, 
whether they were effective and why they should be taken (Gwynn et al., 2014). Pharmacists 
are able to fulfil these needs if given the opportunity. 
 
GPs appear to be unaware of the services community pharmacists offer when people are 
discharged from hospital and how these services fit into the overall system. A recent 
systematic review found that GPs were not aware of the services community pharmacists 
offered (Hindi, Jacobs and Schafheutle, 2018). In a study of interprofessional collaboration 
between community pharmacists and GPs in Germany, Löffler et al., (2017) established that 
community pharmacists felt they were competent in solving medicines-related problems. This 
view is not necessarily supported by GPs; the systematic review mentioned above found that 
GPs doubted the competence of community pharmacists and the value of the extended 
services they provided (Hindi, Jacobs and Schafheutle, 2018). 
 
Despite this, collaboration between community pharmacists and GPs is desired (Kelly et al., 
2013) even though existing relationships are perceived to be poor (Hindi, Jacobs and 
Schafheutle, 2018). A survey of community pharmacists and GPs in Canada concerning 
collaborative working found that 96.9% of GPs and 99.5% of community pharmacists thought 
that collaboration between the professions would improve patient outcomes. This was despite 
33.5% of GPs and 26.3% of community pharmacists stating that they had never, or rarely 
collaborated. The barriers to collaborations were lack of time and compensation, and the 
necessity to deal with multiple pharmacists/GPs (Kelly et al., 2013). Pharmacists are willing and 
able to support patients after discharge, so embedding them in the discharge process would 
give them more confidence in their role and wider endorsement of the value of the services 
they offer. Further research would be required to establish whether embedding community 
pharmacists into the discharge care pathway would enhance collaboration and improve 
patient outcomes. 
 
Coupled with this lack of engagement from GPs and patients, is a pressure from some 
pharmacy companies for pharmacists to complete certain numbers of MURs in a given time 
period. This is not conducive to pharmacists choosing the patients who have greatest need. 
PD-MURs tend to take longer and are more complex; this is not reflected in the remuneration, 
or satisfaction from GPs and patients with the service. It is therefore unsurprising that 
community pharmacists do not report conducting very many PD-MURs. 
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The findings and attitudinal statements that have emerged from the community pharmacist 
interviews were used to provide a rationale for the questions included in the survey of 
community pharmacists. The survey was able to explore whether the views and experiences of 
community pharmacists in the interviews were more widely held. 
 
7.5 Strengths and limitations of the community pharmacist interviews 
As with any research technique, there are strengths and limitations of the approach taken. For 
semi-structured interviews, this is no different. The strengths of this part of the study were the 
ability to gain in-depth information about what it is really like to be a community pharmacist 
providing the MUR service in England at the current time. The pharmacists gave rich and 
detailed accounts of their role and were able to pinpoint exactly where problems were 
present. As the PI did not have any recent experience of working in the community 
environment, this was invaluable to ensure that the questionnaire was developed based on 
up-to-date experiences of the target population, rather than assumptions of the PI. This 
ensured that the questionnaire was relevant and asked the right types of question.  
 
The limitations were due to the relatively small number of participants. Data saturation may 
not have been reached and those pharmacists who were interviewed may have been in some 
way different to other community pharmacists, representing volunteer bias. Response bias 
may have been present if the participants were answering the questions in a certain way 
because they had a particular ‘axe to grind’ in relation to the MUR service. All participants 
worked for large multiples and unfortunately there were no participants from independent 
pharmacies to establish whether their views and experiences differed. 
 
7.6 Future research 
The future research areas to emerge from the interviews would involve further exploration of 
the issues that the community pharmacists raised; the survey aimed to address some of these 
outstanding questions. Other potential areas for research could focus on the optimal method 
for sending discharge summaries to community pharmacists. Also, understanding how sending 
discharge summaries to community pharmacists affects patients’ knowledge about their 
medicines, levels of medicines reconciliation, adherence and outcomes would provide more 
robust evidence. 
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7.7 Summary of the community pharmacist interviews subchapter 
The community pharmacist interviews gave a fascinating insight into what it is like to be 
involved in providing the MUR service. The pharmacists that were interviewed were strikingly 
honest in their accounts of the challenges they faced and what measures could be taken to 
improve the service, not only for them but also for patients and other HCPs caring for those 
patients. 
 
It is unsurprising that community pharmacists were so easily able to suggest improvements to 
the MUR and particularly the PD-MUR system, given that they are caring for post-discharge 
patients on a regular basis. The survey will give a larger cohort of community pharmacists the 
opportunity to share their experiences and opinions about the service. Conducting the 
interviews ensured that the survey questions were rooted in the lived experiences of those 
working in current practice. 
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7.8 Questionnaire Development 
The findings of the patient and community pharmacist interviews were used to develop the 
questions and attitudinal statements for the questionnaire for community pharmacists. This 
represented an interim phase in the sequential exploratory strategy, following the qualitative 


























Figure 7-8 Schematic of study – Questionnaire development 
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7.8.1 Designing the questionnaire 
The questions and rationale for including them in the questionnaire are presented in the 
following sections. There are various strategies that can be employed with the aim of 
encouraging participants to complete the whole of a questionnaire. They are described below: 
• The inclusion of a variety of different types of questions to maintain respondents’ 
interest (Oppenheim, 1992). In this study, there were simple closed questions, 
multiple choice questions, questions asking about quantity, Likert scales and ranking 
questions as well as the option for free-text responses. 
• Having a variety of open and closed questions with free-text boxes to allow 
respondents to add detail to their responses (Boynton and Greenhalgh, 2004). 
• Using closed questions that are quick to answer, analyse and compare but be aware of 
a loss of spontaneity of responses (Oppenheim, 1992; Bryman, 2008). 
• Using open questions near the end of the questionnaire, where respondents can give 
their own opinions, ideas and theories but being aware that if there are many 
responses, they can be difficult to analyse and some respondents may find these 
questions off-putting as they are more work to complete (Oppenheim, 1992; Bryman, 
2008). 
• Making the question wording interesting to hold the respondents’ attention 
(Boynton, 2004). 
• Topic of high interest, that engage the respondents can result in an increased 
response rate (Oppenheim, 1992) 
• Putting demographic questions at the end saying why the information is being 
collected and how it will be used (Boynton et al., 2004). 
 
These recommendations were considered when designing the questionnaire in terms of the 
types of questions, their order, how they were worded and how they would be analysed. The 
following sections summarise the sections included in the questionnaire and the rationale for 
their inclusion. The full questionnaire can be found in Appendix D. 
 
7.8.2 Community pharmacists’ personal experiences of MURs and discharge 
communication – Questions 1 to 5 
The first question asked whether the community pharmacist had ever conducted a MUR. This 
was a screening question designed to filter out non-community pharmacists and ensure that 
those pharmacists who went on to complete the questionnaire had experience of the MUR 
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process. Following on from this question, community pharmacists were asked about their 
involvement in the MUR service and how they usually found out that one of their patients had 
been admitted to hospital and whether they ever received any discharge information. These 
were all information gathering questions that could be analysed separately and also used to 
give context to the attitudinal statements. 
 
7.8.3 Attitudinal statements – Questions 6 to 9 
The list of attitudinal statements that were formulated from the patient and community 
pharmacist interviews were discussed with the supervisory team and a final list of 31 
statements were agreed (see Table 7-1). The statements were presented to community 
pharmacists with Likert scale options for the responses; strongly agree, agree, neither agree or 
disagree, disagree and strongly disagree. The attitudinal statements were presented to 
respondents in a random order in an attempt to remove the possibility of respondents 
indiscriminately agreeing or disagreeing with all of the statements. 
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Table 7-1 Attitudinal statements included in questionnaire and their sources 
Attitudinal statements  Source of statement 
Two-way communication is an important part of good 
relationship with GPs.  
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
Community pharmacists are able to build long-lasting 
trusting relationships with their patients. 
Patient interviews: Theme = Relationships 
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
The majority of patients are aware of the MUR advanced 
services. 
Patient interviews: Theme = Health literacy 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
Community pharmacists are able to make valuable 
contributions to patient care through the MUR service. 
Patient interviews: Theme = Health literacy 
GPs in my local area ask for my advice about medicines-
related issues for their patients. 
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
Community pharmacists have the right skills to perform 
high-quality MURs. 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
PD-MURs are more complex and time consuming than other 
types of MURs. 
Community pharmacist interviews: Theme = Role 
in patient safety and education 
GPS have a high regard for the contribution that community 
pharmacists make to the care of their patients. 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
Patients value the contribution that community pharmacists 
make to their care, over and above the supply of medicines. 
Patient interviews: Theme = Relationships 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
Community pharmacists cannot conduct MURs properly 
unless they have access to the patients’ GP medical record. 
Community pharmacist interviews: Theme = 
Practical issues 
MURs are a waste of time. Community pharmacist interviews: Theme = 
Practical issues 
Community pharmacists would be able to provide a better 
service to patients recently discharged from hospital if they 
could conduct PD-MURs in the patient’s home. 
Community pharmacist interviews: Theme = Role 
in patient safety and education 
GPs view community pharmacists as just the suppliers of 
their patients’ medicines. 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
Hospital pharmacists should promote the PD-MUR service 
to patients when they are in hospital. 
Community pharmacist interviews: Theme = 
Primary-Secondary care interface issues 
GPs know where to find medicines-related information to 
make safe prescribing decisions. 
Community pharmacist interviews: Theme = Role 
in patient safety and education 
MURs are a waste of money. Community pharmacist interviews: Theme = 
Practical issues 
Patients see community pharmacists as just the suppliers of 
their medicines. 
Patient interviews: Theme = Relationships 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
I find conducting MURs a satisfying part of my job. Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
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Community pharmacists require access to the patient’s GP 
medical records to conduct a PD-MUR. 
Community pharmacist interviews: Theme = 
Practical issues 
GPs should refer patients to community pharmacists for 
MURs. 
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
Community pharmacists can provide patients with better 
information about medication safety and use than GPs. 
Community pharmacist interviews: Theme = Role 
in patient safety and education 
I believe that MURs help patients to get the most benefit 
from their medicines. 
Patient interviews: Theme = Health literacy 
Community pharmacists should automatically be sent a 
copy of the patient’s discharge summary. 
Community pharmacist interviews: Theme = 
Primary-Secondary care interface issues 
Community pharmacist interviews: Theme = 
Practical issues 
GPs should feedback to community pharmacists when 
recommendations are made as a result of a MUR. 
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
MURs are not conducted on the patients with the most 
complex medicines needs. 
Community pharmacist interviews: Theme = Role 
in patient safety and education 
Patients are willing to discuss post-discharge medicines-
related issues with their community pharmacist. 
Patient interviews: Theme = Relationships 
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
Community pharmacists routinely identify major issues 
relating to patient safety. 
Community pharmacist interviews: Theme = Role 
in patient safety and education 
Patients should have to make an appointment with their 
community pharmacist for a MUR. 
Community pharmacist interviews: Theme = 
Practical issues 
Community pharmacists and hospital pharmacists should 
have a two-way process for communication. 
Community pharmacist interviews: Theme = 
Practical issues 
GPs should conduct more thorough medicines reviews for 
patients, so MURs are not required. 
Community pharmacist interviews: Theme = 
Community pharmacists’ views of self and 
relationships with others 
Community pharmacist interviews: Theme = 
Relationships with other healthcare professionals 
There is the right skill-mix in the pharmacy to enable MURs 
to be conducted. 
Community pharmacist interviews: Theme = 
Practical issues 
 
7.8.4 Discharge arrangement questions – Questions 10 to 13 
Following on from the attitudinal statements, community pharmacists were asked for more 
detail about their views of post-discharge medication review in terms of which HCP should 
conduct a post-discharge medication review, how appropriate each HCP was in conducting a 
post-discharge medication review, what information they would like when a patient is 
discharged and how they would prefer to receive this information.  
 
7.8.5 Free text comments – Questions 14 to 15 
Next, community pharmacists were given two free text questions where they could leave 
comments specifically about the discharge process, and also any other more general 
comments. 
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7.8.6 Demographic questions – Questions 16 to 22 
The final set of questions asked the community pharmacists for some demographic details; 
again, this was to enable descriptive and inferential statistical analysis of the responses they 
had given. The respondents were asked to enter details of their gender, year of qualification, 
whether they worked in other pharmacy sectors, the postcode of their usual pharmacy, 
whether it was located within a GP surgery and its usual opening hours. Locum pharmacists 
were screened out before the questions about pharmacy location as it was anticipated that 
they might work in multiple locations which would make answering the pharmacy specific 
questions difficult. 
 
7.9 Summary of the questionnaire development subchapter 
This chapter has summarised the results of the interviews with community pharmacists and 
demonstrated how they were used, along with the findings of the patient interviews, to design 
a questionnaire for community pharmacists. The aim of the questionnaire was to find out 
about the experiences and attitudes of community pharmacists who provided the MUR service 
in England. The questionnaire content, format and design were based on evidence from the 
published literature with the aim of maximising the completion rate from respondents when 
they accessed the questionnaire.  
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In this chapter, the results of the community pharmacist survey are presented. The chapter 
starts with a summary of the methods used to collect these data, followed by the descriptive 
and inferential statistics and that were used to analyse the data and finally a discussion of how 
these data compare with previously published studies. 
 
8.1 Introduction  
As shown in the previous chapter, the findings from the patient interviews and pharmacist 
interviews were used to develop a questionnaire for community pharmacists. The 
questionnaire was the quantitative tool used as the final part of the sequential exploratory 
strategy, see Figure 8-1. It was used to gather data about community pharmacists’ experiences 














































Figure 8-1 Schematic of study - Respondents to survey 
 
8.2 Methods for Survey of Community Pharmacists 
This section is focussed on the methods that were used to prepare the questionnaire for use 
and the recruitment of respondents. 
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8.2.1 Use of questionnaires as data collection tools 
Bryman (2008) has defined survey research as data collected by questionnaire or structured 
interview from more than one case, at a single point in time (cross-sectional), to gather 
quantitative or quantifiable data in connection with two or more variables, which are then 
examined to detect patterns of relationships between the variables (Bryman, 2008). This type 
of survey would be described as descriptive because the purpose of it is to count, from a 
sample of the population of interest, how many respondents display an opinion or 
characteristic. The results can be used to describe associations and issues of interest but this 
type of survey is not designed to determine causality or explain associations (Oppenheim, 
1992; Bowling, 2009). 
 
In this study a self-completion online questionnaire was used as the tool to gather quantitative 
data. This method of data collection had the advantage of removing interviewer effects and 
interviewer variability and reduced the chance of social desirability bias. The process was 
convenient for the respondent as the questionnaires were completed independently (Bryman, 
2008). The disadvantages of using self-completion questionnaires are the lack of personal 
interaction from the researcher to assist or expand the information from the respondent when 
completing the questionnaire, respondents can become bored and fail to complete 
questionnaires that are not important to them, only limited numbers and types of questions 
can be asked so as not to deter respondents and to minimise missing data, and response rates 
can be low (Bryman, 2008). Nonetheless, self-completion questionnaires allow researchers to 
gather quantitative data relatively quickly and easily from their population of interest. 
 
8.2.2 Use of online survey software 
In this study, online survey software was used to distribute the questionnaire, gather the data 
and export the data in a format suitable for analysis. Once the content and order of the 
questions for the survey had been decided, they were formatted into an electronic 
questionnaire using online survey software from SurveyMonkey (SurveyMonkey Inc., San 
Mateo, California, USA). This enabled the questionnaire to be made freely available on the 
internet and links to the questionnaire to be sent out on social media and via email. A paper 
version of the questionnaire was also generated and offered as a method of response to those 
who did not want to use the online platform. 
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There are advantages and disadvantages to using online survey tools, as detailed below: 
Advantages: 
• Cost efficiency – no stationery or postal costs. 
• Time efficient – no need to print questionnaire, fill envelopes, organise posting, input 
data. 
• Faster response times – answers immediately available. 
• No geographical limits – potential for diverse range of respondents not limited by 
location. 
• Reach - larger sample sizes possible compared to paper-based questionnaires. 
• Open questions – some researchers have found better responses to these questions. 
• Completeness – some researchers have found fewer missed questions and the 
software can help to guide respondents to complete the survey correctly. 
• Anonymity and privacy – perceived anonymity and privacy are high, resulting in 
reduced social desirability bias and increased candour. 
Disadvantages: 
• Response rates – can be lower than paper-based questionnaires. 
• Online – responses limited to those who are online. 
• Anonymity and confidentiality – some respondents may be deterred by concerns. 
• Sample bias - the whole of population cannot be characterised. Respondents may not 
be representative of the whole population. 
• Ambiguities in communication - no linguistic cues from the researcher (this is true for 
any questionnaire that is completed remotely). 
• Reliability and trustworthiness of data – individuals may complete the questionnaire 
multiple times or may not be who they purport to be. 
(Bryman, 2008; Hewson and Laurent, 2008; Hewson, 2017) 
Despite the potential disadvantages of using an online survey tool, it was decided to use one in 
this study due to the time and costs involved with accessing an equivalent-sized sample offline, 
the hope to gather data from community pharmacists throughout England and the potential to 
have a larger reach. Online and social media publicity methods were used to recruit 
respondents as described in section 8.2.8. 
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8.2.3 Ethical considerations of online data collection methods 
It has been argued that the ethical considerations of online research are not fundamentally 
different to that of traditional research tools or offline environments (Markham and Buchanan, 
2012). Table 8-1 details the ethical considerations that need to be considered when 
conducting an online survey and how they were addressed in the current study. 
 
Table 8-1 Ethical considerations of online survey research 
Principle 
(Eynon, Fry and Schroeder, 2017) 
Description 
(Eynon, Fry and Schroeder, 2017) 
How it was addressed in this study 
Risk of harm to respondent The researcher should ensure, as 
far as practicable, that the 
respondent does not come to any 
harm by participating in the 
research. Harm could include 
adverse psychological reactions to 
the research topic or loss of 
anonymity. It can be difficult for 
researchers to assess this in an 
online environment. 
It was not anticipated that the 
study would cause any harm to the 
respondents as the topic of interest 
was not sensitive or personal.  
Risk of harm to researcher The researcher may discover 
distressing or harmful information 
and must then decide if or how 
they act on it. 
Nothing of this nature was 
disclosed but if it had, it would 
have been discussed with the 
supervisory team.  
Confidentiality / anonymity Respondents have a right to expect 
confidentiality and anonymity if it 
has been promised. This is 
important for all stages of the data 
collection and research process. 
Respondents were able to 
complete the questionnaire 
anonymously and had the option to 
add their email address if they 
wished to enter the prize draw. 
Participants were asked for their 
pharmacy postcode, but this was 
only used to determine the urban 
or rural location of the pharmacy 
and not used to identify the 
pharmacy. 
Confidentiality was maintained by 
storing and analysing the data 
securely. 
Informed consent Potential respondents must have 
access to sufficient information to 
ensure that they are able to make 
an informed decision about 
participating in any research. They 
must be able to access additional 
information if they wish and have 
the ability to withdraw from the 
study if they wish. In online 
environments it is not possible to 
check the person’s ability to give 
informed consent. 
The survey was intended for 
community pharmacists who would 
have the capacity to provide 
informed consent. Participant 
information was available on the 
second page of the questionnaire, 
with the contact details of the 
research team so they could access 
additional information if necessary. 
Consent was presumed by 
completion of the questionnaire. 
Respondents were given details of 
how they could withdraw from the 
study. 
 




8.2.4 Questionnaire formatting and design considerations 
When formatting and designing the layout and style of the questionnaire, there were a variety 
of factors to consider with the aim of maximising the number of respondents. Published texts 
(Oppenheim, 1992; Boynton, 2004; Boynton and Greenhalgh, 2004; Bryman, 2008) are 
focussed on paper-based tools rather than electronic tools, but some principles to maximise 
the response rate can still be applied. Table 8-2 details the factors that have been shown to 
affect response rates to questionnaire surveys and how they were addressed in the current 
study. 
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Table 8-2 Factors affecting questionnaire survey response rate 
Factor Evidence to increase response rate Considerations for this study 
Piloting and testing The questionnaire should have been 
through this process before distribution 
(Boynton, 2004). 
The questionnaire was piloted prior to use, 
see section 8.2.6. 
Advanced publicity Informing potential respondents of the 
questionnaire (Oppenheim, 1992). 
A study blog and Twitter were used to 
publicise the study and questionnaire prior 
to period of data collection. 
Purpose The aims of the questionnaire are 
explained clearly and the questionnaire has 
a defined purpose (Boynton, 2004). 
The study information was included on the 
first page of the questionnaire, summarised 
on the study blog and linked to social 
media posts. 
Further information A member of the research team is able to 
respond to any questions (Boynton, 2004). 
Contact details for the research team were 
included on the first page of the 
questionnaire, summarised on the study 
blog and linked to social media posts. 
Instructions on how to withdraw from the 
study were included on the second page of 
the questionnaire, and respondents could 
access this from the original weblink they 
used to access the questionnaire. 
Sponsorship Sponsorship by an organisation can be a 
motivator for respondent completion 
(Oppenheim, 1992). 
The University logo was included on all 
pages of the questionnaire. 
Confidentiality and anonymity Only the researcher team will have access 
to participant responses and no identifiable 
information will be published (Oppenheim, 
1992). 
Confidentiality and anonymity were 
guaranteed to respondents. They had free 
choice about whether to enter their email 
for the prize draw and this was not linked 
to their responses. 
Length of questionnaire If too long, respondents will be deterred 
from completion (Bryman, 2008) 
The questionnaire was as succinct as 
possible; 24 questions over 14 pages. 
An estimation of the time to complete the 
questionnaire was included on the first 
page. 
A progress bar was included so 
respondents had a visual cue of progress. 
Questionnaire layout and 
appearance 
The questionnaire should have a clear 
design, simple layout and be visually 
appealing (Oppenheim, 1992; Boynton, 
2004; Bryman, 2008). 
Ensured sufficient clear space around 
questions so layout was uncluttered. 
Pleasing accent colour scheme (pale blue) 
chosen. 
Instructions for completion Need to be clear and easy to follow 
(Boynton and Greenhalgh, 2004; Bryman, 
2008). 
Instructions for completion included prior 
to each question. 
Wayfinding Ensures that instructions for routing or the 
skipping of excluded questions are easy to 
follow (Boynton et al., 2004). Although this 
is more important for paper rather than 
electronic questionnaires. 
Questionnaire tested to ensure that 
skipping of questions occurred correctly 
depending on respondent’s previous 
answers. 
Reminders Can be used to encourage potential 
respondents to complete the questionnaire 
(Oppenheim, 1992). 
Blog and social media used to publicise 
study at frequent intervals when 
questionnaire was live. 
Incentives Completion of the questionnaire offers 
respondents an incentive or chance to win 
a prize (Oppenheim, 1992; Boynton, 2004). 




Chapter Eight | Survey of community pharmacists 
 
 234 
8.2.5 Reliability and validity of the questionnaire 
When designing questionnaires, their reliability and validity must be considered. For a tool to 
be valid, a prerequisite is that it must also be reliable (Oppenheim, 1992; Bryman, 2008). 
Reliability refers to the consistency of the tool in measuring the construct it is designed to 
measure. It includes not only the characteristics of the tool but also the way it is administered 
(Oppenheim, 1992); so tools that are reliable should give consistent results from repeated 
samples administered by different researchers over time (Boynton and Greenhalgh, 2004). 
There are three main factors that can be used to establish whether a tool is reliable: 
• Stability – testing and retesting whether a measure is stable over time in the same 
cohort of respondents (Bryman, 2008). This method was not used in this study. 
• Internal reliability – whether respondents scores on a particular item are related to 
their scores on another item (Bryman, 2008); this is most commonly used for 
questions with Likert scale responses (Laerd Statistics, 2018). This can be tested using 
Cronbach’s alpha, which estimates reliability by investigating all possible correlations 
between items on a scale (Bowling, 2009). This measure has been used in this study 
and is discussed in more detail in section 8.6.5. 
• Inter-observer consistency – when more than one observer is involved in a study, the 
consistency of their decisions could affect reliability (Bryman, 2008). This was not 
applicable to this study. 
 
Validity refers to whether the tool actually measures what it intends, or is supposed to 
measure (Oppenheim, 1992). Ideally, a previously validated tool should be used, but often this 
is not possible as such a tool does not exist. There are various types of validity, some of which 
are presented here:  
• Face validity refers to whether the researcher or others with relevant experience 
assess that the tool is actually measuring the item of interest (Bryman, 2008; Bowling, 
2009). This was assessed by the PI and the supervisory team. 
• Content validity aims to establish that the questions represent a balanced way of 
examining the full area of interest (Oppenheim, 1992; Bowling, 2009). This was 
assessed by the PI, the supervisory team and two national pharmacy organisations, see 
section 8.2.8.1. 
• Construct validity uses a hypothesis to predict how the tool will perform and examines 
the data to test whether the hypothesis is correct (Bowling, 2009). 
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8.2.6 Piloting the questionnaire 
Once the content and format of the questionnaire had been finalised, the plan was for it to be 





Figure 8-2 Community pharmacist progression through the study 
 
When the community pharmacists were interviewed, they had been asked if they were 
prepared to be involved in piloting the finalised questionnaire; all agreed. All five community 
pharmacists were contacted and four replied positively. Three requested a weblink to pilot the 
survey online and one requested a paper version. Two pharmacists who had shown an interest 
in being interviewed but had not participated in an interview were also contacted but did not 
respond. A small purposively selected sample of five community pharmacists, who had not 
previously participated in the study, were also contacted and one response was received to 
complete the pilot online. The link to the online pilot questionnaire was also shared with the 
three members of the supervisory team.  
 
Six pharmacists accessed the pilot questionnaire and completed it to varying degrees. As the 
pilot questionnaire was completed anonymously in SurveyMonkey it was not possible to 
definitely say how many were pharmacists that had been interviewed or not. However, it was 






Up to three community 
pharmacists who were 
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Up to three community 
pharmacists who were not 
interviewed
Refine questionnaire and 
disseminate
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possible to identify that of the six; two had been interviewed, one had not, and for the 
remaining three it was unclear if they had already been involved with the study. 
 
Community pharmacists who completed the pilot questionnaire were asked for comments 
about aspects of the questionnaire that worked well, any problems encountered and 
comments about the time for completion. One pharmacist responded that some of the 
statements with Likert responses swapped from being positively to negatively phrased; this 
was intentional to ensure that respondents thought about the statements rather than just 
completing them without thinking. The other comments were more general and thought the 
questionnaire was focussed on a useful topic. The piloting showed that the questionnaire 
logistics worked in both electronic and paper formats and the questionnaire took on average 
16 minutes to complete.  
 
8.2.7 Sampling 
In this study, an online survey tool was chosen to distribute the questionnaire. As there was 
not access to online contact details for the whole community pharmacist population in 
England it was not possible to use a probability (random) sampling method to recruit 
respondents. Therefore, a non-probability, or convenience sampling approach was used 
(Bowling, 2009; Fricker, 2017). Within this approach two subtypes of sampling were used: 
‘unrestricted, self-selected’ sampling and snowballing (Bowling, 2009; Fricker, 2017). 
‘Unrestricted, self-selected’ sampling describes the fact that the survey was accessible online 
to anyone who had access to the link; participants were self-selected and had to choose to 
‘opt-in’ (Fricker, 2017). Snowballing (Bowling, 2009) was used by promoting the study on social 
media sites such as Twitter and LinkedIn and hoping that other users (particularly influential 
people in the pharmacy profession) shared the study details, thus recruiting more 
respondents.  
 
8.2.8 Recruitment of respondents 
Recruitment and distribution of the questionnaire to community pharmacists was through 
pharmacy organisations, contractors, professional networks and social media. 
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8.2.8.1 National pharmacy organisations and contractors 
With the aim of ensuring the questionnaire survey reached as many community pharmacists as 
possible, national pharmacy organisations and community pharmacy contractors were 
contacted to facilitate the publicity of the study and the distribution of the electronic 
questionnaire link. Four national pharmacy organisations, of the six contacted, agreed: 
• The Pharmaceutical Services Negotiating Committee (PSNC). 
• The National Pharmacy Association (NPA). 
• Association of Independent Multiple Pharmacies (AiMP). 
• The PDA (Pharmacists’ Defence Association) – approached and agreed to help 
publicise the study after it was live. 
 




• Day Lewis. 
 
One national pharmacy organisation (the PSNC) and one contractor (Boots) wanted to review 
the questionnaire and approve its contents before they assisted with the distribution of the 
electronic link to their members or employees.  
• Boots requested that the questionnaire went through their research approval process, 
which was akin to the ethical approval process of the University. The feedback from 
Boots was resolved through correspondence, clarifying the rational for certain 
decisions such as question order. Minor formatting and explanations of abbreviations 
were included in the revised version of the questionnaire. 
• The PSNC gave feedback about the order of the questions and this was resolved by 
talking to the organisation and making minor changes to the order of the Likert 
statements. 
 
For all the above organisations, a message was written by the PI and sent to the contact at the 
organisation for them to distribute as they saw best. The method of distribution was outside of 
the control of the PI, but the PI was aware of email distribution and messages posted on 
internal websites for some organisations. The PSNC posted information about the study on 
their homepage on the first working day the study was live, see Appendix D for screenshots. 




As previously agreed with the NHS Ethics Committee who granted the original ethics approval, 
the questionnaire was submitted for final ethics approval, which was granted, see section 4.3.2 
and appendix B. 
 
8.2.8.2 Professional networks and social media 
As well as enlisting the help of the pharmacy organisations detailed above, professional 
networks and social media were also used to publicise the study and achieve a greater reach.  
• Professional networks  
o The RPS agreed to facilitate with publicity for the study and tweeted the study 
details to their followers. They also posted the details of the study on their 
Community Pharmacy and Research and Evaluation networks message boards. 
A message was also posted by the PI on to the message boards of the 35 local 
practice forum (LPF) groups in England which included a link to the 
questionnaire and the blog. 
o The LPCs were also contacted by the PI, and of the 64 LPCs in England that 
were contacted, 46 responded to say they were willing to publicise the study 
to their members. 
o A post was also placed on the Pharmacy Forum (https://www.pharmacy-
forum.co.uk) locum page containing a link to the questionnaire. This was an 
attempt to include locum pharmacists in the study who may not have been 
aware of the study through other routes such as employers.  
• Blog 
o A blog (https://thepaperstudy.wordpress.com) was also created by the PI. It 
included information and updates about the study, and the details of the PI 
and study team. A blog post was written when the survey went live and 
included a survey link. 
• Social Media 
o Twitter (www.twitter.com) was used by the PI who posted regular tweets 
whilst the questionnaire was live. Other pharmacists on Twitter also 
retweeted these messages to their followers. 
o The PI posted a message on LinkedIn (www.linkedin.com) and the post was 
shared twice by a member of the supervisory team with >500 connections. 
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8.2.9 Completion of the questionnaire 
Participants who clicked the link to access the study were taken to the first page of the 
questionnaire which gave them a one-line summary of the study, how long it should take to 
complete and details of the prize draw. The prize draw was included as an incentive to 
complete the questionnaire. First prize was a £25 Amazon voucher and there were two 
runner-up prizes of £10 Amazon vouchers. Pharmacists who completed their details at the end 
of the questionnaire could enter the draw and winners were informed by email after the 
questionnaire had closed. The voucher was then sent to them as an electronic link. The 
questionnaire was open for four weeks. During this time, the PDA agreed to publicise the study 
(see promotional email sent to PDA members in Appendix D), so the study remained open for 
an additional three weeks and a second prize draw, identical to the first, was offered for 
pharmacists who responded during this additional time period. 
 
When respondents clicked to the second page of the questionnaire, they were presented with 
the approved participant information sheet, which contained the full details of the study and 
the contact details for the PI and supervisory team. If they continued and clicked to the 
following page, they were presented with the questionnaire. Consent was presumed by the 
completion of the questionnaire. If pharmacists had wanted to withdraw from the study, they 
could contact a member of the study team (details were available from the link they used to 
access the questionnaire or via the blog). Their responses would have been removed from the 
analysis, but no respondents requested that. 
 
8.2.10 Statistical analysis plan for the questionnaire survey 
When the survey had closed, the data collected in SurveyMonkey were automatically 
transferred into IBM SPSS Statistics (IBM Statistical Package for the Social Sciences, version 
24). The results of the survey  were analysed using descriptive statistics, inferential statistics 
and factor analysis (see section 8.6 for more details of this technique) 1, in SPSS. An analysis 
plan for the survey responses was written and is presented in appendix E.  
 
The responses entered into the SurveyMonkey software were stored there until the analysis 
was complete, before being deleted. A copy of the anonymised survey results will be stored 
                                                             
1 Factor analysis analyses quantitative data and tries to elucidate if there are underlying attitudes that 
affect how people behave in a given situation. 
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securely on a password-protected computer for a period of five years and then deleted. If any 
paper questionnaires had been completed, they would have been stored securely on NHS 
premises for a period of five years after the study was completed. After this time, they would 
have been shredded as confidential waste. 
 
8.2.11 Level of significance 
A p-value of <0.01 was selected as the level for showing statistical significance, due to the 
number of tests performed. 
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8.3 Survey results 
8.3.1 Eligibility to complete questionnaire and number of responses received 
Four hundred and ninety-five community pharmacists started the questionnaire and of those, 
353 completed all questions with the remainder partially completing the questionnaire. All 
respondents completed the electronic version of the questionnaire that was available online; 
no respondents requested a paper copy of the questionnaire. 
 
As the questionnaire link was sent out via community pharmacy contractors, national 
pharmacy organisations, professional networks and promoted on social media platforms, it 
was not possible to calculate a response rate as the denominator was unknown. The General 
Pharmaceutical Council (GPhC) Workforce census (Phelps et al., 2014) surveyed approximately 
two thirds of all registered pharmacists in 2013, approximately 76.4% (34,190) of the 44,751 
registered pharmacists were working in England, and of those 64% (21,882) were working in 
community pharmacy settings only. A rough estimate suggests that this sample represents 
approximately 2.3% of the total community pharmacist workforce in England; acknowledging 
that the total number of registered pharmacists will have changed since the workforce census 
was completed in 2013. 
 
The first question in the survey asked whether the community pharmacist had personally 
carried out a MUR. Four hundred and eighty-three pharmacists (97.6%) responded ‘yes’ and 
were eligible to complete the remainder of the questionnaire. Twelve pharmacists (2.4%) 
responded ‘no’ and were therefore ineligible to complete the survey; they were directed to a 
page that thanked them for their interest in the study and explained that they were not able to 
complete the remainder of the questionnaire. 
 
8.4 Descriptive statistical analysis 
8.4.1.1 Gender 
The sex distribution of the respondents was 145 (40.5%) male and 204 (57.0%) female, while 9 
(2.5%) preferred not to disclose this information (n=358). These results appear to be 
comparable with the registered pharmacist population from 2013 (Phelps et al., 2014) which 
found that, of the sample surveyed, 39.6% of registered pharmacists were male and 60.4% 
female. 
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8.4.1.2 Year of registration 
Respondents were asked which year they first registered as pharmacists, either with the Royal 
Pharmaceutical Society of Great Britain (RPSGB) or the GPhC. The responses to this question 
were then used to estimate the age of the pharmacists and compared with the 2013 
Workforce census data. This assumes that the pharmacist registered at the age of 22, if 
registration occurred in 2001 or earlier, and age 23, if registration occurred in 2002 or later 
due to the change from the Bachelor of Pharmacy (BPharm) to the Master of Pharmacy 
(MPharm) degree. 
 
Table 8-3 Age of community pharmacist respondents to questionnaire survey compared to 
GPhC Workforce census 2013 
Age band Questionnaire survey respondents 
(n=312) 
GPhC Workforce census 2013  
Percentages stated only 
(n=30,040)* 
Less than 30 84 (26.9%) 21.6% 
30 – 39 97 (31.1%) 31.9% 
40 – 49 63 (20.2%) 22.4% 
50 – 59 48 (15.4%) 17.4% 
60 and over 20 (6.4%) 6.8% 
*Workforce census sampled 30,040 of 44,751 registered pharmacists in 2013 
Totals do not always add to 100% due to rounding 
 
This shows that there were a higher percentage of pharmacists under the age of 30 completing 
the questionnaire, but the percentage of pharmacists in other age bands were broadly similar 
when compared to the 2013 Workforce census. 
 
The year of qualification was also used to determine whether the pharmacists qualified with a 
BPharm degree or a MPharm degree. In 1997 the degree course was changed from a 3-year 
BPharm degree to a 4-year MPharm degree; the first MPharm cohort graduated in 2001 and 
registered with the RPSGB in 2002. Of the respondents (n=312), 139 (44.6%) graduated with a 
BPharm degree and 173 (55.4%) graduated with a MPharm degree. 
 
Likewise, the year of qualification was used to determine whether pharmacists qualified 
before or after the introduction of the new community pharmacy contract in April 2005, which 
heralded the introduction of MURs. Of the respondents, 159 (51.0%) qualified before the 
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introduction of the contract and 153 (49.0%) qualified after the introduction of the new 
contract. 
 
The reason for stratifying the pharmacists into these groups was to enable further analysis to 
be conducted to discover whether the duration someone had been qualified as a pharmacist 
had any bearing on their attitudes towards and experiences of providing MUR services. 
 
8.4.1.3 Locum work 
Respondents were asked about whether their main role was working as a locum pharmacist. It 
was anticipated that locum pharmacists may work in various different locations. Eighty 
pharmacists (22.3%) responded that they were locums and 279 (77.7%) were not (n=359). 
Locum pharmacists were given the opportunity to enter the prize draw, but they were not 
asked to enter details of the pharmacies they worked in. 
 
8.4.1.4 Other pharmacy sector working 
Respondents were asked what sectors of pharmacy they worked in. As this was a survey of 
community pharmacists, unsurprisingly all pharmacists reported that they worked in 
community settings, but 65 pharmacists also reported working in other sectors. Figure 8-3 
shows the other sectors that community pharmacists also worked in. Respondents who stated 
‘other’ mainly reported working for LPCs or other pharmacy organisations. 
 




Figure 8-3 Sectors of pharmacy currently worked in (n=359) 
 
8.4.1.5 Pharmacy location 
Pharmacists were asked about the location of the pharmacy that they usually worked in. The 
location was denoted by the respondent entering the postcode of the pharmacy. If they were 
not able to remember the postcode, they were invited to enter the address. Postcodes or 
address details were entered by 235 respondents. The postcode (or the postcode derived from 
the address details) was entered into the Office for National Statistics (ONS) Postcode 
Directory look-up service (ONS, 2017a) and this allowed the location of the pharmacy to be 
categorised as being in an urban or rural location. 
 
Of the respondents who completed location information for their pharmacy (n=235), 200 
(85.1%) pharmacies were located in urban areas and 35 (14.9%) in rural areas. 
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8.4.1.6 Type of pharmacy 
Respondents were asked about the type of pharmacy that they usually worked in. The 
responses are summarised in Figure 8-4. The majority of pharmacists (65.2%) worked for large 
multiples with the remainder working in other types of pharmacies. 
 
 
Figure 8-4 Type of pharmacy worked in (n=273) 
 
8.4.1.7 Co-location of pharmacy within GP surgery 
Respondents were asked whether the community pharmacy they usually worked in was 
located within a GP surgery. Of the 274 pharmacists who answered this question, 39 (14.2%) 
worked in a pharmacy within a GP surgery and 4 (1.5%) worked in a pharmacy adjacent to a GP 
surgery. The remaining 231 (84.3%) respondents reported that the pharmacy they usually 
worked in was not within or adjacent to a GP surgery. 
 
8.4.1.8 Opening hours of the pharmacy 
Respondents were asked how many hours their pharmacy was open each week. The responses 
are shown in Figure 8-5. The majority of pharmacists (56.6%) worked in pharmacies that were 
open for 50 to 99 hours per week, with a smaller proportion (32.5%) working in pharmacies 
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Figure 8-5 Pharmacy opening hours (n=274) 
 
8.4.2 Number of prescription items dispensed 
The postcode was used to determine the number of prescription items that were dispensed in 
a one-month period. The NHS Business Services Authority publishes monthly prescription data 
for every pharmacy in England on its website as it is deemed to be in the public interest (NHS 
Business Services Authority, 2018). The postcode of the pharmacy that the respondent 
entered into the questionnaire was searchable in the monthly spreadsheet, and the number of 
prescription items dispensed (on both paper and electronic prescription forms) could be 
recorded. The data for October 2017 are shown in Figure 8-6. The data for the number of 
prescriptions dispensed could only be found for 179 of the 235 pharmacies where postcode or 
address information was provided. This was because in some circumstances it was not possible 
to identify the pharmacy from the address details entered; when no postcode was supplied, if 
the postcode was incomplete and therefore covered an area that was too large to identify the 
Chapter Eight | Survey of community pharmacists 
 247 
pharmacy, or if the postcode was incorrect, and no pharmacy could be confidently identified. 




Figure 8-6 Prescription items dispensed (n=179) 
 
8.4.3 Involvement in MUR services 
Respondents were asked to estimate the number of MURs they had completed in the previous 
month; the results are shown in Table 8-4. There was a broadly even spread of responses to 
this question. 
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Table 8-4 Community pharmacists’ estimation of the number of MURs completed in the 
previous month (n=439) 
Number of MURs completed in 
previous month 
Frequency Percentage 
Up to 10 117 26.7 
11 to 20 74 16.9 
21 to 30 116 26.4 
More than 30 105 23.9 
Prefer not to say 10 2.3 
Other 17 3.9 
Percentage total >100% due to rounding. 
 
Community pharmacists were then asked to estimate what percentage of these MURs were 
PD-MURs. More than half of the pharmacists reported that they had not conducted any PD-
MURs in the previous month. 
 
 
Figure 8-7 Percentage of MURs that were PD-MURs (n=366) 
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8.4.4 Communication when patients are in hospital 
8.4.4.1 Who informs community pharmacists that their patients are in hospital 
Respondents were asked about who informed them when one of their patients had been 




Figure 8-8 Who informs community pharmacist when a patient is admitted to hospital 
(n=432) 
 
It is quite reassuring to note that in the majority of cases (79.1%) the community pharmacist 
does find out that one of their regular patients has been admitted to hospital. This shows that 
when the pharmacist is informed it is often in an ad hoc manner. It also does not take into 
account when they find out, as often this may be after the patient has been discharged. 
 
Chapter Eight | Survey of community pharmacists 
 
 250 
8.4.4.2 How community pharmacists are informed their patients are in hospital 
Following on from the previous question, respondents were asked how they were usually 
informed that one of their patients had been admitted to hospital. They were able to select as 
many different ways as they had experienced. 
 
 
Figure 8-9 How community pharmacists are notified their patients are in hospital (534 
responses from n=364) 
 
This shows that at the time of this study (September 2017), telephone and fax communication 
are still the most common ways that a community pharmacist finds out that one of their 
patients has been admitted to hospital. Very few pharmacists reported that they were notified 
by electronic means. The category denoted ‘other’ included: noticing that the prescription had 
changed, picking up a problem with the patient’s prescription, finding out accidently or by 
using the SCR. 
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8.4.4.3 Most appropriate healthcare professional to conduct post-discharge medication 
reviews 
Participants were asked about which single healthcare professional would be most appropriate 
to conduct a medication review after someone had been in hospital.  
 
 
Figure 8-10 Most appropriate healthcare professional to conduct a medication review after 
hospital discharge (n=363) 
 
Community pharmacists overwhelming thought that a pharmacist would be the best HCP to 
conduct post-discharge medication reviews; 90.1% expressed that view. However, there was 
disagreement about the optimal role, with community pharmacists undecided between 
choosing pharmacists specifically employed to ensure safe transfer of care, pharmacists 
working in a GP surgery or community pharmacists. They also thought a hospital pharmacist 
would be preferable to a GP. 
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Respondents who selected ‘other’ suggested that it should be the healthcare professional that 
knows the patient best, it depended on why the patient had been in hospital, or a combination 
of different healthcare professionals would be best. 
 
Respondents were then asked to rate each healthcare professional to gauge whether they 
considered each HCP to be appropriate to conduct a post-discharge medication review.  
 
 
Figure 8-11 Community pharmacists’ rating of most appropriate healthcare professional to 
conduct a post-discharge medication review (n=351-361) 
 
Interestingly, no pharmacists thought a practice nurse would be the most appropriate 
healthcare professional to conduct a PD-MUR. However, when asked to rate the 
appropriateness of a practice nurse conducting this task, they still gave them a score of 4.3 out 
of 10, meaning they did think practice nurses could be appropriate to some degree. 
 
Community pharmacists rated themselves with the same appropriateness as hospital 
pharmacists and GPs for conducting this task. 
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8.4.4.4 What information community pharmacists require on hospital discharge 
When respondents were asked what information they required when one of their patients was 
discharged from hospital, they responded overwhelmingly that they would like a copy of the 




Figure 8-12 Information community pharmacists would prefer on discharge (n=363) 
 
The respondents who stated ‘other’ felt that they only required discharge information for 
patients who used compliance aids. 
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8.4.4.5 How community pharmacists would like to be informed of a patient’s discharge 
Respondents were asked how they would prefer to receive discharge information.  
 
 
Figure 8-13 How community pharmacists would prefer to receive discharge information 
(n=363) 
 
The majority (78.8%) thought it would be best if it was sent by some electronic means, with 
most responding to say they would prefer for it to integrated directly into their patient 
medication record (PMR). 
 
8.4.4.6 Responses to Likert statements 
The attitudes of the community pharmacists to the Likert statements they were presented 
with are summarised in Tables 8.5, 8.6, 8.7 and 8.8. Any statements where more than 70% of 
respondents shared the same overall opinion, i.e. strongly agree + agree or strongly disagree + 
disagree, are highlighted blue in the tables; this figure was chosen arbitrarily just to give a 
flavour of the responses where most respondents concurred. The highlighted statements show 
that community pharmacists feel they have the skills to provide additional services to patients 
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and contribute to the primary healthcare team, but that this is dependent on relationships and 
communication with others such as GPs and the patients themselves. 
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Table 8-5 Reponses to Likert statements – Question 6 
Question 6 Strongly Agree Agree Neither agree or 
disagree 
Disagree Strongly disagree Don’t know n 
Two-way communication is an important part of a 
good relationship with GPs. 80.6% 333 17.2% 71 1.2% 5 0.5% 2 0.2% 1 0.2% 1 413 
Community pharmacists are able to build long-lasting 
trusted relationships with their patients. 73.0% 302 22.0% 91 3.1% 13 1.7% 7 0.2% 1 0.0% 0 414 
The majority of patients are aware of the MUR 
advanced services. 6.1% 25 25.9% 107 22.3% 92 34.6% 143 10.2% 42 1.0% 4 413 
Community pharmacists are able to make valuable 
contributions to patient care through the MUR service. 38.5% 159 39.5% 163 11.4% 47 5.1% 21 5.6% 23 0.0% 0 413 
GPs in my local area ask for my advice about 
medicines-related issues for their patients. 10.4% 43 39.6% 164 19.8% 82 15.0% 62 13.5% 56 1.7% 7 414 
Community pharmacists have the right skills to 
perform high-quality MURs. 49.2% 203 34.9% 144 10.2% 42 4.1% 17 1.5% 6 0.2% 1 413 
PD-MURs are more complex and time consuming than 
other types of MURs. 16.8% 69 28.6% 118 27.4% 113 10.9% 45 1.5% 6 14.8% 61 412 
GPs have a high regard for the contribution that 
community pharmacists make to the care of their 
patients. 
4.9% 20 13.6% 56 28.2% 116 27.7% 114 19.2% 79 6.3% 26 411 
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Table 8-6 Responses to Likert statements – Question 7 
Question 7 Strongly Agree Agree Neither agree or 
disagree 
Disagree Strongly disagree Don’t know n 
Patients value the contribution that community 
pharmacists make to their care, over and above the 
supply of medicines. 
29.6% 117 48.1% 190 11.1% 44 8.4% 33 2.3% 9 0.5% 2 395 
Community pharmacists cannot conduct MURs 
properly unless they have access to the patient’s GP 
medical record. 
12.9% 51 28.8% 114 21.7% 86 31.6% 125 4.8% 19 0.3% 1 396 
MURs are a waste of time. 8.2% 32 9.0% 35 18.7% 73 28.9% 113 34.5% 135 0.8% 3 391 
Community pharmacists would be able to provide a 
better service to patients recently discharged from 
hospital if they could conduct PD-MURs in the 
patient’s home. 
17.2% 68 35.4% 140 24.5% 97 11.9% 47 4.3% 17 6.8% 27 396 
GPs view community pharmacists as just the suppliers 
of their patients’ medicines. 18.7% 74 38.2% 151 22.0% 87 14.7% 58 3.5% 14 2.8% 11 395 
Hospital pharmacists should promote the PD-MUR 
service to patients when they are in hospital. 43.9% 173 42.6% 168 6.9% 27 1.8% 7 2.3% 9 2.5% 10 394 
GPs know where to find medicines-related information 
to make safe prescribing decisions. 9.1% 36 45.2% 179 26.3% 104 10.1% 40 2.5% 10 6.8% 27 396 
MURs are a waste of money. 11.7% 46 10.9% 43 18.7% 74 25.8% 102 30.6% 121 2.3% 9 395 
 
  




Table 8-7 Responses to Likert statements – Question 8 
Question 8 Strongly Agree Agree Neither agree or 
disagree 
Disagree Strongly disagree Don’t know n 
Patients see community pharmacists as just the 
suppliers of their medicines. 8.9% 34 26.3% 100 16.5% 63 37.3% 142 10.2% 39 0.8% 3 381 
I find conducting MURs a satisfying part of my job. 26.4% 101 39.0% 149 14.4% 55 12.0% 46 8.1% 31 0.0% 0 382 
Community pharmacists require access to the patient’s 
GP medical record to conduct a PD-MUR. 17.8% 68 37.2% 142 17.8% 68 17.5% 67 2.1% 8 7.6% 29 382 
GPs should refer patients to community pharmacists 
for MURs. 37.1% 142 44.1% 169 10.4% 40 5.5% 21 2.6% 10 0.3% 1 383 
Community pharmacists can provide patients with 
better information about medicine safety and use than 
GPs. 
30.4% 116 43.7% 167 18.3% 70 4.7% 18 2.4% 9 0.5% 2 382 
I believe that MURs help patients to get the most 
benefit from their medicines. 33.4% 127 47.6% 181 10.3% 39 4.0% 15 4.5% 17 0.3% 1 380 
Community pharmacists should automatically be sent 
a copy of the patient’s discharge summary. 56.5% 216 32.5% 124 6.5% 25 2.6% 10 1.8% 7 0.0% 0 382 
GPs should provide feedback to community 
pharmacists when recommendations are made as the 
result of a MUR. 
44.1% 169 46.5% 178 7.6% 29 1.3% 5 0.5% 2 0.0% 0 383 
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Table 8-8 Responses to Likert statements – Question 9 
Question 9 Strongly Agree Agree Neither agree or 
disagree 
Disagree Strongly disagree Don’t know n 
MURs are not conducted on patients with the most 
complex medicines needs. 12.9% 48 28.2% 105 21.2% 79 27.1% 101 9.7% 36 1.1% 4 373 
Patients are willing to discuss post-discharge 
medicines-related issues with their community 
pharmacist. 
21.4% 80 52.4% 196 17.7% 66 5.4% 20 1.9% 7 1.3% 5 374 
Community pharmacists routinely identify major issues 
relating to patient safety. 17.7% 66 50.4% 188 20.6% 77 9.4% 35 1.6% 6 0.3% 1 373 
Patients should have to make an appointment with 
their community pharmacist for a MUR. 7.8% 29 20.4% 76 23.3% 87 34.1% 127 14.2% 53 0.3% 1 373 
Community pharmacists and hospital pharmacists 
should have a two-way process for communication. 49.6% 185 44.2% 165 4.0% 15 1.3% 5 0.3% 1 0.5% 2 373 
GPs should conduct more thorough medicines reviews 
for patients, so MURs are not required. 10.0% 37 11.9% 44 27.5% 102 31.0% 115 18.6% 69 1.1% 4 371 
There is the right skill-mix in the pharmacy to enable 
MURs to be conducted. 22.5% 84 43.6% 163 13.9% 52 13.9% 52 6.2% 23 0.0% 0 374 
MURs are not conducted on patients with the most 
complex medicines needs. 12.9% 48 28.2% 105 21.2% 79 27.1% 101 9.7% 36 1.1% 4 373 
Chapter Eight | Survey of community pharmacists 
 
 260 
8.5 Inferential statistical analysis 
Following on from the descriptive analyses of the survey responses, bivariate analyses were 
conducted to establish whether there were any relationships between the independent and 
dependent variables. The analyses plan (see Appendix E) detailed the analyses that were 
conducted using these data. 
 
8.5.1 Independent and dependent variables for statistical tests 
The independent variables for the statistical tests were the demographic responses that 
community pharmacists had entered into the questionnaire, or they were derived from their 
responses. The independent variables that fell into this category were: gender, degree type, 
qualification before or after the introduction of the new pharmacy contract in 2005, urban or 
rural location, type of pharmacy, opening hours, sectors of pharmacy worked in, whether they 
also worked in a GP surgery, whether the pharmacy was located in a GP surgery and the 
number of prescription items dispensed. 
 
The dependent variables were: the number of MURs conducted in the previous month, the 
proportion of MURs that were PD-MURs in the previous month, the attitudes to the 
statements scored on Likert scales, the most appropriate HCP to conduct a post-discharge 
medication review, the information required following a hospital discharge and how 
information should be sent following discharge. More detail on these variables can be seen in 
Appendix E. In the following section, only statistical tests that generated significant results are 
reported. 
 
8.5.2 Relationships between independent variables and number of MURs conducted 
The respondents self-reported an estimate of the number of MURs they had conducted in the 
previous month. Rather than asking for exact numbers, respondents were given a range of 
categorised options: up to 10, 11 to 20, 21 to 30, or more than 30 MURs per month. For this 
reason, the data were treated as ordinal data for the purposes of the statistical analysis. The 
data were analysed against the independent variables detailed above. 
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8.5.2.1 Number of MURs conducted by year qualified 
The year of qualification was split into a dichotomous variable of whether the pharmacist had 
qualified with a BPharm or MPharm degree (changed in 2001) or whether they had qualified 




A Mann-Whitney U test revealed a statistically significant difference in the number of MURs 
conducted by pharmacists who graduated with a BPharm (median 11 to 20 MURs per month, 
n=138) or MPharm degree (median 21 to 30 MURs per month, n=172), U=9527, z=-3.083, 
p=0.002, r=0.175. r denotes the size of the effect with 0.1 = small effect, 0.3 = medium effect 
and 0.5 = large effect (p.233) (Pallant, 2016). This means that pharmacists who qualified in 
2002 or later conducted more MURs per month than those who qualified before 2002, but the 
effect was small. 
 
 
Figure 8-14 Estimated number of MURs conducted last month by degree type (n=310) 
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Qualified pre- or post- introduction of new community pharmacy contract 
As this grouping is virtually the same as classifying pharmacists by degree type, it is 
unsurprising that a Mann-Whitney U test found a statistically significant difference in the 
number of MURs conducted by pharmacists who qualified before the introduction of the new 
community pharmacy contract in 2005 (median 11 to 20 MURs per month, n=158) or 
afterwards (median 21 to 30 MURs per month, n=152), U=9791, z=-2.903, p=0.004, r=0.17. 
 
 
Figure 8-15 Estimated number of MURs conducted last month by qualification date (n=310) 
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8.5.2.2 Number of MURs conducted by pharmacy type 
A Kruskal-Wallis Test revealed a statistically significant difference in the number of MURs 
conducted across different types of pharmacy. 
 
Table 8-9 Estimated number of MURs conducted by pharmacy type (n=261) 
Pharmacy type Number of responses Estimated number of MURs 






16 Equally split between categories 







Supermarket 17 11-20 
!2 (4, n=261) =15.704, p=0.003 
 
Mann-Whitney U tests were conducted to interrogate the data further and they revealed that 
there was a statistically significant difference in the number of MURs conducted in the 
previous month by pharmacists in independent pharmacies (median 11-20, n=44) compared to 
large multiples (median 21-30, n=177), U=2724.000, z=-3.209, p=0.001, r=0.2. Also, there was a 
statistically significant difference in the number of MURs conducted by pharmacists in large 
multiples (median 21-30, n=177) compared to supermarkets (median 11-20, n=17), U=962.000, 
z=-2.565, p=0.01, r=0.18. 
 




Figure 8-16 Estimated number of MURs conducted last month by pharmacy type (n=261) 
 
8.5.2.3 Breakdown of MURs conducted by pharmacists in large multiples comparing urban 
and rural areas 
The group of pharmacists working in large multiple pharmacies was much larger (n=177) than 
other categories. A sub-group analysis of the respondents who worked in large multiples was 
conducted to investigate whether there was any difference in the number of MURs conducted 
dependent on an urban or rural location. A Mann-Whitney U test showed that there was a 
statistically significant difference in the number of MURs conducted by pharmacists working 
for large multiples in rural areas (median >30, n=25) compared to those working in urban areas 
(median 21-30, n=129), U=1107.500, z=-2.613, p=0.009, r=0.2. 
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Table 8-10 Number of MURs conducted last month by pharmacists working for large 
multiples stratified by location (n=154) 
 Number of MURs conducted in previous month 
 Up to 10 11-20 21-30 More than 30 
Urban area 19 (14.7%) 17 (13.2%) 49 (38.0%) 43 (33.3%) 
Rural area 3 (12.0%) 0 (0.0%) 6 (24.0%) 15 (60.0%) 
Totals 22 (14.3%) 17 (11.0%) 55 (35.7%) 58 (37.7%) 
 
 
8.5.2.4 Number of MURs by number of prescription items dispensed 
The relationship between the number of MURs conducted in the previous month and the 
number of prescription items dispensed in October 2017 was investigated using Spearman’s 
rho correlation coefficient. A very weak correlation was found between these two variables, 
r=0.189, n=179, p=0.011 with higher numbers of MURs conducted in pharmacies that 
dispensed more prescription items. The p-value in this instance relates to confidence in the 
result and not how strongly the two variables are associated (Pallant, 2016). 
 
8.5.3 Relationships between independent variables and PD-MURs conducted 
Respondents were asked to estimate what percentage of MURs they conducted were PD-
MURs; respondents completed their answers by sliding a marker along a scale to give an exact 
figure, hence this was treated as numerical data. 
 
8.5.3.1 Proportion of MURs that are PD-MURs by pharmacy type 
A Kruskal-Wallis Test revealed a statistically significant difference in the proportion of MURs 
that were PD-MURs conducted across different types of pharmacy: 
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Table 8-11 Estimated number of MURs that were PD-MURs conducted last month by 
pharmacy type (n=226) 
Pharmacy type Number of responses Estimated percentage of MURs 
that were PD-MURs conducted 
last month (Median) 










Supermarket 16 0% 




Figure 8-17 Estimated number of MURs that were PD-MURs conducted last month by 
pharmacy type (n=226) 
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A subgroup analysis using Mann-Whitney U tests revealed that there was a significant 
difference between the number of PD-MURs conducted by pharmacists working in 
independents (median 4%, n=41) compared to large multiples (0%, n=148), U=2182.000, z=-
2.904, p=0.004, r=0.2. There was also a statistically significant difference in the percentage of 
PD-MURs conducted by pharmacists working in independents (median 4%, n=41) compared to 
supermarkets (median 0%, n=16), U=165.500, z=-3.018, p=0.003, r=0.4. This shows that 
independent pharmacies conduct more PD-MURs than large multiples and supermarkets. 
 
8.5.3.2 Breakdown of PD-MURs conducted by pharmacists in large multiples comparing 
urban and rural areas 
As for the previous section, a subgroup analysis was conducted to investigate whether there 
was any difference in the percentage of PD-MURs conducted dependent on the urban or rural 
location of the large multiples. A Mann-Whitney U test showed that there was no statistically 
significant difference between urban (median 1%, n=109) and rural areas (median 0%, n=19) in 
the percentage of PD-MURs conducted, U=949.500, z=-0.615, p=0.538, r=0.05. This intimates 
that although pharmacists working in large multiples in rural areas conduct more MURs, they 
are for patients within other target groups rather than for patients who have recently been 
discharged from hospital. 
 
8.5.4 Relationships between independent variables and appropriate HCP to conduct post-
discharge medication reviews 
8.5.4.1 Most appropriate health care professional to conduct MURs by location of 
pharmacy 
A chi-squared test for independence indicated a statistically significant association between 
the location of the pharmacy and which healthcare professional respondents thought was 
most appropriate to conduct a PD-MUR, ! 2 (4, n=226) =14.136, p=0.007, Cramer’s V=0.250. 
 




Figure 8-18 Most appropriate healthcare professional to conduct a post-discharge 
medication review by pharmacy location (n=226) 
 
This showed that community pharmacists working in urban areas were more likely to suggest a 
pharmacist specifically employed to facilitate transfer of care or a pharmacist working in a GP 
surgery as the most appropriate HCP to conduct a post-discharge medication review. This was 
in contrast to community pharmacists working in rural areas who thought they were the most 
appropriate HCP to fulfil this role. 
 
The next section will report the findings of the factor analysis. 
  
Chapter Eight | Survey of community pharmacists 
 269 
8.6 Factor Analysis 
8.6.1 Introduction to the technique 
Factor analysis is a data reduction technique that can be used to condense the large amounts 
of data produced by a questionnaire survey. It interrogates the data to explore underlying 
correlations and distils them into a smaller number of ‘factors’ (also known as ‘components’ or 
‘dimensions’). Each factor contains items which are grouped in a consistent and coherent 
manner. The factor analysis technique describes how the items group together into these 
factors, to give a more ‘manageable’ set of variables which can be used in further analyses 
(Bowling, 2009, p. 165; Hair et al., 2010, p. 148; Pallant, 2016). 
 
The term factor analysis covers several different but related techniques that use various 
measures of variance. The technique that was used for this dataset was principal component 
analysis, which considers total variance; that is, the sum of common, unique and error 
variance. This approach is preferred when data reduction is the main aim (Bowling, 2009, p. 
165; Hair et al., 2010, p. 148). This technique was used to analyse the data collected from the 
Likert scale responses to the attitudinal statements in the community pharmacist 
questionnaire. 
 
8.6.2 Suitability of sample for Factor Analysis 
The first stage was to ensure that the data were suitable for the factor analysis technique and 
this was assessed by using the following: 
• Sample size. 
• Correlations between statements. 
• Kaiser-Meyer-Olkin Measure of Sampling Adequacy (KMO). 
• Bartlett’s test of sphericity. 
 
8.6.2.1 Sample size 
The minimum number of cases for factor analysis has been suggested as 300 (Bowling, 2009, p. 
165; Pallant, 2016, p. 184). This sample contained between 371 and 414 responses for each 
attitudinal statement, so was of sufficient size for this technique. 
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8.6.2.2 Correlations between the statements 
The correlation matrix showed the intercorrelations between the responses to each of the 
Likert question statements. There should be sufficient correlations with a value >0.3 for factor 
analysis with a sample of >350 (Hair et al., 2010, p. 117). The correlation matrix was inspected 
for statements with correlations >0.3 and a sufficient number were found.  
 
The correlation matrix was also inspected for statements that did not correlate with any of the 
others and four statements fell into this category. They were: 
• Q6. Two-way communication is an important part of a good relationship with GPs. 
• Q6. The majority of patients are aware of the MUR advanced services. 
• Q7. GPs know where to find medicines-related information to make safe prescribing 
decisions. 
• Q9. Patients should have to make an appointment with their community pharmacist 
for a MUR. 
These statements were excluded from the factor analysis on this basis. 
 
8.6.2.3 KMO and Bartlett’s test of sphericity 
The value of the KMO should be >0.6 and Bartlett’s test of sphericity should be statistically 
significant i.e. p<0.05 (Bowling, 2009, p. 166; Pallant, 2016, p. 193). Using these data, the KMO 
was 0.887 and Bartlett’s test of sphericity was <0.001, meaning the data were suitable for 
factor analysis. 
 
8.6.3 Extracting the factors 
The next phase of the analyses involved interrogating the data to decide how many factors 
best described the dataset. A number of tests were performed to assist in this decision. Only 
the 27 statements that correlated with one another were included is this part of the analysis. 
 
8.6.3.1 Kaiser’s Criterion 
This is also known as the eigenvalue rule (Pallant, 2016, p. 185). The eigenvalue of a factor 
represents the amount of the total variance explained by that factor (Pallant, 2016, p. 185), 
also described as a measure of a factor’s power to explain variation between subjects 
(Bowling, 2009, p. 165). Factors with an eigenvalue greater than 1.0 support construct validity 
of the scale and are therefore retained. In this sample seven factors had an eigenvalue >1. 
These seven factors explained 60.167% of the variance. This method tends to retain a greater 
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number of factors and should therefore be used in conjunction with the additional techniques 
described below (Pallant, 2016, p. 185). 
 
Table 8-12 Components extracted with eigenvalues greater than 1 and percentages of 
variance 
Component number Eigenvalue % of variance Cumulative % 
1 7.462 27.503 27.503 
2 2.421 8.966 36.469 
3 1.963 7.271 43.740 
4 1.216 4.502 48.243 
5 1.128 4.177 52.420 
6 1.078 3.994 56.414 
7 1.013 3.754 60.167 
 
8.6.3.2 Scree test 
The scree plot displays the eigenvalues and factors graphically and helped to determine how 
many factors should be retained. The shape of the curve changes and the point at which this 
occurs can help establish which factors contribute most to the variance of the dataset (Pallant, 
2016, p. 185). 
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The scree plot shows that components 1 to 3 produce a line with a different gradient to that 
for components 4 to 27. Using this technique would result in the retention of three factors. 
 
8.6.3.3 Parallel Analysis 
Parallel analysis can also be used to work out which factors to retain. Monte Carlo PCA 
(Pallant, 2016, p. 194), a program for parallel analysis, was used to generate 415 sets of 
random data with corresponding eigenvalues. Only eigenvalues generated from the actual 
dataset that were greater than those generated from the parallel analysis were retained 
(Pallant, 2016, p. 185). 
 
Table 8-13 Comparison of actual and randomly-generated eigenvalues 
Component number Actual eigenvalue from 
current PCA 
Criterion value from 
parallel analysis 
Decision 
1 7.426 1.4987 Accept 
2 2.421 1.4308 Accept 
3 1.963 1.3751 Accept 
4 1.216 1.3248 Reject 
5 1.128 1.2835 Reject 
6 1.078 1.2429 Reject 
7 1.013 1.2025 Reject 
 
This technique indicated that the first three components should be retained.  
 
The component matrix showed that most items load on to factor 1 and fewer items load on to 
the other factors. This makes interpretation of the results more difficult. Factor rotation is 
used to derive a more meaningful solution to the analysis.  
 
8.6.4 Rotating the factors 
8.6.4.1 Rationale for rotating the factors 
Factor rotation is the process of turning the reference axes of the factors about their origin to 
an alternative position with the aim of achieving a simpler structure and a more meaningful 
solution (Pett, Lackey and Sullivan, 2003, p. 132; Hair et al., 2010, p. 149). Rotations can be 
orthogonal or oblique; both aim to simplify the results and enhance their interpretability 
(Bowling, 2009, p. 165; Hair et al., 2010, p. 149). 
 
Chapter Eight | Survey of community pharmacists 
 273 
Unrotated factor solutions extract factors in the order of their extracted variance; this results 
in most statements loading on to one factor and producing most of the variance. The main 
objective of rotating the factors is to redistribute the variance so that it is spread out to other 
factors to achieve a simpler, more meaningful result (Hair et al., 2010, p. 113) 
 
Orthogonal rotations are the simplest as the axes are kept at a 90o angle (Hair et al., 2010, p. 
113) and it is assumed that the factors are independent of one another (Pett, Lackey and 
Sullivan, 2003, p. 134). They can be used to choose the factor solution that minimises overlap 
of factors and aid in interpretability (Bowling, 2009, p. 165). Oblique rotations are when the 
axes are rotated but the angle is not kept at 90o (Hair et al., 2010, p. 113); this assumes that 
the factors are correlated in some way (Pett, Lackey and Sullivan, 2003, p. 134). 
 
Using SPSS, various different rotations, both orthogonal (Varimax rotation) and oblique (Direct 
Oblimin rotation) were applied to the dataset and different numbers of factors were extracted 
until a suitable solution was found. The solution that gave the best results involved the 
extraction of three factors, rotated in an oblique manner using Direct Oblimin rotation with all 
coefficients <0.4 supressed. 
 
The pattern matrix (Table 8-14), structure matrix (Table 8-15) and component correlation 
matrix (Table 8-16) that summarise the results of the factor analysis are shown below. The 
difference between the pattern and structure matrix is as follows: 
“The pattern matrix holds the loadings. Each row of the pattern matrix is 
essentially a regression equation where the standardized observed variable 
is expressed as a function of the factors. The loadings are the regression 
coefficients. The structure matrix holds the correlations between the 
variables and the factors.” 
(IBM Support, 2016) 
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Table 8-14 Pattern matrix from Factor Analysis 
Statements Component 
   1 2 3 
I believe that MURs help patients to get the most benefit from their medicines. .824 
  
MURs are NOT a waste of time .773 
  
Community pharmacists are able to make valuable contributions to patient care through the MUR service. .771 
  
I find conducting MURs a satisfying part of my job. .739 
  
MURs are NOT a waste of money .737 
  
GPs should refer patients to community pharmacists for MURs. .667 
  
Community pharmacists have the right skills to perform high-quality MURs. .667 
  
There is the right skill-mix in the pharmacy to enable MURs to be conducted. .597 
  
Community pharmacists can provide patients with better information about medicine safety and use than GPs. .533 
  
Community pharmacists should automatically be sent a copy of the patient’s discharge summary. .532 
  
Hospital pharmacists should promote the PD-MUR service to patients when they are in hospital. .507 .410 
 
GPs should NOT conduct more thorough reviews of patients’ medicines, so MURs ARE required .500 
  
Community pharmacists are able to build long-lasting trusted relationships with their patients. .494 
  
GPs should provide feedback to community pharmacists when recommendations are made as the result of a MUR. .490 
  
Community pharmacists routinely identify major issues relating to patient safety. .483 
  
Community pharmacists and hospital pharmacists should have a two-way process for communication. .445  
 
Patients value the contribution that community pharmacists make to their care, over and above the supply of medicines. .420 
 
.405 
MURs are not conducted on patients with the most complex medicines needs    
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GPs have a high regard for the contribution that community pharmacists make to the care of their patients. 
  
.739 
GPs DO NOT view community pharmacists as just the suppliers of their patients’ medicines 
 
 .718 
Patients DO NOT see community pharmacists as just the suppliers of their medicines 
  
.537 
GPs in my local area ask for my advice about medicines-related issues for their patients. 
  
.532 
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Table 8-15 Structure matrix from Factor Analysis 
Statements Component 
   1 2 3 
I believe that MURs help patients to get the most benefit from their medicines. .827 
  
Community pharmacists are able to make valuable contributions to patient care through the MUR service. .802 
  
MURs are NOT a waste of time .797 
  
I find conducting MURs a satisfying part of my job. .754 
  
MURs are NOT a waste of money .750 
  
Community pharmacists have the right skills to perform high-quality MURs. .690 
  
GPs should refer patients to community pharmacists for MURs. .676 
  
There is the right skill-mix in the pharmacy to enable MURs to be conducted. .545 
  
Community pharmacists can provide patients with better information about medicine safety and use than GPs. .542 
  
Community pharmacists routinely identify major issues relating to patient safety. .522 
  
Community pharmacists are able to build long-lasting trusted relationships with their patients. .515 
  
GPs should NOT conduct more thorough reviews of patients’ medicines, so MURs ARE required .505 
  
Community pharmacists should automatically be sent a copy of the patient’s discharge summary. .498 
  
GPs should provide feedback to community pharmacists when recommendations are made as the result of a MUR. .448 
  
MURs are not conducted on patients with the most complex medicines needs    













Hospital pharmacists should promote the PD-MUR service to patients when they are in hospital. .545 .473 
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Community pharmacists and hospital pharmacists should have a two-way process for communication. .458 .416 
 
GPs DO NOT view community pharmacists as just the suppliers of their patients’ medicines 
  
.731 
GPs have a high regard for the contribution that community pharmacists make to the care of their patients. 
  
.722 
Patients DO NOT see community pharmacists as just the suppliers of their medicines 
  
.573 
GPs in my local area ask for my advice about medicines-related issues for their patients. 
  
.551 
Patients value the contribution that community pharmacists make to their care, over and above the supply of medicines. .524 
 
.493 
Patients are willing to discuss post-discharge medicines-related issues with their community pharmacist. 
  
.406 
Cronbach’s Alpha 0.890 0.621 0.715 
 
 





Table 8-16 Component correlation matrix from Factor Analysis 
Component 1 2 3 
1 1.000 .120 .221 
2 .120 1.000 -.043 
3 .221 -0.043 1.000 
 
8.6.5 Reliability 
Each factor was subjected to analysis of Cronbach’s coefficient alpha. This measure of 
reliability represents the proportion of total variance in a given scale that can be attributed to 
a common source (Pett, Lackey and Sullivan, 2003, p. 185). Hair et al., (2010, p. 125) states 
that Cronbach’s alpha assesses the consistency of the entire scale and that individual items are 
all measuring the same construct. The generally agreed lower limit for Cronbach’s alpha is 0.7, 
although 0.6 is acceptable for exploratory research (Hair et al., 2010, p. 125). 
 
The structure matrix presented above shows that Cronbach’s alpha is >0.7 for factors one and 
three and >0.6 for factor two. 
 
8.6.6 Explanation of the factors 
Once the structure matrix was finalised a descriptor could be assigned to each of the factors. 
In this study, the factors can be described as follows: 
 
Factor 1  Factor 2  Factor 3 
Expertise of the 
community pharmacist 
 Key characteristics/ 
facilitators of PD-MURs 
 GPs’ and patients’ 
views of pharmacists 
The expertise of the 
community pharmacist, 
the skills they have, the 
relationships they can 
build and what they can 
contribute to patient 
care. 
 Issues that affect 
community pharmacists 
conducting MURs/PD-
MURs more effectively, 
such as having access to 
more information. 
 Community pharmacists’ 
thoughts about how 
others view them and the 
contribution they can 
make to patient care. 
 
 




8.6.7 Further analyses 
Once the statements for each factor had been deduced, the participants’ responses to each of 
the statements for a particular factor were totalled together to give a composite score for 
each factor. This composite score was used in further statistical tests to determine whether 
any of the independent variables were associated with the attitudes to these factors. 
 
8.6.7.1 Statistical analyses using composite score for each factor 
The only factors that were statistically significantly associated with the independent variables 
were as follows: 
• Year of qualification was significantly associated with attitudes to factor 3 
• Type of pharmacy worked in was significantly associated with attitudes to factor 1. 
 
Year of qualification 
To come to these conclusions the composite score of each pharmacist for each factor was 
analysed in a Mann-Whitney U test, investigating whether there was any association with the 
pharmacist’s year of qualification. As explained previously, the year of qualification was split 
into a dichotomous variable of whether the pharmacist had qualified with a BPharm or 
MPharm degree (changed in 2001) or whether they had qualified before or after the 
introduction of the new community pharmacy contract (introduced in April 2005). There was a 
significant difference in responses to statements associated with factor 3 based on the year of 
qualification. A lower composite score indicated that pharmacists were more in agreement 
with the statements that made up factor 3 and a higher composite score indicated pharmacists 
disagreed with the statements that made up factor 3. Pharmacists who qualified with a 
BPharm degree (median = 15.0, n=135) were more in agreement with the statements that 
were included in factor 3 than those who qualified with an MPharm degree (median = 17.0, 
n=173), U=8867, z=-3.632, p<0.0001, r=0.20. 
 
This was also true for pharmacists who qualified before or after the introduction of the new 
community pharmacy contract in April 2005; pharmacists who qualified before the new 
contract were more in agreement with statements that were included in factor 3 (median = 
15.0, n=155), compared to those pharmacists who qualified after the introduction of the new 
contract (median = 17.0, n=153), U=9202, z= -3.406, p=0.001, r=0.19. 
 





This means that pharmacists who qualified longer ago felt that GPs and patients were more 
willing to engage with them and ask for their advice than pharmacists who qualified more 
recently.  
 
Type of pharmacy 
The type of pharmacy worked in also showed a nearly statistically significant association with 
pharmacists’ attitudes to factor 1. This was analysed using a Kruskal-Wallis test. 
 
Table 8-17 Analysis of community pharmacists’ attitudes and experiences of factor 1 and 
pharmacy type 
Group n Median score for factor 1 
Independent (<5 pharmacies) 43 25 
Small multiple (6 – 10 pharmacies) 15 23 
Medium multiple (11 – 50 
pharmacies) 
7 28 
Large multiple (>50 pharmacies) 173 27 
Supermarket 17 31 
Total 255 26 
!2 (4, n=255) = 12.952, p=0.012 
 
A follow-up analysis was conducted using Mann-Whitney U tests to look for which types of 
pharmacy the respondent worked in, compared to their score for attitudes associated with 
factor 1. There was a statistically significant difference when small multiples (median 23, n=15) 
were compared with supermarkets (median 31, n=17), U=40.500, z=-3.291, p=0.001, r=0.6, 
meaning that pharmacists who worked in small multiples had lower scores for factor 1 
compared to those working in supermarkets. This means pharmacists working in small 
multiples were more in agreement with the statements included in this factor which addressed 
the area of the expertise of the community pharmacist. They felt that community pharmacists 
were able to provide expertise to their patients and give them more ‘added value’ compared 
to those pharmacists who worked in supermarkets. 
 
This concludes the presentation of the findings from the factor analysis. 




8.7 Responses to open questions in the survey 
8.7.1 Improvements to patient care after hospital discharge 
Respondents were asked whether they thought there was anything else that should be 
implemented to improve the care of patients recently discharged from hospital. Pharmacists 
were given a free text box to respond to this question and 131 responses were received. 
 
A wide variety of topics were discussed. As the comments were included in a quantitative data 
collection tool, they were not suitable for qualitative analysis methods. The comments were 
reviewed and could be broadly categorised into the following areas: communication, access to 
information, the MUR service and the number of days’ supply of medication. A synopsis of the 
comments is presented here. 
 
8.7.1.1 Communication 
The issue that was raised by most respondents to this question was around communication 
between the different health care professionals, particularly GPs, community pharmacists and 
hospital pharmacists. Community pharmacists felt that improved communication was 
necessary at the interface between secondary and primary care at the time of hospital 
discharge, and that this should occur more quickly. 
 “Improved communication is key. I rarely receive the information I need to 
be able to provide adequate patient care.” 
Pharmacist #359 
8.7.1.2 Access to information 
One pharmacist gave an example of a GP surgery that were not prepared to give them a 
patient’s discharge information. 
“…some GP surgeries refuse to share this information on the basis of 
‘patient confidentiality’, and this can make our job difficult when we are 
trying to help the patient.” 
Pharmacist #494 
Community pharmacists also raised the issue of what information they required when one of 
their patients was discharged from hospital. They reported that often they did not receive any 
information and that could have an impact on patient safety.  





‘…safety incidents which DO happen when patients end up being prescribed 
and dispensed the drugs they were taking before admission, instead, or 
sometimes at the same time, (rather) than those newly prescribed on 
discharge.” 
Pharmacist #358 
A range of responses was received about what information was required, from just being 
informed someone was in hospital to wanting a full discharge summary including new and 
discontinued medicines at the time of discharge. Some pharmacists also highlighted that there 
was a need for information to be made available on a platform that they could access, such as 
NHS mail or the SCR. 
“Information, especially changes in medication should automatically upload 
to SCR.” 
Pharmacist #387 
8.7.1.3 The MUR service 
As the focus of the questionnaire was MURs, there were a number of comments that 
highlighted improvements to the system; several pharmacists felt that patients should be 
informed of the PD-MUR service whilst they were in hospital and encouraged to inform their 
community pharmacist of their hospital admission, including taking the discharge summary to 
show them. Other pharmacists thought PD-MURs should be compulsory or that domiciliary 
PD-MURs should be routinely offered to patients after hospital discharge.  
“they should be signposted to their community pharmacist as a routine and 
where possible book a domiciliary visit from the pharmacist.” 
Pharmacist #332 
One pharmacist felt that a full clinical review by an appropriate pharmacist would be the best 
option: 
 “MUR isn’t really sufficient as it concentrates on medicine use. Need a 
clinical review which would be best done by a pharmacist with access to 
discharge summary, GP notes and community pharmacy PMR (to assist 
with compliance and ordering issues). It doesn’t matter where the 
pharmacist is employed, but they should be empowered and given the time 
and training and access to the required information required to do a good 
job.” 
Pharmacist #95 




8.7.1.4 Number of days’ supply of medication on discharge 
Another topic that was mentioned by several pharmacists was around the number of days’ 
medication supplied when a patient left hospital.  
“A nationally agreed number of day/weeks of medication on discharge (it is 
too variable at present).” 
Pharmacist #274 
This really is a surrogate marker for the timeliness of the community pharmacist receiving the 
information they require. If the community pharmacist had guaranteed access to the discharge 
information more quickly the number of days’ supply of medication on discharge would not be 
so important. Several respondents reported that patients came to the pharmacy because they 
had run out of medicines after a hospital discharge and this caused obvious problems. 
 
The free text comments provided very useful insights into some of the issues that community 
pharmacists face around hospital discharge and where there are risks in the current system. 
 
8.7.2 Additional comments made after completing the questionnaire 
Respondents were also given a free text box to makes any other comments about the subject 
of the questionnaire and 90 comments were received. The comments made were about the 
MUR service more generally and some of the issues that community pharmacists face when 
they are offering this service to their patients. As for the other free text comments, the 
comments were reviewed and could be broadly categorised into the following areas: positive 
aspects of MURs; time pressures and skill mix; employer pressures and the professional 
integrity of the pharmacist; patient selection; and remuneration. 
 
8.7.2.1 Positive aspects of MURs 
Many pharmacists used this opportunity to highlight that MURs were a worthwhile service 
both for the patient and themselves. They felt that the service should be promoted more to 
patients to improve medicines optimisation and adherence. Closer working with GPs would 
also help to improve the service.  
“I believe MURs are a key tool for patients, and pharmacists. However, 
more can be done to improve the effectiveness, including GPs using the 
information and not discarding it.” 
Pharmacist #359 





8.7.2.2 Times pressures and skill mix  
Many pharmacists raised the issue that MURs were time consuming and often conducting a 
MUR caused other pressures in the workload of the pharmacy. This was due to insufficient 
staff and the pharmacist having competing tasks to complete apart from the MUR. This could 
result in interruptions to the pharmacist’s work and even making the pharmacy less safe. 
Pharmacists reported that patients were told a MUR would take two minutes or that MURs 
were being conducted in 60 seconds when medicines were being handed out to the patient. 
Several pharmacists felt that to conduct a proper MUR, sufficient time was necessary to 
ensure that the patient gained most benefit from the process. 
“…to do a proper informative MUR takes longer than the +/- 15 minutes 
allocated to it. Staffing shortages and work pressures mean that often 
MURs are being done too hastily to be of any benefit to anybody, especially 
the patient, who may be confused and needing time to understand what 
you are discussing with them.” 
Pharmacist #483 
One pharmacist thought that for a recently discharged patient with additional needs, up to 30 
minutes would be required for a successful PD-MUR. 
 
8.7.2.3 Employer pressures and the professional integrity of the pharmacist 
A large number of pharmacists commented that they came under pressure from their 
employer to conduct MURs. This was often because they had been given a target of the 
number of MURs that should be conducted each day. All the pharmacists who commented 
viewed this negatively and some stated that they thought the pharmacists must be able to use 
their own judgement about which patients should receive a MUR.  
“…a MUR must be carried out when a pharmacist finds it suitable not when 
the company is placing immense pressure.” 
Pharmacist #365 
“MURs are valuable when the pharmacist is able to use their professional 
judgement regarding who receives one…pharmacists should be beyond 
reproach over the delivery of clinical services, and they should be 
supported and fully protected to ensure their professional integrity is not 
compromised.” 
Pharmacist #301 




A number of pharmacists also thought that educating patients about their medicines was their 
role anyway and this was not dependent on the existence of the MUR service. They also stated 
that they would intervene for the benefit of their patients, rather than for the financial reward 
a MUR would bring. 
 
8.7.2.4 Patient selection 
Due to the time constraints and company pressures many pharmacists reported that ‘easy’ 
patients were selected for MURs. 
“…this often leads to MURs being conducted on those patients that are 
seen as ‘easy’ MURs to reach targets as opposed to dealing with post 
discharge patients or those MURs that would be more complex and thus 
take longer.” 
Pharmacist #391 
“the number one flaw with the system of MURs is that those patients on 
multiple polypharmacy (20+ meds) are NOT targeted for MURs whereas 
those patients on a simple preventer/reliever inhaler regime are targeted. 
Classic cherry picking.” 
Pharmacist #15 
Pharmacists suggested that these ‘easy’ MURs were pointless, unnecessary, and of no benefit 
to the patient. 
 
8.7.2.5 Remuneration for MURs 
Pharmacists reported difficulties resolving the remuneration associated with MURs. Some felt 
that the issues raised as part of a MUR were part of their normal role and so should not attract 
an additional fee. The fact that all MURs received the same fee gave the focus on the number 
of MURs completed rather than the quality of the service provided. This therefore did not 
represent good value for money for the NHS but rather was a ‘money making’ scheme for the 
pharmacy. Many pharmacists used the terms ‘box ticking’ or ‘paper exercise’ when describing 
MURs. 
“…although MURs can be beneficial, I feel that the majority are done as a 
box ticking and target hitting exercise, therefore they are a waste of money 
for the NHS since they do not achieve what the aim of the MUR was.” 
Pharmacist #98 





Several pharmacists felt that the remuneration for MURs and the community pharmacy 
contract needed reviewing to incentivise conducting MURs for the patients who would gain 
most benefit. 
 
The free text comments were insightful, and with the quantitative findings, helped to inform 
the recommendations. This concludes the summary of the free text comments from the 
survey. 
 
8.8 Discussion of results of community pharmacist survey 
8.8.1 The use of social media as a recruitment tool 
The recruitment of participants to studies using social media is a relatively new phenomena 
and there is not much in the published literature about the optimal methods; the ethical issues 
have already been discussed in section 8.2.3. Previous studies have shown that social media 
can be useful in recruiting participants to clinical trials. A study recruited pregnant women to 
investigate the pharmacokinetics of folic acid levels in pregnancy. They compared the 
recruitment of participants traditionally, with those recruited via websites and social media 
(Facebook and Twitter). The authors found that when they used social media they gained 
significantly more participants each month to their study than when they used traditional 
methods (Shere, Zhao and Koren, 2014). Another study of a behavioural support programme 
for smoking cessation compared the recruitment of participants using traditional methods and 
online methods (Facebook) and found that the only difference in respondents was their age; 
with more younger people responding to the online recruitment (Frandsen, Walters and 
Ferguson, 2014). 
 
The use of Twitter to recruit participants to complete surveys in health research has not been 
extensively studied. A published paper reported the use of Twitter to recruit older mothers to 
complete an online questionnaire about antenatal care. The authors found that Twitter was a 
cost-effective method of recruiting participants and provided a way to reach potentially hard-
to-reach groups. It gave the participants anonymity and an accessible way of accessing the 
online questionnaire. The only limitation mentioned by the authors was the risk of selection 
bias (O’Connor et al., 2013). The current study appeared to be reasonably successful in 
recruiting participants using social media and online professional networks but, in this case, 
did not compare these methods to traditional methods. 





The National Institute for Health Research (NIHR) has published guidance on the use of social 
media to actively involve people in research (Involve, 2014). They have suggested the benefits 
of doing so include: increased diversity of participants, convenience for the participant, 
allowing networking between the researchers and participants and between participants, 
anonymity so participants are free to express their opinions, increased accessibility and 
generally free to use. The drawbacks include: selection only of participants with internet 
access, the public nature, transient characteristics of the posts, the need to be skilled at using 
the site, time to engage with potential participants and organisational rules on engagement 
with social media and ethical considerations (Involve, 2014). 
 
8.8.2 Age of pharmacists 
When community pharmacists were asked to estimate the number of MURs they conducted 
during the previous month, this showed a relationship to the age of the pharmacist. Younger 
pharmacists, those with MPharm degrees or who qualified after the introduction of the new 
contract, reported that they conducted more MURs than older pharmacists. When comparing 
younger and older pharmacists; younger pharmacists also felt that GPs and patients were less 
willing to engage with them as demonstrated by their responses to the attitudinal statements 
incorporated into factor 3. 
 
Conversely, older pharmacists would have experience of supporting and educating their 
patients and liaising with GPs to resolve medication problems without the formality or 
remuneration of the MUR system. In the current study older pharmacists felt GPs and patients 
were more willing to engage with them. It could be postulated that older pharmacists may not 
see the benefits of MURs in the same way as younger pharmacists and consequently are not as 
eager to conduct as many of them; they may see some of the activities that have been 
formalised through the MUR system as just part of their normal job, rather than seeking to 
formalise the consultation as a MUR. An analysis of age compared with type of pharmacy 
worked in was conducted using a Chi-squared test. This found a non-significant trend towards 
pharmacists who qualified before the introduction of the new contract being more likely to 
work in independent pharmacies than those who qualified later [!2 (4, n=230) = 9.532, 
p=0.049], which may also result in closer working relationships with GPs and patients. 
 





Younger pharmacists have no experience of working in the community and building 
relationships with GPs in the pre-MUR era. Younger pharmacists have always had the potential 
burden of MUR pressures on them and may find it difficult to exert their professional 
judgement when choosing suitable patients for MURs or deciding how many MURs they 
should conduct. One published paper stated that GPs were reported to place no value on MUR 
forms (McDonald et al., 2010) and this attitude may have been felt by younger pharmacists. 
 
No published papers were found that referred to the age of the pharmacist having an effect on 
the number of MURs conducted or how GPs and patients viewed them. Although a qualitative 
study of pharmacists working in GP practices in England did find that pharmacists who were 
qualified more recently and those with less experience were more minded to undertake 
additional training to equip them for extended roles and to further their careers, than 
pharmacists who had been qualified for longer (Butterworth et al., 2017). 
 
Latif, Pollock and Boardman (2013) found that pharmacists were more likely to conduct MURs 
for patients who had good relationships with pharmacy staff (Latif, Pollock and Boardman, 
2013). It could be postulated that younger pharmacists, who tended to have more negative 
opinions about how patients and GPs viewed them, felt that they would get better results 
conducting MURs on patients they knew well and would get a more favourable response from 
GPs to their recommendations, if they were familiar with them. This may also encourage 
younger pharmacists to conduct simpler and therefore quicker MURs. As with the pharmacists 
who responded in this questionnaire survey, a review of the literature around medication 
reviews found that access to information, good working relationships with other HCPs, 
especially GPs, and pharmacists working as part of the primary care team have been shown to 
enhance the quality of medication reviews (Blenkinsopp, Bond and Raynor, 2012). 
 
Perhaps younger pharmacists who had always worked within the MUR system felt that the 
lack of feedback from GPs about the outcomes of MURs was a reflection of how GPs perceived 
them and made the pharmacists reluctant to engage with them. Community pharmacists have 
previously reported that it is difficult to know whether their interventions have been actioned 
as they do not receive feedback from GPs (Wilcock and Harding, 2008). 
 
One possible confounding factor related to the age of the pharmacists could be the propensity 
for part-time working that may occur for pharmacists who qualified before 2002. These 




pharmacists may be more likely to work part-time due to child care commitments and this 
would account for fewer MURs conducted. The respondents were not asked about how many 
hours they worked per week to allow any further analysis of this aspect. 
 
8.8.3 Type of pharmacy 
The results of the questionnaire survey highlighted that even though pharmacists working in 
larger multiples conduct more MURs, these are less likely to be PD-MURs. This finding was also 
supported by the free-text comments of several community pharmacists who reported 
external, often company pressures, to conduct MURs in large multiples. This is not a new issue 
as many previously published papers have also found pharmacists being put under pressure 
from the companies to conduct MURs (Bradley et al., 2008; Harding and Wilcock, 2010; 
McDonald et al., 2010; Youssef, Hussain and Upton, 2010). 
 
The consequence of this pressure is that pharmacists choose patients on simpler medication 
regimes for MURs and this was also confirmed by some pharmacists’ comments in the free-
text boxes from the questionnaire. This phenomenon is also described in a published paper, 
where pharmacists reported conducting MURs for patients on simpler regimes to ensure MUR 
targets were achieved (Latif, Pollock and Boardman, 2013). PD-MURs may take longer to 
complete (Kennelty et al., 2015) and tend to be more complex (Rutter, Ramsbottom and 
Fitzpatrick, 2017). This additional work would not encourage pharmacists working under 
pressure to conduct PD-MURs rather than standard MURs as there is no additional benefit for 
the pharmacist in terms of workload, fulfilling targets or remuneration. 
 
The current study also found a statistically significant difference in the attitudes of pharmacists 
working in small multiples compared to supermarkets, in terms of their expertise. Pharmacists 
working in small multiples thought that they were more able to offer their expertise and make 
contributions to patient care. This could be explained by the supermarket environment 
perhaps being more geographically isolated from patients and GPs, meaning pharmacists are 
less familiar with these individuals and therefore find it more difficult to pass on their 
expertise. 
 
8.8.4 Location of pharmacy 
There was no statistically significant difference in the number of MURs completed by 
pharmacists working in urban areas compared to rural areas. In a sub-group analysis, 





pharmacists working for large multiples in rural areas conducted significantly more MURs than 
those working for large multiples in urban areas. The reason for this could be twofold; a 
pressure to complete MURs coupled with good patient relationships resulting in high levels of 
MUR recruitment. 
 
Community pharmacists working in urban and rural areas did have different opinions about 
who should conduct post-discharge medication reviews, with those working in rural areas 
much more likely to suggest the community pharmacist, compared to those in urban areas 
who were more likely to suggest a pharmacist specifically employed to ensure the safe transfer 
of care from secondary to primary care. 
 
The nature of working relationships between community pharmacists and GPs may be 
different in urban and rural areas. Löffler et al. (2017) have suggested that ‘urban anonymity’ 
exists in cities, so pharmacists and GPs hardly know one another whereas in rural areas, 
pharmacists and GPs have long-lasting relationships based on trust and appreciation, leading 
to enhanced collaboration (Löffler et al., 2017). The importance of the community pharmacist-
GP relationship for resolving medication issues has been highlighted by other authors who 
propose that for high quality medication reviews, a good relationship is important 
(Blenkinsopp, Bond and Raynor, 2012). Previously, it has been postulated that strong 
collaborative relationships are the exception rather than the norm (Chen and Almeida Neto, 
2007). 
 
Patients who have been recently discharged from hospital may have more complex medicines-
related needs. In rural areas, there may also be less access to interface pharmacists compared 
to urban areas. Community pharmacists working in rural areas, with good patient 
relationships, believe they are in the best position to provide medicines-related support and 
advice after a hospital discharge. Perhaps strong and stable pharmacist-patient-GP 
relationships in rural areas result in greater collaborative working, and a perception that newer 
interface pharmacy roles are not required as the community pharmacist is already providing 
optimal care. 
 
8.8.5 Lack of PD-MUR activity 
There is an inherent difficulty in identifying patients who have recently been discharged from 
hospital and are eligible for a PD-MUR. More than half of the pharmacists had not carried out a 




PD-MUR in the previous month. The majority of respondents (80%) said they did eventually 
find out that a patient had recently been in hospital, but there was no consistency in the 
method of communication. Non-digital methods, such as telephone and fax, were reported by 
more than two-thirds of pharmacists despite the fact that only 17.8% of pharmacists thought 
these were the best methods of communication. These methods rely on an individual, from 
the hospital, taking the time to initiate the communication and this would be dependent on 
the individuals involved and time constraints. Community pharmacists would like to receive a 
full discharge summary (preferred level of information stated by nearly two-thirds of 
respondents) sent to them electronically (seen by less than 10% of respondents currently but 
wanted by nearly four-fifths of pharmacists). 
 
There is a definite need for patients to be supported in managing their medicines after they 
have been discharged from hospital. It has recently been estimated that 1.4% of all medication 
errors occur when a patient is transferring from one care setting to another and of these, 
51.6% have the potential to cause moderate harm and 7.3% the potential to cause severe 
harm (Elliott et al., 2018). One of the major barriers for community pharmacists is in the 
identification of patients who have recently been in hospital. 
 
Pharmacists working in independents were found to conduct more PD-MURs and felt that they 
were able to provide more expertise to their patients than those pharmacists working in 
medium to large multiples or supermarkets. This could be because they know their patients 
better and there is more continuity with staff in independent pharmacies. It could be 
postulated that these pharmacists would be more likely to know that one of their regular 
patients had been discharged from hospital and would be able to offer them a PD-MUR. This 
then contributed to their opinion that they were able to provide greater expertise to their 
patients. This means that pharmacists who are able to offer the more time-consuming and 
greater depth of PD-MURs actually felt that they were able to support their patients better in 
their medicines taking through their expertise. 
 
There is huge pressure on community pharmacists in the current financial climate and even 
though they acknowledge they do have the skills and expertise to conduct PD-MURs they 
thought that practice or interface pharmacists would be better suited to complete the task. 
This may reflect the inherent difficulties in identifying patients, getting the information 
required in the form of a discharge summary and having sufficient time to conduct the more 





time-consuming PD-MURs. As previously mentioned, there are many practical advantages if a 
practice pharmacist conducts PD-MURs. The lack of a specific mechanism for remuneration in 
general practice could be seen as an advantage, as the service is being provided solely for 
patient benefit without the perception or complication of commercial pressures. 
 
8.9 Strengths and limitations of community pharmacist survey 
There are various strengths and limitations to conducting a large-scale survey which are 
discussed in this section. The strengths of this part of the study are the number of pharmacists 
who responded and participated in the online survey. The sample of respondents appeared to 
be representative of community pharmacists as a whole, when compared with the 2013 
workforce survey. The use of social media in health research has already been discussed in 
section 8.8.1. The use of professional networks and social media meant that the publicity and 
distribution costs of the survey were nil. The other advantages of using this type of sampling 
were that when influential social media users or professional organisations with high numbers 
of followers publicised the study, this increased the number of respondents. The study 
recruited sufficient respondents to permit factor analysis to be used as the analytical 
technique and allowed some sub-group analysis of pharmacists who had varying demographic 
characteristics. 
 
There were limitations to this part of the study. Due to the sampling method, it was not 
possible to calculate a response rate due to the lack of an identifiable denominator. It was also 
not possible to publicise the study to all eligible community pharmacists. Community 
pharmacists who were not members or employees of the organisations that publicised the 
survey, or active users of social media for pharmacy-related purposes would not have known 
about the survey; likewise, pharmacists who were not online. In an online questionnaire 
volunteer bias may have occurred, whereby volunteers were in some way different to the 
population of interest (Sedgwick, 2013). 
 
The use of an online survey tool also meant there was the possibility that non-pharmacists or 
pharmacists working in other sectors may have completed the survey, respondents could have 
completed the survey more than once, and there was no way to remind pharmacists about the 
study. For the community pharmacists who did access the survey, there appeared to be quite a 
high rate of attrition when completing the questionnaire; 495 respondents started the survey 
but only 274 completed the full questionnaire; hence missing data was an issue. As with all 




self-completed questionnaires, there is limited opportunity for the respondent to ask 
questions or clarify the questions. All answers were self-reported so for some of the questions 
such as number of MURs conducted, the answers were based on respondents’ recall rather 
than actual data, thus the results could be affected by recall bias. 
 
When analysing the responses to the questionnaire it became apparent that although 
respondents estimated the number of MURs conducted in the previous month, they were not 
asked about how many hours they worked per week. This meant that no accounting was made 
for part-time working compared to full-time working. 
 
8.10 Future research 
Future research should focus on gaining further insights into the recruitment of community 
pharmacists for health services research using online methods including social media. In the 
current study, a cohort of nearly 500 community pharmacists were recruited to participate but 
there is a lack of published evidence about the optimal method of recruitment and whether 
respondents recruited online are any different to those recruited using traditional methods. 
 
It would also be useful to conduct some further research into the differences in attitudes 
between pharmacists working in different types of pharmacies to determine the reasons why 
their practice differs in relation to PD-MURs. 
 
8.11 Summary of survey of community pharmacists chapter 
This chapter has outlined community pharmacists’ experiences and opinions of the MUR 
service in England. Some interesting associations have been found between the age of the 
community pharmacists, type and location of the community pharmacy and variables such as 
the number of MURs conducted and who is best placed to conduct a PD-MUR.  
 
The findings of the HES data study, the patient and pharmacist interviews, and the pharmacist 


















This chapter will synthesise the topics that have been raised by the findings in chapters 6, 7 
and 8. These previous chapters have discussed the findings of each phase of the study in 
relation to the published literature. This chapter will highlight the originality of this study and 
suggest ways that policymakers and future researchers should use the results of this study to 
change practice and build on the findings to further strengthen the evidence-base for the role 
of pharmacists in caring for patients who have recently been discharged from hospital. 
 
9.1 Introduction 
The first aim of this study was to explore the knowledge and attitudes of patients and 
community pharmacists around post-discharge medicines support, particularly PD-MURs. The 
second aim was to determine the implications of the findings on how pharmacists can more 
effectively use their clinical skills, and tools such as PD-MURs, to help patients manage their 
medicines better once discharged from hospital, with a view to reducing medicines-related 
hospital admissions. This chapter will synthesise the findings of the different phases, discuss 
them in the context of the published literature and make recommendations about the 
adjustments necessary to improve the present system. 
 
When considering the findings, the HES data phase is not specifically included as this was a 
preliminary piece of background work rather than a fundamental component of the fieldwork. 
However, the results of the HES study informed the subsequent phases of the fieldwork as 
they demonstrated the continued burden of emergency medicines-related admissions 
between 2008 and 2015. This phase of the study also confirmed that the medicines 
responsible for medicines-related admissions had not changed over time when compared to 
previously published studies. These findings helped to determine the optimum locations and 
types of patients to focus on for the first qualitative phase of the fieldwork which involved 
interviewing patients about their medicines-related hospital admission.  
 
On completion of the fieldwork, the findings and themes of the various phases of the study 
were consolidated on to one page. A period of thought and reflection then followed to deduce 
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the connections between the pertinent points. This process gave rise to three themes that 
form the structure of the discussion chapter and displayed elements of commonality through 
all phases of the fieldwork. These overarching and interrelated themes are expertise; 
relationships; and communication and integration, they are summarised in Figure 9-1. 
 
 
Figure 9-1 Overarching themes 
 
For each of these themes, consideration will be given to how they interlink with one another 
and how policymakers could use this evidence with the aim of improving patient care and 
ultimately reducing medicines-related hospital admissions.  
 
The findings of the current study have led to the development of various recommendations 
that are somewhat interlinked. Due to the interconnected nature of the themes it was 
necessary to briefly mention some points prior to their full discussion, to help contextualise 
the recommendations, hence Figure 9-2 is included here as an overview. One of the key 
recommendations to come from the current study is that PD-MURs should be split into two; an 
initial post discharge medication review and medicines reconciliation conducted by the 
practice pharmacist, followed by a ‘first dispensing’ MUR (FD-MUR) conducted by the 
community pharmacist. The rationale for this recommendation will be explained in the 
following sections of this chapter. 




LOCATION Hospital GP Surgery Community Pharmacy 
 
   










ACTIVITY • Medicines reconciliation on 
admission. 
• Medicines reconciliation on 
discharge. 
• Accurate and timely discharge 
summary. 
• Post-discharge medicines 
reconciliation, review and 
patient education. Ideally with 
the patient present. 
• Update repeat prescription 
template. 
• First-dispensing MUR (FD-
MUR) when collecting first 
prescription after discharge. 
• Patient education. 
• Patient support. 
INFORMATION FLOW Free flow of information between hospital, GP surgery and community pharmacy. 
Eventually, read and write access for all. 
Figure 9-2 Suggested optimal care for patients discharged from secondary care to primary care




This section focusses on the theme of expertise; specifically, the expertise of community 
pharmacists and how their unique training and knowledge of medicines can enhance the 
care of patients who have recently been discharged from hospital. 
 
9.2.1 Pharmacists as the experts in medicines 
Pharmacists see themselves as the experts in medicines; their unique role means they can 
have an impact on any aspect of patient care that involves the use of medicines. 
Community pharmacists who were interviewed highlighted their distinct place in ensuring 
medicines safety and providing medicines-related information to patients and other HCPs. 
The HES data study identified the medicines that are most commonly implicated in 
medicines-related hospital admissions, and pharmacists are in the ideal position to identify 
patients at risk. Other studies have also shown that pharmacists see themselves as the HCP 
with most expertise in the use of medicines (Weiss and Sutton, 2009; Elvey, Hassell and 
Hall, 2013). Indeed, the GPhC definition of the core role of pharmacists includes ensuring 
that medicines prescribed to patients are suitable, and advising patients about medicines 
(GPhC, 2018). 
 
Some patients in the current study were aware of the services offered by community 
pharmacists and said they would use them; for some this was in preference to their GP due 
to their community pharmacist’s accessibility, without the need for an appointment, and 
their knowledge about medicines. However, this was not an attitude that was reflected by 
all patients; a survey of 607 patients by Healthwatch Suffolk found that 29% of respondents 
thought that pharmacists were not qualified to provide medical advice. Unfortunately, the 
survey report did not provide any further information about why this was the case 
(Healthwatch Suffolk, 2015). 
 
Satisfaction with information about medicines has been shown to have a positive effect on 
adherence (Horne, Hankins and Jenkins, 2001). A study assessing patients’ information 
needs, surveyed 400 people collecting prescriptions from various pharmacies in the east of 
England and found that patients who had received an extended community pharmacy 
service, such as a MUR, were twice as likely to be adherent to their medicines and more 
likely to be satisfied with the information they had received about their medicines (Twigg 
et al., 2016). 
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It appears that some GPs may need convincing about how community pharmacists can 
benefit them and the patients they care for. For example, only 50% of community 
pharmacists in the current study said that GPs asked them for advice about medicines-
related issues and only 54.3% of respondents thought that GPs knew how to find 
medicines-related information. This suggests that GPs may not be convinced of the skills 
and expertise that community pharmacists possess. Some authors have postulated that 
potential barriers to GPs using the skills of community pharmacists include the medical 
culture or ‘turf wars’, where it could be perceived that pharmacists duplicate GPs’ roles and 
compete for remuneration (Freeman et al., 2012). 
 
The current study investigated some of the factors that affected the ability of community 
pharmacists to conduct effective PD-MURs that may have a beneficial effect on reducing 
medicines-related hospital admissions. As shown in the current HES data study, medicines-
related hospital admissions are an increasing problem, and this will become more apparent 
in the forthcoming years due to an ageing population taking increasing numbers of 
medicines for multiple medical problems. In 2016, 18% of the UK population was over 65 
and it has been estimated that this proportion will increase to 25% by 2046 (ONS, 2017b). 
Between 1991 and 2011, a population-based study of older people in England found that 
the number of people taking five or more medicines per day increased from 12% to 49% 
(Gao et al., 2017). This represents a huge financial burden for the future NHS; partly due to 
the increased risk of medicines-related hospital admissions and their associated costs with 
the greater number of medicines taken, but also the time taken for HCPs to prescribe these 
medicines safely, rationalise patients’ medication regimes and educate patients to use 
medicines most effectively. 
 
Reducing medicines-related hospital admissions and minimising the impact of medicines-
related problems is a priority, and as previously mentioned in section 3.4.7, it has been 
suggested that this could be achieved by utilising the skills of pharmacists in a number of 
ways: 
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1. Medicines reconciliation at admission and discharge – inclusion of the community 
pharmacist in discharge communication as well as the GP. 
2. Person-centred patient education – a focus on what is important to the patient 
and presented in a format that is accessible to them. 
3. Shared decision making – ensuring that patients and their carers are involved. 
4. Follow up with community pharmacy – referral from the hospital pharmacy to the 
community pharmacy for NMS or a PD-MUR. 
(Barnett and Blagburn, 2016) 
Pharmacists, through their specialised training, see themselves as the experts in medicines 
and efforts should be made to ensure that patients and other healthcare professionals are 
aware of their unique knowledge and skills. Community pharmacists need to utilise every 
opportunity to impart their specialist knowledge about medicines to patients and GPs in a 
manner that could be considered to be ‘self-promotion’. They need to ensure that they talk 
to patients when they issue repeat medicines and discuss treatment options with GPs, 
rather than handing out prescriptions with no advice and having solely problem-based 
discussions with GPs. If they are seen to be offering high-quality medicines advice to 
patients and GPs, and extended services to patients, their role will become more visible 
and raise the profile of what community pharmacists can offer. People will get to know 
them, trust them and use them. 
 
9.2.2 Evidence for MURs and PD-MURs  
In the current study only one patient with a long-term condition had participated in a MUR. 
The patients who had not participated in a MUR reported that they were either not aware 
of the MUR service or did not think it was something that was for ‘someone like them.’ This 
view was also seen in a feasibility study that aimed to recruit and refer patients for PD-
MURs, which found that 27.8% of patients refused to participate because they saw no 
benefit for them in a PD-MUR (Ramsbottom, Fitzpatrick and Rutter, 2016). This study also 
found that only 3.2% of eligible patients were identified by hospital pharmacists for referral 
for a PD-MUR (Ramsbottom, Fitzpatrick and Rutter, 2016). A recent evaluation of the 
discharge medicines review (DMR) service in Wales also found that only 2% of all patients 
discharged from hospital actually participated in a DMR (Hodson et al., 2018). As well as 
publicising MURs and PD-MURs and their benefits to patients, there are various other 
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patient, social, medicines-related and disease-related factors that can influence whether 
MURs or PD-MURs are acceptable to patients. 
 
At the current time, there is a dearth of evidence for the effects of MURs on ‘hard’ 
outcomes such as morbidity or mortality. There is also limited evidence that medication 
reviews by pharmacists actually have any effect on hospitalisations; a systematic review of 
studies that investigated medication review and cooperation between the pharmacist and 
GP found that some studies showed statistically significant decreases in hospitalisations, 
others no effect and one study an increase in hospitalisations (Geurts et al., 2012). A 2013 
systematic review of GP-pharmacist collaboration noted that medication reviews by 
pharmacists did not show any effect on outcomes such as mortality or hospital admissions, 
but did lead to improvements on ‘soft’ outcomes such as knowledge about medicines and 
adherence (Kwint et al., 2013). Another systematic review that focussed on the role of 
community pharmacists in the transfer of care of post-discharge patients found that they 
could have an effect on the identification and resolution of medicines-related problems. 
The included studies showed that the number of times the patient had contact with the 
community pharmacist did not make any difference to how effective the intervention was. 
This emphasised the complex interlinked nature of the various elements involved in a 
successful intervention delivered by community pharmacists (Nazar et al., 2015). 
 
It has been suggested by multiple authors that a large-scale randomised controlled trial 
with enough participants to give the study sufficient power, is required to determine 
whether medication review by pharmacists has any significant effect on ‘hard’ outcomes 
such as hospitalisation rates and cost-effectiveness (Bryant et al., 2011; Geurts et al., 2012; 
Leendertse et al., 2013). Prior to conducting the literature review, the intention for the 
current study was to conduct a RCT to establish whether PD-MURs had any effect on 
medicines-related hospital readmissions. When the literature was reviewed, it became 
apparent that this RCT was beyond the scope of an unfunded PhD study due to the number 
of patients who would need to be recruited. Some authors have shone a spotlight on the 
lack of evidence for ‘economic, clinical and humanistic outcomes’ for community 
pharmacists’ interventions for post-discharge patients. They have warned that if other 
HCPs gain this evidence, community pharmacists could find themselves excluded from 
roles in caring for post-discharge patients (Nazar et al., 2015). 
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9.2.2.1 Post-discharge medicines reconciliation and review provided by pharmacists 
The MUR in England is focussed on improving patients’ understanding of their medicines, 
highlighting side effects, improving adherence and reducing waste (PSNC, 2018j); there is 
no specific guidance to ensure that medicines reconciliation occurs as part of this process. 
Conversely, in Wales, the DMR service description specifically states that the first part of 
the consultation with the community pharmacist involves them ‘checking that the 
medicines prescribed in the hospital match those prescribed by the GP’ (Community 
Pharmacy Wales, 2011). 
 
The RPS Transfer of Care Report, published in 2012, highlighted the scale of changes in 
medication that patients must cope with when they are discharged from hospital: 
‘The likelihood that an elderly medical patient will be discharged on the 
same medicines that they were admitted on is less than 10%. Between 
28-40% of medicines are discontinued during hospitalisation and 45% of 
medicines prescribed at discharge are new medicines. 60% of patients 
have 3 or more medicines changed during their hospital stay.’ 
(The Royal Phamaceutical Society, 2012) 
In the current study, several of the community pharmacists interviewed intimated that 
they did attempt to conduct medicines reconciliation when they knew a patient had been 
discharged from hospital, by querying medication discrepancies they had identified, 
although this was not necessarily as part of a formal PD-MUR. The desire of community 
pharmacists to receive a copy of the full hospital discharge summary when patients left 
hospital was an acknowledgement that they wanted to know what changes had been made 
to the patient’s medicines and what the current medication regime looked like. In the 
community pharmacist interviews during the current study, one pharmacist highlighted 
that problems had occurred when discharge information was entered into the GP record by 
untrained staff. 
 
There is published evidence to show that medicines reconciliation after hospital discharge 
has a beneficial effect on patient care. A recently published systematic review and meta-
analysis has assessed the effectiveness of medicines reconciliation, rather than medication 
review, in the community by pharmacists after hospital discharge. The review included 14 
papers, but only one considered medicines reconciliation conducted in a community 
pharmacy; the remainder were conducted in the patient’s home or other locations. Four 
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studies found that the intervention identified and resolved discrepancies in medicines and 
two studies indicated that medicines reconciliation could reduce the number of ADRs after 
a care transition. The meta-analysis did not find a statistically significant effect of 
pharmacist medicines reconciliation on readmission rate, with a RR of 0.91 (95% CI 0.66-
1.25); although the authors noted a high degree of heterogeneity amongst the studies. The 
authors concluded that there were a lack of high-quality studies in this area and at the 
current time, medicines reconciliation in the community by pharmacists could not be 
recommended as a way of reducing hospital admissions. There is still a paucity of evidence 
as to whether this intervention has any effect on ‘hard’ outcomes such as hospital 
readmissions, patient outcomes such as morbidity or mortality, or HCP workload (McNab et 
al., 2018). 
 
Conversely, another systematic review that focussed on medicines reconciliation 
conducted by pharmacists and initiated prior to hospital discharge found that this did have 
a statistically significant effect on hospital readmissions (RR 0.81, 95% CI 0.70-0.95), ED 
visits (RR 0.72, 95% CI 0.57-0.92) and ADR-related readmissions (RR 0.33, 95% CI 0.20-0.53). 
However, there was no statistically significant effect on mortality (RR 1.05, 95% CI 0.95-
1.16). The interventions included in the review were varied and again statistical analysis 
showed a high degree of heterogeneity for the meta-analysis of readmissions and ED visits 
(Mekonnen, McLachlan and Brien, 2016). A RCT that was excluded from the meta-analysis 
by Mekonnen, McLachlan and Brien, (2016) because the results were not presented in a 
suitable form, investigated the effect of intensive pharmacist-delivered care initiated in 
hospital and continued post-discharge for patients over 80 years of age in Sweden. The 
authors found that the intervention reduced ADR-related hospital admissions by 80% (RR 
0.20, 95% CI 0.10-0.41) compared to a control group who received standard care (Gillespie 
et al., 2009). 
 
Although there are promising signs that medicines reconciliation after hospital discharge is 
advantageous for patients, there still appear to be some reservations about the best HCP to 
conduct this task. A study of GPs and community pharmacists in Ireland found that 
although only 40% of GPs had a formal system for medicines reconciliation after a patient 
moved from one setting to another, 75.4% thought their practice in this area was good to 
excellent. Furthermore, 74% of GPs and 82% of community pharmacists thought the role of 
community pharmacists should include the prevention of prescribing problems after a 
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patient moved from one setting to another (Redmond et al., 2016). This was despite only 
22% of GPs thinking that medicines reconciliation after a care transition was best 
conducted by a pharmacist, compared to the 74% of community pharmacists who thought 
they were best HCP to perform this task (Redmond et al., 2016). Other studies have 
confirmed that community pharmacists see medicines reconciliation as part of their role 
(Kennelty et al., 2015) and some GPs also see this task as something that pharmacists 
would excel at; Clare Gerada, past chairperson of the Council of the Royal College of 
General Practitioners, has said: 
‘Pharmacists do medicines reconciliation incredibly well. Why don’t they 
liaise with hospitals before patients are discharged? Why don’t they go 
into hospitals even before they’re discharged and put them (medicines) 
directly on to the record? Why don’t they reconcile the hospital record 
with the GP record when a patient comes out?’ 
(Sukkar, 2015) 
 
It seems that medicines reconciliation as part of a PD-MUR is important and the service 
specification in England should be altered to mirror that in Wales, whereby the post-
discharge medication review formally includes medicines reconciliation. In the US, 
community pharmacists have found that medicines reconciliation after a patient has been 
discharged from hospital is time consuming and some pharmacists have highlighted the 
lack of reimbursement as a disadvantage (Kennelty et al., 2015). The system of 
remuneration in England also needs reviewing and this will be discussed further in section 
9.2.3.3. 
 
At the current time the HCP best placed to conduct medicines reconciliation and post-
discharge medication reviews is the practice pharmacist, as they have access to the 
patient’s discharge summary and medical records. This does not mean that community 
pharmacists should not be involved in the care of post-discharge patients, rather they 
should conduct a FD-MUR; a MUR that takes place when the patient receives their first 
repeat prescription after a hospital admission. The FD-MUR would involve the community 
pharmacist ensuring the patient was collecting the correct medicines, checking if they had 
experienced any problems since their medicines reconciliation and medication review with 
the practice pharmacist, and confirming that their information needs about their new 
medication regime have been fulfilled. 
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RECOMMENDATION 1 
A practice pharmacist should conduct medicines reconciliation and medication review, in 
the practice or at the patient’s home, as soon as possible after hospital discharge. Details 
of the review should be shared electronically with the patient’s community pharmacist. 
Patients should have a ‘first-dispensing’ MUR conducted by a community pharmacist, to 
check their use and understanding of their medicines when they collect their first 
prescription after they have been discharged from hospital. 
 
 
9.2.3 Facilitators and barriers for community pharmacists conducting MURs and PD-
MURs 
In the current study, there were several factors that affected whether community 
pharmacists were more or less likely to participate in MURs and PD-MURs. These factors 
have been distilled down into the following areas: the identification of high-risk patients; 
clinical skills and knowledge; and incentivisation to complete MURs. 
 
9.2.3.1 Identification of high-risk patients  
The targeting of patients at high-risk of a medicines-related readmission to hospital is 
critical to ensuring that pharmacists’ skills benefit the patients in most need. The HES data 
background work that was part of the current study demonstrated that the medicines most 
likely to cause a medicines-related readmission have not really altered over a number of 
years. This knowledge of high-risk medicines could be used as a very crude way of 
pinpointing patients who may require additional medicines-related support. Community 
pharmacists who were interviewed and surveyed for the current study also described how 
they were often unaware that a patient had been in hospital. Therefore, a quick way of 
identifying patients who may benefit most from a MUR would be to look for those taking 
high-risk medicines and/or those who have recently been in hospital. 
 
NICE has also suggested that tools such as the Living with Medicines questionnaire, version 
3 (LMQ-3) could help HCPs to provide more individualised care to patients (NICE, 2016). 
When people using community pharmacies in south east England completed the LMQ-3 it 
showed that those who pay prescription charges, use more than four medicines, take 
medicines more than twice a day and need support using medicines, have the highest 
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medicines burden. Interestingly, older people (>65 years) reported lower levels of 
medicines burden than younger people (Krska, Katusiime and Corlett, 2018). 
 
More complex tools are available that combine a greater number of parameters to identify 
patients, in the community or in hospital, who are at high risk of a medicines-related 
admission to hospital. Barnett and Blagburn (2016) have suggested the use of the PINCER 
tool by GP practices and the PREVENT tool by hospital and community services to reduce 
medicines-related readmissions. The PINCER tool can be used with GP computer systems to 
target patients taking high-risk medicines (University of Nottingham, 2018); integration into 
community pharmacy PMR systems could be one way of identifying patients in a more 
sophisticated manner. 
 
The use of integrated IT systems would mean that the identification of patients recently 
discharged from hospital and those taking high-risk medicines would be an easy and 
straightforward task. At the current time, with a lack of integrated IT systems, this could be 
achieved by hospitals sending information to community pharmacists using 
PharmOutcomes or community pharmacy PMRs ‘flagging-up’ suitable patients. Fully 
integrated IT systems will be discussed further in section 9.4.1.3 but until they are 
available, methods for community pharmacists to identify patients in greatest need of 
medicines support should make more efficient use of time, and use the skills of community 
pharmacists effectively, especially their specific knowledge about medicines.  
 
RECOMMENDATION 2 
Community pharmacists should use their specialised knowledge of high-risk medicines, 
information about whether their patient has recently been in hospital and an awareness 
of those who experience the greatest burden of medicine-taking to prioritise patients for 
MURs. This should be facilitated by currently available IT solutions, and in the future, 
should be fully integrated across different healthcare providers. 
 
 
9.2.3.2 Clinical skills and knowledge 
The results of the survey showed that community pharmacists were more likely to conduct 
MURs if they were younger. Younger community pharmacists will have only been qualified 
since the introduction of MURs in 2005 and will not have worked in community pharmacy 
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before this time. Participation in MURs is an advanced service that involves the pharmacist 
working in a more patient-focussed manner rather than in a dispensing or supply function. 
Younger pharmacists will have been trained in a different way during their undergraduate 
studies and are more likely to have the skills to enable them to be more confident 
delivering this type of service. They will also have different expectations of the roles they 
will undertake in their future careers. For older pharmacists that feel less confident in 
providing new services, further training may be required to equip them with the requisite 
skills, such as increased clinical knowledge, medication review, consultations skills and 
coaching methods for example. This could be through formal training, e.g. a clinical 
diploma or an independent prescribing qualification or through personal CPD. This finding 
may be particularly relevant to older pharmacists because the NHS landscape is changing 
and the roles that pharmacists now find themselves in require additional training to ensure 
the public have access to pharmacists who are highly skilled and able to pass on their 
expertise. 
 
Older pharmacists in the survey agreed more with the attitudinal statements around GP 
and patient views of MURs and what community pharmacists offered over and above the 
supply of medicines. They were more likely to think that GPs and patients appreciated their 
additional input into patient care, through their clinical knowledge, and provision of MURs, 
rather than seeing them solely as the suppliers of medicines. These pharmacists may have 
been able to build longer-standing relationships with GPs and patients in their locality, but 
they may also have had more time to gain the skills required to provide advanced services 
to a high-standard. Younger pharmacists could therefore benefit from further training to 
equip them with the additional skills they require and allow them to feel more appreciated 
for their advanced roles also. 
 
To support the effective development of pharmacy the Pharmacy Integration Fund (PhIF) 
was set up in October 2016, with the aim of ensuring pharmacists and pharmacy 
technicians had the skills to deliver high-quality, safe, effective services for patients as part 
of an integrated primary care team (NHS England, 2018b). One of the workstreams it 
supports is education and development. In 2018/19 the Fund is financing £40million of 
training for pharmacy professionals in areas including clinical and professional leadership, 
clinical education, independent prescribing and clinical skills for pharmacists working in 
general practice (Health Education England, 2018b). These training opportunities should be 
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utilised by community pharmacists to ensure they have current clinical knowledge and the 
skills required to serve patients effectively. 
 
The future spending of the PhIF monies has not been determined at the current time; 
although further funding will be made available, it is not yet clear what it will be spent on 
(PSNC, 2018n). This fund gives community pharmacists the opportunity to be ‘upskilled’ 
and they should make the most of that chance. In terms of how community pharmacists 
feel about more advanced roles, a systematic review found that most pharmacists viewed 
the extension of their role as an opportunity for role expansion and professional 




Community pharmacists should access the Pharmacy Integration Fund to finance formal 
and informal training, to increase their skills in caring for post-discharge patients. The 
Fund should also be used to promote innovative ways of working, by commissioning 
direct services from pharmacists such as first-dispensing MURs or developing IT solutions 
to facilitate the integration of pharmacy and GP IT systems. 
 
 
9.2.3.3 Incentivisation to complete MURs 
The community pharmacists survey showed that pharmacists working in large multiples 
conducted more MURs than those working in other types of pharmacy. This may reflect a 
more commercial, target-driven approach to the recruitment of patients for MURs which 
pharmacists working for large multiples feel compelled to adhere to. Pharmacists that were 
interviewed for the current study did talk about external pressures to complete MURs, but 
also stressed that they still had the professional autonomy to choose the most appropriate 
patients for the service. This pressure to meet MUR targets has also been reported by 
community pharmacists in other studies (McDonald et al., 2010; Ferguson, Ashcroft and 
Hassell, 2011; Latif, Pollock and Boardman, 2013). A change in the way community 
pharmacists are remunerated for MURs and PD-MURs may be required for the focus to 
change from quantity to quality. 
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The time taken to conduct a PD-MUR was also a factor when community pharmacists chose 
patients for this service. Latif, Pollock and Boardman (2013) found that staff in community 
pharmacies tended to choose patients who were on fewer medicines for MURs. 
Pharmacists in the current study also said that PD-MURs were more complex and therefore 
time consuming to complete than standard MURs. Rutter, Ramsbottom and Fitzpatrick 
(2017) found that on average a PD-MUR took between 20 and 39 minutes to complete and 
in their systematic review, McNab et al., (2018) found that post-discharge medicines 
reconciliation took between 1 hour 27 minutes and 3 hours 51 minutes to complete. The 
current method of remuneration for MURs encourages pharmacists, if they are under 
pressure, to select the ‘easy’ or ‘straightforward’ patients for MURs rather than considering 
which patients will gain most benefit as those (PD)-MURs are likely to be more ‘difficult’ or 
‘complicated’. 
 
It has been suggested that remuneration should be increased to cover the time and work 
involved in providing advanced services and pharmacists would be more likely to engage 
with service provision for greater financial reward. Direct remuneration has also been 
considered to be an option in some cases (Hindi, Jacobs and Schafheutle, 2018). An 
alternative method of remuneration has also been suggested by Clare Gerada, whereby, 
like GPs, pharmacists have a registered list, managing patients with long-term conditions 
and would be paid in a way that is akin to GPs (Sukkar, 2015). 
 
A change in the community pharmacy contract is required so that the care of post-
discharge patients is given greater priority. The current method of remuneration does not 
incentivise community pharmacists to support every patient who has been discharged from 
hospital. The lack of PD-MURs conducted by community pharmacists in the current study 
highlights that community pharmacists can easily reach their MUR annual quota with 
patients from the other target groups. They do not feel the need to prioritise post-
discharge patients, even though they are a vulnerable group with perhaps a greater need 
for support than patients in the other target groups. 
  




Remuneration for post-discharge medication reviews and support by community or 
practice pharmacists should be based on the proportion of discharged patients (on four 
or more medicines) who have their medicines reconciled and, are offered further advice 
and support with their medicines. This should be done in a similar manner to the GP 
quality and outcomes framework (QOF) system. 
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9.3 Relationships 
The next overarching theme to emerge from the various phases of the current study was 
relationships. This was a very broad topic area and encompassed all of the relationships 
that existed between the patient, community pharmacist and GP as well as others such as 
family members or carers. The interplay of the relationships that patients found most 
important to them was complex and varied for each individual. The patient’s locus of 
control also strongly influenced who they involved in decisions about their health, and this 
along with their level of health literacy determined what health-related information they 
felt they required. The patient interviews highlighted just how much importance the 
patient put on their relationship with their GP and how they felt about pharmacists 
becoming more engaged in their care. The pharmacist interviews and survey emphasised 
the complex interplay of factors that impact on community pharmacists providing high-
quality advanced services to patients and how their role fits into the primary care 
landscape. 
 
9.3.1 Pharmacists’ and patients’ relationships 
As mentioned in the introduction, the findings of this study have shown that there are a 
complex network of relationships and the values that patients put on those relationships 
impact on the behaviour of patients with regard to medicines-taking, accessing the 
expertise of community pharmacists and accepting the role of the pharmacist in the 
primary healthcare team. Pharmacists in this study also reported variable levels of 
engagement with advanced services from patients. All of these factors affect a patient’s 
optimisation of their medicines and their risk of being admitted to hospital because of a 
medicines-related problem. 
 
The findings from the patient interviews, pharmacist interviews and survey gave an insight 
into the relationships between the different individuals involved in the care of a patient. 
These relationships have been summarised in Figure 9-3, which shows the dynamics of the 
usual relationships that exist and demonstrates that community pharmacists’ relationships 
can be very variable.  
  





   Generally, well established relationships 
   Variable relationships, in some cases strong, in others non-existent 
 
Figure 9-3 Relationships between patients and others involved in their care 
 
At one end of the spectrum community pharmacists could be considered to be on the 
periphery of care and may find difficulty in building and maintaining relationships; this 
would be even more apparent for locum community pharmacists. At the other end of the 
spectrum, in terms of the depth of relationships, some community pharmacists have been 
able to build strong and trusted relationships with GPs and patients. Indeed, some patients 
in the current study described how they used a single pharmacy and had a good 
relationship with their community pharmacist. This familiarity meant they readily asked 
them about medicines-related issues. This was reflected in the results of a survey of over 
1000 members of the general public in England; those who took regular medicines or who 
used a pharmacy frequently, were more likely to agree to participate in a medicines-related 
service than the general population (Rodgers et al., 2016). 
 
Another survey of 2661 members of the general public in England about attitudes towards 
community pharmacies and the services they provide, reported that people over the age of 
65, and frequent pharmacy users expressed a preference for using the same pharmacy. 
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the staff and the staff knew them. They expressed negative attitudes towards pharmacies 
in supermarkets (Saramunee et al., 2016). This suggests that it is important for community 
pharmacists to build relationships with patients with the aim of achieving better 
engagement, particularly with advanced services. 
 
There have been concerns, from the hospital sector, that patients do not use a regular 
community pharmacy so sending discharge information to the correct pharmacy would be 
difficult. This appears not to be the case as Urban et al., (2013), have estimated from 
previous studies that 58-94% of patients use the same community pharmacy consistently. 
However, this wide-ranging figure emphasises the variation that exists, whereby some 
patients have a closer relationship with their community pharmacist than others. 
 
From the results of the current study, there is new information about the relationships that 
community pharmacists are able to build with patients and how this is somewhat 
dependent on the type of pharmacy they work in. Community pharmacists working in 
independents and small multiples were more likely to conduct PD-MURs and were also 
more likely to think that they were able to provide patients and GPs with their expertise 
compared to pharmacists working in other types of pharmacy. This may reflect the depth 
of relationships that community pharmacists are able to build with patients and GPs when 
working in these smaller companies; which may be a consequence of a more static 
pharmacy workforce and fewer people - both patients and GPs - that they need to acquaint 
themselves with. 
 
There have been suggestions, from pharmacy representative bodies, that for community 
pharmacists to be seen as professionals they should have their own clientele and this lends 
itself to the idea of nomination or registration with a particular community pharmacy 
(Edmunds and Calnan, 2001). This is the case in countries such as the Netherlands (NHS, 
2018), although it should be noted that registering or nominating a community pharmacy 
there does not necessarily mean continuity, as patients have the freedom to use 
alternative pharmacies. 
 
Continuity of care from the same GP is appreciated both by GPs and patients, particularly 
older people, and those with complex health problems (Levene et al., 2018). It has been 
shown, in a systematic review, that the same GP caring for the patient results in a 
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statistically significant lower mortality rate (Pereira Gray et al., 2018), increased 
concordance with medication regimes and lower hospital admission rates amongst other 
markers (Levene et al., 2018). Extrapolating from this, it would be fair to expect that the 
same could be true for continuity of care from other HCPs such as community pharmacists, 
but at the current time there is insufficient evidence that a longstanding patient-
pharmacist relationship confers the same benefits. 
 
A potential facilitator for patients to become more familiar with their community 
pharmacist would be for patients to nominate their preferred community pharmacy. This 
already occurs when patients specify which pharmacy they would like to dispense their 
regular medicines if they use the electronic prescription service (NHS Digital, 2018c). This 
should become more formalised with all patients nominating a pharmacy and this being 
formally recorded in the medical records, community pharmacy records, and therefore also 
the summary care record. This will be discussed further in section 9.4.1.1. Referrals to 
secondary care should automatically include this information. A process allowing both 
primary and secondary care HCPs to have read and write access to this record should also 
be enabled. This would mean that any pertinent medicines-related information about the 
patient would be accessible to all HCPs involved in a patient’s care, although it is 
acknowledged that this is an idealistic aspiration at the current time. 
 
9.3.1.1 Patients’ HLOC, health literacy and the effect on relationships 
Findings from the current study suggested that, from a patient’s perspective, the 
relationships they have with HCPs and their family in relation to their health was influenced 
by their HLOC and level of health literacy. Figure 9-4 shows the HLOC and levels of health 
literacy for patients interviewed in the current study.  
 
  



















Figure 9-4 HLOC and health literacy of patients interviewed 
 
The patients interviewed fell into two distinct categories, with either a high level of health 
literacy and internal locus of control or, a lower level of health literacy and an external 
locus of control. 
 
There have been few studies that consider HLOC and health literacy and the links that may 
exist between the two constructs, and this area warrants further investigation. A national 
survey of Taiwanese adults considered self-efficacy, or the ability to improve and maintain 
health, and how health literacy and HLOC affected it (Tsai, Lee and Tsai, 2015). The study of 
over 3 500 people found that individuals with low levels of health literacy were more likely 
to depend on others and have an E-HLOC compared to those with high levels of health 
literacy, who were more likely to have an I-HLOC. The authors postulated that people with 
higher levels of health literacy had more ability to work their way through the health 
system and attributed their health status to their own actions rather than due to chance 
(Tsai, Lee and Tsai, 2015). They found that although there were links between health 
literacy, HLOC and self-efficacy, these were all independent factors and represented 
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different aspects of a person’s behaviour (Tsai, Lee and Tsai, 2015). The importance of 
empowering patients and encouraging an I-HLOC was underlined by a RCT of 136 older 
patients in Australia, who had been discharged from hospital into transitional care. It found 
that those with an I-HLOC had a better quality of life and physical functioning 12 months 
after hospital discharge compared to those with an E-HLOC (Milte et al., 2014). 
 
These studies suggest that modification of HLOC from external to internal would benefit 
patients’ long-term health prospects. It may not be possible for all patients to have an I-
HLOC so for some, an E-HLOC with some features of an I-HLOC may be appropriate. If a 
patient has an E-HLOC it may be beneficial if the doctor supports them in making health-
related decisions but also puts the emphasis on empowering them to have the confidence 
to also make some beneficial decisions themselves such as losing weight, giving up smoking 
or adhering to their medicines, which would benefit their long-term health. 
 
For health literacy, it is already known from systematic reviews that patients who have low 
health literacy are more likely to have difficulties taking their medicines properly, problems 
reading the labels on medicines, have poorer health status, be more likely to be admitted 
to hospital and have higher mortality rates than those with higher levels of health literacy 
(Berkman et al., 2011). Further systematic reviews and meta-analyses have also shown that 
higher levels of health literacy are associated with better medicines adherence. Although 
the authors suggest that beliefs about medicines, patient knowledge and communication 
between the patient and HCP can also affect medicines adherence (Zhang, Terry and 
McHorney, 2014). This was borne out in the current study as the patients who appeared to 
demonstrate lower levels of health literacy reported difficulties managing their medicines 
and relied on others to help them with this function. A relatively old paper from 1990 that 
investigated the information needs of patients reported that patients differed in how they 
dealt with their conditions and the treatments they were given. They suggested that 
patients required different amounts and types of information at the various stages of their 
condition and they postulated that if the communication from the HCP had been poor and 
not tailored to the patient, providing written information would not have any effect on 
adherence (Weinman, 1990). Unsurprisingly, the current study showed that patients varied 
in their opinions about the level and quantity of medicines-related information they 
required. 
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Community pharmacists are in an ideal position as HCPs to increase the health literacy of 
patients. They may be viewed by patients as being more approachable than GPs, they are 
seen frequently, and they are more accessible. Measures to improve health literacy would 
enable patients and their families to gain more control of their health and medicines-
taking. All HCPs should use interactions with patients, no matter how brief, to encourage 
patients to have confidence in their own health literacy and provide 
information/interventions to facilitate this, ideally using an approach and information that 
is tailored to the needs of the individual. This could take the form of an individual 
medicines review; the use of different consultation approaches such as ‘teach back’ or 
‘chunk and check’; or, if time and resources allowed, an informal group education session. 
NHS Scotland has excellent resources on its website ‘The Health Literacy Place’ 
(http://www.healthliteracyplace.org.uk) and these resources could be used to assist 
community pharmacists to have more patient-centred consultations. 
 
By providing tailored patient information in the most appropriate way, patients will 
become more knowledgeable about their medicines and conditions. The hope would be 
that this should increase their confidence and perhaps even nudge them into having more 
control over their health. However, it should be noted that even if patients are given 
information that is individualised, there is no guarantee that this will affect how they take 
their medicines. One study of community pharmacists found that they felt that patients 
would not necessarily disclose exactly how they took their medicines, meaning that the 
pharmacist’s ability to change behaviour was limited, as once the patient was at home, 
they would choose how they used their medicines (Latif, Waring, et al., 2018). 
 
RECOMMENDATION 5 
Community pharmacists should use the guidance contained in the NICE clinical guideline 
on medicines adherence (NICE, 2009) to engage with patients to determine the amount, 
depth and level of information they need according to their health beliefs and level of 
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9.3.1.2 Patients’ views of pharmacists providing advanced services 
In this study there were three different standpoints with regard to engagement with MURs 
from the seven patients that participated in the interviews. The first group were 
‘participants’; they had participated in a MUR and valued the knowledge and input of their 
community pharmacist in their care and were willing to participate in the service again. The 
second were ‘willing participants’; they were not aware of the MUR service, although when 
informed about the concept, appeared to be receptive to participating in future. The final 
group were ‘unwilling’; they did not think MURs were for them because they felt they could 
not cope with the information given, were not interested, or thought that their GP was 
superior in status and knowledge to the community pharmacist, so they would not utilise 
the expertise of the community pharmacist. This final standpoint was also seen in a 
feasibility study that investigated the referral of patients to their community pharmacist, 
specifically for a PD-MUR, which found that 32% of older patients refused to participate in 
the study with the most commonly cited reason being that they did not see the benefit in 
having a PD-MUR with their community pharmacist (Ramsbottom, Fitzpatrick and Rutter, 
2016). 
 
There appears to be a lack of awareness on the part of patients about the MUR service. In 
the current study only 32% of community pharmacists thought that the majority of patients 
were aware of MURs. There have been various published studies that have demonstrated 
that the general public are unaware of the advanced services provided by community 
pharmacists. A survey of the general population in south east England, not just patients 
who frequented pharmacies, which asked about willingness to use the advanced services 
provided by community pharmacists, demonstrated that only 18.2% of people were aware 
of MURs and 8.6% the NMS service (Rodgers et al., 2016). A systematic review of patient 
and public perspectives of community pharmacies found that patients viewed their 
community pharmacy as the place to have medicines dispensed and to get advice on the 
treatment of minor conditions and there was low knowledge amongst patients and the 
public about the advanced services that community pharmacies offered (Hindi, Schafheutle 
and Jacobs, 2017). 
 
Conversely, there are also several studies that show patients accept community 
pharmacists as part of the healthcare team and highlight the qualities that meant they 
were comfortable discussing their medicines-related issues with them. When members of 
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the public were asked whether they would be willing to have a discussion with a 
community pharmacist because they had recently been discharged from hospital, 65.6% of 
people agreed they would (Rodgers et al., 2016). In a synthesis of qualitative studies about 
the role of community pharmacists, pharmacists were seen to be friendly, accessible and 
helpful and patients felt they could discuss issues with them that they had not been able to 
with their GP (Hall, Donovan and Wilkes, 2018). Members of the general public who had 
experienced advanced pharmacy services said their opinion of what the pharmacist could 
offer had changed, so they would be more likely to use them in future because they were 
more accessible and had more knowledge about medicines than the GP (Rodgers et al., 
2016). This view was reflected by the patient in the current study who said they would ask 
the pharmacist about their medicines, in preference to the GP, because in the past they 
had not got the answer they wanted from the GP. 
 
There does appear to be some confusion from patients about the purpose of the MUR and 
worryingly that was apparent even when the patient had participated in a consultation. In 
this study, even when the service was described to patients, some required further 
clarification to determine whether or not they had participated in a MUR. In one postal 
survey of over 300 community pharmacists in England, 46.3% of pharmacists thought that 
even when patients agreed to have a MUR, they were not aware of its purpose (Rodgers et 
al., 2016). When the MUR and NMS service was described to the general public to explore 
their willingness to participate; 53.2% (Rodgers et al., 2016) of people said they would use 
the service as they were ‘wanting to help the pharmacist’ (Latif, Boardman and Pollock, 
2013; Rodgers et al., 2016). Even when patients have had a MUR with a community 
pharmacist, some reported that they felt it had not changed how they used their medicines 
or increased their knowledge about their medicines (Latif, Boardman and Pollock, 2013). 
 
To increase the knowledge of patients and the general public about MURs and in particular 
PD-MURs, publicity is required. This was also one of the recommendations from a 
systematic review investigating community pharmacy users’ opinions about the 
contribution of community pharmacy to improving public health, which suggested that 
more active promotion is required to alert the public to the role of community pharmacists 
in providing general health advice (Anderson, Blenkinsopp and Armstrong, 2004). Careful 
consideration is required as to how this is achieved to ensure maximum effectiveness. A 
survey of 2661 members of the general public in England found that when promoting 
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lifestyle advice and cardiovascular screening by community pharmacies, people were more 
likely to engage with these services if they had received a personal recommendation of the 
service from a HCP, family member or friend. They also reported that advertising using 
posters and leaflets was preferred over mass-media methods such as newspaper or radio 
advertising (Saramunee et al., 2016). A national survey of over 2000 members of the 
general public about medical information in 2016 found that 65% of people thought that 
their friends’ and family’s experiences were a trustworthy source of information (ComRes, 
2016). In the current study, the patient who had participated in a MUR said they would 
recommend it to others and would attend again themselves. This shows how powerful a 
personal recommendation can be and how important social relationships are to patients. 
 
Professional bodies, for example the RPS, should take the lead and work with trade 
organisations such as the NPA and the PSNC and health service organisations including NHS 
England and local CCGs, to co-ordinate efforts to publicise the advanced services on offer in 
community pharmacies to patients. Commissioning new services such as FD-MURs would 
help to provide authentication and validation of the service from the patient’s point of 
view. A range of other publicity methods should also be employed including, posters, 
verbal endorsement by GPs, the use of technology such as screens in GP surgery waiting 
areas, and social media, through targeted, promoted posts on Twitter, Facebook and 
Instagram. Strategies are already being employed by various organisations for this purpose, 
but continued and expanded efforts are required. Patients who have taken part in 
advanced services should be encouraged to share their experiences with their peers to also 
increase awareness and uptake. The overall aim of any publicity should be to increase 
uptake of advanced services which would have the knock-on effect of promoting the 
service through word-of-mouth from those who have taken part. 
 
RECOMMENDATION 6 
The role and skills of community pharmacists should be promoted to patients through 
advertising, word of mouth, endorsement from other HCPs and commissioning of novel 
services, such as first-dispensing MURs. Community pharmacists should be seen as the 
first ‘port of call’ for patients who require assistance with any aspect of managing their 
medicines. 
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9.3.1.3 Domiciliary medication reviews by pharmacists 
For some patients, even if they are aware of PD-MURs, there are practical issues that make 
it difficult for them to attend their community pharmacy to participate. A study from south 
east England aimed to educate hospital in-patients about the availability of PD-MURs when 
they left hospital by giving them leaflets during their admission and at the time of 
discharge; this was to encourage them to attend their community pharmacy for a PD-MUR. 
Of the 83 patients who completed the study, 47% were aware of MURs prior to their 
admission but after discharge only 7% had participated in one. The main reason for not 
attending a PD-MUR was due to morbidity or mobility problems (Lam, Dodds and Corlett, 
2016). In the current study, no patients were followed-up, so it was not possible to 
determine whether they had participated in a PD-MUR or not. If patients experience a 
period of reduced mobility or excess morbidity the availability of domiciliary PD-MURs 
would be a useful option. 
 
The HMR service in Australia, which has been in existence since 2001 (Pharmaceutical 
Society of Australia, 2011), could provide a framework for initiating this service in England. 
Australian GPs refer patients to pharmacists for this service and there is good evidence that 
it reduces drug burden and increases appropriateness of medicines. Sadly, there is still a 
lack of evidence to show the effect on clinical and patient reported outcomes (Chen, 2016). 
 
In the UK there is scant evidence from small-scale studies that home medication review can 
realise economic benefits as well as improved clinical outcomes. The studies quoted below 
all suggest that home medication review results in cost-savings, however, all of the 
included studies used expert opinion to determine whether a hospital admission was 
avoided and then extrapolated to calculate the predicted cost savings, therefore 
subjectivity must be considered as a potential issue. An evaluation of the Exeter Cluster 
Clinical Pharmacy service in south west England, which provided home medication reviews 
for frail older people referred by their GP, found that 79% of the patients seen were not 
able to get to the GP surgery or community pharmacy to discuss medicines-related 
problems. Prior to the medication review, 76% of these patients were at high-risk of 
developing medicines-related problems. The population served by the scheme was 145,000 
and it was estimated that the scheme prevented 109 hospital admissions per year and 
saved £100,000 per year for the health economy (Dilks et al., 2016). In London, a scheme 
where clinical pharmacists conducted domiciliary clinical medication reviews, assessed 268 
Chapter Nine | Discussion 
 
 322 
patients and made 1741 interventions over an 18-month period. Of the interventions, 2% 
prevented harm or hospital admission and the authors estimated that this saved the NHS 
£128,556. Of the patients who had participated in the reviews, 91% were highly likely to 
recommend the service to family and friends (Central London Community Healthcare NHS 
Trust, 2018). A further study conducted in central England found that when community 
pharmacists conducted domiciliary MURs, they self-reported that a hospital admission was 
possibly or likely prevented for 35.3% of patients (Latif, Baguiasri, et al., 2018). 
 
Despite the fact that patients recently discharged from hospital are in one of the target 
groups for MURs, this population are still underserved. In the current study very few 
pharmacists reported completing PD-MURs, and only one of the patients interviewed had 
ever had a MUR of any type. The MUR service has also been found to not fulfil the needs of 
other marginalised groups within the general population such as people with disabilities, 
the housebound and refugees, amongst others. A recent study found that those who are 
socially isolated lacked support in regard to their health and for people who belonged to 
more than one marginalised group this presented greater barriers (Latif, Tariq, et al., 2018). 
Domiciliary medication reviews would be one way of helping to support these marginalised 
groups. 
 
This concludes the subsection on patient relationships, the next sub-section will focus on 
interprofessional relationships. 
 
9.3.2 Pharmacists’ and GPs’ relationships 
9.3.2.1 GP superiority and HCP hierarchy 
Despite community pharmacists and GPs being core members of the primary healthcare 
team, there are still attitudes and opinions that inhibit these relationships and hamper 
optimal teamworking. A situation of mutual respect for each other’s skills and roles they 
can play in patient care should be the starting point for this relationship, but unfortunately 
this does not always seem to be the case. In the current study community pharmacists 
were ambivalent when asked whether they thought GPs had a high regard for the 
contribution they could make to patient care. Community pharmacists in other studies also 
report similar feelings; a study of community pharmacists’ and GPs’ views about 
collaboration in Germany found that often community pharmacists surmised that GPs had 
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negative opinions about episodes of contact with them and thought their requests were 
‘invasive and controlling’ (Löffler et al., 2017). 
 
Although these results are not based on research with GPs themselves, they emphasise 
how community pharmacists think GPs view them. This highlights the significant obstacles 
that must be overcome to achieve a successful, professional, relationship of equals. When 
lay people and HCPs are asked about the contribution that community pharmacists can 
make to patient care, traditional views are still firmly held, whereby the GP is seen as 
superior and the community pharmacist, subordinate to the GP (Hall, Donovan and Wilkes, 
2018). GPs themselves believe they have a higher status than community pharmacists and 
hold a more powerful position (Rieck, 2014). 
 
The superiority that GPs feel could be linked to their opinions about, and previous 
experience of, working with community pharmacists. Studies of GPs’ opinions of 
pharmacists have found that GPs perceive pharmacists to lack the knowledge (Rieck, 2014; 
Hindi, Schafheutle and Jacobs, 2017; Löffler et al., 2017), training (Hindi, Schafheutle and 
Jacobs, 2017) and the competence required to provide advanced services such as MURs 
(Hindi, Jacobs and Schafheutle, 2018). Furthermore, some GPs thought that extended 
community pharmacists’ activities should be supervised and authorised by GPs (Hindi, 
Jacobs and Schafheutle, 2018). Interviews with prescribers working in primary care have 
found that sometimes limits have been imposed on pharmacist prescribers by GPs, which 
further strengthens the GPs’ status at the top of the medical hierarchy (Weiss et al., 2016). 
 
These negative opinions are possibly based on previous encounters GPs have had with 
community pharmacists. Often community pharmacists contact GPs when they have a 
query about a prescription, meaning that the interactions are inherently brief and problem-
orientated. The studies presented in this section demonstrate the difficulties community 
pharmacists can face when attempting to build collaborative relationships with GPs; 
indeed, some of these views will be so firmly held it may be difficult for community 
pharmacists to change them. 
 
In Lewisham, a programme called ‘Walk in my shoes’ was developed as an inter-
professional exchange project where community pharmacists, GPs and practice staff spent 
time in each other’s location of work (NHS Lewisham CCG, 2016; PSNC, 2017). The scheme 
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helped the different staff groups to understand each other’s roles, work more closely 
together and work out how to streamline processes so patients got better care (NHS 
Lewisham CCG, 2016). Projects such as this could be rolled-out in other locations. 
 
9.3.2.2 The professional status of community pharmacists in the primary healthcare 
team 
Community pharmacists have high levels of expertise, as shown by the estimated 
reductions in hospital admissions after domiciliary MURs (Dilks et al., 2016; Latif, Baguiasri, 
et al., 2018). They are keen to support patients in their medicine taking, but it appears that 
often others see them as merely the suppliers of medicines. This was evidenced by 
community pharmacists who took part in the interviews and also in the survey; 57% of 
community pharmacists thought that GPs saw them as just the suppliers of their patients’ 
medicines. This stance was also seen in a qualitative study that included community 
pharmacists, pharmacy staff, patients and pharmacy stakeholders; it was found that GPs 
could present themselves as diagnosticians and consultants whereas community 
pharmacists were seen to be implementing the GP’s decisions and as little more than ‘sales 
technicians’ (Rapport et al., 2011). 
 
In other studies, GPs have viewed community pharmacists more negatively due to the 
commercial aspect of their role, whereby income can be generated from offering 
professional services (Urban, Rivers and Morgan, 2008; Hindi, Schafheutle and Jacobs, 
2017). In the current study, community pharmacists’ professional autonomy to choose 
patients was somewhat compromised by a requirement to complete a certain number of 
MURs, rather than being able to choose those patients who would gain most benefit 
despite the MUR consultation taking longer; for example, if patients had a complex 
medication regime. This conflict in the community pharmacists’ role coupled with the 
commercial nature of running a community pharmacy meant that GPs viewed them as 
lower in the hierarchy, compared to other HCPs such as themselves, nurses or 
physiotherapists, who provided their professional knowledge without any prospect of 
financial gain (Rieck, 2014). Community pharmacists themselves thought that GPs were 
sceptical about the value of MURs and GPs thought community pharmacists may be using 
them as a method of income generation (Urban, Rivers and Morgan, 2008). A systematic 
review also found that GPs had concerns about the possible financial motives of 
community pharmacists (Hindi, Schafheutle and Jacobs, 2017). This view was also seen in 
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GPs who expressed negative views about the NMS service; they thought it was 
unnecessary, they were unclear about the benefits to patients and dubious about the 
community pharmacists’ intentions (Latif, Waring, et al., 2018). 
 
These professional perceptions seem to have affected how community pharmacists choose 
to engage with GPs in their locality. Some community pharmacists who already have good 
working relationships with GPs are keen to maintain these relationships. A systematic 
review found that when a good GP-community pharmacist relationship existed, there was 
evidence that community pharmacists were not pursuing MURs so vigorously, so as not to 
harm that relationship (Hall, Donovan and Wilkes, 2018). There was also a conflict between 
the perceived benefits of the MUR service; pharmacists felt that the main benefit to GPs 
was a reduced workload, but GPs were not convinced that this was the case (Hindi, Jacobs 
and Schafheutle, 2018). This shows the desire of community pharmacists to assist GPs and 
provide high-quality services but demonstrated the difficulty in trying to convince GPs of 
the benefit of advanced services. Other pharmacists felt that the ‘top-down’ pressure they 
experienced to conduct high volume, rather than high quality MURs, undermined the 
service and would affect how patients and GPs perceived it (Hall, Donovan and Wilkes, 
2018). The difficulties of the community pharmacist-GP relationship were also 
demonstrated in the current study where one pharmacist said they asked patients to liaise 
with their GP to resolve medicines-related problems rather than them making direct 
contact themselves. 
 
Community pharmacists are aware of professional boundaries and do not want to impinge 
on the territory of GPs (Edmunds and Calnan, 2001). In one systematic review community 
pharmacists thought that the general public were not clear about their extended roles and 
they could be viewed as crossing GP boundaries (Hindi, Jacobs and Schafheutle, 2018). 
Indeed, one patient interviewed in the current study also felt that their GP should 
‘approve’ any changes to his medicines suggested by a community pharmacist or even 
changes to his prescription made by another doctor. An evaluation of the NMS in England 
found that some community pharmacists felt the service impinged on the GPs’ role (Latif, 
Waring, et al., 2018). 
 
Initiatives to increase the professional status of pharmacists in general and particularly 
community pharmacists are required. A report of a qualitative study of community 
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pharmacists’ professionalism concluded that ‘the public are surprised by the pharmacists’ 
degree of knowledge, especially in relation to the GP’ (Rapport et al., 2011). Initiatives to 
expand the role of community pharmacists should enhance their status, but as with the 
introduction of pharmacist prescribing this has not necessarily been the case. One 
qualitative study of pharmacist prescribers found that some community pharmacists 
welcomed their prescribing role as they felt it enhanced their professional status, whilst 
others felt it had made no difference; furthermore, a proportion still felt they should have 
final approval from the doctor for their prescriptions (Weiss and Sutton, 2009). 
 
Even though pharmacists are highly trusted members of the healthcare team, their 
professional status appears to be somewhat constrained by others’ perceptions of their 
traditional supply role (Britten, 2001). This can only be changed by education of others and 
familiarity with pharmacists in new roles. An appreciation of the role of community 
pharmacists by GPs is required to attempt to change the mindset that some GPs appear to 
have. Commissioning of novel services, perhaps as pilots initially, to encourage and compel 
HCPs to work together differently would force others to take notice of the skills that 
community pharmacists can bring to the primary health care team. There is further 
discussion of interprofessional working in section 9.3.2.4, including strategies to increase 
collaboration between pharmacists and GPs. Also, students embarking on careers as HCPs 
in any field, should experience interprofessional learning at undergraduate level, as is 
happening in some places currently. 
 
Collaboration between the RPS, the NPA and the British Medical Association (BMA) should 
be encouraged. Previous collaborations have taken place between the NPA and the GP 
committee of the BMA who published a toolkit for improving communication between 
community pharmacy and general practice (NPA & BMA, 2009), and the PSNC, Pharmacy 
Voice and the GP committee of the BMA who provided information about advanced 
pharmacy services (BMA, 2018). The RPS and the Royal College of General Practitioners 
(RCGP) have collaborated on the production of a policy statement on GP practice-based 
pharmacists (The Royal Pharmaceutical Society, 2015). These collaborations should be built 
upon in future to further advocate joint working. 
 
Chapter Nine | Discussion 
 327 
9.3.2.3 GPs’ awareness of advanced services provided by community pharmacists  
In the current study, some community pharmacists that were interviewed stated that they 
thought GPs were not aware of the different services that they offered. They also said that 
when they did make suggestions to GPs about adjusting medicines following a MUR, they 
did not get any feedback. This was despite 91% of community pharmacists saying they 
thought GPs should inform them of the outcome of their recommendations made after a 
MUR. This underlines the problems with the current MUR system and highlights the 
potential for better community pharmacist-GP relationships to improve the system for the 
benefit of patients. 
 
It has been shown that there is low awareness amongst GPs about the extended services 
that community pharmacists offer (Hindi, Schafheutle and Jacobs, 2017; Hall, Donovan and 
Wilkes, 2018; Hindi, Jacobs and Schafheutle, 2018). Both pharmacists and GPs thought 
collaboration could be improved through better relationships. Pharmacists also felt that 
recommendation of their services by other HCPs would be the best way of raising 
awareness of extended services (Hindi, Jacobs and Schafheutle, 2018), which was also seen 
in the current study. Another way to enhance collaborative working could be to incentivise 
the MUR service. Latif, Pollock and Boardman (2013) suggested that MURs and similar 
services should be incorporated into the QOF measures as a way of encouraging GPs to 
engage with them.  
 
The remuneration for community pharmacists conducting a FD-MUR should be revised, as 
mentioned in section 9.2.3.3 and recommendation 4, to a system where payments are 
made for the proportion of patients that have medicines reconciliation and medication 
review with the practice pharmacist and a FD-MUR with the community pharmacist. This 
would help to put the focus on quality of post-discharge care and shift it away from a 
purely commercial motivation. Obviously, there would need to be some valid exclusions to 
the payment system as some patients may refuse to participate, others may require 
domiciliary PD-MURs and others may require input from the GP themselves. This focus on 
quality of care would also mean that GPs would have a reduced workload in caring for 
patients recently discharged from hospital, as the technical details of reconciling the 
patient’s medicines, updating the repeat prescription template and supporting and 
educating patients would be conducted by pharmacists in the practice and the community 
pharmacy. 




9.3.2.4 Interprofessional teamwork 
In the current study only 18.5% of respondents thought that GPs had a high regard for the 
contribution that community pharmacists could make to patient care. Even though GPs 
were not asked for their opinions in the current study, an evidence-based approach to 
improving interprofessional relationships would be advantageous to community 
pharmacists working as part of the primary care team. Some authors have suggested that 
in teams where each prescribing professional, whether that be GPs, nurses or pharmacists, 
were respected for their different skills and appreciated as part of the team, they were 
more likely to have a positive impact on patient care (Weiss et al., 2016). This mutual 
respect would appear to be the minimum starting point. Other authors, through systematic 
review, have suggested methods for increasing and improving interprofessional 
relationships by focussing on factors such as: flexibility, feeling part of the team, support 
for innovation, having a team vision or goals, quality audit, recognition, group problem-
solving, team meetings, decision-making processes, open communication, supportive 
colleagues, and having champions or facilitators (Mulvale, Embrett and Razavi, 2016). 
 
McDonough and Doucette (2001) have devised a model for collaborative working 
relationships between doctors and pharmacists as shown in Figure 9-5. They postulated 
that as the relationship increased, there were more contributions from each party and the 
relationships became stronger (McDonough and Doucette, 2001).  
 
 
Adapted from McDonough and Doucette, 2001, reproduced with permission 
Figure 9-5 Staged Approach to Developing the Pharmacist-Physician Collaborative 
Working Relationship  
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Other authors have also built on this model using qualitative techniques with pharmacists 
and GPs to establish the factors that lead to better collaborative working. They devised a 
more comprehensive list of elements including: locality, service provision, trust, ‘knowing’ 
one another, communication, professional respect and acknowledgement of professional 
roles which affect the pharmacist-GP relationship. They also acknowledged that there is a 
mismatch between the power and status of pharmacists and GPs (Bradley, Ashcroft and 
Noyce, 2012). It takes time and effort to build the sort of collaborative relationships that 
are represented by stage four in Figure 9-5 and Bradley, Ashcroft and Noyce, (2012) have 
highlighted that this is more difficult when pharmacists are working part-time or there is 
regular locum cover in a pharmacy. 
 
It appears that with the increasing complexity of patients and workload of GPs, GPs would 
like the support and assistance of knowledgeable pharmacists, but this can only be 
achieved if GPs trust and value them, both as individuals, and as a profession (Löffler et al., 
2017). 
 
Teams including community pharmacists and GPs should be promoted and the principles of 
improved interprofessional collaboration should be championed as a way of improving how 
the team works for the benefit of patients. Teams should start working on small, 
manageable, pilot projects that will benefit patients in their locality initially, and then move 
on to bigger and more complex issues or wider geographical areas. Localities where 
interprofessional primary care teams have achieved improved patient outcomes should be 
used as examples for other areas to follow; this could be through dissemination of the 
methods and results from the successful implementation of projects such as those that 
have been awarded Health Service Journal or other awards. Pilot collaborative projects 
conducted by researchers and supported by research funding could establish the evidence 
base for what is effective to then allow professional groups to gain financial support from 
the PhIF or CCGs to establish and maintain these schemes in practice.  
 
Interprofessional education and training of pharmacists, doctors and other HCPs already 
occurs at undergraduate level, but postgraduate integrated training and development in 
locality areas would also be beneficial. This should also be promoted through initiatives 
such as Training Hubs where the educational needs of the multi-disciplinary primary care 
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team are met by bringing together different parties such as NHS organisations, local 
authorities and community providers (Health Education England, 2018c). Different areas 
have implemented various projects to enable their teams to work more collaboratively so 
best practice should be shared, to allow other areas to learn from the more well-
established learning hubs. 
 
The role and skills of community pharmacists should be promoted to GPs. This should be 
achieved through the commissioning of pilot programmes focussed on medicines-related 
issues such as: 
• highlighting and implementing best practice in Government documents, for 
example: 
o sending discharge information to a patient’s community pharmacy and/or 
ensuring extra support is available through pharmacist counselling or 
telephone follow-up for discharged patients (NICE, 2015c). 
o the prevention of medicines-related adverse events through the 
implementation of principles from the PINCER study or use of the 
STOPP/START criteria (NICE, 2015c), facilitated by enhanced IT solutions. 
• interprofessional learning, at both undergraduate and postgraduate levels, for 
example: 
o compulsory undergraduate interprofessional training. 
o shared learning from medicines-related patient safety incidents (NICE, 
2015c). 
o using toolkits such as ‘Walk in my shoes’ to identify and collaboratively 
resolve locally agreed medicines-related issues (PSNC, 2017). 
 
RECOMMENDATION 7 
The role and skills of community pharmacists should be promoted to GPs, facilitated by 
regular, personal contact. This should be achieved through the commissioning of pilot 
programmes focussed on medicines-related issues and interprofessional learning. 
Representative organisations, such as the RPS and BMA, should jointly publicise 
successful pilots to their members to aid in the dissemination of best practice. 
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9.3.3 The GP-pharmacist-patient triumvirate  
The success of MURs is not only dependent on collaborative working between the GP and 
community pharmacist; it is a triumvirate that also includes the patient. All three 
individuals need to work together to ensure that the patient is empowered to use their 
medicines effectively and safely to maximise the benefits of the medicines prescribed. For 
this to occur, there must be a partnership between the people involved. This current study 
has shown that on the whole this is not the case; patients are not always willing to fully 
engage with community pharmacists as they perceive that their GP holds the power for 
prescribing and modifying their medicines. They have certain views about the role a 
community pharmacist should play in their care and this generally involved dispensing 
medicines rather than providing advanced services. This was also reflected in what the 
community pharmacists reported when they described how it was difficult to approach and 
recruit patients for MURs and also to engage GPs in the resolution of interventions raised 
during the MUR process.  
 
Patients’ experiences of the interactions between GPs and community pharmacists and 
their perceptions of how each profession views the other also influence which healthcare 
services and sources of information the patient uses and how they access them. The 
patients’ opinion will be framed by their perception of: 
1. the quality of care provided by the different HCPs - when patients reported 
excellent service from their GP, they were more likely to feel that they did not need 
the input of a pharmacist (Hindi, Schafheutle and Jacobs, 2017). 
2. which HCPs perform which tasks - a study of the burden of medicine taking by 
patients with long-term conditions established that 15.7% of patients in the study 
thought their GP did not listen to their opinion about the use of medicines and 
20.6% felt the GP did not give them enough information about the medicines 
(Krska, Katusiime and Corlett, 2018); these ‘gaps’ could be filled by the patient 
consulting their community pharmacist. 
3. the relationship between HCPs - in a survey of 1000 members of the general 
public, nearly three-quarters (73.3%) of respondents said they would prefer to use 
a community pharmacy where the pharmacist had a good relationship with their 
GP surgery (Gammie et al., 2016). Furthermore, if the patient does not think the GP 
promotes or values MURs, they will be less likely to participate in one themselves. 
A RCT of a complex intervention that included GP education, pharmacist 
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medication review and case conferences to identify and resolve medication-related 
problems did not find any significant effect on patient outcomes but 92% of GPs 
and 94% of pharmacists thought the intervention had benefitted patients 
(Sorensen et al., 2004). The high satisfaction rate of both groups of HCPs involved 
in this collaborative intervention would result in all HCPs promoting the service and 
giving patients confidence in the services provided by HCPs other than GPs. 
 
Participants in the patient interview phase of the current study with high and low levels of 
health literacy displayed some of these behaviours, such as some of those with an E-HLOC 
thinking that the GP was supreme or the patient with an I-HLOC who felt that their GP held 
the power to change prescriptions and would want their GP’s approval for any changes in 
medication, hence there was no point seeing the community pharmacist. It appears that 
this viewpoint is not uncommon as patients in other studies have also reported that they 
would want the GP to authorise any recommendations made by a pharmacist (Hindi, 
Schafheutle and Jacobs, 2017). From a qualitative study of GPs and community pharmacists 
working together to manage patients with chronic diseases, it would appear that if GPs had 
experience of beneficial contact with community pharmacists previously, their trust and 
propensity to collaborate in future would be increased (Rieck, 2014). 
 
When patients were asked about which HCP they would use, GPs were mentioned for a 
variety of different reasons. Focus groups with the general public in Scotland found that 
patients trust GPs more than pharmacists and this was based on various factors, including; 
the GP registration and appointment system, the practice environment, and the position of 
the GP at the top of the primary healthcare hierarchy (Gidman, Ward and McGregor, 2012). 
When exploring who the general public would use for advice about medicines-related 
problems, over two thirds of people said they would go to their community pharmacy, but 
25% would go to their GP. The reasons for choosing the GP over the pharmacist were 
because they thought the GP had greater knowledge of them and their health; the 
pharmacist would not be able to help or have the power to change medicines and; the 
expectation that the pharmacist would refer them to the GP anyway (Rodgers et al., 2016). 
 
This section shows that even though pharmacists are highly trained HCPs, they are still not 
perceived to be working at the same level as GPs, and this is evident in the opinions of 
patients, GPs and also themselves. There is still a long way to go to enlighten some GPs and 
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patients about the knowledge and skills that community pharmacists possess and the 
contributions they can make to patient care through the provision of advanced services. In 
the current study 81.2% of community pharmacists thought that GPs should refer patients 
to community pharmacists for a MUR. GPs are not really promoting the MUR service to 
patients so to change these opinions, greater publicity and information about the extended 
role of community pharmacists should be made available to patients and GPs. 
 
RECOMMENDATION 8 
GPs should refer patients for advanced community pharmacy services such as MURs and 
the NMS. When community pharmacists make recommendations to GPs as a result of 
these consultations, GPs should inform both patients and pharmacists of the outcome. 
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9.4 Communication and integration 
9.4.1 Communication 
9.4.1.1 Communication across the primary-secondary care interface 
Effective, timely communication is essential when caring for patients who are making 
transitions from one care setting to another and this is particularly true when patients 
leave hospital and return to primary care. Discharge summaries have been sent to GP 
surgeries electronically since 1 October 2015 (NHS Digital, 2015a), but there are no 
requirements to send this information to community pharmacists. The community 
pharmacists in the current study overwhelmingly thought that they should be included in 
discharge communications, with 89% of respondents thinking they should automatically be 
sent a copy of the discharge summary and 78.8% preferring to receive it electronically. 
Community pharmacists in the US have also expressed a wish to receive information 
electronically at the time of care transitions (Kennelty et al., 2015). 
 
Despite the desire to be party to discharge communications, this is not the case at present; 
the pharmacists who were interviewed said they often did not know that one of their 
regular patients had been in hospital and from the questionnaire it was apparent that 
when they did find out it was often in an impromptu manner with no defined route of 
communication or flow of information. This was also found in a qualitative study of 14 
community pharmacists who reported that they usually found out about an admission 
during an ad hoc conversation with the patient or their representative, and if they did 
receive discharge information, it was generally for patients who were seen as complex 
(Urban et al., 2013). 
 
When patients transition from secondary to primary care, there is inherent risk, particularly 
around medicines. Of the respondents to the questionnaire in the current study, 68.1% 
thought that community pharmacists routinely identified issues relating to patient safety. It 
has been estimated that 1.4% of all medication errors occur when a patient is transferred 
from once care setting to another, and of these 51.6% have the potential to cause 
moderate harm and 7.3% the potential to cause severe harm (Elliott et al., 2018). 
Community pharmacists have been shown to play an important role in identifying 
medicines-related problems when a patient is discharged from hospital (Braund et al., 
2014). In two studies from New Zealand, medicines-related problems were identified 
commonly. In the first study, 18% of patients (n=401) experienced a medicines-related 
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problem and 9% (n=840) of prescription items were affected by a clinical medicines-related 
problem (Maxwell et al., 2013). In the second study, 9% of prescriptions received by 
community pharmacists from secondary care contained an error of omission or incorrect 
information (Braund et al., 2014). In a study conducted by community pharmacists in 
several European countries (excluding the UK), 63.7% of patients experienced a medicines-
related problem on discharge from hospital, with the majority related to patient education. 
Of all medicines-related problems, 24% were due to clinical issues such as interactions or 
dosing queries (Paulino et al., 2004). A study from the Netherlands that analysed 100 
discharge summaries received by a single community pharmacy has also confirmed that the 
higher the number of medicines prescribed, the greater risk of a medicines-related 
problem occurring after hospital discharge (Geurts et al., 2013). 
 
Poor communication across the primary-secondary care interface is not a new issue; in 
fact, there are papers published nearly 30 years ago extolling the need for improved 
discharge communication between hospitals and GP practices. A study published in the 
British Medical Journal in 1992 of patients discharged from a hospital in the north-east of 
England found discrepancies between what medicines the patient should have been taking 
and what they were actually taking after a hospital discharge. The authors suggested that 
better communication was required between the hospital and community (Cochrane et al., 
1992). A study from Scotland, published in 1997, found that 96% of GPs and 94% of 
community pharmacists would like information about changes in medication, but that they 
did not receive them (Munday et al., 1997). 
 
There have been many initiatives over the years that have aimed to solve the problem of 
poor communication across the primary-secondary care interface and improve patient care 
during this transition. Involving community pharmacists in quite simple interventions has 
been shown to have a significant effect on solving medicines-related problems. Nominating 
a community pharmacy has already been mentioned in section 9.3.1. A RCT that studied 
501 patients discharged from one hospital in London found that when patients took a copy 
of their discharge summary to their community pharmacist, there was a statistically 
significant reduction in the number of medication discrepancies (p<0.001) and 
discrepancies that had an adverse effect after discharge (p<0.01) (Duggan et al., 2011). 
Other, more recent initiatives have shown community pharmacists to make a significant 
difference to patient care; this includes the use of PharmOutcomes to send discharge 
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summaries to community pharmacies in north east England, so patients could have a PD-
MUR or a NMS consultation. An evaluation of this system found that those patients who 
had a follow-up consultation with their community pharmacist had a statistically significant 
lower rate of readmission, although in the study only 31% of patients referred actually had 
the community pharmacist’s consultation (Nazar et al., 2016). The Refer-to-Pharmacy 
system that is operational in north west England, is where community pharmacists are 
automatically sent an electronic copy of the patient’s discharge summary, using a 
specifically designed system, to enable them to support patients post-discharge. It has 
been estimated that between October 2015 and April 2018, 100 fewer patients have been 
readmitted to hospital (Randall, 2018). These services comply with the current NICE 
Medicines Optimisation guidelines which state that when patients move from one care 
setting to another, ‘consideration should be made to sending a person's medicines 
discharge information to their nominated community pharmacy, when possible and in 
agreement with the person’ (NICE, 2015c). A system similar to PharmOutcomes and Refer-
to-Pharmacy is in operation in Wales, where patients are referred to community 
pharmacists, or patients can present to the pharmacy with a copy of their hospital 
discharge summary to access a discharge medicines-use review. An evaluation of this 
system found that during a PD-MUR, community pharmacists identified an average of 1.3 
medication discrepancies. It was estimated that the service prevented 1860 readmissions, 
saving the NHS in Wales £3.9million between October 2011 and December 2013 (Hodson 
et al., 2014). 
 
Sending discharge information to community pharmacies and referring patients for 
advanced services is only one factor in the whole process. Studies have highlighted the 
difficulties community pharmacists face when recruiting patients to participate in the 
interventions (PD-MUR or NMS) that they have been referred for. Even though patients 
consent to the sharing of their discharge summaries, once they have been discharged it has 
proved difficult to engage them in the services available (Nazar et al., 2016; Rutter, 
Ramsbottom and Fitzpatrick, 2017). This lack of engagement from patients may underpin 
the fact that in the current study 50% of community pharmacists had not conducted a PD-
MUR in the previous month, and of those who had, the actual number was relatively low 
despite post-discharge patients being on the target list for MURs. 
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As other authors have said, the ultimate aim of sending discharge summaries to community 
pharmacists would be to reduce medication-related problems post-discharge and ensure a 
seamless transition (Urban et al., 2013). A starting point for this would be to make the 
sending of discharge summaries to community pharmacists mandatory in the first instance. 
 
RECOMMENDATION 9 
Patients should nominate a community pharmacy, allowing hospital pharmacy teams to 
automatically inform them, using enhanced IT systems, when a patient is admitted to, or 
discharged from hospital. Community pharmacists should automatically receive a copy of 
the patient’s discharge summary when the patient leaves hospital. 
 
 
9.4.1.2 Access to patients’ medical records 
Community pharmacists in England currently do not have access to the patient’s medical 
record which is held at the GP surgery; this is despite community pharmacists taking clinical 
responsibility for the prescriptions they dispense. This lack of information has potential 
patient safety implications, particularly at the times that patients transfer from one care 
setting to another. When community pharmacists in the current study were asked whether 
they routinely identified major safety issues with patients’ medicines, more than two thirds 
(68.1%) agreed that they did. This is in spite of not having the full clinical information about 
the patient. Likewise, 97.8% of respondents to the questionnaire survey in the current 
study thought that two-way communication between community pharmacists and GPs was 
important and 93.8% of respondents thought two-way communication between 
community and hospital pharmacists was important. The PhIF is prioritising funding to 
‘evaluate the impact of digital technologies on the healthcare system to improve 
efficiencies and modernise’ (NHS England, 2016b). 
 
In the current study, 55% of respondents said that they thought access to the GPs’ medical 
records was required to enable them to conduct a PD-MUR properly. In the US, the lack of 
community pharmacists’ access to the medical records affected the time it took to conduct 
a medicines reconciliation after a hospital discharge (Kennelty et al., 2015). Even patients 
have highlighted that a community pharmacist’s lack of access to medical records, and 
difficulties in communicating with other HCPs would be a barrier to them providing 
advanced services (Hindi, Schafheutle and Jacobs, 2017).  
Chapter Nine | Discussion 
 
 338 
Since 2017, community pharmacies have been able to access the patient’s SCR, which 
provides a read-only version of a portion of the patient’s medical record (PSNC, 2018o).This 
has proven to be useful but further progress is required. 
 
Some authors have suggested that GPs would not want pharmacists to be given access to 
medical records, as this might threaten the GP’s position at the top of the medical 
hierarchy (Hindi, Schafheutle and Jacobs, 2017). This opinion appears to have been 
overridden by the Government, as in 2017 the pharmacy minister gave full support to NHS 
England’s plans to enable community pharmacies to have read and write access to 
patients’ primary care records as soon as possible (Anon, 2018). Furthermore, the RPS is 
targeting community pharmacists’ access to the patient health record as one of their 
current campaigns with support from the Chair of the All-Party Pharmacy group and the 
Royal College of GPs amongst others (The Royal Pharmaceutical Society, 2018). It has been 
acknowledged that this may take time due to constraints, such as differences in IT systems, 
but this is what the NHS is aiming for (Anon, 2018). According to the PSNC, a pilot project 
involving pharmacists having ‘write’ access to the patient’s medical record is underway 
(PSNC, 2018p). 
 
The obvious next step on from this would be read and write access to secondary care 
medical records from those working in primary care and vice versa. This has been 
suggested by other authors (Urban et al., 2013), although it would seem to be an aspiration 
for the future rather than something that could be implemented at the current time. 
 
9.4.1.3 IT solutions 
Getting the right IT systems and ensuring that they integrate and are compatible with 
systems used in other parts of the healthcare system is critical to improving patient care. 
Community pharmacists having access to discharge summaries and the patient’s medical 
record would be beneficial initially, but the long-term aim should be for a patient record 
that all HCPs can access and make entries to, irrespective of whether they are in primary or 
secondary care. In the current study it can be seen that community pharmacists want this, 
as nearly a third of respondents to the survey wanted discharge summaries to 
automatically integrate into their PMR. They highlighted their role in identifying major 
patient safety incidents (although these may not have been specifically due to lack of 
access to information) and during the interviews, they gave examples of situations where 
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they had made fortuitous interventions by chance rather than on a more systematic basis 
with full access to the patient information. 
 
There is some evidence for pharmacy interventions that have relied on electronic means to 
transfer discharge information to community pharmacies. It is not possible to conclude 
whether the success of these interventions has been due to the electronic transmission or 
just the provision of the information, but the results of the following studies provide at 
least some evidence of improved patient outcomes by providing discharge information 
electronically to community pharmacists.  
 
One such study has demonstrated how electronic transmission of discharge information to 
a patient’s community pharmacy can have an effect on hospital readmissions. This paper 
reported the results of a study conducted in north east England that involved the hospital 
pharmacy identifying patients who they thought would benefit from follow-up with a 
community pharmacist after their hospital discharge. Patients consented to a referral from 
the hospital to their usual community pharmacy using the PharmOutcomes system. Of the 
2029 patients that started the study, only 619 (30.5%) completed the process and had a 
consultation with their community pharmacist. The odds of readmission were significantly 
lower in the group of patients who had a follow-up consultation with their community 
pharmacist at 30, 60 and 90 days; for example, the odds ratio for readmission at 30 days 
was 3.1 (95% CI 2.1 – 4.7) (Nazar et al., 2016). Of the referrals made by the hospital, those 
made to multiples were significantly more likely to be completed than for other types of 
pharmacy (Nazar et al., 2016). 
 
As already mentioned in section 9.4.1.1, the Refer-to-Pharmacy electronic discharge 
communication system has been in operation in the north of England since 2015 and 
automatically transfers a patient’s discharge summary to their community pharmacist 
when they have been discharged from hospital. The aim of the referral is to act as a notifier 
to the community pharmacist of the hospital admission, but also to trigger them to 
consider a NMS or PD-MUR for the patient. All patients who consent are referred and there 
is no attempt to identify and target patients at high-risk of a readmission. A qualitative 
study with the pharmacy staff from primary and secondary care who were involved with 
the service found that since the service has been introduced community pharmacists 
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reported they had improved communication with GPs. The pharmacists also felt that the 
service reduced the risk of error and saved time (Ferguson, Seston and Ashcroft, 2018). 
 
Enhanced IT capabilities should be pursued by the all sectors of the NHS; in 2016 
Parliament issued a briefing that said by 2020, NHS England intended to connect electronic 
health records across primary, secondary and social care. It also acknowledged that there 
were ‘a range of technological and organisational challenges to implementation such as 
interoperability, staff training and maintaining the privacy of patient data’ (House of 
Parliament - Parliamentary Office of Science and Technology, 2016). With less than two 








9.4.2.1 Community pharmacists’ integration into the primary care team 
Community pharmacists are part of the primary care healthcare team but do not always 
feel that way. As previously mentioned, cohorts of both patients and GPs think of them as 
purely suppliers of medicines and do not appear to value the training and unique skills they 
possess. Pharmacists have been singled-out as a profession that should be better utilised 
by the NHS to improve patient care, through the use of their knowledge and expertise. This 
strategy, alongside innovations in IT, should be exploited for the benefit of patients. Figure 
9-6 illustrates how community pharmacists could be better integrated into the primary 
care team and summarises how the different sectors should be linked, with facilitation 
from enhanced and improved IT systems allowing the free flow of information. 
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Figure 9-6 Integration of community pharmacists into the primary care team 
 
A study that sought the opinions of community pharmacists, GPs and practice nurses about 
who they viewed as being a member of their multi-disciplinary team (MDT) found that 78% 
of community pharmacists considered themselves to be part of the MDT. This was 
compared to 99% of GPs and 98% of practice nurses who felt they were part of the MDT. 
When GPs and nurses were asked whether they considered community pharmacists to be 
part of their MDT, 56% of GPs and 57% of practices nurses thought they were. This was 
mainly due to GPs and nurses having little contact with community pharmacists and some 
viewed them as being situated outside the NHS or being business-focussed (Weiss et al., 
2018). 
 
In the current study, the community pharmacists who were interviewed wanted to be 
more integrated into the primary care team. From the survey, community pharmacists 
working in rural areas thought they were best suited to providing PD-MURs. It could be 
postulated that this was because they felt more integrated and had better relationships 
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with other members of the primary care team compared to pharmacists working in urban 
areas. It was also shown in the study from Germany that community pharmacists working 
in rural areas had more positive interactions with GPs than those working in urban areas. 
This was attributed to long-lasting working relationships based on trust and mutual 
esteem. In contrast, pharmacists working in urban areas often did not know the GPs they 
were speaking to (Löffler et al., 2017). 
 
Patients appear to be confused about how the services offered by community pharmacists 
‘fit’ into their journey through the NHS, and this confusion over care pathways also needs 
to be addressed. Although encouragingly, in the current study nearly three-quarters 
(73.8%) of the community pharmacists surveyed thought that patients were willing to 
discuss post-discharge medication-related issues with them. In some studies, despite 
confidence in the community pharmacists’ skills and an initial boost in their professional 
profile, there were still reservations about how the services they provided fitted into the 
overall primary care offering. In one study patients reported that community pharmacists 
were skilled healthcare professionals with the ability to provide medicines-related 
information, but there was confusion about how the services they provided integrated with 
those provided by the GP (Hall, Donovan and Wilkes, 2018). A study published in 2008, 
three years after the introduction of MURs, found that community pharmacists in the north 
of England providing the MUR service felt their profile had been raised in the eyes of 
patients and patients were more confident in them since the introduction of MURs (Urban, 
Rivers and Morgan, 2008). From the patient’s point of view, it appears that even after more 
than a decade of community pharmacists providing MURs, still more work is required to 
establish the place of pharmacists and MURs in practice. It seems that these early 
indications of a change in perception of community pharmacists may not have come to 
fruition. 
 
The NHS Five Year Forward View, published in 2014, set out the vision of the future of the 
NHS in England. This was based on the key assumptions that the NHS should continue to be 
funded by taxation, free at the point of use and able to meet the needs of the population 
(NHS England, 2014). One of the overarching aims was that the NHS should focus on 
providing high quality services to fulfil the needs of patients; this must be done against a 
background of efficiency savings and increasing demands on NHS services year-on-year. 
Several different ways of achieving this aim were suggested, including more integrated 
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systems that bridged primary and secondary care and more innovative ways of working 
(NHS England, 2014; The Royal Phamaceutical Society, 2014). 
 
The RPS briefed pharmacists and encouraged them to get involved in these new care 
models, engage with the NHS sustainability and transformation plans (that were a 
requirement of the Five Year Forward View) and take advantage of these new 
opportunities in primary care (The Royal Phamaceutical Society, 2014). Community 
Pharmacy organisations responded to the Five Year Forward View with a report called 
Community Pharmacy Forward View which suggested that: 
‘Pharmacies should be operating as part of integrated primary care 
networks; their staff meeting regularly with GP practice teams to align 
and monitor their approach to medicines optimisation.’ 
(Pharmacy Voice, 2016) 
Health Education England is also working with NHS England to ensure that the pharmacy 
workforce is able to provide these new integrated services in the future. Pharmacists and 
pharmacy technicians need to have the clinical skills to provide high-quality patient care as 
part of the multi-disciplinary primary care team (Health Education England, 2018a). 
 
A systematic review looking at collaboration between GPs and pharmacists and 
implementation of suggestions following medication reviews found that the better the GP-
pharmacist relationship, the more interventions that were effected (Kwint et al., 2013). 
Other authors have suggested facilitators for effective medication reviews, such as an 
established relationship between the pharmacist and GP and having meetings in person to 
discuss the outcomes of the medication reviews (Kwint et al., 2013). A systematic review 
and qualitative study with the general public has also found that if GPs demonstrate their 
confidence in pharmacists’ skills and endorse the advanced services they provide, patients 
trust in them would be increased and they would partake in their services more frequently 
(Gidman, Ward and McGregor, 2012; Hindi, Schafheutle and Jacobs, 2017).  
 
Some authors have suggested that by extending the role of the community pharmacist 
there will be a variety of benefits such as reducing the burden on GPs, increasing the 
professional profile of community pharmacists, improving patient outcomes and increasing 
patient satisfaction (Hall, Donovan and Wilkes, 2018). Community pharmacists need to 
capitalise on these opportunities and the result will be better satisfaction with their role, 
Chapter Nine | Discussion 
 
 344 
greater acceptance by patents and GPs and therefore enhanced integration into the 
primary care team. Recommendation 8 has already highlighted the necessity for good 
teamwork from all members of the primary care team. 
 
9.4.2.2 Practice pharmacists 
In the current study of community pharmacists, 57.3% of respondents thought that the 
HCP best suited to conducting a post-discharge review of a patient’s medicines was either a 
pharmacist specifically employed to care for patients during their transfer of care or a 
practice pharmacist. Only 24.5% of respondents thought that community pharmacists were 
best placed for that task. Community pharmacists feel that they do have the expertise to 
conduct PD-MURs but the difficulties of providing the service, such as lack of time, 
problems identifying patients and the flat rate of remuneration, hamper these efforts. 
Practice pharmacists are in a better position to provide post-discharge medication reviews 
due to their location, use of an appointment system, access to information and the ability 
to update prescriptions. 
 
The increase in GP surgeries having pharmacists as part of their core team stems from a 
pilot scheme announced in 2015 to encourage GP practices to employ clinical pharmacists 
by providing £15 million of funding (NHS England, 2015b). By November 2015 this funding 
was doubled to £31 million due to the demand from GP surgeries (Torjesen, 2015). The 
General Practice Forward View report, published in 2016, suggested several ways to 
address the workload issues facing GPs. The report stated that: 
‘Pharmacists remain one of the most underutilised professional 
resources in the system and we must bring their considerable skills in to 
play more fully.’ 
(NHS England, 2016a) 
By 2020/2021 there will be an extra 1500 pharmacists working in general practice due to 
£100 million funding announced in 2016 after the successful pilot (Kmietowicz, 2016). An 
analysis of the effectiveness of pharmacists working in GP practices was published in 2018; 
it noted that there was better collaboration between pharmacists and GPs when they 
worked in the same location and the pharmacist had access to the patient’s medical 
record. To ensure that pharmacists were integrated into the primary care team, they 
needed to be ‘visible, communicate well and be flexible and innovative’ as well as 
adaptable to the practice environment they found themselves working in (Mann et al., 
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2018). After the pilot period is completed, GP surgeries or clusters of surgeries will be 
required to fund these clinical pharmacist posts themselves (NHS England, 2015a).  
 
The involvement of practice pharmacists in caring for patients after hospital discharge and 
conducting medication reviews for them, is endorsed by the RPS as one of the key 
medicines optimisation functions of pharmacists working in GP surgeries (The Royal 
Pharmaceutical Society, 2014; The Royal Phamaceutical Society, 2016). Furthermore, the 
evaluation of pharmacists working in GP practices in England found that 63% of practice 
pharmacists were involved in post-discharge medicines reconciliation on a daily basis and 
21% involved several times a week (Mann et al., 2018). 
 
There is good evidence that pharmacists working in GP surgeries can have an impact on 
patient care. A systematic review and meta-analysis of pharmacist services provided in 
general practice clinics found that the majority of studies included interventions that 
involved medication review by pharmacists, either face-to-face or using the patient’s 
records. The meta-analysis showed that interventions delivered by the pharmacists 
resulted in statistically significant improvements in blood pressure, glycosylated 
haemoglobin, cholesterol and Framingham risk score. The authors stated that the review 
showed the benefit of pharmacists working in the same location as GPs. Medication 
reviews were more effective when they were followed by a face-to-face discussion 
between the pharmacist and GP and even more benefit was seen if the pharmacist also 
offered additional services such as providing adherence assessments, lifestyle advice or 
adjusting medications for the patient. There was no evidence for any effect on ‘hard 
outcomes’ such as morbidity or mortality (Tan et al., 2014). And some GPs appear to like 
having pharmacists available to provide input to patient care; a recently published study of 
pharmacists providing medication reviews in the GP surgery or patient’s homes in Iceland 
found that once GPs had experience of where pharmacists could add value to patient care, 
they wanted access to their skills on a daily basis (Blondal, Sporrong and Almarsdottir, 
2017). 
 
Practice-based pharmacists or pharmacists specifically involved when patients transfer 
from one setting to another could also look to IMM programmes for evidence of the 
efficacy of pharmacists during transfer of care. An evaluation of an IMM programme in 
London offering personalised pharmaceutical care, working across boundaries and 
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including post-discharge follow-up found a statistically significant reduction in preventable 
medicines-related readmissions to hospital, with only two out of 744 patients who 
participated in the intervention being admitted to hospital with a preventable medicines-
related readmission. For every £1 spent on running the scheme, £3 was saved by the health 
economy (Barnett et al., 2016). In Northern Ireland, a scheme which involved the free flow 
of information between hospital doctors, hospital pharmacists, GPs and community 
pharmacists (the discharge summary was posted to the GP and the community 
pharmacist), found that the intervention reduced the length of stay by 5.86 days if patients 
were readmitted (p=0.013). The study also showed that the number of readmissions was 
reduced and the time from the first admission to a readmission was lengthened, although 
these results were not statistically significant (Scullin et al., 2011). IMM schemes have also 
been shown to be effective in other countries such as Sweden, Norway and the 
Netherlands (Barnett, 2016). 
 
The findings of the current study suggest that practice pharmacists should complete an 
initial medication review and medicines reconciliation with the patient when they have 
been discharged from hospital. This should ideally be completed with the patient at the GP 
surgery. This does not mean that community pharmacists should not be involved in 
medication review for patients after a hospital discharge; in fact, there is plenty of scope 
for their input. After a practice pharmacist has conducted a post-discharge medication 
review and updated the patient’s prescription template on the practice computer system, 
the details of this consultation should be available to all members of the primary care 
team, including the community pharmacist. The community pharmacist can ensure the 
patient collects the correct medicines for their first dispensing after discharge and continue 
the education and support of the patient with their new medication regime. This could be 
in the form of a FD-MUR. Ideally, this scenario should involve two-way communication 
between the GP surgery and community pharmacy, read and write access to the patient’s 
clinical record and endorsement of the service from the GP team. The evaluation of clinical 
pharmacists working in GP surgeries in England found evidence that they could work with 
community pharmacists and increase their collaboration through the use of examples of 
good practice and innovation (Mann et al., 2018). 
 
There are several advantages to the practice pharmacist conducting this initial medication 
review with post-discharge patients. They have access to the information required, are able 
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to adjust the clinical record, can provide the service within the GP surgery, can update the 
repeat medicines template and they operate using an appointment-based system which 
not only allocates time for these processes but also seems to give more authority to the 
pharmacist conducting the review. One systematic review found that it took community 
pharmacists on average 45 minutes to complete a medicines reconciliation for a patient 
who had been discharged from hospital (Geurts et al., 2013); this would prove difficult to 
deliver in a busy community pharmacy, especially if only one pharmacist was available. 
 
As noted previously in this chapter, for some patients getting to the GP surgery after their 
hospital discharge may be difficult, so a domiciliary visit from the practice pharmacist 
would overcome this potential barrier. Within the current framework for providing MURs 
there is limited scope for community pharmacists to provide a domiciliary service as it 
requires specific agreement from NHS England (PSNC, 2018c), but practice pharmacists do 
not have the same constraints. 
 
The views of patients towards having a consultation with the pharmacist must also be 
considered. In the current study there were definite reservations from patients in engaging 
with a service from a community pharmacist, including how this would impact on the 
relationship with their GP. A qualitative synthesis of studies that explored the role of 
community pharmacists found that patients did not want to harm their relationship with 
their GP and this made them apprehensive about engaging in an advanced service with a 
community pharmacist without endorsement from the GP (Hall, Donovan and Wilkes, 
2018). From the patients’ point-of-view, the co-location of practice-based pharmacists in 
the GP surgery may provide an unconscious endorsement of the service by the GP. This 
gives the practice pharmacist an opportunity to provide these services to patients who 
would not attend a community pharmacy for a MUR or PD-MUR. Also, the ability of 
practice pharmacists to conduct domiciliary visits as discussed in section 9.3.1.3 is an added 
advantage. 
 
Medication review and medicines reconciliation are vitally important for patients after a 
hospital discharge. The findings of the current study suggest that pharmacists have the 
unique skills to conduct these tasks and embedding them into the package of ‘standard 
care’ for patients who have been in hospital would benefit not only patients but also GPs 
and the whole healthcare system. 




9.4.2.3 The next steps to integration: The ‘hybrid’ pharmacist 
Pharmacists in the current study were prepared to use opportunities to work in different 
ways to improve patient care. One such transformation would be in the way that 
pharmacists care for patients in the community and support them to use their medicines 
most effectively. Community and practice pharmacists are equally important for the future 
of the NHS in the provision of medicines-related expertise, but there are geographical, 
professional and other barriers that currently exist. These could be overcome to some 
extent, through a novel model of pharmaceutical care provided by a ‘hybrid’ pharmacist. 
  






















Figure 9-7 The Hybrid Pharmacist Model 
 
The hybrid pharmacist’s role would encompass tasks that have been traditionally provided 
by community pharmacists and more recently by practice pharmacists. It would be 
anticipated that pharmacists working in a hybrid role would work across the GP-community 
pharmacy boundary by spending time in each location caring for a group of patients who 
require more intensive support with their medicines. In reality this cohort of patients are 
likely to be older, have one or more long-term conditions and would be dealing with 
complex medication regimes, or a combination of these factors. The hybrid pharmacist 
would provide medicines expertise and continuity of care to ensure that this group of 
patients received personalised care, tailored to their needs and delivered by the same 
person at both the GP surgery and community pharmacy. To facilitate this model, 
commissioning and funding would need to be revised to focus on individualised, holistic 
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how hybrid pharmacists would benefit patients, rather than concentrating on the more 
traditional pharmacy functions of supplying medicines or medication review. 
 
Pharmacists working in hybrid roles could work on specific days in the GP surgery or 
surgeries, and community pharmacy. They would have a case-load of patients to care for 
who they would see on an appointment basis in the GP surgery and then oversee the 
supplies of their medicines in the community pharmacy. The patients would also be able to 
access their advice and support outside of these set times, with the aim of facilitating 
joined-up care for the patient in the primary care environment. The hybrid pharmacist 
would have access to the patients’ records at both the GP surgery and community 
pharmacy and have the ability to write in these records as necessary. Importantly, hybrid 
pharmacists would be independent prescribers which would allow them not only to update 
the prescriptions in the GP surgery but also to adjust patients’ medication regimes as 
required to gain the best health outcomes for the patients they care for. Their role would 
be supported by the GP who would coordinate patients’ care with the hybrid pharmacist. 
Pharmacists working in hybrid roles would most likely have already been working with the 
GP practice as a practice, CCG or community pharmacist and have built a good working 
relationships with other HCPs in the locality, rather than someone completely new to that 
particular primary care team. The roles and responsibilities of hybrid pharmacists may grow 
organically and differ between localities based on the patient population and needs of the 
patients. Pharmacists who had completed their pre-registration training in cross-sector 
placements that included community pharmacies and GP surgeries would be ideally placed 
to work in these roles. The overall aim of this model would be to reduce medicines-related 
problems, particularly medicines-related hospital admissions. This model would require a 
funded pilot to establish how it could work in practice. 
 
This concludes the discussion of the findings. Figure 9-8 shows the main themes of the 
discussion and the interlinked relationships between them. It highlights the current and 
potential scenarios for pharmacists working in community pharmacy/primary care. 
 













Nowhere in England 
has fully integrated IT 
solutions that allow 
read and write access 
for all HCPs, and 
automatic integration 
between primary and 
secondary care 
systems. 
In some areas this is 
the best scenario at 
the current time: 
community 
pharmacists are 
recognised as the 
experts in medicines 
by patients and GPs 
and have good 
relationships with 
both. 
The ideal situation: community 
pharmacists are fully accepted members of 
the primary healthcare team, experiencing 
good relationships with patients and other 
HCPs, supported by completely integrated 
records that are accessible and have input 
from all HCPs in primary and secondary 
care. 
Without good 
relationships and fully 
functioning IT 
systems, community 
pharmacists have the 
expertise, but others 
are not able to 
benefit fully from it. 
Practice pharmacists are 
closest to the ideal situation 
as they are integrated into the 
GP practice, have access to 
patients’ medical records and 
the expertise of their 
pharmacy training. 
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9.5 Strengths and Limitations  
The strengths and limitations of each phase of the study have already been discussed in 
previous sections; section 5.5 for the HES data study, 6.4 for the patient interviews, 7.5 for 
the pharmacist interviews and 8.9 for the pharmacist survey. They have not been restated 
here, but the strengths and limitations of the study as a whole are included in this section. 
 
The rationale for choosing mixed methods has already been presented in section 4.2.2.1 
and this study has exploited the benefits of using both qualitative and quantitative 
techniques. The use of the sequential exploratory strategy meant that the results of the 
qualitative phases of the study were used to guide and develop the quantitative tool, 
ensuring that the questions asked were relevant to both the population and topic being 
studied. This ensured that the study was always rooted in the attitudes and experiences of 
the people involved, rather than relying on the prior knowledge or assumptions of the PI. If 
the questionnaire had been designed without the initial qualitative phase, it would not 
have asked the right questions to gain a full understanding of the experiences of the 
patients and pharmacists involved. The qualitative interviews allowed the quantitative data 
from the survey to be contextualised which gave them greater meaning and enabled more 
robust recommendations to be made. 
 
The results of the various phases of the study enabled triangulation of the findings. From 
the patient interviews, pharmacist interviews and survey, the themes of relationships, 
expertise, and communication and integration were all present. Patients and community 
pharmacists talked about these aspects from different perspectives, but the assimilation 
and integration of these findings strengthened the rationale for the recommendations. 
 
This study used novel approaches that do not appear to have been previously described in 
the published literature. One distinctive factor that underpinned the whole research study 
was the use of the patients’ experiences as the driver for the study. This was to ensure that 
patients were at the heart of the research and guaranteed that their voice was heard. 
Indeed, it is becoming more common for quantitative studies focussed on patient 
outcomes to include qualitative techniques to also research patients’ experiences (Liabo et 
al., 2018). The use of IPA as the method of analysing the patient interviews, again 
enshrined the patient and their experiences at the heart of the study. Finally, the use of 
factor analysis to discern the attitudes of community pharmacists towards their role in 
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supporting patients and analysing the responses according to their personal and 
demographic characteristics. 
 
The limitations of mixed methods research generally occur during the planning and 
fieldwork stages. Mixed methods studies tend to be more time consuming and complex to 
conduct due to the collection and analyses of two types of data. This was true for this 
study; considerable time and effort was required not only for the planning and execution of 
the fieldwork but also for the thought required to present and discuss each phase of the 
study and then interpret and contextualise the findings as a whole.  
 
9.6 Areas for future research 
The discussion chapter has already drawn attention to several areas where future research 
should focus. These are listed here for clarity. 
• A RCT is required with multiple arms to compare the outcomes for patients who 
receive various levels of pharmaceutical support from pharmacists in different 
settings after hospital discharge. This RCT should compare outcomes such as 
hospital readmission rates, medicines-related ADRs, morbidity and mortality. 
Patients should be allocated to various groups including standard care; medicines 
reconciliation and medication review with a practice pharmacist followed by a FD-
MUR with a community pharmacist; a PD-MUR from a community pharmacist 
alone or a medication review by a practice-based pharmacist alone. This study 
would need to recruit several thousand patients to gain sufficient outcome data to 
show which model of care is most effective. An economic evaluation should also be 
conducted alongside the RCT to ascertain which model is most cost-effective. 
• The role of hybrid pharmacists working in GP surgeries and community pharmacies 
could be explored further through a commissioned pilot study and evaluation. The 
aim would be to establish whether providing co-ordinated care in this manner 
would benefit specific groups of patients who require additional support to 
manage their medicines. 
• A trial of alternative funding for post-discharge medicines support is required to 
ascertain whether a QOF-type arrangement for practice and community 
pharmacists would work in practice. 
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• An evaluation of post-graduate interprofessional learning and collaborative 
working is required to determine best practice for HCPs and beneficial outcomes 
for patients. 
 
9.7 Summary of the Discussion chapter 
This chapter has brought the findings of the various stages of the fieldwork together and 
presented them in the context of the published literature. The findings from all phases of 
the current study have been discussed under the themes of: expertise, relationships and, 
communication and integration. Figure 9-8 showed the interlinked nature of these themes, 
the position of HCPs working in the NHS in England at the current time, and where the NHS 
should be aiming in the future.  
 
Chapter 10 will state the recommendations of the study and draw the thesis to a close. 
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This chapter will present the conclusions and recommendations of the study. 
 
10.1 Conclusions 
This multi-phase study has explored the knowledge and attitudes of patients and community 
pharmacists about post-discharge medicines support, focussing especially on medication 
reviews. The findings have demonstrated an imperfect service with the potential for 
improvements that would benefit not only patients but also the pharmacists that care for 
them. 
 
For patients, their locus of control, level of health literacy and other more practical issues, such 
as their mobility, affect whether they access the services provided by their community 
pharmacist. Patients need to be educated about the provision of advanced services that are 
available from community pharmacies after hospital discharge. The remuneration and target-
based MUR quota system should be revised so that community pharmacists are rewarded 
differently; perhaps in a similar manner to GPs working within the QOF system, thus 
acknowledging their level of expertise. 
 
There are also community pharmacist specific factors that affect their willingness to engage all 
patients in advanced services. It is imperative that the hospital discharge process includes 
community pharmacists and their contribution is embedded in the system. This could happen 
in a number of ways and would provide a clear signal to patients that community pharmacists 
are integral to patient support and safety at the time of hospital discharge. 
 
IT solutions are vital to enable community pharmacists to become more involved in post-
discharge patient care. The ability of community pharmacists to access the patient’s medical 
record and discharge information is imperative to the NHS exploiting the unique skills of 
community pharmacists. 
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Recommendations have been made, based on the findings of the current study. These can be 
used by pharmacy organisations, representative bodies, policy-makers and the NHS to 
promote and encourage the use of pharmacists and their unique skills to benefit patients in 




The rationale for the recommendations of the research have been presented in Chapter 9. 
They are presented here as a numbered list for clarity. 
1. A practice pharmacist should conduct medicines reconciliation and medication review, 
in the practice or at the patient’s home, as soon as possible after hospital discharge. 
Details of the review should be shared electronically with the patient’s community 
pharmacist. Patients should have a ‘first-dispensing’ MUR conducted by a community 
pharmacist, to check their use and understanding of their medicines when they collect 
their first prescription after they have been discharged from hospital. 
2. Community pharmacists should use their specialised knowledge of high-risk medicines, 
information about whether their patient has recently been in hospital and an 
awareness of those who experience the greatest burden of medicine-taking to 
prioritise patients for MURs. This should be facilitated by currently available IT 
solutions, and in the future, should be fully integrated across different healthcare 
providers. 
3. Community pharmacists should access the Pharmacy Integration Fund to finance 
formal and informal training, to increase their skills in caring for post-discharge 
patients. The Fund should also be used to promote innovative ways of working, by 
commissioning direct services from pharmacists such as first-dispensing MURs or 
developing IT solutions to facilitate the integration of pharmacy and GP IT systems. 
4. Remuneration for post-discharge medication reviews and support by community or 
practice pharmacists should be based on the proportion of discharged patients (on 
four or more medicines) who have their medicines reconciled and, are offered further 
advice and support with their medicines. This should be done in a similar manner to 
the GP QOF system. 
5. Community pharmacists should use the guidance contained in the NICE clinical 
guideline on medicines adherence (NICE, 2009) to engage with patients to determine 
the amount, depth and level of information they need according to their health beliefs 
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and level of health literacy. This would empower patients to gain the most benefit 
from their medicines. 
6. The role and skills of community pharmacists should be promoted to patients through 
advertising, word of mouth, endorsement from other HCPs and commissioning of 
novel services, such as first-dispensing MURs. Community pharmacists should be seen 
as the first ‘port of call’ for patients who require assistance with any aspect of 
managing their medicines. 
7. The role and skills of community pharmacists should be promoted to GPs, facilitated 
by regular, personal contact. This should be achieved through the commissioning of 
pilot programmes focussed on medicines-related issues and interprofessional learning. 
Representative organisations, such as the RPS and BMA, should jointly publicise 
successful pilots to their members to aid in the dissemination of best practice. 
8. GPs should refer patients for advanced community pharmacy services such as MURs 
and the NMS. When community pharmacists make recommendations to GPs as a 
result of these consultations, GPs should inform both patients and pharmacists of the 
outcome. 
9. Patients should nominate a community pharmacy, allowing hospital pharmacy teams 
to automatically inform them, using enhanced IT systems, when a patient is admitted 
to, or discharged from hospital. Community pharmacists should automatically receive 
a copy of the patient’s discharge summary when the patient leaves hospital. 
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12.1 Literature searches for medicines-related hospital admissions 
The search terms detailed in Table 12-1 were used to find published papers that focussed on 
medicines-related hospital admissions. The search was carried out in Medline (1946 – March 
2013), Embase (1980 – March 2013) and CINAHL (1981 – March 2013) with email updates 
when new papers were published that fulfilled the search criteria. The abstracts of the papers 
were reviewed and the full text of papers of interest obtained. The reference lists of useful 
papers were also searched for further relevant literature. 
 
Table 12-1- Search terms used to find published papers focussing on medicines-related 
hospital admissions 
1 ("drug induced" OR "drug related").ti,ab 
2 ("medic* induced" OR "medic* related").ti,ab 
3 iatrogenic.ti,ab 
4 “adverse event”.ti,ab 
5 1 OR 2 OR 3 OR 4 
6 (readmission* OR rehospitali*).ti,ab 
7 5 AND 6 
af = all fields; ti = title; ab = abstract 
 
12.2 Literature searches for medication review 
The search terms detailed in Table 12-2 were used in the systematic review by Geurts et al., 
(2012) and were used in the current study to search both Medline (1946 – November 2013) 
and Embase (1980 – November 2013) with email updates when new papers were published 
that fulfilled the search criteria. The abstracts of the papers were reviewed and the full text of 
papers of interest obtained. The reference lists of useful papers were also searched for further 
relevant literature. 
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Table 12-2 - Search terms used to find published papers focussing on medication review 
1 PHARMACISTS 
2 PHARMACEUTICAL SERVICES 
3 “pharmaceutical care”.af 
4 “pharmaceutical service*”.af 
5 pharmacists.af 
6 pharmacist.af 
7 “pharmaceutical practice*”.af 
8 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 
9 PHYSICIANS, FAMILY/ 
10 FAMILY PRACTICE/ 
11 “family practice”.ti,ab 
12 “general practice”.ti,ab 
13 “general practitioner”.ti,ab 
14 “family practitioner”.ti,ab 
15 9 OR 10 OR 11 OR 12 OR 13 OR 14 
16 PATIENT CARE/ 
17 INTERPROFESSIONAL RELATIONS/ 
18 cooperation.af 
19 REFERRAL AND CONSULTATION/ 
20 consultation.af 
21 “patient care”.af 
22 review*.ti,ab 
23 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 
24 (medical AND record*).ti,ab 
25 (prescription AND record*).ti,ab 
26 “pharmaceutical care”.ti,ab 
27 medication.ti,ab 
28 24 OR 25 OR 26 OR 27 
29 8 AND 15 AND 23 AND 28 
af = all fields; ti = title; ab = abstract 
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Table 14-1 ICD-10 codes indicating a medicines-related admission 
ICD-10 chapters 4 Character Diagnoses 
D Drug-induced anaemia D52.1 Drug-induced folate deficiency anaemia 
  D59.0 Drug-induced autoimmune haemolytic anaemia 
  D59.2 Drug-induced nonautoimmune haemolytic anaemia 
  D61.1 Drug-induced aplastic anaemia 
E Endocrine, nutritional and 
metabolic diseases 
E03.2 Hypothyroidism due to medicaments and other exogenous 
substances 
  E06.4 Drug-induced thyroiditis 
  E16.0 Drug-induced hypoglycaemia without coma 
  E23.1 Drug-induced hypopituitarism 
  E24.2 Drug-induced Cushing's syndrome 
  E27.3 Drug-induced adrenocortical insufficiency 
  E66.1 Drug-induced obesity 
F Mental and behavioural 
disorders 
F13  Mental and behavioural disorders due to use of sedatives or 
hypnotics 
  F19 Mental and behavioural disorders due to multiple drug use and 
use of other psychoactive substances 
G Diseases of the nervous 
system 
G21.0 Malignant neuroleptic syndrome 
  G21.1 Other drug-induced secondary parkinsonism 
  G24.0 Drug-induced dystonia 
  G25.1 Drug-induced tremor 
  G25.4 Drug-induced chorea 
  G25.6 Drug-induced tics 
  G44.4 Drug-induced headache, not elsewhere classified 
  G62.0 Drug-induced polyneuropathy 
  G72.0 Drug-induced myopathy 
H Diseases of the eye and 
ears 
H26.3 Drug-induced cataract 
  H91.0 Ototoxic hearing loss 
I   Diseases of the circulatory 
system 
I42.7 Cardiomyopathy due to drugs and other external agents 
  I95.2 Hypotension due to drugs 
J Diseases of the respiratory 
system 
J70.2 Acute drug-induced interstitial lung disorders 
  J70.3 Chronic drug-induced interstitial lung disorders 
  J70.4 Drug-induced interstitial lung disorders, unspecified 
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K Diseases of the digestive 
system 
K71 Toxic liver disease 
L Diseases of the skin and 
subcutaneous tissue 
L23.3 Allergic contact dermatitis due to drugs in contact with the skin 
  L24.4 Irritant contact dermatitis due to drugs in contact with the skin 
  L25.1 Unspecified contact dermatitis due to drugs in contact with the 
skin 
  L27.0 Generalized skin eruptions due to drugs and medicaments 
  L27.1 Localized skin eruptions due to drugs and medicaments 
  L51.2 Toxic epidermal necrolysis (Lyell's Syndrome) 
  L56.0 Drug phototoxic response 
  L56.1 Drug photoallergic response 
M Diseases of the 
musculoskeletal system 
and connective tissue 
M02.2 Postimmunization arthropathy 
  M10.2 Drug-induced gout 
  M32.0 Drug-induced systemic lupus erythematosus 
  M34.2 Systemic sclerosis induced by drugs or chemicals 
  M80.4 Drug-induced osteoporosis with pathological fracture 
  M81.4 Drug-induced osteoporosis without pathological fracture 
  M83.5 Other drug-induced osteomalacia in adults 
  M87.1 Osteonecrosis due to drugs 
N Diseases of the 
genitourinary system 
N14.1 Nephropathy induced by other drugs, medicaments and 
biological substances 
  N14.2 Nephropathy induced by unspecified drugs, medicaments and 
biological substances 
T Injuries and consequences 
of external causes 
T80.5 Complications following infusion, transfusion and therapeutic 
injection: anaphylactic shock due to serum 
  T80.6 Complications following infusion, transfusion and therapeutic 
injection: other serum reactions 
  T80.8 Other complications following infusion, transfusion or 
therapeutic injection 
  T80.9 Unspecified complication following infusion, transfusion or 
therapeutic injection 
  T88.0 Infection following immunization 
  T88.1 Infection complication following immunization 
  T88.2 Shock due to anaesthesia 
  T88.3 Malignant hyperthermia due to anaesthesia 
  T88.6 Anaphylactic shock due to adverse effect of correct drug or 
medicament properly administered 
  T88.7 Unspecified adverse event of drug or medicament 
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Table 14-2 ICD-10 codes indicating an external cause of a medicines-related admission 
Y40 Systemic antibiotics 
Y41 Other systemic anti-infectives and antiparasitics 
Y42 Hormones and their synthetic substitutes and antagonists 
Y43 Primarily systemic agents 
Y44 Agents primarily affecting blood constituents 
Y45 Analgesics, antipyretics and anti-inflammatory drugs 
Y46 Antiepileptics and Anti-Parkinsonism drugs 
Y47 Sedatives, hypnotics and anti-anxiety drugs 
Y48 Anaesthetics and therapeutic gases 
Y49 Psychotropic drugs, not elsewhere categorised 
Y50 Central nervous system stimulants, not elsewhere classified 
Y51 Drugs primarily affecting the autonomic nervous system 
Y52 Agents primarily affecting the cardiovascular system 
Y53 Agents primarily affecting the gastrointestinal system 
Y54 Agents primarily affecting the water-balance and mineral and uric acid system 
Y55 Agents primarily acting on smooth and skeletal muscle and respiratory system 
Y56 Topical agent primarily affecting skin and mucous membranes and ophthalmological, otorhinolaryngological and dental drugs 
Y57 Other and unspecified drugs and medicaments 
Y58 Bacterial vaccines 
Y59 Other and unspecified vaccines and biological substance 
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15.1 Email to hospital pharmacists at GRH publicising the study 
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15.2 Poster displayed in pharmacy department and on wards publicising the study 
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15.3 One-page resume of study for HCPs recruiting patients for the study 
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15.4 Patient information sheet (supplied in booklet format) 
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15.5 Patient consent form 
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15.7 Out-patient interview topic guide 
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15.8 Community pharmacist information sheet 
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15.9 Community pharmacist consent form 
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15.10 Community pharmacist interview topic guide 
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If respondents answered ‘No’ to 
this question, they were directed 
to the thank you page at the end 
of the questionnaire and were not 
eligible to complete the survey. 
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If respondents answered ‘Yes’ to 
this question, they were directed 
to the thank you page at the end 
of the questionnaire and were 
not asked questions about their 
regular pharmacy. 
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15.12 Screenshots of publicity on PSNC website 
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15.13 Email to community pharmacists sent by the PDA 
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16.1 Patient interviews: Thematic analysis photograph 
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16.2 Community Pharmacist Survey: Plan of statistical tests 
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17.1 Presentation abstracts 
17.1.1 Health Services Research and Pharmacy Practice Conference 2016 
Oral presentation at the University of Reading, 7-8 April 2016 
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17.1.2 Health Services Research and Pharmacy Practice Conference 2017 
Oral presentation at the University of Nottingham, 10-11 April 2017 
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17.1.3 Health Services Research and Pharmacy Practice Conference 2019 
Oral presentation at the University of Birmingham, 8-9 April 2019 (in press) 
Improving communication across the primary-secondary care interface: a survey of the attitudes and 
experiences of community pharmacists in England 
Veeren, JCa,b; Rogersa, PJ; Taylora, ADJ; Weiss, Ma 
aUniversity of Bath, UK 




Transitions of care, such as when patients are discharged from hospital, are a high-risk time. Errors or 
discrepancies in medication affect 30-70% of patients during these tranitions1  and the cost to the NHS 
of post-discharge medication-related harm in older adults is an estimated £396 million per 
year.2  Community pharmacists are in an ideal position to support patients during these transitions. 
Aims 
The aim of the survey was to determine the attitudes and experiences of community pharmacists 
providing the Medicines Use Review (MUR) service in England, with an emphasis on the provision of 
discharge medicines support. 
Methods 
A questionnaire was designed based on interviews with patients (n=7) who had been admitted to 
hospital with a medicines-related problem, interviews with community pharmacists who provided the 
MUR service in England (n=5) and a review of the literature. It was piloted with academic pharmacists 
and community pharmacists. The questionnaire contained a variety of attitudinal statements that were 
measured using Likert scale responses and factual questions about the community pharmacists 
themselves, their pharmacy and their provision of MURs. The questionnaire was completed 
electronically by 495 community pharmacists in England. As they were recruited via professional 
networks and social media, it was not possible to determine the response rate. The responses to the 
questionnaire were analysed with IBM SPSS Statistics, version 24, using descriptive statistics and non-
parametric tests including the Kruskal-Wallis and Mann-Whitney U tests. 
Results 
The results showed that 17.4% (n=432) of community pharmacists who responded did not find out 
when one of their regular patients had been in hospital. When they did find out, the information came 
from a variety of sources, highlighting deficiencies in communication. Community pharmacists want to 
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be involved in supporting patients with their medicines post-discharge. Eighty nine percent (n=382) of 
community pharmacists said they would like to see the full discharge summary and 78.8% (n=363) 
wanted it to be sent or accessed electronically. Respondents wanted to be more integrated into the 
teams caring for patients at the time of discharge. As shown by the 93.8% (n=373) of community 
pharmacists who thought they should have two-way communication with hospital pharmacists and the 
55% (n=382) who thought they should have access to the patient’s medical record to conduct a post-
discharge MUR. Pharmacists believed they were well placed to provide patients with medicines-related 
support after discharge as 94.9% (n=414) felt they could build long-lasting, trusted relationships with 
patients and 73.8% (n=374) thought that patients would be willing to discuss post-discharge medicines-
related issues with them. Pharmacists working in independents (≤ 5 pharmacies) were more likely to 
conduct post-discharge MURs (p<0.001), which may reflect the closer relationships established by 
pharmacists with patients in this type of pharmacy. 
Conclusions 
The results highlight the willingness of community pharmacists view to provide discharge medicines 
support. Measures to improve the accessibility of information for community pharmacists, integrate 
them more into primary care teams and promote the advanced services they offer would enhance the 
level of care they can provide to patients after a hospital discharge. As this study only looked at 
community pharmacists’ views, further research is needed to assess their ability to provide these 
services should appropriate discharge communication systems be in place. 
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